

2023

Drug Formulary

Formulario de Medicamentos

HMO – 1 Tier

Imperial Insurance Traditional Plus (HMO) 007



IMPERIAL INSURANCE COMPANIES

007 - Imperial Insurance Traditional Plus (HMO)

2023 Formulary (List of Covered Drugs)

**PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION
ABOUT THE DRUGS WE COVER IN THIS PLAN**

HPMS Approved Formulary File Submission ID 00023510, Version Number 8.

This formulary was updated on 02/21/2023. For more recent information or other questions, please contact Imperial Health Plan of California, Inc. (HMO) (HMO SNP) Customer Service at 1-800-838-8271, or, for TTY users, 711, October 1 – March 31: Monday – Sunday, from 8:00 a.m. – 8:00 p.m. or April 1 – September 30: Monday – Friday, from 8:00 a.m. – 8:00 p.m., or visit www.imperialhealthplan.com.

Important Message About What You Pay for Vaccines - Our plan covers most Part D vaccines at no cost to you, even if you haven't paid your deductible. Call Member Services for more information.

Important Message About What You Pay for Insulin - You won't pay more than \$35 for a one-month supply of each insulin product covered by our plan, no matter what cost-sharing tier it's on, even if you haven't paid your deductible.

IR_344 H2793 Drug Formulary 1T_C ENG 09/16/22

Contents

| | |
|---|-----|
| What is the Imperial Health Plan Formulary?..... | 3 |
| Can the Formulary (drug list) change? | 3 |
| How do I use the Formulary? | 4 |
| What are generic drugs?..... | 4 |
| Are there any restrictions on my coverage? | 4 |
| What if my drug is not on the Formulary?..... | 5 |
| How do I request an exception to the Imperial Health Plan Formulary? | 5 |
| What do I do before I can talk to my doctor about changing my drugs or requesting an exception? | 5 |
| For more information | 6 |
| Imperial Insurance Companies' Formulary | 6 |
| Index of Drugs..... | 199 |

Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take.

When this drug list (formulary) refers to “we,” “us”, or “our,” it means Imperial Insurance Companies, Inc. (HMO) (HMO SNP). When it refers to “plan” or “our plan,” it means Imperial Insurance Companies.

This document includes a list of the drugs (formulary) for our plan which is current as of 02/21/2023. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2023, and from time to time during the year.

What is the Imperial Insurance Companies Formulary?

A formulary is a list of covered drugs selected by our plan in consultation with a team of health care providers, which represents the prescription therapies believed to be a necessary part of a quality treatment program. We will generally cover the drugs listed in our formulary as long as the drug is medically necessary, the prescription is filled at an Imperial Insurance Companies network pharmacy, and other plan rules are followed. For more information on how to fill your prescriptions, please review your Evidence of Coverage.

Can the Formulary (drug list) change?

Most changes in drug coverage happen on January 1, but we may add or remove drugs on the Drug List during the year, move them to different cost-sharing tiers, or add new restrictions. We must follow the Medicare rules in making these changes.

Changes that can affect you this year: In the below cases, you will be affected by coverage changes during the year:

- **New generic drugs.** We may immediately remove a brand-name drug on our Drug List if we are replacing it with a new generic drug that will appear on the same or lower cost-sharing tier and with the same or fewer restrictions. Also, when adding the new generic drug, we may decide to keep the brand-name drug on our Drug List, but immediately move it to a different cost-sharing tier or add new restrictions. If you are currently taking that brand-name drug, we may not tell you in advance before we make that change, but we will later provide you with information about the specific change(s) we have made.
 - If we make such a change, you or your prescriber can ask us to make an exception and continue to cover the brand-name drug for you. The notice we provide you will also include information on how to request an exception, and you can find information in the section below titled “How do I request an exception to the Imperial Health Plan Formulary?”
- **Drugs removed from the market.** If the Food and Drug Administration deems a drug on our formulary to be unsafe or the drug’s manufacturer removes the drug from the market, we will immediately remove the drug from our formulary and provide notice to members who take the drug.
- **Other changes.** We may make other changes that affect members currently taking a drug. For instance, we may add a generic drug that is not new to the market to replace a brand-name drug currently on the formulary or add new restrictions to the brand-name drug or move it to a different cost-sharing tier or both (only for plans 003 & 004). Or we may make changes based on new clinical guidelines. If we remove drugs from our formulary, or add prior authorization, quantity limits and/or step therapy restrictions on a drug or move a drug to a higher cost-sharing tier, we must notify affected members of the change at least 30 days before the change becomes effective, or at the time the member requests a refill of the drug, at which time the member will receive a 30-day supply of the drug.
 - If we make these other changes, you or your prescriber can ask us to make an exception and continue to cover the brand-name drug for you. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below entitled “How do I request an exception to the Imperial Insurance Companies Formulary?”

Changes that will not affect you if you are currently taking the drug. Generally, if you are taking a drug on our 2023 formulary that was covered at the beginning of the year, we will not discontinue or reduce coverage of the drug during the 2023 coverage year except as described above. This means these drugs will remain available at the same cost-sharing and with no new restrictions for those members taking them for the remainder of the coverage year. You will not get direct notice this year about changes that do not affect you. However, on January 1 of the next year, such changes would affect you, and it is important to check the Drug List for the new benefit year for any changes to drugs.

The enclosed formulary is current as of 02/21/2023. To get updated information about the drugs covered by our plan please contact us. Our contact information appears on the front and back cover pages. In the event of non-maintenance changes to the formulary throughout the plan year, we may make changes via errata sheets mailed to you. Additionally, you may visit our website for a link to the errata sheet.

How do I use the Formulary?

There are two ways to find your drug within the formulary:

Medical Condition

The formulary begins on page 19. The drugs in this formulary are grouped into categories depending on the type of medical conditions that they are used to treat. For example, drugs used to treat a heart condition are listed under the category, "CARDIOVASCULAR". If you know what your drug is used for, look for the category name in the list that begins on 14. Then look under the category name for your drug.

Alphabetical Listing

If you are not sure what category to look under, you should look for your drug in the Index that begins on page 199. The Index provides an alphabetical list of all of the drugs included in this document. Both brand-name drugs and generic drugs are listed in the Index. Look in the Index and find your drug. Next to your drug, you will see the page number where you can find coverage information. Turn to the page listed in the Index and find the name of your drug in the first column of the list.

What are generic drugs?

Our plan covers both brand-name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand-name drug. Generally, generic drugs cost less than brand-name drugs.

Are there any restrictions on my coverage?

Some covered drugs may have additional requirements or limits on coverage. These requirements and limits may include:

- **Prior Authorization:** Our plan requires you or your physician to get prior authorization for certain drugs. This means that you will need to get approval from us before you fill your prescriptions. If you don't get approval, we may not cover the drug.
- **Quantity Limits:** For certain drugs, our plan limits the amount of the drug that we will cover. For example, our plan provides 60 per prescription for celecoxib. This may be in addition to a standard one-month or three-month supply.
- **Step Therapy:** In some cases, our plan requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, we may not cover Drug B unless you try Drug A first. If Drug A does not work for you, we will then cover Drug B.

You can find out if your drug has any additional requirements or limits by looking in the formulary that begins on page 19. You can also get more information about the restrictions applied to specific covered drugs by visiting our website. We have posted online documents that explain our prior authorization and step therapy restrictions. You may also ask us to send you a copy. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You can ask us to make an exception to these restrictions or limits or for a list of other, similar drugs that may treat your health condition. See the section, "How do I request an exception to the Imperial Insurance Companies formulary?" on page 5 for information about how to request an exception.

What if my drug is not on the Formulary?

If your drug is not included in this formulary (list of covered drugs), you should first contact Member Services and ask if your drug is covered.

If you learn that our plan does not cover your drug, you have two options:

- You can ask Member Services for a list of similar drugs that are covered by our plan. When you receive the list, show it to your doctor and ask him or her to prescribe a similar drug that is covered by our plan.
- You can ask our plan to make an exception and cover your drug. See below for information about how to request an exception.

How do I request an exception to the Imperial Insurance Companies Formulary?

You can ask us to make an exception to our coverage rules. There are several types of exceptions that you can ask us to make.

- You can ask us to cover a drug even if it is not on our formulary. If approved, this drug will be covered at a pre-determined cost-sharing level, and you would not be able to ask us to provide the drug at a lower cost-sharing level.
- You can ask us to cover a formulary drug at lower cost-sharing level unless the drug is on the specialty tier. If approved, this would lower the amount you must pay for your drug.
- You can ask us to waive coverage restrictions or limits on your drug. For example, for certain drugs, our plan limits the amount of the drug that we will cover. If your drug has a quantity limit, you can ask us to waive the limit and cover a greater amount.

Generally, we will only approve your request for an exception if the alternative drugs included on the plan's formulary, the lower cost-sharing drug or additional utilization restrictions would not be as effective in treating your condition and/or would cause you to have adverse medical effects.

You should contact us to ask us for an initial coverage decision for a formulary, tier (only for plans 003 & 004), or utilization restriction exception. **When you request a formulary, tier (only for plans 003 & 004), or utilization restriction exception you should submit a statement from your prescriber or physician supporting your request.** Generally, we must make our decision within 72 hours of getting your prescriber's supporting statement. You can request an expedited (fast) exception if you or your doctor believe that your health could be seriously harmed by waiting up to 72 hours for a decision. If your request to expedite is granted, we must give you a decision no later than 24 hours after we get a supporting statement from your doctor or other prescriber.

What do I do before I can talk to my doctor about changing my drugs or requesting an exception?

As a new or continuing member in our plan you may be taking drugs that are not on our formulary. Or, you may be taking a drug that is on our formulary but your ability to get it is limited. For example, you may need a prior authorization from us before you can fill your prescription. You should talk to your doctor to decide if you should switch to an appropriate drug that we cover or request a formulary exception so that we will cover the drug you take. While you talk to your doctor to determine the right course of action for you, we may cover your drug in certain cases during the first 90 days you are a member of our plan.

For each of your drugs that is not on our formulary or if your ability to get your drugs is limited, we will cover a temporary 30-day supply. If your prescription is written for fewer days, we'll allow refills to provide up to a maximum 30-day supply of medication. After your first 30-day supply, we will not pay for these drugs, even if you have been a member of the plan less than 90 days.

If you are a resident of a long-term care facility and you need a drug that is not on our formulary or if your ability to get your drugs is limited, but you are past the first 90 days of membership in our plan, we will cover a 31-day emergency supply of that drug while you pursue a formulary exception.

Exceptions are available for beneficiaries who have experienced a change in the level of care they are receiving which requires them to transition from one facility or treatment center to another. Examples of situations in which beneficiaries would be eligible for the one-time temporary fill exception when they are outside of the three-month effective date into the Part D program are as follows:

1. Beneficiary was discharged from the hospital and was provided a discharge list of medications based upon the formulary of the hospital.
2. Beneficiaries who end their skilled nursing facility Medicare Part A stay (where payments include all pharmacy charges) and who need to revert back to their Part D plan formulary.
3. Beneficiaries who give up Hospice Status to revert back to standard Medicare Part A and B benefits.
4. Beneficiaries who are discharged from Chronic Psychiatric Hospitals with medication regimens that are highly individualized.

For more information

For more detailed information about your plan's prescription drug coverage, please review your Evidence of Coverage and other plan materials.

If you have questions about Imperial Insurance Companies, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

If you have general questions about Medicare prescription drug coverage, please call Medicare at 1-800-MEDICARE (1-800-633-4227) 24 hours a day/7 days a week. TTY users should call 1-877-486-2048 or, visit <http://www.medicare.gov>.

Imperial Insurance Companies Formulary

The formulary that begins on the next page provides coverage information about the drugs covered by our plan. If you have trouble finding your drug in the list, turn to the Index that begins on page 199.

The first column of the chart lists the drug name. Brand-name drugs are capitalized (e.g., HUMIRA) and generic drugs are listed in lower-case italics (e.g., *celecoxib*).

The information in the Requirements/Limits column tells you if our plan has any special requirements for coverage of your drug.

007 - Imperial Insurance Traditional Plus (HMO)

Formulario para 2023 (Lista de medicamentos cubiertos)

**LEA LO SIGUIENTE: ESTE DOCUMENTO CONTIENE INFORMACIÓN
ACERCA DE LOS MEDICAMENTOS QUE CUBRIMOS EN ESTE PLAN**

HPMS Approved Formulary File Submission ID 00023510, Version Number 8.

Este formulario se actualizó el 21/02/2023. Para obtener información más reciente o si tiene otras preguntas, comuníquese con el Departamento de Servicio al Cliente de Imperial, Inc. (HMO) (HMO SNP) llamando al 1-800-838-8271, o para los usuarios de TTY al 711, del 1 de octubre al 31 de marzo: lunes a domingo, de 6:00 a.m. a 8:00 p.m. PST o del 1 de abril al 30 de septiembre: lunes a viernes, de 6:00 a.m. a 8:00 p.m. PST, o visite www.imperialhealthplan.com.

Mensaje importante sobre lo que paga por las vacunas: nuestro plan cubre la mayoría de las vacunas de la Parte D sin costo para usted, incluso si no ha pagado su deducible. Llame a nuestro Departamento de membresía para obtener más información.

Mensaje importante sobre lo que paga por la insulina: no pagará más de \$35 por un suministro de un mes de cada producto de insulina cubierto por nuestro plan, sin importar en qué nivel de costo compartido se encuentre, incluso si no ha pagado su deducible.

IR_344 H2793 Drug Formulary 1T_C ENG 09/16/22

Contenido

| | |
|---|-----|
| ¿Qué es el Formulario de Imperial Health Plan? | 9 |
| ¿Puede cambiar el Formulario (lista de medicamentos) ? | 9 |
| ¿Cómo utilizo el Formulario? | 10 |
| ¿Qué son los medicamentos genéricos? | 10 |
| ¿Hay alguna restricción en mi cobertura? | 11 |
| ¿Qué pasa si mi medicamento no está en el Formulario? | 11 |
| ¿Cómo puedo solicitar que se haga una excepción al Formulario de Imperial Health Plan? | 11 |
| ¿Qué debo hacer antes de hablar con mi médico sobre el cambio de los medicamentos que tomo o la solicitud de una excepción? | 12 |
| Para obtener más información..... | 13 |
| Formulario de Imperial Insurance Companies | 13 |
| Índice de drogas | 199 |

Nota para los miembros actuales: este Formulario ha cambiado con respecto al año pasado. Revise este documento para asegurarse de que aún contiene los medicamentos que toma.

Cuando esta Lista de medicamentos (Formulario) menciona “nosotros”, “nos” o “nuestro”, hace referencia a Imperial Insurance Companies, Inc. (HMO) (HMO SNP). Cuando dice “plan” o “nuestro plan”, hace referencia a Imperial Insurance Companies.

Este documento incluye una lista de los medicamentos (Formulario) de nuestro plan, la cual está en vigencia desde el 21/02/2023. Para obtener un formulario actualizado, comuníquese con nosotros. Nuestra información de contacto, junto con la fecha de la última actualización del Formulario, aparece en las páginas de la portada y la portada posterior.

Generalmente, debe concurrir a las farmacias de la red para usar el beneficio de medicamentos con receta. Los beneficios, el formulario, la red de farmacias o los copagos/el coseguro pueden cambiar el 1 de enero de 2023 y periódicamente durante el año.

¿Qué es el Formulario de Imperial Insurance Companies?

Un Formulario es una lista de medicamentos cubiertos seleccionados por nuestro plan con la colaboración de un equipo de proveedores de atención médica, que representa los tratamientos con receta que se considera que son parte necesaria de un programa de tratamiento de calidad. Normalmente, cubriremos los medicamentos incluidos en el formulario, siempre que el medicamento sea médicamente necesario, el medicamento con receta se obtenga en una farmacia de la red de Imperial Insurance Companies y se cumpla con otras normas del plan. Para obtener más información sobre cómo obtener sus medicamentos con receta, consulte la Evidencia de cobertura.

¿Puede cambiar el Formulario (lista de medicamentos) ?

La mayoría de los cambios en la cobertura de los medicamentos ocurre el 1 de enero, pero nosotros podríamos agregar o quitar medicamentos de la Lista de medicamentos durante el año, moverlos a diferentes niveles de costo compartido o agregar nuevas restricciones. Debemos seguir las normas de Medicare al hacer estos cambios.

Cambios que pueden afectarlo este año: en los casos a continuación, usted se verá afectado por los cambios de cobertura durante el año:

- **Nuevos medicamentos genéricos.** Podemos eliminar inmediatamente un medicamento de marca de nuestra Lista de medicamentos si lo reemplazamos con un nuevo medicamento genérico que aparecerá en el mismo nivel de costo compartido o en un nivel de costo compartido más bajo y con las mismas restricciones o menos. Además, cuando agreguemos el nuevo medicamento genérico, podemos decidir mantener el medicamento de marca en nuestra Lista de medicamentos, pero inmediatamente moverlo a un nivel de costo compartido diferente o agregar nuevas restricciones. Si actualmente está tomando ese medicamento de marca, quizás no le informemos con antelación antes de que realicemos el cambio, pero más adelante le proporcionaremos información sobre los cambios específicos que hemos realizado.
 - Si realizamos un cambio, usted o la persona autorizada a dar recetas pueden solicitarnos que hagamos una excepción y sigamos cubriendo el medicamento de marca para usted. En el aviso que le proporcionamos también se incluirá información sobre cómo solicitar una excepción, y usted puede encontrar información en la sección a continuación titulada “¿Cómo puedo solicitar que se haga una excepción al Formulario de Imperial Insurance Companies?”
- **Medicamentos retirados del mercado.** Si la Administración de Drogas y Alimentos considera que un medicamento de nuestro Formulario es inseguro o el fabricante del medicamento lo retira del mercado, eliminaremos de inmediato dicho medicamento de nuestro Formulario y les notificaremos a los miembros que toman el medicamento en cuestión.
- **Otros cambios.** Podemos hacer otros cambios que afectan a los miembros que actualmente toman un medicamento. Por ejemplo, podemos agregar un medicamento genérico que no es nuevo en el mercado para reemplazar un medicamento de marca que actualmente se encuentre en el Formulario, o agregar nuevas restricciones al medicamento de marca o moverlo a un nivel de costo compartido diferente o ambos (solo para los planes 003 y 004) o ambas cosas. O bien, podemos hacer cambios en función de las nuevas pautas clínicas. Si retiramos medicamentos de nuestro Formulario, o agregamos autorizaciones previas, restricciones de límite de cantidad o de tratamiento escalonado en un medicamento o si pasamos un medicamento a un nivel superior de costo compartido, debemos notificarles a los miembros afectados por el cambio al menos 30 días antes de que entre en vigencia dicho cambio, o cuando el miembro solicite un resurtido del medicamento, momento en el cual el miembro recibirá un suministro del medicamento para 30 días.

- Si realizamos estos otros cambios, usted o la persona autorizada a dar recetas pueden solicitarnos que hagamos una excepción y sigamos cubriendo el medicamento de marca para usted. En el aviso que le proporcionamos también se incluirá información sobre cómo solicitar una excepción, y usted también puede encontrar información en la sección a continuación titulada “¿Cómo puedo solicitar que se haga una excepción al Formulario de Imperial Insurance Companies?”

Cambios que no lo afectarán si actualmente toma el medicamento. En general, si usted toma un medicamento de nuestro Formulario para 2023 que estaba cubierto al comienzo del año, nosotros no discontinuaremos ni reduciremos la cobertura del medicamento durante el año de cobertura 2023, excepto como se describe anteriormente. Esto significa que, por el resto del año de cobertura, estos medicamentos continuarán disponibles al mismo costo compartido y sin nuevas restricciones para aquellos miembros que estén tomándolos. No recibirá un aviso directo este año sobre cambios que no lo afectan. Sin embargo, dichos cambios lo afectarían a partir del 1 de enero del año siguiente, y es importante que verifique la Lista de medicamentos del nuevo año de beneficios por cualquier cambio en los medicamentos.

El Formulario adjunto es vigente a partir del 21/02/2023. Para recibir información actualizada sobre los medicamentos cubiertos por nuestro plan, comuníquese con nosotros. Nuestra información de contacto aparece en las páginas de la portada y la portada posterior. En caso de cambios al formulario durante el año del plan que no sean relacionados al mantenimiento, podemos realizar cambios a través de las hojas de correcciones que le enviemos. Además, puede visitar nuestro sitio web para encontrar un enlace a la hoja de correcciones.

¿Cómo utilizo el Formulario?

Hay dos formas para encontrar su medicamento dentro del Formulario:

Afección médica

El Formulario comienza en la página 19. Los medicamentos de este Formulario están agrupados en categorías según el tipo de afección médica para cuyo tratamiento se los emplea. Por ejemplo, los medicamentos utilizados para tratar una afección cardíaca se enumeran dentro de la categoría “CARDIOVASCULAR”. Si sabe para qué se utiliza su medicamento, busque el nombre de la categoría en la lista que empieza en la página 16. Luego, busque su medicamento debajo del nombre de la categoría.

Listado alfabético

Si no está seguro de qué categoría consultar, debe buscar su medicamento en el Índice que comienza en la página 199. El Índice proporciona una lista alfabética de todos los medicamentos incluidos en este documento. En el Índice, están tanto los medicamentos de marca como los genéricos. Busque en el Índice y encuentre su medicamento. Junto a su medicamento, verá el número de página donde puede encontrar información acerca de la cobertura. Vaya a la página que figura en el Índice y encuentre el nombre de su medicamento en la primera columna de la lista.

¿Qué son los medicamentos genéricos?

Nuestro plan cubre tanto los medicamentos de marca como los genéricos. Un medicamento genérico está aprobado por la Administración de Drogas y Alimentos (FDA) dado que se considera que tiene el mismo ingrediente activo que el medicamento de marca. Normalmente, los medicamentos genéricos cuestan menos que los de marca.

¿Hay alguna restricción en mi cobertura?

Algunos medicamentos cubiertos pueden tener requisitos o límites adicionales de cobertura. Estos requisitos y límites pueden incluir:

- **Autorización previa:** Nuestro plan exige que usted o su médico obtenga una autorización previa para determinados medicamentos. Esto significa que necesitará contar con la aprobación de nosotros antes de obtener sus medicamentos con receta. Si no consigue la autorización, es posible que no cubramos el medicamento.
- **Límites de cantidad:** para ciertos medicamentos, nuestro plan limita la cantidad del medicamento que cubriremos. Por ejemplo, nuestro plan proporciona 60 por receta para celecoxib. Esto puede ser complementario a un suministro estándar para un mes o tres meses.
- **Tratamiento escalonado:** en algunos casos, nuestro plan requiere que usted primero pruebe ciertos medicamentos para tratar su afección médica antes de que cubramos otro medicamento para esa enfermedad. Por ejemplo, si el medicamento A y el medicamento B tratan su afección médica, es posible que no cubramos el medicamento B a menos que usted pruebe primero el medicamento A. Si el medicamento A no funciona para usted, entonces cubriremos el medicamento B.

Para averiguar si su medicamento tiene requisitos o límites adicionales, consulte el Formulario que empieza en la página 19. También puede obtener más información sobre las restricciones que se aplican a medicamentos cubiertos específicos en nuestro sitio Web. Hemos publicado documentos en línea que explican nuestras restricciones de autorización previa y tratamiento escalonado. También puede pedirnos que le enviemos una copia. Nuestra información de contacto, junto con la fecha de la última actualización del Formulario, aparece en las páginas de la portada y la portada posterior.

Puede pedirnos que hagamos una excepción a estas restricciones o límites, o puede solicitarnos una lista de otros medicamentos similares que puedan tratar su afección médica. Consulte la sección “¿Cómo puedo solicitar que se haga una excepción al Formulario de Imperial Insurance Companies?” en la página 11 para obtener información acerca de cómo solicitar una excepción.

¿Qué pasa si mi medicamento no está en el Formulario?

Si el medicamento que toma no está incluido en este Formulario (lista de medicamentos cubiertos), primero debe comunicarse con nuestro Departamento de Membresía y preguntar si su medicamento está cubierto.

Si resulta que nuestro plan no cubre el medicamento que toma, tiene dos alternativas:

- Puede pedir a nuestro Departamento de Membresía una lista de medicamentos similares que estén cubiertos por nuestro plan. Cuando reciba la lista, muéstresela a su médico y pídale que le recete un medicamento similar que esté cubierto por nuestro plan.
- Puede solicitar que nuestro plan haga una excepción y cubra su medicamento. Consulte a continuación para obtener información sobre cómo solicitar una excepción.

¿Cómo puedo solicitar que se haga una excepción al Formulario de Imperial Insurance Companies

Puede solicitarnos que hagamos una excepción a nuestras normas de cobertura. Hay varios tipos de excepciones que puede solicitarnos.

- Puede pedirnos que cubramos un medicamento, incluso si no está en nuestro Formulario. Si se aprueba, este medicamento estará cubierto a un nivel de costo compartido predeterminado, y usted no podrá pedirnos que le brindemos el medicamento a un nivel de costo compartido menor.

- Puede pedirnos que cubramos un medicamento del Formulario a un nivel de costo compartido menor, a menos que el medicamento esté incluido en el nivel de medicamentos especializados. Si se aprueba, esto reduciría el monto que usted debe pagar por su medicamento.
- Puede pedirnos que no apliquemos restricciones o límites de cobertura para su medicamento. Por ejemplo, para ciertos medicamentos, nuestro plan limita la cantidad del medicamento que cubriremos. Si su medicamento tiene un límite de cantidad, puede pedirnos que hagamos una excepción al límite y cubramos una cantidad mayor.

Por lo general, solo aprobaremos su pedido de excepción si los medicamentos alternativos incluidos en el Formulario del plan, el medicamento de menor costo compartido o las restricciones de uso adicionales no fueran tan efectivos para tratar su afección o pudieran causarle efectos médicos adversos.

Debe comunicarse con nosotros para solicitarnos una decisión inicial de cobertura para una excepción al Formulario, nivel (solo para los planes 003 y 004), o a la restricción de uso. **Cuando solicita una excepción al Formulario, nivel (solo para los planes 003 y 004), o a la restricción de uso, debe presentar una declaración de su médico o de la persona autorizada a dar recetas que respalde su solicitud.** Por lo general, debemos tomar una decisión dentro de las 72 horas a partir de la fecha de haber recibido la declaración que respalda su solicitud por parte de la persona autorizada a dar recetas. Puede solicitar una excepción acelerada (rápida) si usted o su médico consideran que esperar 72 horas para la toma de la decisión podría perjudicar gravemente su salud. Si se le concede el trámite rápido de la excepción, debemos comunicarle nuestra decisión a más tardar dentro de las 24 horas después de haber recibido la declaración de respaldo de su médico o de otra persona autorizada a dar recetas.

¿Qué debo hacer antes de hablar con mi médico sobre el cambio de los medicamentos que tomo o la solicitud de una excepción?

Como miembro nuevo o permanente de nuestro plan, es posible que esté tomando medicamentos que no están incluidos en el Formulario. También es posible que esté tomando un medicamento incluido en el Formulario, pero su capacidad de conseguirlo sea limitada. Por ejemplo, puede necesitar nuestra autorización previa antes de poder obtener su medicamento con receta. Debe consultar con su médico para decidir si debe cambiar su medicamento por uno apropiado que nosotros cubramos o solicitar una excepción al formulario para que le cubramos el medicamento que toma. Mientras evalúa con su médico el procedimiento adecuado para seguir en su caso, podemos cubrir su medicamento, en ciertos casos, durante los primeros 90 días en que usted sea miembro de nuestro plan.

Para cada uno de sus medicamentos que no está incluido en el Formulario o si su capacidad para conseguir los medicamentos es limitada, cubriremos un suministro temporal para 30 días. Si su receta está indicada para menos días, permitiremos que realice resurtidos por un máximo de hasta 30 días del medicamento. Después del primer suministro para 30 días, no seguiremos pagando estos medicamentos, incluso si ha sido miembro del plan durante menos de 90 días.

Si es residente de un centro de atención a largo plazo y necesita un medicamento que no está en el Formulario o si su capacidad para conseguir los medicamentos es limitada, pero ya pasaron los primeros 90 días de membresía en nuestro plan, cubriremos un suministro de emergencia del medicamento para 31 días mientras solicita la excepción al formulario.

Las excepciones se encuentran disponibles para aquellos beneficiarios que hayan sufrido un cambio de nivel en la atención que reciben, el cual exige que se muden de una instalación o centro de tratamiento a otro. Los siguientes son ejemplos de las situaciones en las que los beneficiarios serían elegibles para una excepción de una sola vez de un surtido temporal al encontrarse fuera del plazo de los tres meses posteriores a la fecha de vigencia del programa de la Parte D:

1. El beneficiario fue dado de alta del hospital y recibió una lista de medicamentos del alta según el formulario del hospital.
2. Los beneficiarios quienes terminan su estancia de Medicare Parte A en un centro de enfermería especializada (en la que los pagos incluyen todas las tarifas de farmacia) y quienes necesitan volver al formulario de su plan de la Parte D.
3. Los beneficiarios que pierden su estatus de hospicio para volver a los beneficios estándares de Medicare Parte A y B.
4. Los beneficiarios que son dados de alta de hospitales psiquiátricos crónicos con regímenes de medicamentos altamente individualizados.

Para obtener más información

Para obtener información más detallada sobre la cobertura para medicamentos con receta de su plan, consulte la Evidencia de cobertura y otra documentación del plan.

Si tiene alguna pregunta sobre Imperial Insurance Companies, comuníquese con nosotros. Nuestra información de contacto, junto con la fecha de la última actualización del Formulario, aparece en las páginas de la portada y la portada posterior.

Si tiene preguntas generales sobre su cobertura para medicamentos con receta de Medicare, llame a Medicare al 1-800-MEDICARE (1-800-633-4227), las 24 horas, los 7 días de la semana. Los usuarios de TTY deben llamar al 1-877-486-2048, o visite <http://www.medicare.gov>.

Formulario de Imperial Insurance Companies

El formulario que comienza en la siguiente página proporciona información acerca de la cobertura de los medicamentos cubiertos por nuestro plan. Si tiene alguna dificultad para encontrar el medicamento que toma en la lista, consulte el Índice que comienza en la página 199.

La primera columna de la tabla menciona el nombre del medicamento. Los medicamentos de marca están en letra mayúscula (por ejemplo, HUMIRA), y los medicamentos genéricos están en letra minúscula y cursiva (por ejemplo, *celecoxib*).

La información incluida en la columna de Requisitos/límites indica si nuestro plan tiene algún requisito especial para la cobertura del medicamento.

Imperial MAPD 2023 1-Tier (List of Covered Drugs)

List of Drugs by Medical Condition

| | |
|--|----|
| ANALGESICS..... | 19 |
| ANESTHETICS..... | 21 |
| ANTI-ADDICTION/ SUBSTANCE ABUSE TREATMENT AGENTS..... | 21 |
| ANTIBACTERIALS | 22 |
| ANTICONVULSANTS | 28 |
| ANTIDEMENTIA AGENTS..... | 31 |
| ANTIDEPRESSANTS | 32 |
| ANTIEMETICS..... | 35 |
| ANTIFUNGALS | 36 |
| ANTIGOUT AGENTS | 37 |
| ANTIMIGRAINE AGENTS | 38 |
| ANTIMYASTHENIC AGENTS | 39 |
| ANTIMYCOBACTERIALS | 39 |
| ANTINEOPLASTICS..... | 39 |
| ANTIPARASITICS..... | 46 |
| ANTIPARKINSON AGENTS..... | 47 |
| ANTIPSYCHOTICS | 48 |
| ANTISPASTICITY AGENTS | 52 |
| ANTIVIRALS..... | 52 |
| ANXIOLYTICS..... | 56 |
| BIPOLAR AGENTS..... | 57 |
| BLOOD GLUCOSE REGULATORS | 57 |
| BLOOD PRODUCTS AND MODIFIERS | 61 |
| CARDIOVASCULAR AGENTS | 62 |
| CENTRAL NERVOUS SYSTEM AGENTS | 70 |
| DENTAL AND ORAL AGENTS..... | 72 |
| DERMATOLOGICAL AGENTS..... | 72 |
| ELECTROLYTES/MINERALS/METALS/VITAMINS | 76 |
| GASTROINTESTINAL AGENTS..... | 79 |
| GENETIC OR ENZYME OR PROTEIN DISORDER: REPLACEMENT, MODIFIERS, TREATMENT | 81 |
| GENITOURINARY AGENTS | 82 |

| | |
|--|------------|
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (ADRENAL) | 83 |
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (PITUITARY)..... | 84 |
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (SEX HORMONES/ MODIFIERS)..... | 84 |
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (THYROID)..... | 90 |
| HORMONAL AGENTS, SUPPRESSANT (PITUITARY) | 90 |
| HORMONAL AGENTS, SUPPRESSANT (THYROID) | 91 |
| IMMUNOLOGICAL AGENTS | 91 |
| INFLAMMATORY BOWEL DISEASE AGENTS..... | 97 |
| METABOLIC BONE DISEASE AGENTS..... | 98 |
| OPHTHALMIC AGENTS..... | 98 |
| OTIC AGENTS | 101 |
| RESPIRATORY TRACT/ PULMONARY AGENTS..... | 102 |
| SKELETAL MUSCLE RELAXANTS | 106 |
| SLEEP DISORDER AGENTS..... | 106 |

Imperial MAPD 2023 1-Tier (Lista de Medicamentos Cubiertos)

Lista de medicamentos por condición médica

| | |
|---|-----|
| AGENTES ANTIESPASTICIDAD | 107 |
| AGENTES ANTIMIASTENICOS..... | 107 |
| AGENTES ANTIMIGRAÑOSOS..... | 107 |
| AGENTES ANTIPARKINSON | 108 |
| AGENTES BIPOLARES | 109 |
| AGENTES CARDIOVASCULARES | 110 |
| AGENTES DE ANTIDEMENCIA..... | 118 |
| AGENTES DEL SISTEMA NERVIOSO CENTRAL | 118 |
| AGENTES DENTALES Y ORALES | 120 |
| AGENTES DERMATOLÓGICOS | 121 |
| AGENTES GASTROINTESTINALES..... | 124 |
| AGENTES GENITOURINARIOS | 127 |
| AGENTES HORMONALES, ESTIMULANTES/ DE REEMPLAZO/ MODIFICADORES (HORMONAS SEXUALES/ MODIFICADORES) | 128 |
| AGENTES HORMONALES, ESTIMULANTES/ DE REEMPLAZO/ MODIFICADORES (PITUITARIA) | 133 |
| AGENTES HORMONALES, ESTIMULANTES/ DE REEMPLAZO/ MODIFICADORES (SUPRARRENALES)..... | 134 |
| AGENTES HORMONALES, ESTIMULANTES/ DE REEMPLAZO/ MODIFICADORES (TIROIDES)..... | 135 |
| AGENTES HORMONALES, SUPRESORES (PITUITARIA)..... | 135 |
| AGENTES HORMONALES, SUPRESORES (TIROIDES)..... | 136 |
| AGENTES INMUNOLÓGICOS | 136 |
| AGENTES METABÓLICOS PARA LA ENFERMEDAD ÓSEA | 142 |
| AGENTES OFTÁLMICOS..... | 143 |
| AGENTES ÓTICOS..... | 146 |
| AGENTES PARA ENFERMEDAD INTESTINAL INFLAMATORIA..... | 147 |
| AGENTES PARA TRASTORNO DEL SUEÑO | 147 |
| AGENTES PARA TRASTORNO GENÉTICO, DE ENZIMAS o PROTEÍNAS: REEMPLAZO, MODIFICADORES, TRATAMIENTO..... | 148 |
| AGENTES PARA TRATAMIENTO DE ABUSO DE SUSTANCIAS/ANTI-ADICCIÓN | 149 |
| AGENTES PARA TRATAMIENTO DE LA GOTA | 150 |
| AGENTES PULMONARES/ TRACTO RESPIRATORIO..... | 150 |
| ANALGÉSICOS..... | 154 |

| | |
|--|------------|
| ANESTÉSICOS | 156 |
| ANSIOLÍTICOS | 157 |
| ANTIBACTERIANOS..... | 158 |
| ANTICONVULSIVOS | 164 |
| ANTIDEPRESIVOS | 167 |
| ANTIEMÉTICOS..... | 170 |
| ANTIMICOBACTERIANOS..... | 171 |
| ANTIMICÓTICOS | 172 |
| ANTINEOPLÁSICOS | 173 |
| ANTIPARASITARIOS | 181 |
| ANTIPSIKÓTICOS | 181 |
| ANTIVIRALES | 185 |
| ELECTROLITOS/MINERALES/METALES/VITAMINAS..... | 189 |
| PRODUCTOS Y MODIFICADORES DE SANGRE..... | 192 |
| REGULADORES DE GLUCOSA EN SANGRE..... | 194 |
| RELAJANTES DEL MÚSCULO ESQUELÉTICO | 198 |

Legend

1: Covered Medications

BvD: Part B vs. Part D- This prescription drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

MO: Mail Order Eligible- This prescription may also be available via mail.

PA: Prior Authorization- You (or your physician) are required to get prior authorization before you fill your prescription for this drug. Without prior approval, we may not cover this drug.

QL: Quantity Limit- There is a limit on the amount of this drug that is covered per prescription, or within a specific time frame.

ST: Step Therapy - In some cases, you may be required to first try certain drugs to treat your medical condition before we will cover another drug for that condition.

La leyenda

1: Medicamentos cubiertos

BvD: Algunos medicamentos pueden tener cobertura de la Parte B o D de Medicare, según las circunstancias.

MO: El pedido por correo es elegible.

PA: Autorización previa. Usted (o su médico) debe obtener una autorización previa antes de que llene su receta para este medicamento. Sin aprobación previa, es posible que no cubramos este medicamento.

QL: Limite de cantidad. Un limite de cantidad se ha implementado en el medicamento recetado.

ST: Terapia escalonada. Los requisitos de la terapia escalonada deben cumplirse antes de surtir el medicamento recetado.

Imperial MAPD 2023 1-Tier (List of Covered Drugs)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-------------------------|
| ANALGESICS | | |
| <i>Analgesics</i> | | |
| <i>butalbital-apap-caffeine oral tablet 50-325-40mg</i> | 1 | QL (180 EA per 30 days) |
| <i>butalbital-asa-caff-codeine oral capsule 50-325-40-30mg</i> | 1 | QL (180 EA per 30 days) |
| <i>butalbital-aspirin-caffeine oral capsule 50-325-40mg</i> | 1 | QL (180 EA per 30 days) |
| <i>Nonsteroidal Anti-Inflammatory Drugs</i> | | |
| <i>celecoxib oral capsule 100mg, 200mg, 400mg, 50mg</i> | 1 | MO |
| <i>diclofenac potassium oral tablet 50mg</i> | 1 | MO |
| <i>diclofenac sodium er oral tablet extended release 24-hour 100mg</i> | 1 | MO |
| <i>diclofenac sodium external gel 1%</i> | 1 | |
| <i>diclofenac sodium oral tablet delayed release 25mg, 50mg, 75mg</i> | 1 | MO |
| <i>diflunisal oral tablet 500mg</i> | 1 | MO |
| <i>etodolac oral capsule 200mg, 300mg</i> | 1 | MO |
| <i>etodolac oral tablet 400mg, 500mg</i> | 1 | MO |
| <i>flurbiprofen oral tablet 100mg</i> | 1 | MO |
| IBU ORAL TABLET 600MG, 800MG | 1 | MO |
| <i>ibuprofen oral suspension 100mg/5ml</i> | 1 | |
| <i>ibuprofen oral tablet 400mg, 600mg, 800mg</i> | 1 | MO |
| <i>indomethacin er oral capsule extended release 75mg</i> | 1 | MO |
| <i>indomethacin oral capsule 25mg, 50mg</i> | 1 | MO |
| <i>ketorolac tromethamine oral tablet 10mg</i> | 1 | |
| <i>meloxicam oral tablet 15mg, 7.5mg</i> | 1 | MO |
| <i>nabumetone oral tablet 500mg, 750mg</i> | 1 | MO |
| <i>naproxen oral suspension 125mg/5ml</i> | 1 | MO |
| <i>naproxen oral tablet 250mg, 375mg, 500mg</i> | 1 | MO |
| <i>naproxen oral tablet delayed release 375mg, 500mg</i> | 1 | MO |
| <i>naproxen sodium oral tablet 275mg, 550mg</i> | 1 | MO |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------|
| <i>oxaprozin oral tablet 600mg</i> | 1 | MO |
| <i>piroxicam oral capsule 10mg, 20mg</i> | 1 | MO |
| <i>sulindac oral tablet 150mg, 200mg</i> | 1 | MO |
| Opioid Analgesics, Long-Acting | | |
| <i>fentanyl transdermal patch 72-hour 100mcg/hr, 12mcg/hr, 25mcg/hr, 37.5mcg/hr, 50mcg/hr, 62.5mcg/hr, 75mcg/hr, 87.5mcg/hr</i> | 1 | PA; QL (10 EA per 30 days) |
| <i>methadone hcl oral tablet 10mg, 5mg</i> | 1 | QL (240 EA per 30 days) |
| <i>morphine sulfate er oral tablet extended release 100mg, 15mg, 200mg, 30mg, 60mg</i> | 1 | QL (90 EA per 30 days) |
| <i>oxycodone hcl er oral tablet er 12-hour abuse-deterrent 10mg, 20mg, 40mg, 80mg</i> | 1 | |
| Opioid Analgesics, Short-Acting | | |
| <i>acetaminophen-codeine #3 oral tablet 300-30mg</i> | 1 | QL (360 EA per 30 days) |
| <i>acetaminophen-codeine oral solution 120-12mg/5ml</i> | 1 | QL (5000ML per 30 days) |
| <i>acetaminophen-codeine oral tablet 300-15mg, 300-60mg</i> | 1 | QL (360 EA per 30 days) |
| <i>codeine sulfate oral tablet 15mg, 30mg, 60mg</i> | 1 | QL (180 EA per 30 days) |
| <i>fentanyl citrate buccal lozenge on a handle 1200mcg, 1600mcg, 200mcg, 400mcg, 600mcg, 800mcg</i> | 1 | PA; QL (120 EA per 30 days) |
| <i>hydrocodone-acetaminophen oral solution 7.5-325mg/15ml</i> | 1 | QL (5500ML per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 10-325mg, 5-325mg, 7.5-325mg</i> | 1 | QL (360 EA per 30 days) |
| <i>hydrocodone-ibuprofen oral tablet 10-200mg, 5-200mg, 7.5-200mg</i> | 1 | QL (150 EA per 30 days) |
| <i>hydromorphone hcl oral liquid 1mg/ml</i> | 1 | QL (1920ML per 30 days) |
| <i>hydromorphone hcl oral tablet 2mg, 4mg</i> | 1 | QL (360 EA per 30 days) |
| <i>hydromorphone hcl oral tablet 8mg</i> | 1 | QL (240 EA per 30 days) |
| <i>morphine sulfate (concentrate) oral solution 20mg/ml</i> | 1 | QL (600ML per 30 days) |
| <i>morphine sulfate oral solution 10mg/5ml</i> | 1 | QL (1800ML per 30 days) |
| <i>morphine sulfate oral solution 20mg/5ml</i> | 1 | QL (1500ML per 30 days) |
| <i>morphine sulfate oral tablet 15mg, 30mg</i> | 1 | QL (180 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-------------------------|
| <i>oxycodone hcl oral concentrate 100mg/5ml</i> | 1 | QL (180ML per 30 days) |
| <i>oxycodone hcl oral solution 5mg/5ml</i> | 1 | QL (1080ML per 30 days) |
| <i>oxycodone hcl oral tablet 10mg, 15mg, 20mg, 30mg, 5mg</i> | 1 | QL (180 EA per 30 days) |
| <i>oxycodone-acetaminophen oral solution 5-325mg/5ml</i> | 1 | QL (1080ML per 30 days) |
| <i>oxycodone-acetaminophen oral tablet 10-325mg, 2.5-325mg, 5-325mg, 7.5-325mg</i> | 1 | QL (360 EA per 30 days) |
| <i>tramadol hcl oral tablet 100mg</i> | 1 | QL (120 EA per 30 days) |
| <i>tramadol hcl oral tablet 50mg</i> | 1 | QL (240 EA per 30 days) |
| <i>tramadol-acetaminophen oral tablet 37.5-325mg</i> | 1 | QL (240 EA per 30 days) |

ANESTHETICS

Local Anesthetics

| | | |
|---|---|----------------------------|
| <i>lidocaine external patch 5%</i> | 1 | PA; QL (90 EA per 30 days) |
| <i>lidocaine hcl external solution 4%</i> | 1 | QL (50ML per 30 days) |
| <i>lidocaine viscous hcl mouth/throat solution 2%</i> | 1 | |
| <i>lidocaine-prilocaine external cream 2.5-2.5%</i> | 1 | QL (30GM per 30 days) |

ANTI-ADDICTION/ SUBSTANCE ABUSE TREATMENT AGENTS

Alcohol Deterrents/Anti-Craving

| | | |
|--|---|----|
| <i>acamprosate calcium oral tablet delayed release 333mg</i> | 1 | MO |
| <i>disulfiram oral tablet 250mg</i> | 1 | MO |
| <i>naltrexone hcl oral tablet 50mg</i> | 1 | |
| VIVITROL INTRAMUSCULAR SUSPENSION RECONSTITUTED 380MG | 1 | |

Opioid Dependence

| | | |
|---|---|--|
| <i>buprenorphine hcl sublingual tablet sublingual 2mg, 8mg</i> | 1 | |
| <i>buprenorphine hcl-naloxone hcl sublingual tablet sublingual 2-0.5mg, 8-2mg</i> | 1 | |
| SUBOXONE SUBLINGUAL FILM 12-3MG, 2-0.5MG, 4-1MG, 8-2MG | 1 | |

Opioid Reversal Agents

| | | |
|---------------------------------|---|--|
| KLOXXADO NASAL LIQUID 8MG/0.1ML | 1 | |
|---------------------------------|---|--|

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| <i>naloxone hcl injection solution 0.4mg/ml</i> | 1 | |
| <i>naloxone hcl injection solution cartridge 0.4mg/ml</i> | 1 | |
| <i>naloxone hcl injection solution prefilled syringe 2mg/2ml</i> | 1 | |
| <i>naloxone hcl nasal liquid 4mg/0.1ml</i> | 1 | |
| NARCAN NASAL LIQUID 4MG/0.1ML | 1 | |
| ZIMHI INJECTION SOLUTION PREFILLED SYRINGE 5MG/0.5ML | 1 | |
| Smoking Cessation Agents | | |
| <i>bupropion hcl er (smoking det) oral tablet extended release 12-hour 150mg</i> | 1 | |
| NICOTROL INHALATION INHALER 10MG | 1 | |
| <i>varenicline tartrate oral tablet 0.5mg, 1mg</i> | 1 | |
| <i>varenicline tartrate oral tablet therapy pack 0.5mg x 11 & 1mg x 42</i> | 1 | |
| ANTIBACTERIALS | | |
| Aminoglycosides | | |
| <i>amikacin sulfate injection solution 500mg/2ml</i> | 1 | BvD |
| ARIKAYCE INHALATION SUSPENSION 590MG/8.4ML | 1 | PA |
| <i>gentamicin in saline intravenous solution 0.8-0.9mg/ml-%, 1-0.9mg/ml-%, 1.2-0.9mg/ml-%, 1.6-0.9mg/ml-%</i> | 1 | |
| <i>gentamicin sulfate external cream 0.1%</i> | 1 | |
| <i>gentamicin sulfate external ointment 0.1%</i> | 1 | |
| <i>gentamicin sulfate injection solution 40mg/ml</i> | 1 | |
| <i>neomycin sulfate oral tablet 500mg</i> | 1 | |
| <i>paromomycin sulfate oral capsule 250mg</i> | 1 | |
| <i>tobramycin sulfate injection solution 10mg/ml, 80mg/2ml</i> | 1 | BvD |
| ZEMDRI INTRAVENOUS SOLUTION 500MG/10ML | 1 | |
| Antibacterials, Other | | |
| <i>aztreonam injection solution reconstituted 1gm</i> | 1 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>aztreonam injection solution reconstituted 2gm</i> | 1 | BvD |
| <i>clindamycin hcl oral capsule 150mg, 300mg, 75mg</i> | 1 | |
| <i>clindamycin palmitate hcl oral solution reconstituted 75mg/5ml</i> | 1 | |
| <i>clindamycin phosphate in d5w intravenous solution 300mg/50ml, 600mg/50ml, 900mg/50ml</i> | 1 | |
| <i>clindamycin phosphate injection solution 300mg/2ml, 600mg/4ml, 900mg/6ml</i> | 1 | BvD |
| <i>clindamycin phosphate vaginal cream 2%</i> | 1 | |
| <i>colistimethate sodium (cba) injection solution reconstituted 150mg</i> | 1 | BvD |
| <i>daptomycin intravenous solution reconstituted 350mg, 500mg</i> | 1 | |
| FIRVANQ ORAL SOLUTION RECONSTITUTED 25MG/ML, 50MG/ML | 1 | |
| <i>linezolid intravenous solution 600mg/300ml</i> | 1 | PA |
| <i>linezolid oral tablet 600mg</i> | 1 | PA |
| <i>methenamine hippurate oral tablet 1gm</i> | 1 | |
| <i>metronidazole external cream 0.75%</i> | 1 | |
| <i>metronidazole external gel 0.75%, 1%</i> | 1 | |
| <i>metronidazole external lotion 0.75%</i> | 1 | |
| <i>metronidazole intravenous solution 500mg/100ml</i> | 1 | BvD |
| <i>metronidazole oral tablet 250mg, 500mg</i> | 1 | |
| <i>metronidazole vaginal gel 0.75%</i> | 1 | |
| <i>nitrofurantoin macrocrystal oral capsule 100mg, 25mg, 50mg</i> | 1 | |
| <i>nitrofurantoin monohyd macro oral capsule 100mg</i> | 1 | |
| <i>tigecycline intravenous solution reconstituted 50mg</i> | 1 | BvD |
| <i>tinidazole oral tablet 250mg, 500mg</i> | 1 | |
| <i>trimethoprim oral tablet 100mg</i> | 1 | |
| <i>vancomycin hcl intravenous solution reconstituted 1gm, 10gm, 500mg, 750mg</i> | 1 | |
| <i>vancomycin hcl oral capsule 125mg, 250mg</i> | 1 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| <i>vancomycin hcl oral solution reconstituted 250mg/5ml</i> | 1 | |
| XIFAXAN ORAL TABLET 200MG | 1 | |
| XIFAXAN ORAL TABLET 550MG | 1 | MO |
| Beta-Lactam, Cephalosporins | | |
| <i>cefaclor er oral tablet extended release 12-hour 500mg</i> | 1 | |
| <i>cefaclor oral capsule 250mg, 500mg</i> | 1 | |
| <i>cefaclor oral suspension reconstituted 125mg/5ml, 250mg/5ml, 375mg/5ml</i> | 1 | |
| <i>cefadroxil oral capsule 500mg</i> | 1 | |
| <i>cefadroxil oral suspension reconstituted 250mg/5ml, 500mg/5ml</i> | 1 | |
| <i>cefadroxil oral tablet 1gm</i> | 1 | |
| <i>cefazolin sodium injection solution reconstituted 1gm, 10gm, 500mg</i> | 1 | |
| <i>cefdinir oral capsule 300mg</i> | 1 | |
| <i>cefdinir oral suspension reconstituted 125mg/5ml, 250mg/5ml</i> | 1 | |
| <i>cefepime hcl injection solution reconstituted 1gm, 2gm</i> | 1 | |
| <i>cefixime oral capsule 400mg</i> | 1 | |
| <i>cefixime oral suspension reconstituted 100mg/5ml, 200mg/5ml</i> | 1 | |
| <i>cefotetan disodium injection solution reconstituted 1gm, 2gm</i> | 1 | BvD |
| <i>cefoxitin sodium intravenous solution reconstituted 1gm, 10gm, 2gm</i> | 1 | BvD |
| <i>cefpodoxime proxetil oral suspension reconstituted 100mg/5ml, 50mg/5ml</i> | 1 | |
| <i>cefpodoxime proxetil oral tablet 100mg, 200mg</i> | 1 | |
| <i>cefprozil oral suspension reconstituted 125mg/5ml, 250mg/5ml</i> | 1 | |
| <i>cefprozil oral tablet 250mg, 500mg</i> | 1 | |
| <i>ceftazidime injection solution reconstituted 1gm, 6gm</i> | 1 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| <i>ceftazidime intravenous solution reconstituted 2gm</i> | 1 | |
| <i>ceftriaxone sodium injection solution reconstituted 1gm, 2gm, 250mg, 500mg</i> | 1 | |
| <i>ceftriaxone sodium intravenous solution reconstituted 10gm</i> | 1 | |
| <i>cefuroxime axetil oral tablet 250mg, 500mg</i> | 1 | |
| <i>cefuroxime sodium injection solution reconstituted 750mg</i> | 1 | BvD |
| <i>cefuroxime sodium intravenous solution reconstituted 1.5gm</i> | 1 | BvD |
| <i>cephalexin oral capsule 250mg, 500mg</i> | 1 | |
| <i>cephalexin oral suspension reconstituted 125mg/5ml, 250mg/5ml</i> | 1 | |
| <i>cephalexin oral tablet 250mg, 500mg</i> | 1 | |
| TEFLARO INTRAVENOUS SOLUTION RECONSTITUTED 400MG, 600MG | 1 | BvD |
| Beta-Lactam, Penicillins | | |
| <i>amoxicillin oral capsule 250mg, 500mg</i> | 1 | |
| <i>amoxicillin oral suspension reconstituted 125mg/5ml, 200mg/5ml, 250mg/5ml, 400mg/5ml</i> | 1 | |
| <i>amoxicillin oral tablet 500mg, 875mg</i> | 1 | |
| <i>amoxicillin oral tablet chewable 125mg, 250mg</i> | 1 | |
| <i>amoxicillin-pot clavulanate er oral tablet extended release 12-hour 1000-62.5mg</i> | 1 | |
| <i>amoxicillin-pot clavulanate oral suspension reconstituted 200-28.5mg/5ml, 250-62.5mg/5ml, 400-57mg/5ml, 600-42.9mg/5ml</i> | 1 | |
| <i>amoxicillin-pot clavulanate oral tablet 250- 125mg, 500- 125mg, 875- 125mg</i> | 1 | |
| <i>amoxicillin-pot clavulanate oral tablet chewable 200-28.5mg, 400-57mg</i> | 1 | |
| <i>ampicillin oral capsule 500mg</i> | 1 | |
| <i>ampicillin sodium injection solution reconstituted 1gm, 125mg</i> | 1 | BvD |
| <i>ampicillin sodium intravenous solution reconstituted 10gm</i> | 1 | BvD |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| <i>ampicillin-sulbactam sodium injection solution reconstituted 1.5 (1-0.5) gm, 3 (2-1) gm</i> | 1 | |
| <i>ampicillin-sulbactam sodium intravenous solution reconstituted 15 (10-5) gm</i> | 1 | |
| BICILLIN L-A INTRAMUSCULAR SUSPENSION 2400000UNIT/4ML | 1 | |
| BICILLIN L-A INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 1200000UNIT/2ML, 600000UNIT/ML | 1 | |
| <i>dicloxacillin sodium oral capsule 250mg, 500mg</i> | 1 | |
| <i>naftillin sodium injection solution reconstituted 1gm, 2gm</i> | 1 | BvD |
| <i>naftillin sodium intravenous solution reconstituted 10gm</i> | 1 | BvD |
| <i>oxacillin sodium in dextrose intravenous solution 1gm/50ml, 2gm/50ml</i> | 1 | BvD |
| <i>oxacillin sodium injection solution reconstituted 1gm, 2gm</i> | 1 | BvD |
| <i>oxacillin sodium intravenous solution reconstituted 10gm</i> | 1 | BvD |
| <i>penicillin g pot in dextrose intravenous solution 40000unit/ml, 60000unit/ml</i> | 1 | |
| <i>penicillin g potassium injection solution reconstituted 2000000unit</i> | 1 | BvD |
| <i>penicillin g procaine intramuscular suspension 600000unit/ml</i> | 1 | |
| <i>penicillin g sodium injection solution reconstituted 5000000unit</i> | 1 | BvD |
| <i>penicillin v potassium oral solution reconstituted 125mg/5ml, 250mg/5ml</i> | 1 | |
| <i>penicillin v potassium oral tablet 250mg, 500mg</i> | 1 | |
| <i>piperacillin sod-tazobactam so intravenous solution reconstituted 2.25 (2-0.25) gm, 3.375 (3-0.375) gm, 4.5 (4-0.5) gm</i> | 1 | |
| Carbapenems | | |
| <i>ertapenem sodium injection solution reconstituted 1gm</i> | 1 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------|
| <i>imipenem-cilastatin intravenous solution reconstituted 250mg, 500mg</i> | 1 | |
| <i>meropenem intravenous solution reconstituted 1gm, 500mg</i> | 1 | |
| Macrolides | | |
| <i>azithromycin intravenous solution reconstituted 500mg</i> | 1 | BvD |
| <i>azithromycin oral packet 1gm</i> | 1 | |
| <i>azithromycin oral suspension reconstituted 100mg/5ml, 200mg/5ml</i> | 1 | |
| <i>azithromycin oral tablet 250mg, 250mg (6 pack), 500mg, 500mg (3 pack), 600mg</i> | 1 | |
| <i>clarithromycin er oral tablet extended release 24-hour 500mg</i> | 1 | |
| <i>clarithromycin oral suspension reconstituted 125mg/5ml, 250mg/5ml</i> | 1 | |
| <i>clarithromycin oral tablet 250mg, 500mg</i> | 1 | |
| DIFICID ORAL SUSPENSION RECONSTITUTED 40MG/ML | 1 | PA; QL (136ML per 10 days) |
| DIFICID ORAL TABLET 200MG | 1 | PA; QL (20 EA per 10 days) |
| ERYTHROCIN LACTOBIONATE INTRAVENOUS SOLUTION RECONSTITUTED 500MG | 1 | BvD |
| <i>erythromycin base oral capsule delayed release particles 250mg</i> | 1 | |
| <i>erythromycin base oral tablet 250mg, 500mg</i> | 1 | |
| <i>erythromycin ethylsuccinate oral suspension reconstituted 200mg/5ml, 400mg/5ml</i> | 1 | |
| <i>erythromycin ethylsuccinate oral tablet 400mg</i> | 1 | |
| <i>erythromycin oral tablet delayed release 250mg, 333mg, 500mg</i> | 1 | |
| Quinolones | | |
| <i>ciprofloxacin hcl ophthalmic solution 0.3%</i> | 1 | |
| <i>ciprofloxacin hcl oral tablet 100mg, 250mg, 500mg, 750mg</i> | 1 | |
| <i>ciprofloxacin in d5w intravenous solution 200mg/100ml</i> | 1 | BvD |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------|
| <i>levofloxacin in d5w intravenous solution 500mg/100ml, 750mg/150ml</i> | 1 | |
| <i>levofloxacin intravenous solution 25mg/ml</i> | 1 | |
| <i>levofloxacin oral solution 25mg/ml</i> | 1 | |
| <i>levofloxacin oral tablet 250mg, 500mg, 750mg</i> | 1 | |
| <i>moxifloxacin hcl in nacl intravenous solution 400mg/250ml</i> | 1 | BvD |
| <i>moxifloxacin hcl oral tablet 400mg</i> | 1 | |
| <i>ofloxacin oral tablet 300mg, 400mg</i> | 1 | |
| Sulfonamides | | |
| <i>sulfacetamide sodium (acne) external lotion 10%</i> | 1 | |
| <i>sulfadiazine oral tablet 500mg</i> | 1 | |
| <i>sulfamethoxazole-trimethoprim oral suspension 200-40mg/5ml</i> | 1 | |
| <i>sulfamethoxazole-trimethoprim oral tablet 400-80mg, 800-160mg</i> | 1 | |
| Tetracyclines | | |
| DOXY 100 INTRAVENOUS SOLUTION RECONSTITUTED 100MG | 1 | BvD |
| <i>doxycycline hyclate oral capsule 100mg, 50mg</i> | 1 | |
| <i>doxycycline hyclate oral tablet 100mg, 20mg</i> | 1 | |
| <i>doxycycline monohydrate oral capsule 100mg, 50mg</i> | 1 | |
| <i>doxycycline monohydrate oral tablet 100mg, 50mg, 75mg</i> | 1 | |
| <i>minocycline hcl oral capsule 100mg, 50mg, 75mg</i> | 1 | |
| <i>minocycline hcl oral tablet 100mg, 50mg, 75mg</i> | 1 | |
| <i>tetracycline hcl oral capsule 250mg, 500mg</i> | 1 | |
| ANTICONVULSANTS | | |
| Anticonvulsants, Other | | |
| BRIVIACT ORAL SOLUTION 10MG/ML | 1 | MO; QL (600ML per 30 days) |
| BRIVIACT ORAL TABLET 10MG, 100MG, 25MG, 50MG, 75MG | 1 | MO; QL (60 EA per 30 days) |
| DIACOMIT ORAL CAPSULE 250MG, 500MG | 1 | PA; MO |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--------------------------------|
| DIACOMIT ORAL PACKET 250MG, 500MG | 1 | PA; MO |
| EPIDIOLEX ORAL SOLUTION 100MG/ML | 1 | PA; MO |
| <i>felbamate oral suspension 600mg/5ml</i> | 1 | |
| <i>felbamate oral tablet 400mg, 600mg</i> | 1 | MO |
| FINTEPLA ORAL SOLUTION 2.2MG/ML | 1 | PA; MO |
| FYCOMPA ORAL SUSPENSION 0.5MG/ML | 1 | ST; MO; QL (720ML per 30 days) |
| FYCOMPA ORAL TABLET 10MG, 12MG, 4MG, 6MG | 1 | ST; QL (30 EA per 30 days) |
| FYCOMPA ORAL TABLET 2MG, 8MG | 1 | ST; MO; QL (30 EA per 30 days) |
| <i>lamotrigine er oral tablet extended release 24-hour 100mg, 200mg, 25mg, 250mg, 300mg, 50mg</i> | 1 | MO |
| <i>lamotrigine oral kit 25 & 50 & 100mg</i> | 1 | |
| <i>lamotrigine oral tablet 100mg, 150mg, 200mg, 25mg</i> | 1 | MO |
| <i>lamotrigine oral tablet chewable 25mg, 5mg</i> | 1 | MO |
| <i>lamotrigine oral tablet dispersible 100mg, 200mg, 25mg, 50mg</i> | 1 | MO |
| <i>lamotrigine starter kit-blue oral kit 35 x 25mg</i> | 1 | |
| <i>lamotrigine starter kit-green oral kit 84 x 25mg & 14x100mg</i> | 1 | |
| <i>lamotrigine starter kit-orange oral kit 42 x 25mg & 7 x 100mg</i> | 1 | |
| <i>levetiracetam er oral tablet extended release 24-hour 500mg, 750mg</i> | 1 | MO |
| <i>levetiracetam oral solution 100mg/ml</i> | 1 | MO |
| <i>levetiracetam oral tablet 1000mg, 250mg, 500mg, 750mg</i> | 1 | MO |
| <i>phenobarbital oral elixir 20mg/5ml</i> | 1 | MO; QL (1500ML per 30 days) |
| <i>phenobarbital oral tablet 100mg, 16.2mg, 32.4mg, 64.8mg, 97.2mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>phenobarbital oral tablet 15mg, 60mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>phenobarbital oral tablet 30mg</i> | 1 | MO; QL (300 EA per 30 days) |
| <i>primidone oral tablet 250mg, 50mg</i> | 1 | MO |
| SPRITAM ORAL TABLET DISINTEGRATING SOLUBLE 1000MG | 1 | ST; MO; QL (90 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------------|
| SPRITAM ORAL TABLET DISINTEGRATING SOLUBLE 250MG, 500MG, 750MG | 1 | ST; MO; QL (120 EA per 30 days) |
| <i>valproic acid oral capsule 250mg</i> | 1 | MO |
| <i>valproic acid oral solution 250mg/5ml</i> | 1 | MO |
| XCOPRI (250MG DAILY DOSE) ORAL TABLET THERAPY PACK 100 & 150MG | 1 | MO; QL (56 EA per 28 days) |
| XCOPRI (350MG DAILY DOSE) ORAL TABLET THERAPY PACK 150 & 200MG | 1 | MO; QL (56 EA per 28 days) |
| XCOPRI ORAL TABLET 100MG, 150MG, 200MG, 50MG | 1 | MO; QL (60 EA per 30 days) |
| XCOPRI ORAL TABLET THERAPY PACK 14 X 12.5MG & 14 X 25MG, 14 X 150MG & 14 X200MG, 14 X 50MG & 14 X100MG | 1 | QL (28 EA per 28 days) |
| Calcium Channel Modifying Agents | | |
| CELONTIN ORAL CAPSULE 300MG | 1 | ST; MO |
| <i>ethosuximide oral capsule 250mg</i> | 1 | MO |
| <i>ethosuximide oral solution 250mg/5ml</i> | 1 | MO |
| ZONISADE ORAL SUSPENSION 100MG/5ML | 1 | MO; QL (900ML per 30 days) |
| <i>zonisamide oral capsule 100mg, 25mg, 50mg</i> | 1 | MO |
| Gamma-Aminobutyric Acid (GABA) Augmenting Agents | | |
| <i>clobazam oral suspension 2.5mg/ml</i> | 1 | MO; QL (480ML per 30 days) |
| <i>clobazam oral tablet 10mg, 20mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>diazepam rectal gel 10mg, 2.5mg, 20mg</i> | 1 | |
| <i>gabapentin oral capsule 100mg, 300mg, 400mg</i> | 1 | MO; QL (270 EA per 30 days) |
| <i>gabapentin oral solution 250mg/5ml</i> | 1 | MO |
| <i>gabapentin oral tablet 600mg, 800mg</i> | 1 | MO; QL (180 EA per 30 days) |
| NAYZILAM NASAL SOLUTION 5MG/0.1ML | 1 | |
| SYMPAZAN ORAL FILM 10MG, 20MG | 1 | ST; QL (60 EA per 30 days) |
| SYMPAZAN ORAL FILM 5MG | 1 | ST; MO; QL (60 EA per 30 days) |
| <i>tiagabine hcl oral tablet 12mg, 16mg, 2mg, 4mg</i> | 1 | MO |
| VALTOCO 10MG DOSE NASAL LIQUID 10MG/0.1ML | 1 | ST |
| VALTOCO 15MG DOSE NASAL LIQUID THERAPY PACK 7.5MG/0.1ML | 1 | ST |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------|
| VALTOCO 20MG DOSE NASAL LIQUID THERAPY PACK 10MG/0.1ML | 1 | ST |
| VALTOCO 5MG DOSE NASAL LIQUID 5MG/0.1ML | 1 | ST |
| <i>vigabatrin oral packet 500mg</i> | 1 | PA; QL (180 EA per 30 days) |
| <i>vigabatrin oral tablet 500mg</i> | 1 | PA; QL (180 EA per 30 days) |
| Sodium Channel Agents | | |
| APTIOM ORAL TABLET 200MG, 400MG, 800MG | 1 | ST; QL (30 EA per 30 days) |
| APTIOM ORAL TABLET 600MG | 1 | ST; QL (60 EA per 30 days) |
| <i>carbamazepine er oral capsule extended release 12-hour 100mg, 200mg, 300mg</i> | 1 | MO |
| <i>carbamazepine er oral tablet extended release 12-hour 100mg, 200mg, 400mg</i> | 1 | MO |
| <i>carbamazepine oral suspension 100mg/5ml</i> | 1 | MO |
| <i>carbamazepine oral tablet 200mg</i> | 1 | MO |
| <i>carbamazepine oral tablet chewable 100mg</i> | 1 | MO |
| DILANTIN ORAL CAPSULE 30MG | 1 | ST; MO |
| EPITOL ORAL TABLET 200MG | 1 | MO |
| <i>lacosamide oral solution 10mg/ml</i> | 1 | MO; QL (1395ML per 30 days) |
| <i>lacosamide oral tablet 100mg, 150mg, 200mg, 50mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>oxcarbazepine oral suspension 300mg/5ml</i> | 1 | MO |
| <i>oxcarbazepine oral tablet 150mg, 300mg, 600mg</i> | 1 | MO |
| <i>phenytoin oral suspension 125mg/5ml</i> | 1 | MO |
| <i>phenytoin oral tablet chewable 50mg</i> | 1 | MO |
| <i>phenytoin sodium extended oral capsule 100mg, 200mg, 300mg</i> | 1 | MO |
| <i>rufinamide oral suspension 40mg/ml</i> | 1 | QL (2760ML per 30 days) |
| <i>rufinamide oral tablet 200mg</i> | 1 | MO; QL (480 EA per 30 days) |
| <i>rufinamide oral tablet 400mg</i> | 1 | QL (240 EA per 30 days) |
| ANTIDEMENTIA AGENTS | | |
| Antidementia Agents, Other | | |
| <i>memantine hcl er oral capsule extended release 24-hour 14mg, 21mg, 28mg, 7mg</i> | 1 | MO; QL (30 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|--------------------------------|
| <i>memantine hcl oral solution 2mg/ml</i> | 1 | MO; QL (360ML per 30 days) |
| <i>memantine hcl oral tablet 10mg, 5mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>memantine hcl oral tablet 28 x 5mg & 21 x 10mg</i> | 1 | QL (49 EA per 28 days) |
| NAMZARIC ORAL CAPSULE ER 24-HOUR THERAPY PACK 7 & 14 & 21 & 28 -10MG | 1 | PA |
| NAMZARIC ORAL CAPSULE EXTENDED RELEASE 24-HOUR 14-10MG, 21-10MG, 28-10MG, 7-10MG | 1 | PA; MO |
| Cholinesterase Inhibitors | | |
| <i>donepezil hcl oral tablet 10mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>donepezil hcl oral tablet 23mg, 5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>donepezil hcl oral tablet dispersible 10mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>donepezil hcl oral tablet dispersible 5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>galantamine hydrobromide er oral capsule extended release 24-hour 16mg, 24mg, 8mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>galantamine hydrobromide oral solution 4mg/ml</i> | 1 | MO; QL (200ML per 30 days) |
| <i>galantamine hydrobromide oral tablet 12mg, 4mg, 8mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>rivastigmine tartrate oral capsule 1.5mg, 3mg, 4.5mg, 6mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>rivastigmine transdermal patch 24-hour 13.3mg/24hr, 4.6mg/24hr, 9.5mg/24hr</i> | 1 | MO; QL (30 EA per 30 days) |
| ANTIDEPRESSANTS | | |
| Antidepressants, Other | | |
| AUVELITY ORAL TABLET EXTENDED RELEASE 45-105MG | 1 | ST; MO; QL (60 EA per 30 days) |
| <i>bupropion hcl er (sr) oral tablet extended release 12-hour 100mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>bupropion hcl er (sr) oral tablet extended release 12-hour 150mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>bupropion hcl er (sr) oral tablet extended release 12-hour 200mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>bupropion hcl er (xl) oral tablet extended release 24-hour 150mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>bupropion hcl er (xl) oral tablet extended release 24-hour 300mg</i> | 1 | MO; QL (90 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---------------------------------|
| <i>bupropion hcl er (xl) oral tablet extended release 24-hour 450mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>bupropion hcl oral tablet 100mg</i> | 1 | MO; QL (180 EA per 30 days) |
| <i>bupropion hcl oral tablet 75mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>mirtazapine oral tablet 15mg, 30mg, 45mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>mirtazapine oral tablet 7.5mg</i> | 1 | MO; QL (45 EA per 30 days) |
| <i>mirtazapine oral tablet dispersible 15mg, 30mg, 45mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>olanzapine-fluoxetine hcl oral capsule 12-25mg, 12-50mg, 6-50mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>olanzapine-fluoxetine hcl oral capsule 3-25mg, 6-25mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>Monoamine Oxidase Inhibitors</i> | | |
| <i>EMSAM TRANSDERMAL PATCH 24-HOUR 12MG/24HR, 6MG/24HR, 9MG/24HR</i> | 1 | ST; QL (30 EA per 30 days) |
| <i>MARPLAN ORAL TABLET 10MG</i> | 1 | ST; MO; QL (180 EA per 30 days) |
| <i>phenelzine sulfate oral tablet 15mg</i> | 1 | MO |
| <i>tranylcypromine sulfate oral tablet 10mg</i> | 1 | MO |
| <i>SSRIS/SNRIS (Selective Serotonin Reuptake Inhibitor/Serotonin and Norepinephrine Reuptake Inhibitor)</i> | | |
| <i>citalopram hydrobromide oral capsule 30mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>citalopram hydrobromide oral solution 10mg/5ml</i> | 1 | MO; QL (600ML per 30 days) |
| <i>citalopram hydrobromide oral tablet 10mg, 40mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>citalopram hydrobromide oral tablet 20mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>desvenlafaxine er oral tablet extended release 24-hour 100mg, 50mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>desvenlafaxine succinate er oral tablet extended release 24-hour 100mg, 25mg, 50mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>DRIZALMA SPRINKLE ORAL CAPSULE DELAYED RELEASE SPRINKLE 20MG, 30MG, 40MG, 60MG</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>duloxetine hcl oral capsule delayed release particles 20mg, 30mg, 40mg, 60mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>escitalopram oxalate oral solution 5mg/5ml</i> | 1 | MO; QL (600ML per 30 days) |
| <i>escitalopram oxalate oral tablet 10mg</i> | 1 | MO; QL (45 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------|
| <i>escitalopram oxalate oral tablet 20mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>escitalopram oxalate oral tablet 5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| FETZIMA ORAL CAPSULE EXTENDED RELEASE 24-HOUR 120MG, 20MG, 40MG, 80MG | 1 | MO; QL (30 EA per 30 days) |
| FETZIMA TITRATION ORAL CAPSULE ER 24-HOUR THERAPY PACK 20 & 40MG | 1 | QL (28 EA per 28 days) |
| <i>fluoxetine hcl oral capsule 10mg, 20mg, 40mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>fluoxetine hcl oral solution 20mg/5ml</i> | 1 | MO; QL (600ML per 30 days) |
| <i>fluoxetine hcl oral tablet 10mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>fluoxetine hcl oral tablet 20mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>fluvoxamine maleate oral tablet 100mg, 25mg, 50mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>nefazodone hcl oral tablet 100mg, 150mg, 200mg, 250mg, 50mg</i> | 1 | MO |
| <i>paroxetine hcl oral suspension 10mg/5ml</i> | 1 | MO; QL (900ML per 30 days) |
| <i>paroxetine hcl oral tablet 10mg, 20mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>paroxetine hcl oral tablet 30mg, 40mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>sertraline hcl oral capsule 150mg, 200mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>sertraline hcl oral concentrate 20mg/ml</i> | 1 | MO; QL (300ML per 30 days) |
| <i>sertraline hcl oral tablet 100mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>sertraline hcl oral tablet 25mg, 50mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>trazodone hcl oral tablet 100mg, 150mg, 300mg, 50mg</i> | 1 | MO |
| TRINTELLIX ORAL TABLET 10MG, 20MG, 5MG | 1 | ST; MO; QL (30 EA per 30 days) |
| <i>venlafaxine besylate er oral tablet extended release 24-hour 112.5mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>venlafaxine hcl er oral capsule extended release 24-hour 150mg, 37.5mg, 75mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>venlafaxine hcl er oral tablet extended release 24-hour 150mg, 225mg, 37.5mg, 75mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>venlafaxine hcl oral tablet 100mg, 25mg, 37.5mg, 50mg, 75mg</i> | 1 | MO; QL (90 EA per 30 days) |
| VIIBRYD STARTER PACK ORAL KIT 10 & 20MG | 1 | QL (30 EA per 30 days) |
| <i>vilazodone hcl oral tablet 10mg, 20mg, 40mg</i> | 1 | MO; QL (30 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| Tricyclics | | |
| <i>amitriptyline hcl oral tablet 10mg, 100mg, 150mg, 25mg, 50mg, 75mg</i> | 1 | MO |
| <i>amoxapine oral tablet 100mg, 150mg, 25mg, 50mg</i> | 1 | MO |
| <i>clomipramine hcl oral capsule 25mg, 50mg, 75mg</i> | 1 | MO |
| <i>desipramine hcl oral tablet 10mg, 100mg, 150mg, 25mg, 50mg, 75mg</i> | 1 | MO |
| <i>doxepin hcl oral capsule 10mg, 100mg, 150mg, 25mg, 50mg, 75mg</i> | 1 | MO |
| <i>doxepin hcl oral concentrate 10mg/ml</i> | 1 | MO |
| <i>imipramine hcl oral tablet 10mg, 25mg, 50mg</i> | 1 | MO |
| <i>nortriptyline hcl oral capsule 10mg, 25mg, 50mg, 75mg</i> | 1 | MO |
| <i>nortriptyline hcl oral solution 10mg/5ml</i> | 1 | MO |
| <i>protriptyline hcl oral tablet 10mg, 5mg</i> | 1 | MO |
| <i>trimipramine maleate oral capsule 100mg, 25mg, 50mg</i> | 1 | MO |

ANTIEMETICS

Antiemetics, Other

| | | |
|---|---|---------|
| <i>meclizine hcl oral tablet 12.5mg, 25mg</i> | 1 | |
| <i>prochlorperazine maleate oral tablet 10mg, 5mg</i> | 1 | BvD; MO |
| <i>prochlorperazine rectal suppository 25mg</i> | 1 | |
| <i>promethazine hcl oral syrup 6.25mg/5ml</i> | 1 | |
| <i>promethazine hcl oral tablet 12.5mg, 25mg, 50mg</i> | 1 | |
| <i>promethazine hcl rectal suppository 12.5mg, 25mg</i> | 1 | |
| <i>scopolamine transdermal patch 72-hour 1mg/3days</i> | 1 | |

Emetogenic Therapy Adjuncts

| | | |
|--|---|-----------------------------|
| <i>aprepitant oral capsule 125mg, 40mg, 80mg</i> | 1 | BvD; QL (30 EA per 30 days) |
| <i>aprepitant oral capsule 80 & 125mg</i> | 1 | BvD; QL (12 EA per 30 days) |
| <i>dronabinol oral capsule 10mg, 2.5mg, 5mg</i> | 1 | PA; QL (60 EA per 30 days) |
| <i>granisetron hcl oral tablet 1mg</i> | 1 | BvD; QL (60 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| <i>ondansetron hcl oral solution 4mg/5ml</i> | 1 | BvD |
| <i>ondansetron hcl oral tablet 4mg, 8mg</i> | 1 | BvD |
| <i>ondansetron oral tablet dispersible 4mg, 8mg</i> | 1 | BvD |
| VARUBI (180MG DOSE) ORAL TABLET THERAPY PACK 2 X 90MG | 1 | BvD |

ANTIFUNGALS

Antifungals

| | | |
|---|---|-----|
| ABELCET INTRAVENOUS SUSPENSION 5MG/ML | 1 | BvD |
| AMBISOME INTRAVENOUS SUSPENSION RECONSTITUTED 50MG | 1 | BvD |
| <i>amphotericin b intravenous solution reconstituted 50mg</i> | 1 | BvD |
| <i>caspofungin acetate intravenous solution reconstituted 50mg, 70mg</i> | 1 | |
| <i>ciclopirox olamine external cream 0.77%</i> | 1 | |
| <i>ciclopirox olamine external suspension 0.77%</i> | 1 | |
| <i>clotrimazole external cream 1%</i> | 1 | |
| <i>clotrimazole external solution 1%</i> | 1 | |
| <i>clotrimazole mouth/throat troche 10mg</i> | 1 | |
| <i>econazole nitrate external cream 1%</i> | 1 | |
| ERAXIS INTRAVENOUS SOLUTION RECONSTITUTED 100MG, 50MG | 1 | BvD |
| <i>fluconazole in sodium chloride intravenous solution 200-0.9mg/100ml-%, 400-0.9mg/200ml-%</i> | 1 | BvD |
| <i>fluconazole oral suspension reconstituted 10mg/ml, 40mg/ml</i> | 1 | |
| <i>fluconazole oral tablet 100mg, 150mg, 200mg, 50mg</i> | 1 | |
| <i>flucytosine oral capsule 250mg, 500mg</i> | 1 | |
| <i>griseofulvin microsize oral suspension 125mg/5ml</i> | 1 | |
| <i>griseofulvin microsize oral tablet 500mg</i> | 1 | |
| <i>griseofulvin ultramicrosize oral tablet 125mg, 250mg</i> | 1 | |
| <i>itraconazole oral capsule 100mg</i> | 1 | PA |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| <i>itraconazole oral solution 10mg/ml</i> | 1 | PA |
| JUBLIA EXTERNAL SOLUTION 10% | 1 | |
| <i>ketoconazole external cream 2%</i> | 1 | |
| <i>ketoconazole external shampoo 2%</i> | 1 | |
| <i>ketoconazole oral tablet 200mg</i> | 1 | |
| NOXAFIL ORAL PACKET 300MG | 1 | PA |
| NOXAFIL ORAL SUSPENSION 40MG/ML | 1 | PA |
| NYAMYC EXTERNAL POWDER 100000UNIT/GM | 1 | |
| <i>nystatin external cream 100000unit/gm</i> | 1 | |
| <i>nystatin external ointment 100000unit/gm</i> | 1 | |
| <i>nystatin external powder 100000unit/gm</i> | 1 | |
| <i>nystatin mouth/throat suspension 100000unit/ml</i> | 1 | |
| <i>nystatin oral tablet 500000unit</i> | 1 | |
| NYSTOP EXTERNAL POWDER 100000UNIT/GM | 1 | |
| <i>posaconazole oral tablet delayed release 100mg</i> | 1 | PA; MO |
| <i>terbinafine hcl oral tablet 250mg</i> | 1 | |
| <i>terconazole vaginal cream 0.4%, 0.8%</i> | 1 | |
| <i>terconazole vaginal suppository 80mg</i> | 1 | |
| <i>voriconazole intravenous solution reconstituted 200mg</i> | 1 | PA |
| <i>voriconazole oral suspension reconstituted 40mg/ml</i> | 1 | PA |
| <i>voriconazole oral tablet 200mg, 50mg</i> | 1 | PA |

ANTIGOUT AGENTS

Antigout Agents

| | | |
|--|---|--------|
| <i>allopurinol oral tablet 100mg, 300mg</i> | 1 | MO |
| <i>colchicine oral capsule 0.6mg</i> | 1 | |
| <i>colchicine oral tablet 0.6mg</i> | 1 | |
| <i>colchicine-probenecid oral tablet 0.5-500mg</i> | 1 | MO |
| <i>febuxostat oral tablet 40mg, 80mg</i> | 1 | PA; MO |
| <i>probenecid oral tablet 500mg</i> | 1 | MO |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------|
| ANTIMIGRAINE AGENTS | | |
| <i>Ergot Alkaloids</i> | | |
| <i>dihydroergotamine mesylate nasal solution 4mg/ml</i> | 1 | |
| <i>ergotamine-caffeine oral tablet 1-100mg</i> | 1 | QL (40 EA per 28 days) |
| <i>Prophylactic</i> | | |
| EMGALITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR 120MG/ML | 1 | PA; MO |
| EMGALITY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 120MG/ML | 1 | PA; MO |
| EPRONTIA ORAL SOLUTION 25MG/ML | 1 | MO |
| <i>propranolol hcl er oral capsule extended release 24-hour 80mg</i> | 1 | MO |
| <i>propranolol hcl oral tablet 80mg</i> | 1 | MO |
| <i>topiramate er oral capsule er 24-hour sprinkle 100mg, 150mg, 200mg, 25mg, 50mg</i> | 1 | MO |
| <i>topiramate oral capsule sprinkle 15mg, 25mg</i> | 1 | MO |
| <i>topiramate oral tablet 100mg, 200mg, 25mg, 50mg</i> | 1 | MO |
| UBRELVY ORAL TABLET 100MG, 50MG | 1 | PA; QL (16 EA per 30 days) |
| <i>Serotonin (5-HT) Receptor Agonist</i> | | |
| <i>naratriptan hcl oral tablet 1mg, 2.5mg</i> | 1 | QL (9 EA per 30 days) |
| <i>rizatriptan benzoate oral tablet 10mg, 5mg</i> | 1 | QL (12 EA per 30 days) |
| <i>rizatriptan benzoate oral tablet dispersible 10mg, 5mg</i> | 1 | QL (12 EA per 30 days) |
| <i>sumatriptan nasal solution 20mg/act</i> | 1 | QL (12 EA per 30 days) |
| <i>sumatriptan nasal solution 5mg/act</i> | 1 | QL (18 EA per 30 days) |
| <i>sumatriptan succinate oral tablet 100mg, 25mg, 50mg</i> | 1 | QL (9 EA per 30 days) |
| <i>sumatriptan succinate refill subcutaneous solution cartridge 4mg/0.5ml, 6mg/0.5ml</i> | 1 | QL (4ML per 30 days) |
| <i>sumatriptan succinate subcutaneous solution 6mg/0.5ml</i> | 1 | QL (4ML per 30 days) |
| <i>sumatriptan succinate subcutaneous solution auto-injector 4mg/0.5ml, 6mg/0.5ml</i> | 1 | QL (4ML per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------|
| zolmitriptan oral tablet 2.5mg, 5mg | 1 | QL (6 EA per 30 days) |
| zolmitriptan oral tablet dispersible 2.5mg, 5mg | 1 | QL (6 EA per 30 days) |
| ANTIMYASTHENIC AGENTS | | |
| Parasympathomimetics | | |
| pyridostigmine bromide oral solution 60mg/5ml | 1 | |
| pyridostigmine bromide oral tablet 30mg, 60mg | 1 | |
| ANTIMYCOBACTERIALS | | |
| Antimycobacterials, Other | | |
| dapsone oral tablet 100mg, 25mg | 1 | MO |
| PRIFTIN ORAL TABLET 150MG | 1 | |
| rifabutin oral capsule 150mg | 1 | |
| Antituberculars | | |
| ethambutol hcl oral tablet 100mg, 400mg | 1 | |
| isoniazid oral syrup 50mg/5ml | 1 | MO |
| isoniazid oral tablet 100mg, 300mg | 1 | MO |
| pyrazinamide oral tablet 500mg | 1 | |
| rifampin intravenous solution reconstituted 600mg | 1 | |
| rifampin oral capsule 150mg, 300mg | 1 | |
| SIRTURO ORAL TABLET 100MG, 20MG | 1 | PA |
| TRECTOR ORAL TABLET 250MG | 1 | |
| ANTINEOPLASTICS | | |
| Alkylating Agents | | |
| cyclophosphamide oral capsule 25mg, 50mg | 1 | BvD |
| cyclophosphamide oral tablet 25mg, 50mg | 1 | BvD |
| GLEOSTINE ORAL CAPSULE 10MG, 100MG, 40MG | 1 | PA |
| LEUKERAN ORAL TABLET 2MG | 1 | |
| MATULANE ORAL CAPSULE 50MG | 1 | PA |
| VALCHLOR EXTERNAL GEL 0.016% | 1 | PA; QL (60GM per 14 days) |
| Antiandrogens | | |
| abiraterone acetate oral tablet 250mg, 500mg | 1 | PA; QL (120 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------|
| <i>bicalutamide oral tablet 50mg</i> | 1 | |
| ERLEADA ORAL TABLET 60MG | 1 | PA; QL (120 EA per 30 days) |
| LYSODREN ORAL TABLET 500MG | 1 | |
| <i>nilutamide oral tablet 150mg</i> | 1 | QL (60 EA per 30 days) |
| NUBEQA ORAL TABLET 300MG | 1 | PA; QL (120 EA per 30 days) |
| XTANDI ORAL CAPSULE 40MG | 1 | PA; QL (120 EA per 30 days) |
| XTANDI ORAL TABLET 40MG | 1 | PA; QL (120 EA per 30 days) |
| XTANDI ORAL TABLET 80MG | 1 | PA; QL (90 EA per 30 days) |
| YONSA ORAL TABLET 125MG | 1 | PA; QL (120 EA per 30 days) |
| Antiangiogenic Agents | | |
| <i>lenalidomide oral capsule 10mg, 15mg, 2.5mg, 20mg, 25mg, 5mg</i> | 1 | PA; QL (28 EA per 28 days) |
| POMALYST ORAL CAPSULE 1MG, 2MG, 3MG, 4MG | 1 | PA; QL (21 EA per 28 days) |
| THALOMID ORAL CAPSULE 100MG, 200MG, 50MG | 1 | PA; QL (30 EA per 30 days) |
| THALOMID ORAL CAPSULE 150MG | 1 | PA; QL (60 EA per 30 days) |
| Antiestrogens/Modifiers | | |
| EMCYT ORAL CAPSULE 140MG | 1 | |
| SOLTAMOX ORAL SOLUTION 10MG/5ML | 1 | PA; MO |
| <i>tamoxifen citrate oral tablet 10mg, 20mg</i> | 1 | MO |
| <i>toremifene citrate oral tablet 60mg</i> | 1 | PA |
| Antimetabolites | | |
| DROXIA ORAL CAPSULE 200MG, 300MG, 400MG | 1 | MO |
| <i>hydroxyurea oral capsule 500mg</i> | 1 | |
| INQOVI ORAL TABLET 35-100MG | 1 | PA |
| <i>mercaptopurine oral tablet 50mg</i> | 1 | |
| ONUREG ORAL TABLET 200MG, 300MG | 1 | PA |
| PURIXAN ORAL SUSPENSION 2000MG/100ML | 1 | |
| TABLOID ORAL TABLET 40MG | 1 | PA |
| Antineoplastics, Other | | |
| IDHIFA ORAL TABLET 100MG | 1 | PA; QL (30 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------|
| IDHIFA ORAL TABLET 50MG | 1 | PA; QL (60 EA per 30 days) |
| KISQALI FEMARA (400MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5MG | 1 | PA |
| KISQALI FEMARA (600MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5MG | 1 | PA |
| KISQALI FEMARA(200MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5MG | 1 | PA |
| <i>leucovorin calcium oral tablet 10mg, 15mg, 25mg, 5mg</i> | 1 | |
| LONSURF ORAL TABLET 15-6.14MG, 20-8.19MG | 1 | PA |
| LUMAKRAS ORAL TABLET 120MG | 1 | PA; QL (240 EA per 30 days) |
| LYNPARZA ORAL TABLET 100MG | 1 | PA; QL (180 EA per 30 days) |
| LYNPARZA ORAL TABLET 150MG | 1 | PA; QL (120 EA per 30 days) |
| MESNEX ORAL TABLET 400MG | 1 | |
| NINLARO ORAL CAPSULE 2.3MG, 3MG, 4MG | 1 | PA |
| ORGOVYX ORAL TABLET 120MG | 1 | PA; QL (60 EA per 30 days) |
| SYNRIBO SUBCUTANEOUS SOLUTION RECONSTITUTED 3.5MG | 1 | PA |
| VIJOICE ORAL TABLET THERAPY PACK 125MG, 200 & 50MG, 50MG | 1 | PA |
| WELIREG ORAL TABLET 40MG | 1 | PA; QL (90 EA per 30 days) |
| XATMEP ORAL SOLUTION 2.5MG/ML | 1 | BvD |
| XPOVIO (100MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50MG | 1 | PA |
| XPOVIO (40MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40MG | 1 | PA |
| XPOVIO (40MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40MG | 1 | PA |
| XPOVIO (60MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60MG | 1 | PA |
| XPOVIO (60MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20MG | 1 | PA |
| XPOVIO (80MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40MG | 1 | PA |
| XPOVIO (80MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20MG | 1 | PA |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------|
| ZOLINZA ORAL CAPSULE 100MG | 1 | PA; QL (120 EA per 30 days) |
| <i>Aromatase Inhibitors, 3rd Generation</i> | | |
| <i>anastrozole oral tablet 1mg</i> | 1 | MO |
| <i>exemestane oral tablet 25mg</i> | 1 | MO |
| <i>letrozole oral tablet 2.5mg</i> | 1 | MO |
| <i>Molecular Target Inhibitors</i> | | |
| ALECENSA ORAL CAPSULE 150MG | 1 | PA |
| ALUNBRIG ORAL TABLET 180MG | 1 | PA; QL (30 EA per 30 days) |
| ALUNBRIG ORAL TABLET 30MG | 1 | PA; QL (180 EA per 30 days) |
| ALUNBRIG ORAL TABLET 90MG | 1 | PA; QL (60 EA per 30 days) |
| ALUNBRIG ORAL TABLET THERAPY PACK 90 & 180MG | 1 | PA; QL (30 EA per 30 days) |
| AYVAKIT ORAL TABLET 100MG, 200MG, 25MG, 300MG, 50MG | 1 | PA; QL (30 EA per 30 days) |
| BALVERSA ORAL TABLET 3MG | 1 | PA; QL (90 EA per 30 days) |
| BALVERSA ORAL TABLET 4MG | 1 | PA; QL (60 EA per 30 days) |
| BALVERSA ORAL TABLET 5MG | 1 | PA; QL (30 EA per 30 days) |
| BOSULIF ORAL TABLET 100MG | 1 | PA; QL (120 EA per 30 days) |
| BOSULIF ORAL TABLET 400MG, 500MG | 1 | PA; QL (30 EA per 30 days) |
| BRAFTOVI ORAL CAPSULE 75MG | 1 | PA; QL (180 EA per 30 days) |
| BRUKINSA ORAL CAPSULE 80MG | 1 | PA; QL (120 EA per 30 days) |
| CABOMETYX ORAL TABLET 20MG, 40MG, 60MG | 1 | PA |
| CALQUENCE ORAL CAPSULE 100MG | 1 | PA; QL (60 EA per 30 days) |
| CALQUENCE ORAL TABLET 100MG | 1 | PA; QL (60 EA per 30 days) |
| CAPRELSA ORAL TABLET 100MG | 1 | PA; QL (60 EA per 30 days) |
| CAPRELSA ORAL TABLET 300MG | 1 | PA; QL (30 EA per 30 days) |
| COMETRIQ (100MG DAILY DOSE) ORAL KIT 80 & 20MG | 1 | PA; QL (56 EA per 28 days) |
| COMETRIQ (140MG DAILY DOSE) ORAL KIT 3 X 20MG & 80MG | 1 | PA; QL (112 EA per 28 days) |
| COMETRIQ (60MG DAILY DOSE) ORAL KIT 20MG | 1 | PA; QL (84 EA per 28 days) |
| COPIKTRA ORAL CAPSULE 15MG, 25MG | 1 | PA; QL (60 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------|
| COTELLIC ORAL TABLET 20MG | 1 | PA; QL (63 EA per 28 days) |
| DAURISMO ORAL TABLET 100MG, 25MG | 1 | PA |
| ERIVEDGE ORAL CAPSULE 150MG | 1 | PA |
| <i>erlotinib hcl oral tablet 100mg, 150mg</i> | 1 | PA; QL (30 EA per 30 days) |
| <i>erlotinib hcl oral tablet 25mg</i> | 1 | PA; QL (90 EA per 30 days) |
| <i>everolimus oral tablet 10mg, 2.5mg, 5mg, 7.5mg</i> | 1 | PA; QL (30 EA per 30 days) |
| <i>everolimus oral tablet soluble 2mg, 3mg</i> | 1 | PA; QL (30 EA per 30 days) |
| <i>everolimus oral tablet soluble 5mg</i> | 1 | PA; QL (60 EA per 30 days) |
| EXKIVITY ORAL CAPSULE 40MG | 1 | PA |
| FOTIVDA ORAL CAPSULE 0.89MG, 1.34MG | 1 | PA; QL (21 EA per 28 days) |
| GAVRETO ORAL CAPSULE 100MG | 1 | PA; QL (120 EA per 30 days) |
| GILOTRIF ORAL TABLET 20MG, 30MG, 40MG | 1 | PA; QL (30 EA per 30 days) |
| IBRANCE ORAL CAPSULE 100MG, 125MG, 75MG | 1 | PA |
| IBRANCE ORAL TABLET 100MG, 125MG, 75MG | 1 | PA |
| ICLUSIG ORAL TABLET 10MG, 30MG, 45MG | 1 | PA; QL (30 EA per 30 days) |
| ICLUSIG ORAL TABLET 15MG | 1 | PA; QL (60 EA per 30 days) |
| <i>imatinib mesylate oral tablet 100mg</i> | 1 | PA; QL (90 EA per 30 days) |
| <i>imatinib mesylate oral tablet 400mg</i> | 1 | PA; QL (60 EA per 30 days) |
| IMBRUVICA ORAL CAPSULE 140MG | 1 | PA; QL (120 EA per 30 days) |
| IMBRUVICA ORAL CAPSULE 70MG | 1 | PA; QL (28 EA per 28 days) |
| IMBRUVICA ORAL SUSPENSION 70MG/ML | 1 | PA; QL (240ML per 30 days) |
| IMBRUVICA ORAL TABLET 140MG, 280MG, 420MG, 560MG | 1 | PA; QL (28 EA per 28 days) |
| INLYTA ORAL TABLET 1MG | 1 | PA; QL (180 EA per 30 days) |
| INLYTA ORAL TABLET 5MG | 1 | PA; QL (60 EA per 30 days) |
| INREBIC ORAL CAPSULE 100MG | 1 | PA; QL (120 EA per 30 days) |
| IRESSA ORAL TABLET 250MG | 1 | PA |
| JAKAFI ORAL TABLET 10MG, 15MG, 20MG, 25MG, 5MG | 1 | PA; QL (60 EA per 30 days) |
| KISQALI (200MG DOSE) ORAL TABLET THERAPY PACK 200MG | 1 | PA |
| KISQALI (400MG DOSE) ORAL TABLET THERAPY PACK 200MG | 1 | PA |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------|
| KISQALI (600MG DOSE) ORAL TABLET THERAPY PACK 200MG | 1 | PA |
| KOSELUGO ORAL CAPSULE 10MG | 1 | PA; QL (240 EA per 30 days) |
| KOSELUGO ORAL CAPSULE 25MG | 1 | PA; QL (120 EA per 30 days) |
| <i>lapatinib ditosylate oral tablet 250mg</i> | 1 | PA; QL (180 EA per 30 days) |
| LENVIMA (10MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10MG | 1 | PA |
| LENVIMA (12MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 3 X 4MG | 1 | PA |
| LENVIMA (14MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 & 4MG | 1 | PA |
| LENVIMA (18MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10MG & 2 X 4MG | 1 | PA |
| LENVIMA (20MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 10MG | 1 | PA |
| LENVIMA (24MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 10MG & 4MG | 1 | PA |
| LENVIMA (4MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 4MG | 1 | PA |
| LENVIMA (8MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 4MG | 1 | PA |
| LORBRENA ORAL TABLET 100MG | 1 | PA; QL (30 EA per 30 days) |
| LORBRENA ORAL TABLET 25MG | 1 | PA; QL (120 EA per 30 days) |
| MEKINIST ORAL TABLET 0.5MG | 1 | PA; QL (120 EA per 30 days) |
| MEKINIST ORAL TABLET 2MG | 1 | PA; QL (30 EA per 30 days) |
| MEKTOVI ORAL TABLET 15MG | 1 | PA; QL (180 EA per 30 days) |
| NERLYNX ORAL TABLET 40MG | 1 | PA; QL (180 EA per 30 days) |
| ODOMZO ORAL CAPSULE 200MG | 1 | PA |
| PEMAZYRE ORAL TABLET 13.5MG, 4.5MG, 9MG | 1 | PA; QL (14 EA per 21 days) |
| PIQRAY (200MG DAILY DOSE) ORAL TABLET THERAPY PACK 200MG | 1 | PA |
| PIQRAY (250MG DAILY DOSE) ORAL TABLET THERAPY PACK 200 & 50MG | 1 | PA |
| PIQRAY (300MG DAILY DOSE) ORAL TABLET THERAPY PACK 2 X 150MG | 1 | PA |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------|
| QINLOCK ORAL TABLET 50MG | 1 | PA; QL (90 EA per 30 days) |
| RETEVMO ORAL CAPSULE 40MG | 1 | PA; QL (120 EA per 30 days) |
| RETEVMO ORAL CAPSULE 80MG | 1 | PA; QL (180 EA per 30 days) |
| ROZLYTREK ORAL CAPSULE 100MG | 1 | PA; QL (150 EA per 30 days) |
| ROZLYTREK ORAL CAPSULE 200MG | 1 | PA; QL (90 EA per 30 days) |
| RUBRACA ORAL TABLET 200MG, 250MG, 300MG | 1 | PA |
| RYDAPT ORAL CAPSULE 25MG | 1 | PA; QL (240 EA per 30 days) |
| SCEMBLIX ORAL TABLET 20MG, 40MG | 1 | PA |
| <i>sorafenib tosylate oral tablet 200mg</i> | 1 | PA; QL (120 EA per 30 days) |
| SPRYCEL ORAL TABLET 100MG, 50MG, 70MG, 80MG | 1 | PA; QL (60 EA per 30 days) |
| SPRYCEL ORAL TABLET 140MG | 1 | PA; QL (30 EA per 30 days) |
| SPRYCEL ORAL TABLET 20MG | 1 | PA; QL (90 EA per 30 days) |
| STIVARGA ORAL TABLET 40MG | 1 | PA; QL (84 EA per 28 days) |
| <i>sunitinib malate oral capsule 12.5mg, 25mg, 37.5mg, 50mg</i> | 1 | PA; QL (28 EA per 28 days) |
| TABRECTA ORAL TABLET 150MG, 200MG | 1 | PA; QL (120 EA per 30 days) |
| TAFINLAR ORAL CAPSULE 50MG | 1 | PA; QL (180 EA per 30 days) |
| TAFINLAR ORAL CAPSULE 75MG | 1 | PA; QL (120 EA per 30 days) |
| TAGRISSO ORAL TABLET 40MG, 80MG | 1 | PA |
| TALZENNA ORAL CAPSULE 0.25MG | 1 | PA; QL (120 EA per 30 days) |
| TALZENNA ORAL CAPSULE 0.5MG | 1 | PA; QL (60 EA per 30 days) |
| TALZENNA ORAL CAPSULE 0.75MG, 1MG | 1 | PA; QL (30 EA per 30 days) |
| TASIGNA ORAL CAPSULE 150MG, 200MG, 50MG | 1 | PA; QL (120 EA per 30 days) |
| TAZVERIK ORAL TABLET 200MG | 1 | PA; QL (240 EA per 30 days) |
| TEPMETKO ORAL TABLET 225MG | 1 | PA; QL (60 EA per 30 days) |
| TIBSOVO ORAL TABLET 250MG | 1 | PA; QL (60 EA per 30 days) |
| TRUSELTIQ (100MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 100MG | 1 | PA; QL (21 EA per 28 days) |
| TRUSELTIQ (125MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 100 & 25MG | 1 | PA; QL (42 EA per 28 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------|
| TRUSELTIQ (50MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 25MG | 1 | PA; QL (42 EA per 28 days) |
| TRUSELTIQ (75MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 25MG | 1 | PA; QL (63 EA per 28 days) |
| TUKYSA ORAL TABLET 150MG, 50MG | 1 | PA; QL (120 EA per 30 days) |
| TURALIO ORAL CAPSULE 200MG | 1 | PA; QL (120 EA per 30 days) |
| VENCLEXTA ORAL TABLET 10MG, 100MG, 50MG | 1 | PA |
| VENCLEXTA STARTING PACK ORAL TABLET THERAPY PACK 10 & 50 & 100MG | 1 | PA |
| VERZENIO ORAL TABLET 100MG, 150MG, 200MG, 50MG | 1 | PA |
| VITRAKVI ORAL CAPSULE 100MG | 1 | PA; QL (60 EA per 30 days) |
| VITRAKVI ORAL CAPSULE 25MG | 1 | PA; QL (180 EA per 30 days) |
| VITRAKVI ORAL SOLUTION 20MG/ML | 1 | PA; QL (310ML per 30 days) |
| VIZIMPRO ORAL TABLET 15MG, 30MG, 45MG | 1 | PA; QL (30 EA per 30 days) |
| VONJO ORAL CAPSULE 100MG | 1 | PA |
| VOTRIENT ORAL TABLET 200MG | 1 | PA; QL (120 EA per 30 days) |
| XALKORI ORAL CAPSULE 200MG, 250MG | 1 | PA; QL (120 EA per 30 days) |
| XOSPATA ORAL TABLET 40MG | 1 | PA; QL (90 EA per 30 days) |
| ZEJULA ORAL CAPSULE 100MG | 1 | PA; QL (90 EA per 30 days) |
| ZELBORAF ORAL TABLET 240MG | 1 | PA; QL (240 EA per 30 days) |
| ZYDELIG ORAL TABLET 100MG, 150MG | 1 | PA; QL (60 EA per 30 days) |
| ZYKADIA ORAL TABLET 150MG | 1 | PA; QL (150 EA per 30 days) |
| Retinoids | | |
| <i>bexarotene external gel 1%</i> | 1 | PA |
| <i>bexarotene oral capsule 75mg</i> | 1 | PA; QL (300 EA per 30 days) |
| <i>tretinoin oral capsule 10mg</i> | 1 | |
| ANTIPARASITICS | | |
| Anthelmintics | | |
| <i>albendazole oral tablet 200mg</i> | 1 | |
| EMVERM ORAL TABLET CHEWABLE 100MG | 1 | |
| <i>ivermectin oral tablet 3mg</i> | 1 | PA |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|------------------------|
| Antiprotozoals | | |
| <i>atovaquone oral suspension 750mg/5ml</i> | 1 | |
| <i>atovaquone-proguanil hcl oral tablet 250-100mg, 62.5-25mg</i> | 1 | |
| <i>benznidazole oral tablet 100mg, 12.5mg</i> | 1 | |
| <i>chloroquine phosphate oral tablet 250mg, 500mg</i> | 1 | MO |
| COARTEM ORAL TABLET 20-120MG | 1 | |
| <i>hydroxychloroquine sulfate oral tablet 100mg, 200mg, 300mg, 400mg</i> | 1 | MO |
| LAMPIT ORAL TABLET 120MG, 30MG | 1 | |
| <i>mefloquine hcl oral tablet 250mg</i> | 1 | MO |
| <i>nitazoxanide oral tablet 500mg</i> | 1 | QL (40 EA per 30 days) |
| <i>pentamidine isethionate inhalation solution reconstituted 300mg</i> | 1 | BvD |
| <i>pentamidine isethionate injection solution reconstituted 300mg</i> | 1 | BvD |
| <i>primaquine phosphate oral tablet 26.3 (15 base) mg</i> | 1 | |
| <i>quinine sulfate oral capsule 324mg</i> | 1 | PA |
| ANTIPARKINSON AGENTS | | |
| Anticholinergics | | |
| <i>benztropine mesylate oral tablet 0.5mg, 1mg, 2mg</i> | 1 | MO |
| <i>trihexyphenidyl hcl oral solution 0.4mg/ml</i> | 1 | MO |
| <i>trihexyphenidyl hcl oral tablet 2mg, 5mg</i> | 1 | MO |
| Antiparkinson Agents, Other | | |
| <i>amantadine hcl oral capsule 100mg</i> | 1 | MO |
| <i>amantadine hcl oral solution 50mg/5ml</i> | 1 | MO |
| <i>amantadine hcl oral tablet 100mg</i> | 1 | MO |
| <i>carbidopa-levodopa-entacapone oral tablet 12.5-50-200mg, 18.75-75-200mg, 25-100-200mg, 31.25-125-200mg, 37.5-150-200mg, 50-200-200mg</i> | 1 | MO |
| <i>entacapone oral tablet 200mg</i> | 1 | MO |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------|
| Dopamine Agonists | | |
| <i>bromocriptine mesylate oral capsule 5mg</i> | 1 | MO |
| <i>bromocriptine mesylate oral tablet 2.5mg</i> | 1 | MO |
| KYNMOBI SUBLINGUAL FILM 10MG, 15MG, 20MG, 25MG, 30MG | 1 | PA; QL (150 EA per 30 days) |
| NEUPRO TRANSDERMAL PATCH 24-HOUR 1MG/24HR, 2MG/24HR, 3MG/24HR, 4MG/24HR, 6MG/24HR, 8MG/24HR | 1 | MO |
| <i>pramipexole dihydrochloride oral tablet 0.125mg, 0.25mg, 0.5mg, 0.75mg, 1mg, 1.5mg</i> | 1 | MO |
| <i>ropinirole hcl oral tablet 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg, 5mg</i> | 1 | MO |
| Dopamine Precursors and/or L-Amino Acid Decarboxylase Inhibitors | | |
| <i>carbidopa oral tablet 25mg</i> | 1 | MO |
| <i>carbidopa-levodopa er oral tablet extended release 25-100mg, 50-200mg</i> | 1 | MO |
| <i>carbidopa-levodopa oral tablet 10-100mg, 25-100mg, 25-250mg</i> | 1 | MO |
| <i>carbidopa-levodopa oral tablet dispersible 10-100mg, 25-100mg, 25-250mg</i> | 1 | MO |
| INBRIJA INHALATION CAPSULE 42MG | 1 | |
| RYTARY ORAL CAPSULE EXTENDED RELEASE 23.75-95MG, 36.25-145MG, 48.75-195MG, 61.25-245MG | 1 | ST; MO |
| Monoamine Oxidase B (MAO-B) Inhibitors | | |
| <i>rasagiline mesylate oral tablet 0.5mg, 1mg</i> | 1 | MO |
| <i>selegiline hcl oral capsule 5mg</i> | 1 | MO |
| <i>selegiline hcl oral tablet 5mg</i> | 1 | MO |
| ANTIPSYCHOTICS | | |
| 1st Generation/Typical | | |
| <i>chlorpromazine hcl oral concentrate 100mg/ml, 30mg/ml</i> | 1 | MO |
| <i>chlorpromazine hcl oral tablet 10mg, 25mg</i> | 1 | BvD; MO |
| <i>chlorpromazine hcl oral tablet 100mg, 200mg, 50mg</i> | 1 | MO |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------|
| <i>fluphenazine decanoate injection solution 25mg/ml</i> | 1 | |
| <i>fluphenazine hcl injection solution 2.5mg/ml</i> | 1 | |
| <i>fluphenazine hcl oral concentrate 5mg/ml</i> | 1 | MO |
| <i>fluphenazine hcl oral elixir 2.5mg/5ml</i> | 1 | MO |
| <i>fluphenazine hcl oral tablet 1mg, 10mg, 2.5mg, 5mg</i> | 1 | MO |
| <i>haloperidol decanoate intramuscular solution 100mg/ml, 100mg/ml 1 ml, 50mg/ml, 50mg/ml(1ml)</i> | 1 | |
| <i>haloperidol lactate injection solution 5mg/ml</i> | 1 | |
| <i>haloperidol lactate oral concentrate 2mg/ml</i> | 1 | MO |
| <i>haloperidol oral tablet 0.5mg, 1mg, 10mg, 2mg, 20mg, 5mg</i> | 1 | MO |
| <i>loxapine succinate oral capsule 10mg, 25mg, 5mg, 50mg</i> | 1 | MO |
| <i>molindone hcl oral tablet 10mg, 25mg, 5mg</i> | 1 | MO |
| <i>perphenazine oral tablet 16mg, 2mg</i> | 1 | MO |
| <i>perphenazine oral tablet 4mg, 8mg</i> | 1 | BvD; MO |
| <i>pimozide oral tablet 1mg, 2mg</i> | 1 | MO |
| <i>thioridazine hcl oral tablet 10mg, 100mg, 25mg, 50mg</i> | 1 | MO |
| <i>thiothixene oral capsule 1mg, 10mg, 2mg, 5mg</i> | 1 | MO |
| <i>trifluoperazine hcl oral tablet 1mg, 10mg, 2mg, 5mg</i> | 1 | MO |
| 2nd Generation/Atypical | | |
| ABILIFY MAINTENA INTRAMUSCULAR PREFILLED SYRINGE 300MG, 400MG | 1 | |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 300MG, 400MG | 1 | |
| <i>aripiprazole oral solution 1mg/ml</i> | 1 | MO; QL (750ML per 30 days) |
| <i>aripiprazole oral tablet 10mg, 15mg, 2mg, 20mg, 30mg, 5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>aripiprazole oral tablet dispersible 10mg</i> | 1 | QL (90 EA per 30 days) |
| <i>aripiprazole oral tablet dispersible 15mg</i> | 1 | QL (60 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------|
| <i>asenapine maleate sublingual tablet sublingual</i> 10mg, 2.5mg, 5mg | 1 | MO; QL (60 EA per 30 days) |
| CAPLYTA ORAL CAPSULE 10.5MG, 21MG, 42MG | 1 | |
| FANAPT ORAL TABLET 1MG, 10MG, 12MG, 2MG, 4MG, 6MG, 8MG | 1 | ST; QL (60 EA per 30 days) |
| FANAPT TITRATION PACK ORAL TABLET 1 & 2 & 4 & 6MG | 1 | ST; QL (60 EA per 30 days) |
| INVEGA HAFYERA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 1092MG/3.5ML, 1560MG/5ML | 1 | |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 117MG/0.75ML, 156MG/ML, 234MG/1.5ML, 39MG/0.25ML, 78MG/0.5ML | 1 | |
| INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 273MG/0.88ML, 410MG/1.32ML, 546MG/1.75ML, 819MG/2.63ML | 1 | |
| LATUDA ORAL TABLET 120MG, 20MG, 40MG, 60MG, 80MG | 1 | ST |
| LYBALVI ORAL TABLET 10-10MG, 15-10MG, 20-10MG, 5-10MG | 1 | ST; QL (30 EA per 30 days) |
| NUPLAZID ORAL CAPSULE 34MG | 1 | PA |
| NUPLAZID ORAL TABLET 10MG | 1 | PA |
| <i>olanzapine intramuscular solution reconstituted</i> 10mg | 1 | QL (60 EA per 30 days) |
| <i>olanzapine oral tablet 10mg, 15mg, 2.5mg, 5mg, 7.5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>olanzapine oral tablet 20mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>olanzapine oral tablet dispersible 10mg, 5mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>olanzapine oral tablet dispersible 15mg, 20mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>paliperidone er oral tablet extended release</i> 24-hour 1.5mg, 3mg, 9mg | 1 | MO; QL (30 EA per 30 days) |
| <i>paliperidone er oral tablet extended release</i> 24-hour 6mg | 1 | MO; QL (60 EA per 30 days) |
| <i>quetiapine fumarate er oral tablet extended release 24-hour 150mg</i> | 1 | MO; QL (90 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------|
| <i>quetiapine fumarate er oral tablet extended release 24-hour 200mg, 300mg, 400mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>quetiapine fumarate er oral tablet extended release 24-hour 50mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>quetiapine fumarate oral tablet 100mg, 25mg, 300mg, 400mg, 50mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>quetiapine fumarate oral tablet 200mg</i> | 1 | MO; QL (30 EA per 30 days) |
| REXULTI ORAL TABLET 0.25MG, 0.5MG, 1MG, 2MG, 3MG, 4MG | 1 | |
| RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 12.5MG, 25MG, 37.5MG, 50MG | 1 | |
| <i>risperidone oral solution 1mg/ml</i> | 1 | MO; QL (480ML per 30 days) |
| <i>risperidone oral tablet 0.25mg, 1mg, 2mg, 3mg, 4mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>risperidone oral tablet 0.5mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>risperidone oral tablet dispersible 0.25mg, 1mg, 2mg, 3mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>risperidone oral tablet dispersible 0.5mg, 4mg</i> | 1 | MO; QL (120 EA per 30 days) |
| SECUADO TRANSDERMAL PATCH 24-HOUR 3.8MG/24HR, 5.7MG/24HR, 7.6MG/24HR | 1 | ST; QL (30 EA per 30 days) |
| VRAYLAR ORAL CAPSULE 1.5MG | 1 | ST; QL (60 EA per 30 days) |
| VRAYLAR ORAL CAPSULE 3MG, 4.5MG, 6MG | 1 | ST; QL (30 EA per 30 days) |
| VRAYLAR ORAL CAPSULE THERAPY PACK 1.5 & 3MG | 1 | ST; QL (7 EA per 28 days) |
| <i>ziprasidone hcl oral capsule 20mg, 40mg, 60mg, 80mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>ziprasidone mesylate intramuscular solution reconstituted 20mg</i> | 1 | QL (6 EA per 3 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION RECONSTITUTED 210MG | 1 | ST |
| <i>Treatment-Resistant</i> | | |
| <i>clozapine oral tablet 100mg, 200mg, 25mg, 50mg</i> | 1 | QL (120 EA per 30 days) |
| <i>clozapine oral tablet dispersible 100mg, 12.5mg, 150mg, 200mg, 25mg</i> | 1 | QL (120 EA per 30 days) |
| VERSACLOZ ORAL SUSPENSION 50MG/ML | 1 | ST; QL (540ML per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------|
| ANTISPASTICITY AGENTS | | |
| <i>Antispasticity Agents</i> | | |
| <i>baclofen oral tablet 10mg, 20mg, 5mg</i> | 1 | |
| <i>tizanidine hcl oral tablet 2mg, 4mg</i> | 1 | |
| ANTIVIRALS | | |
| <i>Anti-Cytomegalovirus (CMV) Agents</i> | | |
| LIVTENCITY ORAL TABLET 200MG | 1 | PA |
| PREVYMIS ORAL TABLET 240MG, 480MG | 1 | PA; QL (28 EA per 28 days) |
| <i>valganciclovir hcl oral solution reconstituted 50mg/ml</i> | 1 | MO |
| <i>valganciclovir hcl oral tablet 450mg</i> | 1 | MO |
| ZIRGAN OPHTHALMIC GEL 0.15% | 1 | |
| <i>Anti-Hepatitis B (HBV) Agents</i> | | |
| <i>adefovir dipivoxil oral tablet 10mg</i> | 1 | QL (30 EA per 30 days) |
| BARACLUDGE ORAL SOLUTION 0.05MG/ML | 1 | QL (600ML per 30 days) |
| <i>entecavir oral tablet 0.5mg, 1mg</i> | 1 | MO; QL (30 EA per 30 days) |
| EPIVIR HBV ORAL SOLUTION 5MG/ML | 1 | MO |
| <i>lamivudine oral tablet 100mg</i> | 1 | MO; QL (90 EA per 30 days) |
| VEMLIDY ORAL TABLET 25MG | 1 | QL (30 EA per 30 days) |
| <i>Anti-Hepatitis C (HCV) Agents</i> | | |
| MAVYRET ORAL PACKET 50-20MG | 1 | PA |
| MAVYRET ORAL TABLET 100-40MG | 1 | PA |
| <i>ribavirin oral capsule 200mg</i> | 1 | |
| <i>ribavirin oral tablet 200mg</i> | 1 | |
| <i>sofosbuvir-velpatasvir oral tablet 400-100mg</i> | 1 | PA |
| VOSEVI ORAL TABLET 400-100-100MG | 1 | PA |
| <i>Antitherpetic Agents</i> | | |
| <i>acyclovir oral capsule 200mg</i> | 1 | |
| <i>acyclovir oral suspension 200mg/5ml</i> | 1 | |
| <i>acyclovir oral tablet 400mg, 800mg</i> | 1 | |
| <i>acyclovir sodium intravenous solution 50mg/ml</i> | 1 | BvD |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------|
| <i>famciclovir oral tablet 125mg, 250mg, 500mg</i> | 1 | |
| <i>trifluridine ophthalmic solution 1%</i> | 1 | |
| <i>valacyclovir hcl oral tablet 1gm, 500mg</i> | 1 | |
| <i>Anti-HIV Agents, Integrase Inhibitors (INSTI)</i> | | |
| BIKTARVY ORAL TABLET 30-120-15MG, 50-200-25MG | 1 | QL (30 EA per 30 days) |
| DOVATO ORAL TABLET 50-300MG | 1 | QL (30 EA per 30 days) |
| GENVOYA ORAL TABLET 150-150-200-10MG | 1 | QL (30 EA per 30 days) |
| ISENTRESS HD ORAL TABLET 600MG | 1 | QL (60 EA per 30 days) |
| ISENTRESS ORAL PACKET 100MG | 1 | MO; QL (60 EA per 30 days) |
| ISENTRESS ORAL TABLET 400MG | 1 | QL (60 EA per 30 days) |
| ISENTRESS ORAL TABLET CHEWABLE 100MG, 25MG | 1 | MO; QL (180 EA per 30 days) |
| STRIBILD ORAL TABLET 150-150-200-300MG | 1 | QL (30 EA per 30 days) |
| SYMTUZA ORAL TABLET 800-150-200-10MG | 1 | QL (30 EA per 30 days) |
| TIVICAY ORAL TABLET 10MG | 1 | MO; QL (60 EA per 30 days) |
| TIVICAY ORAL TABLET 25MG, 50MG | 1 | QL (60 EA per 30 days) |
| TIVICAY PD ORAL TABLET SOLUBLE 5MG | 1 | MO; QL (360 EA per 30 days) |
| <i>Anti-HIV Agents, Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)</i> | | |
| COMPLERA ORAL TABLET 200-25-300MG | 1 | QL (30 EA per 30 days) |
| EDURANT ORAL TABLET 25MG | 1 | QL (30 EA per 30 days) |
| <i>efavirenz oral capsule 200mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>efavirenz oral capsule 50mg</i> | 1 | MO; QL (360 EA per 30 days) |
| <i>efavirenz oral tablet 600mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>etravirine oral tablet 100mg</i> | 1 | QL (120 EA per 30 days) |
| <i>etravirine oral tablet 200mg</i> | 1 | QL (60 EA per 30 days) |
| INTELENCE ORAL TABLET 25MG | 1 | MO; QL (120 EA per 30 days) |
| <i>nevirapine er oral tablet extended release 24-hour 100mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>nevirapine er oral tablet extended release 24-hour 400mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>nevirapine oral suspension 50mg/5ml</i> | 1 | MO; QL (1200ML per 30 days) |
| <i>nevirapine oral tablet 200mg</i> | 1 | MO; QL (60 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------|
| PIFELTRO ORAL TABLET 100MG | 1 | QL (30 EA per 30 days) |
| Anti-HIV Agents, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTI) | | |
| <i>abacavir sulfate oral solution 20mg/ml</i> | 1 | MO; QL (960ML per 30 days) |
| <i>abacavir sulfate oral tablet 300mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>abacavir sulfate-lamivudine oral tablet 600-300mg</i> | 1 | MO; QL (30 EA per 30 days) |
| CIMDUO ORAL TABLET 300-300MG | 1 | QL (30 EA per 30 days) |
| DELSTRIGO ORAL TABLET 100-300-300MG | 1 | QL (30 EA per 30 days) |
| DESCOVY ORAL TABLET 120-15MG, 200-25MG | 1 | QL (30 EA per 30 days) |
| <i>efavirenz-emtricitab-tenofo df oral tablet 600-200-300mg</i> | 1 | QL (30 EA per 30 days) |
| <i>efavirenz-lamivudine-tenofovir oral tablet 400-300-300mg, 600-300-300mg</i> | 1 | QL (30 EA per 30 days) |
| <i>emtricitabine oral capsule 200mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>emtricitabine-tenofovir df oral tablet 100-150mg, 133-200mg, 167-250mg, 200-300mg</i> | 1 | QL (30 EA per 30 days) |
| EMTRIVA ORAL SOLUTION 10MG/ML | 1 | MO; QL (680ML per 28 days) |
| JULUCA ORAL TABLET 50-25MG | 1 | QL (30 EA per 30 days) |
| <i>lamivudine oral solution 10mg/ml</i> | 1 | MO; QL (900ML per 30 days) |
| <i>lamivudine oral tablet 150mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>lamivudine oral tablet 300mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>lamivudine-zidovudine oral tablet 150-300mg</i> | 1 | MO; QL (60 EA per 30 days) |
| ODEFSEY ORAL TABLET 200-25-25MG | 1 | QL (30 EA per 30 days) |
| <i>tenofovir disoproxil fumarate oral tablet 300mg</i> | 1 | MO; QL (30 EA per 30 days) |
| TRIZIVIR ORAL TABLET 300-150-300MG | 1 | QL (60 EA per 30 days) |
| VIREAD ORAL POWDER 40MG/GM | 1 | QL (240GM per 30 days) |
| VIREAD ORAL TABLET 150MG, 200MG, 250MG | 1 | QL (30 EA per 30 days) |
| <i>zidovudine oral capsule 100mg</i> | 1 | MO; QL (180 EA per 30 days) |
| <i>zidovudine oral syrup 50mg/5ml</i> | 1 | MO; QL (1680ML per 28 days) |
| <i>zidovudine oral tablet 300mg</i> | 1 | MO; QL (60 EA per 30 days) |
| Anti-HIV Agents, Other | | |
| FUZEON SUBCUTANEOUS SOLUTION RECONSTITUTED 90MG | 1 | QL (60 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------|
| <i>maraviroc oral tablet 150mg, 300mg</i> | 1 | QL (120 EA per 30 days) |
| RUKOBIA ORAL TABLET EXTENDED RELEASE 12-HOUR 600MG | 1 | QL (60 EA per 30 days) |
| SELZENTRY ORAL SOLUTION 20MG/ML | 1 | QL (1800ML per 30 days) |
| SELZENTRY ORAL TABLET 25MG | 1 | MO; QL (120 EA per 30 days) |
| SELZENTRY ORAL TABLET 75MG | 1 | QL (60 EA per 30 days) |
| TRIUMEQ ORAL TABLET 600-50-300MG | 1 | QL (30 EA per 30 days) |
| TRIUMEQ PD ORAL TABLET SOLUBLE 60-5-30MG | 1 | QL (180 EA per 30 days) |
| TYBOST ORAL TABLET 150MG | 1 | MO; QL (30 EA per 30 days) |
| <i>Anti-HIV Agents, Protease Inhibitors (PI)</i> | | |
| APTIVUS ORAL CAPSULE 250MG | 1 | QL (120 EA per 30 days) |
| <i>atazanavir sulfate oral capsule 150mg, 200mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>atazanavir sulfate oral capsule 300mg</i> | 1 | MO; QL (30 EA per 30 days) |
| EVOTAZ ORAL TABLET 300-150MG | 1 | QL (30 EA per 30 days) |
| <i>fosamprenavir calcium oral tablet 700mg</i> | 1 | QL (120 EA per 30 days) |
| LEXIVA ORAL SUSPENSION 50MG/ML | 1 | MO; QL (1575ML per 28 days) |
| <i>lopinavir-ritonavir oral solution 400-100mg/5ml</i> | 1 | MO; QL (400ML per 30 days) |
| <i>lopinavir-ritonavir oral tablet 100-25mg</i> | 1 | MO; QL (300 EA per 30 days) |
| <i>lopinavir-ritonavir oral tablet 200-50mg</i> | 1 | MO; QL (150 EA per 30 days) |
| NORVIR ORAL PACKET 100MG | 1 | MO; QL (360 EA per 30 days) |
| NORVIR ORAL SOLUTION 80MG/ML | 1 | MO; QL (480ML per 30 days) |
| PREZCOBIX ORAL TABLET 800-150MG | 1 | QL (30 EA per 30 days) |
| PREZISTA ORAL SUSPENSION 100MG/ML | 1 | QL (360ML per 30 days) |
| PREZISTA ORAL TABLET 150MG | 1 | MO; QL (240 EA per 30 days) |
| PREZISTA ORAL TABLET 600MG | 1 | QL (60 EA per 30 days) |
| PREZISTA ORAL TABLET 75MG | 1 | MO; QL (480 EA per 30 days) |
| PREZISTA ORAL TABLET 800MG | 1 | QL (30 EA per 30 days) |
| REYATAZ ORAL PACKET 50MG | 1 | MO; QL (180 EA per 30 days) |
| <i>ritonavir oral tablet 100mg</i> | 1 | MO; QL (360 EA per 30 days) |
| VIRACEPT ORAL TABLET 250MG | 1 | QL (300 EA per 30 days) |
| VIRACEPT ORAL TABLET 625MG | 1 | QL (120 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------|
| Anti-Influenza Agents | | |
| <i>oseltamivir phosphate oral capsule 30mg, 45mg, 75mg</i> | 1 | |
| <i>oseltamivir phosphate oral suspension reconstituted 6mg/ml</i> | 1 | |
| RELENZA DISKHALER INHALATION AEROSOL POWDER BREATH ACTIVATED 5MG/ACT | 1 | |
| <i>rimantadine hcl oral tablet 100mg</i> | 1 | |
| XOFLUZA (40MG DOSE) ORAL TABLET THERAPY PACK 1 X 40MG | 1 | |
| XOFLUZA (80MG DOSE) ORAL TABLET THERAPY PACK 1 X 80MG | 1 | |
| ANXIOLYTICS | | |
| Anxiolytics, Other | | |
| <i>buspirone hcl oral tablet 10mg, 15mg, 30mg, 5mg, 7.5mg</i> | 1 | |
| <i>hydroxyzine hcl oral syrup 10mg/5ml</i> | 1 | |
| <i>hydroxyzine hcl oral tablet 10mg, 25mg, 50mg</i> | 1 | |
| <i>hydroxyzine pamoate oral capsule 100mg, 25mg, 50mg</i> | 1 | |
| <i>oxazepam oral capsule 10mg, 15mg, 30mg</i> | 1 | QL (120 EA per 30 days) |
| Benzodiazepines | | |
| ALPRAZOLAM INTENSOL ORAL CONCENTRATE 1MG/ML | 1 | QL (300ML per 30 days) |
| <i>alprazolam oral tablet 0.25mg, 0.5mg</i> | 1 | QL (120 EA per 30 days) |
| <i>alprazolam oral tablet 1mg</i> | 1 | QL (240 EA per 30 days) |
| <i>alprazolam oral tablet 2mg</i> | 1 | QL (150 EA per 30 days) |
| <i>chlordiazepoxide hcl oral capsule 10mg, 25mg, 5mg</i> | 1 | QL (120 EA per 30 days) |
| <i>clonazepam oral tablet 0.5mg, 1mg</i> | 1 | QL (90 EA per 30 days) |
| <i>clonazepam oral tablet 2mg</i> | 1 | QL (300 EA per 30 days) |
| <i>clonazepam oral tablet dispersible 0.125mg, 0.25mg, 0.5mg, 1mg</i> | 1 | QL (90 EA per 30 days) |
| <i>clonazepam oral tablet dispersible 2mg</i> | 1 | QL (300 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-------------------------|
| <i>clorazepate dipotassium oral tablet 15mg, 3.75mg, 7.5mg</i> | 1 | QL (180 EA per 30 days) |
| DIAZEPAM INTENSOL ORAL CONCENTRATE 5MG/ML | 1 | QL (240ML per 30 days) |
| <i>diazepam oral solution 5mg/5ml</i> | 1 | QL (1200ML per 30 days) |
| <i>diazepam oral tablet 10mg, 2mg</i> | 1 | QL (120 EA per 30 days) |
| <i>diazepam oral tablet 5mg</i> | 1 | QL (240 EA per 30 days) |
| LORAZEPAM INTENSOL ORAL CONCENTRATE 2MG/ML | 1 | QL (240ML per 30 days) |
| <i>lorazepam oral tablet 0.5mg, 1mg, 2mg</i> | 1 | QL (150 EA per 30 days) |

BIPOLAR AGENTS

Mood Stabilizers

| | | |
|---|---|----|
| <i>divalproex sodium er oral tablet extended release 24-hour 250mg, 500mg</i> | 1 | MO |
| <i>divalproex sodium oral capsule delayed release sprinkle 125mg</i> | 1 | MO |
| <i>divalproex sodium oral tablet delayed release 125mg, 250mg, 500mg</i> | 1 | MO |
| <i>lithium carbonate er oral tablet extended release 300mg, 450mg</i> | 1 | MO |
| <i>lithium carbonate oral capsule 150mg, 300mg, 600mg</i> | 1 | MO |
| <i>lithium carbonate oral tablet 300mg</i> | 1 | MO |

BLOOD GLUCOSE REGULATORS

Antidiabetic Agents

| | | |
|---|---|----|
| <i>acarbose oral tablet 100mg, 25mg, 50mg</i> | 1 | MO |
| <i>glimepiride oral tablet 1mg, 2mg, 4mg</i> | 1 | MO |
| <i>glipizide er oral tablet extended release 24-hour 10mg, 2.5mg, 5mg</i> | 1 | MO |
| <i>glipizide oral tablet 10mg, 5mg</i> | 1 | MO |
| <i>glipizide-metformin hcl oral tablet 2.5-250mg, 2.5-500mg, 5-500mg</i> | 1 | MO |
| <i>glyburide-metformin oral tablet 1.25-250mg, 2.5-500mg, 5-500mg</i> | 1 | MO |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| INVOKAMET ORAL TABLET 150-1000MG, 150-500MG, 50-1000MG, 50-500MG | 1 | MO |
| INVOKAMET XR ORAL TABLET EXTENDED RELEASE 24-HOUR 150-1000MG, 150-500MG, 50-1000MG, 50-500MG | 1 | MO |
| INVOKANA ORAL TABLET 100MG, 300MG | 1 | MO |
| JANUMET ORAL TABLET 50-1000MG, 50-500MG | 1 | MO |
| JANUMET XR ORAL TABLET EXTENDED RELEASE 24-HOUR 100-1000MG, 50-1000MG, 50-500MG | 1 | MO |
| JANUVIA ORAL TABLET 100MG, 25MG, 50MG | 1 | MO |
| JARDIANCE ORAL TABLET 10MG, 25MG | 1 | MO |
| <i>metformin hcl er oral tablet extended release 24-hour 500mg, 750mg</i> | 1 | MO |
| <i>metformin hcl oral tablet 1000mg, 500mg, 850mg</i> | 1 | MO |
| <i>migliitol oral tablet 100mg, 25mg, 50mg</i> | 1 | MO |
| <i>nateglinide oral tablet 120mg, 60mg</i> | 1 | MO |
| OZEMPIC (0.25 OR 0.5MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2MG/1.5ML | 1 | MO |
| OZEMPIC (1MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 4MG/3ML | 1 | MO |
| OZEMPIC (2MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 8MG/3ML | 1 | MO |
| <i>pioglitazone hcl oral tablet 15mg, 30mg, 45mg</i> | 1 | MO |
| <i>pioglitazone hcl-glimepiride oral tablet 30-2mg, 30-4mg</i> | 1 | MO |
| <i>pioglitazone hcl-metformin hcl oral tablet 15-500mg, 15-850mg</i> | 1 | MO |
| <i>repaglinide oral tablet 0.5mg, 1mg, 2mg</i> | 1 | MO |
| RYBELSUS ORAL TABLET 14MG, 3MG, 7MG | 1 | MO |
| SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR 2700MCG/2.7ML | 1 | PA; MO |
| SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR 1500MCG/1.5ML | 1 | PA; MO |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| SYNJARDY ORAL TABLET 12.5-1000MG, 12.5-500MG, 5-1000MG, 5-500MG | 1 | MO |
| SYNJARDY XR ORAL TABLET EXTENDED RELEASE 24-HOUR 10-1000MG, 12.5-1000MG, 25-1000MG, 5-1000MG | 1 | MO |
| TRULICITY SUBCUTANEOUS SOLUTION PEN-INJECTOR 0.75MG/0.5ML, 1.5MG/0.5ML, 3MG/0.5ML, 4.5MG/0.5ML | 1 | MO |
| VICTOZA SUBCUTANEOUS SOLUTION PEN-INJECTOR 18MG/3ML | 1 | MO |
| XULTOPHY SUBCUTANEOUS SOLUTION PEN-INJECTOR 100-3.6UNIT-MG/ML | 1 | MO |
| <i>Glycemic Agents</i> | | |
| BAQSIMI ONE PACK NASAL POWDER 3MG/DOSE | 1 | |
| <i>diazoxide oral suspension 50mg/ml</i> | 1 | |
| GLUCAGEN HYPOKIT INJECTION SOLUTION RECONSTITUTED 1MG | 1 | |
| <i>glucagon emergency injection kit 1mg</i> | 1 | |
| KORLYM ORAL TABLET 300MG | 1 | PA |
| <i>Insulins</i> | | |
| ASSURE ID INSULIN SAFETY SYR 29G X 1/2" 1ML | 1 | |
| COMFORT ASSIST INSULIN SYRINGE 29G X 1/2" 1ML | 1 | |
| <i>cvs gauze sterile pad 2"x2"</i> | 1 | |
| EXEL COMFORT POINT PEN NEEDLE 29G X 12MM | 1 | |
| FIASP FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100UNIT/ML | 1 | MO |
| FIASP INJECTION SOLUTION 100UNIT/ML | 1 | MO |
| FIASP PENFILL SUBCUTANEOUS SOLUTION CARTRIDGE 100UNIT/ML | 1 | MO |
| LANTUS SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 100UNIT/ML | 1 | MO |
| LANTUS SUBCUTANEOUS SOLUTION 100UNIT/ML | 1 | MO |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| LEVEMIR FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100UNIT/ML | 1 | MO |
| LEVEMIR SUBCUTANEOUS SOLUTION 100UNIT/ML | 1 | MO |
| NOVOLIN 70/30 FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100UNIT/ML | 1 | MO |
| NOVOLIN 70/30 SUBCUTANEOUS SUSPENSION (70-30) 100UNIT/ML | 1 | MO |
| NOVOLIN N FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR 100UNIT/ML | 1 | MO |
| NOVOLIN N SUBCUTANEOUS SUSPENSION 100UNIT/ML | 1 | MO |
| NOVOLIN R FLEXPEN INJECTION SOLUTION PEN-INJECTOR 100UNIT/ML | 1 | MO |
| NOVOLIN R INJECTION SOLUTION 100UNIT/ML | 1 | MO |
| NOVOLOG FLEXPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100UNIT/ML | 1 | MO |
| NOVOLOG INJECTION SOLUTION 100UNIT/ML | 1 | MO |
| NOVOLOG MIX 70/30 FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100UNIT/ML | 1 | MO |
| NOVOLOG MIX 70/30 SUBCUTANEOUS SUSPENSION (70-30) 100UNIT/ML | 1 | MO |
| NOVOLOG PENFILL SUBCUTANEOUS SOLUTION CARTRIDGE 100UNIT/ML | 1 | MO |
| <i>preferred plus insulin syringe 28g x 1/2" 0.5 ml</i> | 1 | |
| RELI-ON INSULIN SYRINGE 29G 0.3ML | 1 | |
| SOLIQUA SUBCUTANEOUS SOLUTION PEN-INJECTOR 100-33 UNT-MCG/ML | 1 | MO |
| TOUJEO MAX SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 300UNIT/ML | 1 | MO |
| TOUJEO SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 300UNIT/ML | 1 | MO |
| TRESIBA FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100UNIT/ML, 200UNIT/ML | 1 | MO |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------|
| TRESIBA SUBCUTANEOUS SOLUTION 100UNIT/ML | 1 | MO |
| BLOOD PRODUCTS AND MODIFIERS | | |
| <i>Anticoagulants</i> | | |
| ELIQUIS DVT/PE STARTER PACK ORAL TABLET THERAPY PACK 5MG | 1 | |
| ELIQUIS ORAL TABLET 2.5MG, 5MG | 1 | MO |
| <i>enoxaparin sodium injection solution prefilled syringe 100mg/ml, 150mg/ml</i> | 1 | QL (60ML per 30 days) |
| <i>enoxaparin sodium injection solution prefilled syringe 120mg/0.8ml, 80mg/0.8ml</i> | 1 | QL (48ML per 30 days) |
| <i>enoxaparin sodium injection solution prefilled syringe 30mg/0.3ml</i> | 1 | QL (18ML per 30 days) |
| <i>enoxaparin sodium injection solution prefilled syringe 40mg/0.4ml</i> | 1 | QL (24ML per 30 days) |
| <i>enoxaparin sodium injection solution prefilled syringe 60mg/0.6ml</i> | 1 | QL (36ML per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 10mg/0.8ml</i> | 1 | QL (24ML per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 2.5mg/0.5ml</i> | 1 | QL (15ML per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 5mg/0.4ml</i> | 1 | QL (12ML per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 7.5mg/0.6ml</i> | 1 | QL (18ML per 30 days) |
| <i>heparin sodium (porcine) injection solution 1000unit/ml, 10000unit/ml, 20000unit/ml, 5000unit/ml</i> | 1 | BvD |
| JANTOVEN ORAL TABLET 1MG, 10MG, 2MG, 2.5MG, 3MG, 4MG, 5MG, 6MG, 7.5MG | 1 | MO |
| <i>warfarin sodium oral tablet 1mg, 10mg, 2mg, 2.5mg, 3mg, 4mg, 5mg, 6mg, 7.5mg</i> | 1 | MO |
| XARELTO ORAL SUSPENSION RECONSTITUTED 1MG/ML | 1 | MO |
| XARELTO ORAL TABLET 10MG, 15MG, 2.5MG, 20MG | 1 | MO |
| XARELTO STARTER PACK ORAL TABLET THERAPY PACK 15 & 20MG | 1 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------|
| Blood Products and Modifiers, Other | | |
| <i>anagrelide hcl oral capsule 0.5mg, 1mg</i> | 1 | MO |
| LEUKINE INJECTION SOLUTION RECONSTITUTED 250MCG | 1 | PA |
| PROMACTA ORAL PACKET 12.5MG | 1 | PA; QL (360 EA per 30 days) |
| PROMACTA ORAL PACKET 25MG | 1 | PA; QL (180 EA per 30 days) |
| PROMACTA ORAL TABLET 12.5MG, 25MG, 50MG, 75MG | 1 | PA; QL (60 EA per 30 days) |
| RETACRIT INJECTION SOLUTION 10000UNIT/ML, 10000UNIT/ML(1ML), 20000UNIT/ML, 4000UNIT/ML, 40000UNIT/ML | 1 | PA; QL (12ML per 28 days) |
| RETACRIT INJECTION SOLUTION 2000UNIT/ML | 1 | PA; QL (23ML per 30 days) |
| RETACRIT INJECTION SOLUTION 3000UNIT/ML | 1 | PA; QL (16ML per 30 days) |
| <i>tranexamic acid oral tablet 650mg</i> | 1 | |
| ZARXIO INJECTION SOLUTION PREFILLED SYRINGE 300MCG/0.5ML, 480MCG/0.8ML | 1 | PA |
| ZIEXTENZO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 6MG/0.6ML | 1 | PA |
| Platelet Modifying Agents | | |
| <i>aspirin-dipyridamole er oral capsule extended release 12-hour 25-200mg</i> | 1 | MO |
| BRILINTA ORAL TABLET 60MG, 90MG | 1 | MO |
| CABLIVI INJECTION KIT 11MG | 1 | PA |
| <i>cilostazol oral tablet 100mg, 50mg</i> | 1 | MO |
| <i>clopidogrel bisulfate oral tablet 75mg</i> | 1 | MO |
| <i>prasugrel hcl oral tablet 10mg, 5mg</i> | 1 | MO |
| CARDIOVASCULAR AGENTS | | |
| Alpha-Adrenergic Agonists | | |
| <i>clonidine hcl oral tablet 0.1mg, 0.2mg, 0.3mg</i> | 1 | MO |
| <i>clonidine transdermal patch weekly 0.1mg/24hr, 0.2mg/24hr, 0.3mg/24hr</i> | 1 | MO; QL (4 EA per 28 days) |
| <i>droxidopa oral capsule 100mg, 200mg, 300mg</i> | 1 | PA; QL (180 EA per 30 days) |
| <i>guanfacine hcl oral tablet 1mg, 2mg</i> | 1 | MO |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------|
| <i>midodrine hcl oral tablet 10mg, 2.5mg, 5mg</i> | 1 | |
| Alpha-Adrenergic Blocking Agents | | |
| <i>doxazosin mesylate oral tablet 1mg, 2mg, 4mg, 8mg</i> | 1 | MO |
| <i>prazosin hcl oral capsule 1mg, 2mg, 5mg</i> | 1 | MO |
| <i>terazosin hcl oral capsule 1mg, 10mg, 2mg, 5mg</i> | 1 | MO |
| Angiotensin II Receptor Antagonists | | |
| <i>candesartan cilexetil oral tablet 16mg, 4mg, 8mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>candesartan cilexetil oral tablet 32mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>irbesartan oral tablet 150mg, 300mg, 75mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>losartan potassium oral tablet 100mg, 25mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>losartan potassium oral tablet 50mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>olmesartan medoxomil oral tablet 20mg, 40mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>olmesartan medoxomil oral tablet 5mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>telmisartan oral tablet 20mg, 40mg, 80mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>valsartan oral tablet 160mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>valsartan oral tablet 320mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>valsartan oral tablet 40mg, 80mg</i> | 1 | MO; QL (90 EA per 30 days) |
| Angiotensin-Converting Enzyme (ACE) Inhibitors | | |
| <i>benazepril hcl oral tablet 10mg, 20mg, 40mg, 5mg</i> | 1 | MO |
| <i>captopril oral tablet 100mg, 12.5mg, 25mg, 50mg</i> | 1 | MO |
| <i>enalapril maleate oral tablet 10mg, 2.5mg, 20mg, 5mg</i> | 1 | MO |
| <i>fosinopril sodium oral tablet 10mg, 20mg, 40mg</i> | 1 | MO |
| <i>lisinopril oral tablet 10mg, 2.5mg, 20mg, 30mg, 40mg, 5mg</i> | 1 | MO |
| <i>moexipril hcl oral tablet 15mg, 7.5mg</i> | 1 | MO |
| <i>perindopril erbumine oral tablet 2mg, 4mg, 8mg</i> | 1 | MO |
| <i>quinapril hcl oral tablet 10mg, 20mg, 40mg, 5mg</i> | 1 | MO |
| <i>ramipril oral capsule 1.25mg, 10mg, 2.5mg, 5mg</i> | 1 | MO |
| <i>trandolapril oral tablet 1mg, 2mg, 4mg</i> | 1 | MO |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| Antiarrhythmics | | |
| <i>amiodarone hcl oral tablet 100mg, 200mg, 400mg</i> | 1 | MO |
| <i>disopyramide phosphate oral capsule 100mg, 150mg</i> | 1 | MO |
| <i>dofetilide oral capsule 125mcg, 250mcg, 500mcg</i> | 1 | MO |
| <i>flecainide acetate oral tablet 100mg, 150mg, 50mg</i> | 1 | MO |
| <i>mexiletine hcl oral capsule 150mg, 200mg, 250mg</i> | 1 | MO |
| MULTAQ ORAL TABLET 400MG | 1 | MO |
| <i>propafenone hcl oral tablet 150mg, 225mg, 300mg</i> | 1 | MO |
| <i>quinidine sulfate oral tablet 200mg, 300mg</i> | 1 | MO |
| <i>sotalol hcl (af) oral tablet 120mg, 160mg, 80mg</i> | 1 | MO |
| <i>sotalol hcl oral tablet 120mg, 160mg, 240mg, 80mg</i> | 1 | MO |
| Beta-Adrenergic Blocking Agents | | |
| <i>acebutolol hcl oral capsule 200mg, 400mg</i> | 1 | MO |
| <i>atenolol oral tablet 100mg, 25mg, 50mg</i> | 1 | MO |
| <i>betaxolol hcl oral tablet 10mg, 20mg</i> | 1 | MO |
| <i>bisoprolol fumarate oral tablet 10mg, 5mg</i> | 1 | MO |
| <i>carvedilol oral tablet 12.5mg, 25mg, 3.125mg, 6.25mg</i> | 1 | MO |
| <i>labetalol hcl oral tablet 100mg, 200mg, 300mg</i> | 1 | MO |
| <i>metoprolol succinate er oral tablet extended release 24-hour 100mg, 200mg, 25mg, 50mg</i> | 1 | MO |
| <i>metoprolol tartrate oral tablet 100mg, 25mg, 37.5mg, 50mg, 75mg</i> | 1 | MO |
| <i>nadolol oral tablet 20mg, 40mg, 80mg</i> | 1 | MO |
| <i>nebivolol hcl oral tablet 10mg, 2.5mg, 20mg, 5mg</i> | 1 | MO |
| <i>pindolol oral tablet 10mg, 5mg</i> | 1 | MO |
| <i>propranolol hcl er oral capsule extended release 24-hour 120mg, 160mg, 60mg</i> | 1 | MO |
| <i>propranolol hcl oral solution 20mg/5ml, 40mg/5ml</i> | 1 | MO |
| <i>propranolol hcl oral tablet 10mg, 20mg, 40mg, 60mg</i> | 1 | MO |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------|
| <i>timolol maleate oral tablet 10mg, 20mg, 5mg</i> | 1 | MO |
| Calcium Channel Blocking Agents, Dihydropyridines | | |
| <i>amlodipine besylate oral tablet 10mg, 2.5mg, 5mg</i> | 1 | MO |
| <i>felodipine er oral tablet extended release 24-hour 10mg, 2.5mg, 5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>isradipine oral capsule 2.5mg, 5mg</i> | 1 | MO |
| KATERZIA ORAL SUSPENSION 1MG/ML | 1 | MO |
| <i>nicardipine hcl oral capsule 20mg, 30mg</i> | 1 | MO |
| <i>nifedipine er oral tablet extended release 24-hour 30mg, 60mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>nifedipine er oral tablet extended release 24-hour 90mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>nifedipine er osmotic release oral tablet extended release 24-hour 30mg, 60mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>nifedipine er osmotic release oral tablet extended release 24-hour 90mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>nifedipine oral capsule 10mg, 20mg</i> | 1 | MO |
| Calcium Channel Blocking Agents, Nondihydropyridines | | |
| CARTIA XT ORAL CAPSULE EXTENDED RELEASE 24-HOUR 120MG, 180MG, 240MG | 1 | MO; QL (60 EA per 30 days) |
| CARTIA XT ORAL CAPSULE EXTENDED RELEASE 24-HOUR 300MG | 1 | MO; QL (30 EA per 30 days) |
| <i>diltiazem hcl er beads oral capsule extended release 24-hour 360mg, 420mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>diltiazem hcl er coated beads oral capsule extended release 24-hour 120mg, 180mg, 240mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>diltiazem hcl er coated beads oral capsule extended release 24-hour 300mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>diltiazem hcl er oral capsule extended release 12-hour 120mg, 60mg, 90mg</i> | 1 | MO |
| <i>diltiazem hcl oral tablet 120mg, 30mg, 60mg, 90mg</i> | 1 | MO |
| <i>dilt-xr oral capsule extended release 24-hour 120mg, 180mg, 240mg</i> | 1 | MO; QL (60 EA per 30 days) |
| TAZTIA XT ORAL CAPSULE EXTENDED RELEASE 24-HOUR 120MG, 180MG, 240MG | 1 | MO; QL (60 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------|
| TAZTIA XT ORAL CAPSULE EXTENDED RELEASE 24-HOUR 300MG, 360MG | 1 | MO; QL (30 EA per 30 days) |
| TIADYLT ER ORAL CAPSULE EXTENDED RELEASE 24-HOUR 120MG, 180MG, 240MG | 1 | MO; QL (60 EA per 30 days) |
| TIADYLT ER ORAL CAPSULE EXTENDED RELEASE 24-HOUR 300MG, 360MG, 420MG | 1 | MO; QL (30 EA per 30 days) |
| <i>verapamil hcl er oral capsule extended release 24-hour 100mg, 120mg, 180mg, 200mg, 240mg, 300mg, 360mg</i> | 1 | MO |
| <i>verapamil hcl er oral tablet extended release 120mg, 180mg, 240mg</i> | 1 | MO |
| <i>verapamil hcl oral tablet 120mg, 40mg, 80mg</i> | 1 | MO |
| Cardiovascular Agents, Other | | |
| <i>aliskiren fumarate oral tablet 150mg, 300mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>amiloride-hydrochlorothiazide oral tablet 5-50mg</i> | 1 | MO |
| <i>amlodipine besy-benazepril hcl oral capsule 10-20mg, 10-40mg, 2.5-10mg, 5-10mg, 5-20mg, 5-40mg</i> | 1 | MO |
| <i>amlodipine besylate-valsartan oral tablet 10-160mg, 10-320mg, 5-160mg, 5-320mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>amlodipine-atorvastatin oral tablet 10-10mg, 10-20mg, 10-40mg, 10-80mg, 2.5-10mg, 2.5-20mg, 2.5-40mg, 5-10mg, 5-20mg, 5-40mg, 5-80mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>amlodipine-olmesartan oral tablet 10-20mg, 10-40mg, 5-20mg, 5-40mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>atenolol-chlorthalidone oral tablet 100-25mg, 50-25mg</i> | 1 | MO |
| <i>benazepril-hydrochlorothiazide oral tablet 10-12.5mg, 20-12.5mg, 20-25mg, 5-6.25mg</i> | 1 | MO |
| <i>bisoprolol-hydrochlorothiazide oral tablet 10-6.25mg, 2.5-6.25mg, 5-6.25mg</i> | 1 | MO |
| CAMZYOS ORAL CAPSULE 10MG, 15MG, 2.5MG, 5MG | 1 | PA; QL (30 EA per 30 days) |
| <i>candesartan cilexetil-hctz oral tablet 16-12.5mg, 32-12.5mg, 32-25mg</i> | 1 | MO; QL (30 EA per 30 days) |
| CORLANOR ORAL TABLET 5MG, 7.5MG | 1 | PA; MO |
| DIGITEK ORAL TABLET 250MCG | 1 | MO; QL (30 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>digoxin oral solution 0.05mg/ml</i> | 1 | MO; QL (255ML per 30 days) |
| <i>digoxin oral tablet 125mcg, 250mcg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>enalapril-hydrochlorothiazide oral tablet 10-25mg, 5-12.5mg</i> | 1 | MO |
| ENTRESTO ORAL TABLET 24-26MG, 49-51MG, 97-103MG | 1 | MO |
| <i>fosinopril sodium-hctz oral tablet 10-12.5mg, 20-12.5mg</i> | 1 | MO |
| <i>irbesartan-hydrochlorothiazide oral tablet 150-12.5mg, 300-12.5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>isosorb dinitrate-hydralazine oral tablet 20-37.5mg</i> | 1 | MO |
| <i>lisinopril-hydrochlorothiazide oral tablet 10-12.5mg, 20-12.5mg, 20-25mg</i> | 1 | MO |
| <i>losartan potassium-hctz oral tablet 100-12.5mg, 100-25mg, 50-12.5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>metoprolol-hydrochlorothiazide oral tablet 100-25mg, 100-50mg, 50-25mg</i> | 1 | MO |
| <i>metyrosine oral capsule 250mg</i> | 1 | |
| <i>olmesartan medoxomil-hctz oral tablet 20-12.5mg, 40-12.5mg, 40-25mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>olmesartan-amlodipine-hctz oral tablet 20-5-12.5mg, 40-10-12.5mg, 40-10-25mg, 40-5-12.5mg, 40-5-25mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>pentoxifylline er oral tablet extended release 400mg</i> | 1 | MO |
| <i>quinapril-hydrochlorothiazide oral tablet 10-12.5mg, 20-12.5mg, 20-25mg</i> | 1 | MO |
| <i>ranolazine er oral tablet extended release 12-hour 1000mg, 500mg</i> | 1 | MO |
| <i>spironolactone-hctz oral tablet 25-25mg</i> | 1 | MO |
| <i>telmisartan-hctz oral tablet 40-12.5mg, 80-12.5mg, 80-25mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>triamterene-hctz oral capsule 37.5-25mg</i> | 1 | MO |
| <i>triamterene-hctz oral tablet 37.5-25mg, 75-50mg</i> | 1 | MO |
| <i>valsartan-hydrochlorothiazide oral tablet 160-12.5mg, 160-25mg, 320-12.5mg, 320-25mg, 80-12.5mg</i> | 1 | MO; QL (30 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------|
| VERQUVO ORAL TABLET 10MG, 2.5MG, 5MG | 1 | PA; MO |
| Diuretics, Loop | | |
| <i>bumetanide injection solution 0.25mg/ml</i> | 1 | |
| <i>bumetanide oral tablet 0.5mg, 1mg, 2mg</i> | 1 | MO |
| <i>furosemide injection solution 10mg/ml</i> | 1 | BvD |
| <i>furosemide oral solution 10mg/ml, 8mg/ml</i> | 1 | MO |
| <i>furosemide oral tablet 20mg, 40mg, 80mg</i> | 1 | MO |
| <i>torseamide oral tablet 10mg, 100mg, 20mg, 5mg</i> | 1 | MO |
| Diuretics, Potassium-Sparing | | |
| <i>amiloride hcl oral tablet 5mg</i> | 1 | MO |
| <i>eplerenone oral tablet 25mg, 50mg</i> | 1 | MO |
| KERENDIA ORAL TABLET 10MG, 20MG | 1 | MO; QL (30 EA per 30 days) |
| <i>spironolactone oral tablet 100mg, 25mg, 50mg</i> | 1 | MO |
| Diuretics, Thiazide | | |
| <i>chlorthalidone oral tablet 25mg, 50mg</i> | 1 | MO |
| <i>hydrochlorothiazide oral capsule 12.5mg</i> | 1 | MO |
| <i>hydrochlorothiazide oral tablet 12.5mg, 25mg, 50mg</i> | 1 | MO |
| <i>indapamide oral tablet 1.25mg, 2.5mg</i> | 1 | MO |
| <i>metolazone oral tablet 10mg, 2.5mg, 5mg</i> | 1 | MO |
| Dyslipidemics, Fibric Acid Derivatives | | |
| <i>fenofibrate micronized oral capsule 130mg, 134mg, 200mg, 67mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>fenofibrate micronized oral capsule 43mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>fenofibrate oral capsule 150mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>fenofibrate oral capsule 50mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>fenofibrate oral tablet 145mg, 160mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>fenofibrate oral tablet 48mg, 54mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>fenofibric acid oral capsule delayed release 135mg, 45mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>gemfibrozil oral tablet 600mg</i> | 1 | MO; QL (60 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------|
| Dyslipidemics, HMG COA Reductase Inhibitors | | |
| <i>atorvastatin calcium oral tablet 10mg, 20mg, 40mg, 80mg</i> | 1 | MO; QL (30 EA per 30 days) |
| LIVALO ORAL TABLET 1MG, 2MG, 4MG | 1 | MO; QL (30 EA per 30 days) |
| <i>lovastatin oral tablet 10mg</i> | 1 | MO; QL (45 EA per 30 days) |
| <i>lovastatin oral tablet 20mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>lovastatin oral tablet 40mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>pravastatin sodium oral tablet 10mg, 20mg, 40mg, 80mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>rosuvastatin calcium oral tablet 10mg, 20mg, 40mg, 5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>simvastatin oral tablet 10mg, 20mg, 40mg, 5mg, 80mg</i> | 1 | MO; QL (30 EA per 30 days) |
| ZYPITAMAG ORAL TABLET 2MG, 4MG | 1 | MO; QL (30 EA per 30 days) |
| Dyslipidemics, Other | | |
| <i>cholestyramine light oral packet 4gm</i> | 1 | MO |
| <i>cholestyramine oral packet 4gm</i> | 1 | MO |
| <i>colestipol hcl oral packet 5gm</i> | 1 | MO |
| <i>colestipol hcl oral tablet 1gm</i> | 1 | MO |
| <i>ezetimibe oral tablet 10mg</i> | 1 | MO; QL (30 EA per 30 days) |
| JUXTAPID ORAL CAPSULE 10MG, 20MG, 30MG, 5MG | 1 | PA |
| <i>niacin er (antihyperlipidemic) oral tablet extended release 1000mg, 500mg, 750mg</i> | 1 | MO |
| <i>omega-3-acid ethyl esters oral capsule 1gm</i> | 1 | MO |
| REPATHA PUSHTRONEX SYSTEM SUBCUTANEOUS SOLUTION CARTRIDGE 420MG/3.5ML | 1 | PA; MO |
| REPATHA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 140MG/ML | 1 | PA; MO |
| REPATHA SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 140MG/ML | 1 | PA; MO |
| VASCEPA ORAL CAPSULE 0.5GM, 1GM | 1 | MO |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| Vasodilators, Direct-Acting Arterial/ Venous | | |
| <i>hydralazine hcl oral tablet 10mg, 100mg, 25mg, 50mg</i> | 1 | MO |
| <i>isosorbide dinitrate oral tablet 10mg, 20mg, 30mg, 5mg</i> | 1 | MO |
| <i>isosorbide mononitrate er oral tablet extended release 24-hour 120mg, 30mg, 60mg</i> | 1 | MO |
| <i>isosorbide mononitrate oral tablet 10mg, 20mg</i> | 1 | MO |
| <i>minoxidil oral tablet 10mg, 2.5mg</i> | 1 | MO |
| NITRO-BID TRANSDERMAL OINTMENT 2% | 1 | MO |
| <i>nitroglycerin sublingual tablet sublingual 0.3mg, 0.4mg, 0.6mg</i> | 1 | MO |
| <i>nitroglycerin transdermal patch 24-hour 0.1mg/hr, 0.2mg/hr, 0.4mg/hr, 0.6mg/hr</i> | 1 | MO |
| <i>nitroglycerin translingual solution 0.4mg/spray</i> | 1 | MO |
| RECTIV RECTAL OINTMENT 0.4% | 1 | |

CENTRAL NERVOUS SYSTEM AGENTS

Attention Deficit Hyperactivity Disorder Agents, Amphetamines

| | | |
|---|---|-----------------------------|
| <i>amphetamine-dextroamphetamine oral tablet 10mg, 12.5mg, 15mg, 20mg, 5mg, 7.5mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>amphetamine-dextroamphetamine oral tablet 30mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>dextroamphetamine sulfate er oral capsule extended release 24-hour 10mg</i> | 1 | MO; QL (180 EA per 30 days) |
| <i>dextroamphetamine sulfate er oral capsule extended release 24-hour 15mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>dextroamphetamine sulfate er oral capsule extended release 24-hour 5mg</i> | 1 | MO; QL (360 EA per 30 days) |
| <i>dextroamphetamine sulfate oral solution 5mg/5ml</i> | 1 | MO; QL (1800ML per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 10mg</i> | 1 | MO; QL (180 EA per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 15mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 20mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 30mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 5mg</i> | 1 | MO; QL (150 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------|
| Attention Deficit Hyperactivity Disorder Agents, Non-Amphetamines | | |
| <i>atomoxetine hcl oral capsule 10mg, 100mg, 18mg, 25mg, 40mg, 60mg, 80mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>dexmethylphenidate hcl oral tablet 10mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>dexmethylphenidate hcl oral tablet 2.5mg</i> | 1 | MO; QL (240 EA per 30 days) |
| <i>dexmethylphenidate hcl oral tablet 5mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>guanfacine hcl er oral tablet extended release 24-hour 1mg, 2mg, 3mg, 4mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>methylphenidate hcl oral tablet 10mg, 20mg, 5mg</i> | 1 | MO; QL (90 EA per 30 days) |
| Central Nervous System, Other | | |
| AUSTEDO ORAL TABLET 12MG, 6MG, 9MG | 1 | PA; QL (120 EA per 30 days) |
| EVRYSDI ORAL SOLUTION RECONSTITUTED 0.75MG/ML | 1 | PA |
| NUEDEXTA ORAL CAPSULE 20-10MG | 1 | PA; MO |
| <i>riluzole oral tablet 50mg</i> | 1 | PA; MO |
| <i>tetrabenazine oral tablet 12.5mg</i> | 1 | PA; QL (240 EA per 30 days) |
| <i>tetrabenazine oral tablet 25mg</i> | 1 | PA; QL (120 EA per 30 days) |
| Fibromyalgia Agents | | |
| <i>pregabalin oral capsule 100mg, 150mg, 25mg, 50mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>pregabalin oral capsule 200mg, 225mg, 300mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>pregabalin oral capsule 75mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>pregabalin oral solution 20mg/ml</i> | 1 | MO; QL (900ML per 30 days) |
| SAVELLA ORAL TABLET 100MG, 12.5MG, 25MG, 50MG | 1 | MO; QL (60 EA per 30 days) |
| SAVELLA TITRATION PACK ORAL 12.5 & 25 & 50MG | 1 | QL (55 EA per 28 days) |
| Multiple Sclerosis Agents | | |
| AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT 30MCG/0.5ML | 1 | PA |
| AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT 30MCG/0.5ML | 1 | PA |
| BETASERON SUBCUTANEOUS KIT 0.3MG | 1 | PA |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--------------------------------|
| COPAXONE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20MG/ML, 40MG/ML | 1 | PA |
| <i>dalfampridine er oral tablet extended release</i> 12-hour 10mg | 1 | PA; MO; QL (60 EA per 30 days) |
| <i>dimethyl fumarate oral capsule delayed release</i> 120mg, 240mg | 1 | PA |
| <i>dimethyl fumarate starter pack oral 120 & 240mg</i> | 1 | PA |
| <i> fingolimod hcl oral capsule 0.5mg</i> | 1 | PA |
| KESIMPTA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 20MG/0.4ML | 1 | PA |
| MAYZENT ORAL TABLET 0.25MG, 1MG, 2MG | 1 | PA |
| MAYZENT STARTER PACK ORAL TABLET THERAPY PACK 0.25MG, 12 X 0.25MG | 1 | PA |

DENTAL AND ORAL AGENTS

Dental and Oral Agents

| | | |
|---|---|----|
| <i>chlorhexidine gluconate mouth/throat solution</i> 0.12% | 1 | |
| PERIOGARD MOUTH/THROAT SOLUTION 0.12% | 1 | |
| <i>pilocarpine hcl oral tablet 5mg, 7.5mg</i> | 1 | MO |
| <i>triamcinolone acetonide mouth/throat paste 0.1%</i> | 1 | |

DERMATOLOGICAL AGENTS

Acne and Rosacea Agents

| | | |
|--|---|----|
| ACCUTANE ORAL CAPSULE 10MG, 20MG, 30MG, 40MG | 1 | |
| <i>acitretin oral capsule 10mg, 17.5mg, 25mg</i> | 1 | PA |
| AMNESTEEM ORAL CAPSULE 10MG, 20MG, 40MG | 1 | |
| <i>benzoyl peroxide-erythromycin external gel 5-3%</i> | 1 | |
| CLARAVIS ORAL CAPSULE 10MG, 20MG, 30MG, 40MG | 1 | |
| <i>clindamycin phos-benzoyl perox external gel</i> 1.2-5% | 1 | |
| <i>isotretinoin oral capsule 10mg, 20mg, 30mg,</i> 40mg | 1 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| <i>tazarotene external cream 0.1%</i> | 1 | PA |
| <i>tazarotene external gel 0.05%, 0.1%</i> | 1 | PA |
| TAZORAC EXTERNAL CREAM 0.05% | 1 | PA |
| <i>tretinoin external cream 0.025%, 0.05%, 0.1%</i> | 1 | PA |
| <i>tretinoin external gel 0.01%, 0.025%, 0.05%</i> | 1 | PA |
| <i>Dermatitis and Pruitus Agents</i> | | |
| <i>alclometasone dipropionate external cream 0.05%</i> | 1 | |
| <i>alclometasone dipropionate external ointment 0.05%</i> | 1 | |
| <i>amcinonide external ointment 0.1%</i> | 1 | |
| <i>ammonium lactate external cream 12%</i> | 1 | |
| <i>ammonium lactate external lotion 12%</i> | 1 | |
| <i>betamethasone dipropionate aug external cream 0.05%</i> | 1 | |
| <i>betamethasone dipropionate aug external lotion 0.05%</i> | 1 | |
| <i>betamethasone dipropionate aug external ointment 0.05%</i> | 1 | |
| <i>betamethasone dipropionate external cream 0.05%</i> | 1 | |
| <i>betamethasone dipropionate external lotion 0.05%</i> | 1 | |
| <i>betamethasone dipropionate external ointment 0.05%</i> | 1 | |
| <i>betamethasone valerate external cream 0.1%</i> | 1 | |
| <i>betamethasone valerate external lotion 0.1%</i> | 1 | |
| <i>betamethasone valerate external ointment 0.1%</i> | 1 | |
| <i>clobetasol propionate e external cream 0.05%</i> | 1 | |
| <i>clobetasol propionate external cream 0.05%</i> | 1 | |
| <i>clobetasol propionate external gel 0.05%</i> | 1 | |
| <i>clobetasol propionate external ointment 0.05%</i> | 1 | |
| <i>clobetasol propionate external solution 0.05%</i> | 1 | |
| <i>desonide external cream 0.05%</i> | 1 | |
| <i>desonide external lotion 0.05%</i> | 1 | |
| <i>desonide external ointment 0.05%</i> | 1 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>desoximetasone external cream 0.05%, 0.25%</i> | 1 | |
| <i>desoximetasone external gel 0.05%</i> | 1 | |
| <i>desoximetasone external ointment 0.25%</i> | 1 | |
| EUCRISA EXTERNAL OINTMENT 2% | 1 | |
| <i>fluocinolone acetonide external cream 0.01%, 0.025%</i> | 1 | |
| <i>fluocinolone acetonide external ointment 0.025%</i> | 1 | |
| <i>fluocinolone acetonide external solution 0.01%</i> | 1 | |
| <i>fluocinonide emulsified base external cream 0.05%</i> | 1 | |
| <i>fluocinonide external gel 0.05%</i> | 1 | |
| <i>fluocinonide external ointment 0.05%</i> | 1 | |
| <i>fluocinonide external solution 0.05%</i> | 1 | |
| <i>fluticasone propionate external cream 0.05%</i> | 1 | |
| <i>fluticasone propionate external ointment 0.005%</i> | 1 | |
| <i>halobetasol propionate external cream 0.05%</i> | 1 | |
| <i>halobetasol propionate external ointment 0.05%</i> | 1 | |
| <i>hydrocortisone (perianal) external cream 2.5%</i> | 1 | |
| <i>hydrocortisone external cream 1%</i> | 1 | |
| <i>hydrocortisone external lotion 2.5%</i> | 1 | |
| <i>hydrocortisone external ointment 1%, 2.5%</i> | 1 | |
| <i>hydrocortisone valerate external cream 0.2%</i> | 1 | |
| <i>hydrocortisone valerate external ointment 0.2%</i> | 1 | |
| <i>mometasone furoate external cream 0.1%</i> | 1 | |
| <i>mometasone furoate external ointment 0.1%</i> | 1 | |
| <i>mometasone furoate external solution 0.1%</i> | 1 | |
| <i>pimecrolimus external cream 1%</i> | 1 | |
| <i>prednicarbate external ointment 0.1%</i> | 1 | |
| PROCTO-MED HC EXTERNAL CREAM 2.5% | 1 | |
| PROCTO-PAK EXTERNAL CREAM 1% | 1 | |
| PROCTOSOL HC EXTERNAL CREAM 2.5% | 1 | |
| PROCTOZONE-HC EXTERNAL CREAM 2.5% | 1 | |
| <i>selenium sulfide external lotion 2.5%</i> | 1 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| <i>tacrolimus external ointment 0.03%, 0.1%</i> | 1 | |
| <i>triamcinolone acetonide external cream 0.025%, 0.1%, 0.5%</i> | 1 | |
| <i>triamcinolone acetonide external lotion 0.025%, 0.1%</i> | 1 | |
| <i>triamcinolone acetonide external ointment 0.025%, 0.1%, 0.5%</i> | 1 | |
| <i>Dermatological Agents, Other</i> | | |
| <i>calcipotriene external solution 0.005%</i> | 1 | |
| <i>clotrimazole-betamethasone external cream 1-0.05%</i> | 1 | |
| <i>clotrimazole-betamethasone external lotion 1-0.05%</i> | 1 | |
| <i>diclofenac sodium external gel 3%</i> | 1 | PA |
| <i>fluorouracil external cream 5%</i> | 1 | |
| <i>fluorouracil external solution 2%, 5%</i> | 1 | |
| <i>global alcohol prep ease pad 70%</i> | 1 | |
| <i>hydrocortisone ace-pramoxine external cream 1-1%</i> | 1 | |
| HYFTOR EXTERNAL GEL 0.2% | 1 | PA |
| <i>imiquimod external cream 5%</i> | 1 | |
| <i>nystatin-triamcinolone external cream 100000-0.1unit/gm-%</i> | 1 | |
| <i>nystatin-triamcinolone external ointment 100000-0.1unit/gm-%</i> | 1 | |
| PANRETIN EXTERNAL GEL 0.1% | 1 | PA |
| <i>podofilox external solution 0.5%</i> | 1 | |
| REGRANEX EXTERNAL GEL 0.01% | 1 | PA |
| SANTYL EXTERNAL OINTMENT 250UNIT/GM | 1 | |
| <i>silver sulfadiazine external cream 1%</i> | 1 | |
| SSD EXTERNAL CREAM 1% | 1 | |
| <i>Pediculicides/Scabicides</i> | | |
| <i>malathion external lotion 0.5%</i> | 1 | |
| <i>permethrin external cream 5%</i> | 1 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| Topical Anti-Infectives | | |
| <i>ciclopirox external gel 0.77%</i> | 1 | |
| <i>ciclopirox external shampoo 1%</i> | 1 | |
| <i>ciclopirox external solution 8%</i> | 1 | |
| <i>clindamycin phosphate external gel 1%</i> | 1 | |
| <i>clindamycin phosphate external lotion 1%</i> | 1 | |
| <i>clindamycin phosphate external solution 1%</i> | 1 | |
| <i>ery external pad 2%</i> | 1 | |
| <i>erythromycin external gel 2%</i> | 1 | |
| <i>erythromycin external solution 2%</i> | 1 | |
| <i>mupirocin calcium external cream 2%</i> | 1 | |
| <i>mupirocin external ointment 2%</i> | 1 | |
| ELECTROLYTES/MINERALS/METALS/VITAMINS | | |
| Electrolyte/ Mineral Replacement | | |
| <i>carglumic acid oral tablet soluble 200mg</i> | 1 | PA |
| ISOLYTE-S PH 7.4 INTRAVENOUS SOLUTION | 1 | BvD |
| <i>kcl in dextrose-nacl intravenous solution 10-5-0.45 meq/l-%-%, 20-5-0.2 meq/l-%-%, 20-5-0.45 meq/l-%-%, 20-5-0.9 meq/l-%-%, 30-5-0.45 meq/l-%-%, 40-5-0.45 meq/l-%-%, 40-5-0.9 meq/l-%-%</i> | 1 | BvD |
| <i>kcl-lactated ringers-d5w intravenous solution 20 meq/l</i> | 1 | BvD |
| KLOR-CON 10 ORAL TABLET EXTENDED RELEASE 10 MEQ | 1 | MO |
| KLOR-CON M10 ORAL TABLET EXTENDED RELEASE 10 MEQ | 1 | MO |
| KLOR-CON M15 ORAL TABLET EXTENDED RELEASE 15 MEQ | 1 | MO |
| KLOR-CON M20 ORAL TABLET EXTENDED RELEASE 20 MEQ | 1 | MO |
| KLOR-CON ORAL PACKET 20 MEQ | 1 | MO |
| KLOR-CON ORAL TABLET EXTENDED RELEASE 8 MEQ | 1 | MO |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| <i>magnesium sulfate injection solution 50%, 50% (10ml syringe)</i> | 1 | |
| PLASMA-LYTE 148 INTRAVENOUS SOLUTION | 1 | BvD |
| PLASMA-LYTE A INTRAVENOUS SOLUTION | 1 | BvD |
| <i>potassium chloride crys er oral tablet extended release 10 meq, 15 meq, 20 meq</i> | 1 | MO |
| <i>potassium chloride er oral capsule extended release 10 meq, 8 meq</i> | 1 | MO |
| <i>potassium chloride er oral tablet extended release 10 meq, 20 meq, 8 meq</i> | 1 | MO |
| <i>potassium chloride in nacl intravenous solution 20-0.45 meq/l-%, 20-0.9 meq/l-%, 40-0.9 meq/l-%</i> | 1 | BvD |
| <i>potassium chloride intravenous solution 2 meq/ml, 2 meq/ml (20 ml), 20 meq/100ml</i> | 1 | BvD |
| <i>potassium chloride oral packet 20 meq</i> | 1 | MO |
| <i>potassium chloride oral solution 20 meq/15ml (10%), 40 meq/15ml (20%)</i> | 1 | MO |
| <i>potassium citrate er oral tablet extended release 10 meq (1080mg), 15 meq (1620mg), 5 meq (540mg)</i> | 1 | |
| <i>potassium cl in dextrose 5% intravenous solution 20 meq/l</i> | 1 | BvD |
| <i>sodium chloride intravenous solution 0.45%, 0.9%, 3%, 5%</i> | 1 | |
| <i>sodium chloride irrigation solution 0.9%</i> | 1 | |
| <i>sodium fluoride oral tablet 2.2 (1 f) mg</i> | 1 | |
| Electrolyte/Mineral/Metal Modifiers | | |
| <i>deferasirox granules oral packet 180mg, 360mg, 90mg</i> | 1 | PA |
| <i>deferasirox oral tablet 180mg, 360mg</i> | 1 | PA |
| <i>deferasirox oral tablet 90mg</i> | 1 | PA; MO |
| <i>deferasirox oral tablet soluble 125mg, 250mg, 500mg</i> | 1 | PA |
| <i>deferiprone oral tablet 1000mg, 500mg</i> | 1 | PA |
| FERRIPROX ORAL SOLUTION 100MG/ML | 1 | PA |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------|
| FERRIPROX TWICE-A-DAY ORAL TABLET 1000MG | 1 | PA |
| LOKELMA ORAL PACKET 10GM, 5GM | 1 | MO |
| <i>sodium polystyrene sulfonate oral powder</i> | 1 | |
| SPS ORAL SUSPENSION 15GM/60ML | 1 | |
| <i>tolvaptan oral tablet 15mg</i> | 1 | PA; QL (120 EA per 30 days) |
| <i>tolvaptan oral tablet 30mg</i> | 1 | PA; QL (60 EA per 30 days) |
| <i>trientine hcl oral capsule 250mg</i> | 1 | PA |
| Electrolytes/Minerals/Metals/Vitamins | | |
| CLINIMIX E/DEXTROSE (2.75/5) INTRAVENOUS SOLUTION 2.75% | 1 | BvD |
| CLINIMIX E/DEXTROSE (4.25/10) INTRAVENOUS SOLUTION 4.25% | 1 | BvD |
| CLINIMIX E/DEXTROSE (4.25/5) INTRAVENOUS SOLUTION 4.25% | 1 | BvD |
| CLINIMIX E/DEXTROSE (5/15) INTRAVENOUS SOLUTION 5% | 1 | BvD |
| CLINIMIX E/DEXTROSE (5/20) INTRAVENOUS SOLUTION 5% | 1 | BvD |
| CLINIMIX/DEXTROSE (4.25/10) INTRAVENOUS SOLUTION 4.25% | 1 | BvD |
| CLINIMIX/DEXTROSE (4.25/5) INTRAVENOUS SOLUTION 4.25% | 1 | BvD |
| CLINIMIX/DEXTROSE (5/15) INTRAVENOUS SOLUTION 5% | 1 | BvD |
| CLINIMIX/DEXTROSE (5/20) INTRAVENOUS SOLUTION 5% | 1 | BvD |
| <i>dextrose intravenous solution 10%, 5%</i> | 1 | BvD |
| <i>dextrose-nacl intravenous solution 10-0.2%, 10-0.45%, 2.5-0.45%</i> | 1 | BvD |
| <i>dextrose-nacl intravenous solution 5-0.2%, 5-0.45%, 5-0.9%</i> | 1 | |
| DOJOLVI ORAL LIQUID 100% | 1 | PA |
| INTRALIPID INTRAVENOUS EMULSION 20%, 30% | 1 | BvD |
| ISOLYTE-P IN D5W INTRAVENOUS SOLUTION | 1 | BvD |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------|
| <i>levocarnitine oral solution 1gm/10ml</i> | 1 | MO |
| <i>levocarnitine oral tablet 330mg</i> | 1 | MO |
| NUTRILIPID INTRAVENOUS EMULSION 20% | 1 | BvD |
| PREMASOL INTRAVENOUS SOLUTION 10% | 1 | BvD |
| <i>prenatal oral tablet 27-1mg</i> | 1 | |
| PROSOL INTRAVENOUS SOLUTION 20% | 1 | BvD |
| TPN ELECTROLYTES INTRAVENOUS CONCENTRATE | 1 | BvD |
| TRAVASOL INTRAVENOUS SOLUTION 10% | 1 | BvD |
| TROPHAMINE INTRAVENOUS SOLUTION 10% | 1 | BvD |
| Phosphate Binders | | |
| AURYXIA ORAL TABLET 1GM 210MG(Fe) | 1 | PA; MO |
| <i>calcium acetate (phos binder) oral capsule 667mg</i> | 1 | MO |
| <i>calcium acetate oral tablet 667mg</i> | 1 | MO |
| <i>sevelamer carbonate oral packet 0.8gm</i> | 1 | QL (540 EA per 30 days) |
| <i>sevelamer carbonate oral packet 2.4gm</i> | 1 | QL (180 EA per 30 days) |
| <i>sevelamer carbonate oral tablet 800mg</i> | 1 | MO; QL (540 EA per 30 days) |
| VELPHORO ORAL TABLET CHEWABLE 500MG | 1 | MO |
| GASTROINTESTINAL AGENTS | | |
| Anti-Constipation Agents | | |
| <i>constulose oral solution 10gm/15ml</i> | 1 | MO |
| <i>enulose oral solution 10gm/15ml</i> | 1 | MO |
| <i>generlac oral solution 10gm/15ml</i> | 1 | MO |
| <i>lactulose oral solution 10gm/15ml</i> | 1 | MO |
| LINZESS ORAL CAPSULE 145MCG, 290MCG, 72MCG | 1 | MO; QL (30 EA per 30 days) |
| <i>lubiprostone oral capsule 24mcg, 8mcg</i> | 1 | MO; QL (60 EA per 30 days) |
| MOVANTIK ORAL TABLET 12.5MG, 25MG | 1 | QL (30 EA per 30 days) |
| Anti-Diarrheal Agents | | |
| <i>alosetron hcl oral tablet 0.5mg, 1mg</i> | 1 | QL (60 EA per 30 days) |
| <i>diphenoxylate-atropine oral liquid 2.5-0.025mg/5ml</i> | 1 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| <i>diphenoxylate-atropine oral tablet 2.5-0.025mg</i> | 1 | |
| <i>loperamide hcl oral capsule 2mg</i> | 1 | |
| Antispasmodics, Gastrointestinal | | |
| <i>dicyclomine hcl oral capsule 10mg</i> | 1 | |
| <i>dicyclomine hcl oral solution 10mg/5ml</i> | 1 | |
| <i>dicyclomine hcl oral tablet 20mg</i> | 1 | |
| <i>glycopyrrolate oral tablet 1mg, 2mg</i> | 1 | |
| Gastrointestinal Agents, Other | | |
| BYLVAY (PELLETS) ORAL CAPSULE SPRINKLE 200MCG | 1 | PA |
| BYLVAY ORAL CAPSULE 1200MCG, 400MCG | 1 | PA |
| CLENPIQ ORAL SOLUTION 10-3.5-12MG-GM -GM/160ML | 1 | |
| GATTEX SUBCUTANEOUS KIT 5MG | 1 | PA |
| GAVILYTE-C ORAL SOLUTION RECONSTITUTED 240GM | 1 | |
| GAVILYTE-G ORAL SOLUTION RECONSTITUTED 236GM | 1 | |
| LIVMARLI ORAL SOLUTION 9.5MG/ML | 1 | PA |
| <i>metoclopramide hcl oral solution 5mg/5ml</i> | 1 | |
| <i>metoclopramide hcl oral tablet 10mg, 5mg</i> | 1 | MO |
| <i>na sulfate-k sulfate-mg sulf oral solution 17.5-3.13-1.6gm/177ml</i> | 1 | |
| <i>peg 3350-kcl-na bicarb-nacl oral solution reconstituted 420gm</i> | 1 | |
| <i>peg-3350/electrolytes oral solution reconstituted 236gm</i> | 1 | |
| SUPREP BOWEL PREP KIT ORAL SOLUTION 17.5-3.13-1.6GM/177ML | 1 | |
| SUTAB ORAL TABLET 1479-225-188MG | 1 | |
| <i>ursodiol oral capsule 300mg</i> | 1 | MO |
| <i>ursodiol oral tablet 250mg, 500mg</i> | 1 | MO |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| Histamine2 (H2) Receptor Antagonists | | |
| <i>famotidine oral suspension reconstituted 40mg/5ml</i> | 1 | MO |
| <i>famotidine oral tablet 20mg, 40mg</i> | 1 | MO |
| <i>nizatidine oral capsule 150mg, 300mg</i> | 1 | MO |
| Protectants | | |
| <i>misoprostol oral tablet 100mcg, 200mcg</i> | 1 | MO |
| <i>sucralfate oral suspension 1gm/10ml</i> | 1 | MO |
| <i>sucralfate oral tablet 1gm</i> | 1 | MO |
| Proton Pump Inhibitors | | |
| <i>dexlansoprazole oral capsule delayed release 30mg, 60mg</i> | 1 | MO |
| <i>esomeprazole magnesium oral capsule delayed release 20mg, 40mg</i> | 1 | MO |
| <i>lansoprazole oral capsule delayed release 15mg, 30mg</i> | 1 | MO |
| <i>omeprazole oral capsule delayed release 10mg, 20mg, 40mg</i> | 1 | MO |
| <i>pantoprazole sodium oral tablet delayed release 20mg, 40mg</i> | 1 | MO |
| GENETIC OR ENZYME OR PROTEIN DISORDER: REPLACEMENT, MODIFIERS, TREATMENT | | |
| Genetic or Enzyme or Protein Disorder: Replacement, Modifiers, Treatment | | |
| <i>betaine oral powder</i> | 1 | |
| CREON ORAL CAPSULE DELAYED RELEASE PARTICLES 12000-38000UNIT, 24000-76000UNIT, 3000-9500UNIT, 36000-114000UNIT, 6000-19000UNIT | 1 | MO |
| <i>cromolyn sodium oral concentrate 100mg/5ml</i> | 1 | MO |
| CYSTAGON ORAL CAPSULE 150MG, 50MG | 1 | PA; MO |
| ENDARI ORAL PACKET 5GM | 1 | PA |
| GALAFOLD ORAL CAPSULE 123MG | 1 | PA |
| <i>miglustat oral capsule 100mg</i> | 1 | PA |
| <i>nitisinone oral capsule 10mg, 2mg, 5mg</i> | 1 | PA |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------|
| ORFADIN ORAL CAPSULE 20MG | 1 | PA |
| PROLASTIN-C INTRAVENOUS SOLUTION RECONSTITUTED 1000MG | 1 | PA |
| RAVICTI ORAL LIQUID 1.1GM/ML | 1 | PA |
| <i>sapropterin dihydrochloride oral packet 100mg, 500mg</i> | 1 | PA |
| <i>sapropterin dihydrochloride oral tablet 100mg</i> | 1 | PA |
| TEGSEDI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 284MG/1.5ML | 1 | PA |
| VYNDAMAX ORAL CAPSULE 61MG | 1 | PA; QL (30 EA per 30 days) |
| XURIDEN ORAL PACKET 2GM | 1 | PA |
| ZENPEP ORAL CAPSULE DELAYED RELEASE PARTICLES 10000-32000UNIT, 15000-47000UNIT, 20000-63000UNIT, 25000-79000UNIT, 3000-10000UNIT, 40000-126000UNIT, 5000-24000UNIT | 1 | MO |

GENITOURINARY AGENTS

Antispasmodics, Urinary

| | | |
|---|---|-----------------------------|
| <i>darifenacin hydrobromide er oral tablet extended release 24-hour 15mg, 7.5mg</i> | 1 | MO |
| <i>fesoterodine fumarate er oral tablet extended release 24-hour 4mg, 8mg</i> | 1 | MO; QL (30 EA per 30 days) |
| MYRBETRIQ ORAL SUSPENSION RECONSTITUTED ER 8MG/ML | 1 | MO; QL (300ML per 30 days) |
| MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24-HOUR 25MG, 50MG | 1 | MO; QL (30 EA per 30 days) |
| <i>oxybutynin chloride er oral tablet extended release 24-hour 10mg, 15mg, 5mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>oxybutynin chloride oral syrup 5mg/5ml</i> | 1 | MO; QL (600ML per 30 days) |
| <i>oxybutynin chloride oral tablet 5mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>solifenacin succinate oral tablet 10mg, 5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>tolterodine tartrate er oral capsule extended release 24-hour 2mg, 4mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>tolterodine tartrate oral tablet 1mg, 2mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>tropium chloride er oral capsule extended release 24-hour 60mg</i> | 1 | MO; QL (30 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------|
| <i>trospium chloride oral tablet 20mg</i> | 1 | MO; QL (60 EA per 30 days) |
| Benign Prostatic Hypertrophy Agents | | |
| <i>alfuzosin hcl er oral tablet extended release 24-hour 10mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>dutasteride oral capsule 0.5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>dutasteride-tamsulosin hcl oral capsule 0.5-0.4mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>finasteride oral tablet 5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>silodosin oral capsule 4mg, 8mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>tamsulosin hcl oral capsule 0.4mg</i> | 1 | MO; QL (60 EA per 30 days) |
| Genitourinary Agents, Other | | |
| <i>bethanechol chloride oral tablet 10mg, 25mg, 5mg, 50mg</i> | 1 | |
| ELMIRON ORAL CAPSULE 100MG | 1 | |
| <i>penicillamine oral tablet 250mg</i> | 1 | |
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (ADRENAL) | | |
| Hormonal Agents, Stimulant/ Replacement/ Modifying (Adrenal) | | |
| <i>dexamethasone oral solution 0.5mg/5ml</i> | 1 | |
| <i>dexamethasone oral tablet 0.5mg, 0.75mg, 1mg, 1.5mg, 2mg, 4mg, 6mg</i> | 1 | |
| <i>fludrocortisone acetate oral tablet 0.1mg</i> | 1 | MO |
| <i>hydrocortisone oral tablet 10mg, 20mg, 5mg</i> | 1 | |
| ISTURISA ORAL TABLET 1MG | 1 | PA; QL (240 EA per 30 days) |
| ISTURISA ORAL TABLET 10MG | 1 | PA; QL (180 EA per 30 days) |
| ISTURISA ORAL TABLET 5MG | 1 | PA; QL (120 EA per 30 days) |
| <i>methylprednisolone oral tablet 16mg, 32mg, 4mg, 8mg</i> | 1 | BvD |
| <i>methylprednisolone oral tablet therapy pack 4mg</i> | 1 | |
| <i>prednisolone oral solution 15mg/5ml</i> | 1 | BvD |
| <i>prednisolone sodium phosphate oral solution 10mg/5ml, 20mg/5ml, 25mg/5ml, 6.7 (5 base) mg/5ml</i> | 1 | BvD |
| <i>prednisolone sodium phosphate oral tablet dispersible 10mg, 15mg, 30mg</i> | 1 | BvD |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| PREDNISONE INTENSOL ORAL CONCENTRATE 5MG/ML | 1 | BvD |
| <i>prednisone oral solution 5mg/5ml</i> | 1 | BvD |
| <i>prednisone oral tablet 1mg, 10mg, 2.5mg, 20mg, 5mg, 50mg</i> | 1 | BvD |
| <i>prednisone oral tablet therapy pack 10mg (21), 10mg (48), 5mg (21), 5mg (48)</i> | 1 | |

HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (PITUITARY)

Hormonal Agents, Stimulant/ Replacement/ Modifying (Pituitary)

| | | |
|---|---|----|
| <i>desmopressin acetate oral tablet 0.1mg, 0.2mg</i> | 1 | MO |
| <i>desmopressin acetate spray nasal solution 0.01%</i> | 1 | MO |
| INCRELEX SUBCUTANEOUS SOLUTION 40MG/4ML | 1 | PA |
| NOCDURNA SUBLINGUAL TABLET SUBLINGUAL 27.7MCG, 55.3MCG | 1 | MO |
| OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE 10MG/1.5ML, 5MG/1.5ML | 1 | PA |
| OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED 5.8MG | 1 | PA |

HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (SEX HORMONES/ MODIFIERS)

Androgens

| | | |
|---|---|----|
| ANDRODERM TRANSDERMAL PATCH 24-HOUR 2MG/24HR, 4MG/24HR | 1 | MO |
| <i>danazol oral capsule 100mg, 200mg, 50mg</i> | 1 | |
| <i>oxandrolone oral tablet 10mg, 2.5mg</i> | 1 | PA |
| <i>testosterone cypionate intramuscular solution 100mg/ml, 200mg/ml, 200mg/ml (1 ml)</i> | 1 | MO |
| <i>testosterone enanthate intramuscular solution 200mg/ml</i> | 1 | MO |
| <i>testosterone transdermal gel 10mg/act (2%), 12.5mg/act (1%), 20.25mg/1.25gm (1.62%), 20.25mg/act (1.62%), 25mg/2.5gm (1%), 40.5mg/2.5gm (1.62%), 50mg/5gm (1%)</i> | 1 | MO |
| <i>testosterone transdermal solution 30mg/act</i> | 1 | MO |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| Estrogens | | |
| DUAVEE ORAL TABLET 0.45-20MG | 1 | MO |
| <i>estradiol oral tablet 0.5mg, 1mg, 2mg</i> | 1 | MO |
| <i>estradiol transdermal patch twice weekly 0.025mg/24hr, 0.0375mg/24hr, 0.05mg/24hr, 0.075mg/24hr, 0.1mg/24hr</i> | 1 | MO |
| <i>estradiol transdermal patch weekly 0.025mg/24hr, 0.0375mg/24hr, 0.05mg/24hr, 0.06mg/24hr, 0.075mg/24hr, 0.1mg/24hr</i> | 1 | MO |
| <i>estradiol vaginal cream 0.1mg/gm</i> | 1 | MO |
| <i>estradiol vaginal tablet 10mcg</i> | 1 | MO |
| IMVEXXY MAINTENANCE PACK VAGINAL INSERT 10MCG, 4MCG | 1 | MO |
| IMVEXXY STARTER PACK VAGINAL INSERT 10MCG, 4MCG | 1 | MO |
| MENEST ORAL TABLET 0.3MG, 0.625MG, 1.25MG, 2.5MG | 1 | MO |
| PREMARIN ORAL TABLET 0.3MG, 0.45MG, 0.625MG, 0.9MG, 1.25MG | 1 | MO |
| PREMARIN VAGINAL CREAM 0.625MG/GM | 1 | MO |
| Hormonal Agents, Stimulant/ Replacement/ Modifying (Sex Hormones/ Modifiers) | | |
| ALTAVERA ORAL TABLET 0.15-30MG-MCG | 1 | MO |
| <i>alyacen 1/35 oral tablet 1-35mg-mcg</i> | 1 | MO |
| APRI ORAL TABLET 0.15-30MG-MCG | 1 | MO |
| ARANELLE ORAL TABLET 0.5/1/0.5-35MG-MCG | 1 | MO |
| AUBRA EQ ORAL TABLET 0.1-20MG-MCG | 1 | MO |
| AVIANE ORAL TABLET 0.1-20MG-MCG | 1 | MO |
| BALZIVA ORAL TABLET 0.4-35MG-MCG | 1 | MO |
| BLISOVI FE 1.5/30 ORAL TABLET 1.5-30MG-MCG | 1 | MO |
| <i>briellyn oral tablet 0.4-35mg-mcg</i> | 1 | MO |
| CRYSSELLE-28 ORAL TABLET 0.3-30MG-MCG | 1 | MO |
| CYRED EQ ORAL TABLET 0.15-30MG-MCG | 1 | MO |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| <i>desogestrel-ethinyl estradiol oral tablet</i> 0.15-0.02/0.01mg (21/5), 0.15-30mg-mcg | 1 | MO |
| <i>drospirenone-ethinyl estradiol oral tablet</i> 3-0.02mg, 3-0.03mg | 1 | MO |
| ELURYNG VAGINAL RING 0.12-0.015MG/24HR | 1 | MO |
| EMOQUETTE ORAL TABLET 0.15-30MG-MCG | 1 | MO |
| ENPRESSE-28 ORAL TABLET 50-30/75-40/ 125-30MCG | 1 | MO |
| ENSKYCE ORAL TABLET 0.15-30MG-MCG | 1 | MO |
| ESTARYLLA ORAL TABLET 0.25-35MG-MCG | 1 | MO |
| <i>ethynodiol diac-eth estradiol oral tablet</i> 1-35mg-mcg, 1-50mg-mcg | 1 | MO |
| <i>etonogestrel-ethinyl estradiol vaginal ring</i> 0.12-0.015mg/24hr | 1 | MO |
| FALMINA ORAL TABLET 0.1-20MG-MCG | 1 | MO |
| FEMYNOR ORAL TABLET 0.25-35MG-MCG | 1 | MO |
| ICLEVIA ORAL TABLET 0.15-0.03MG | 1 | MO |
| INTRAROSA VAGINAL INSERT 6.5MG | 1 | PA; MO |
| INTROVALE ORAL TABLET 0.15-0.03MG | 1 | MO |
| ISIBLOOM ORAL TABLET 0.15-30MG-MCG | 1 | MO |
| JASMIEL ORAL TABLET 3-0.02MG | 1 | MO |
| JULEBER ORAL TABLET 0.15-30MG-MCG | 1 | MO |
| JUNEL 1.5/30 ORAL TABLET 1.5-30MG-MCG | 1 | MO |
| JUNEL 1/20 ORAL TABLET 1-20MG-MCG | 1 | MO |
| JUNEL FE 1.5/30 ORAL TABLET 1.5-30MG-MCG | 1 | MO |
| JUNEL FE 1/20 ORAL TABLET 1-20MG-MCG | 1 | MO |
| KARIVA ORAL TABLET 0.15-0.02/0.01MG (21/5) | 1 | MO |
| KELNOR 1/35 ORAL TABLET 1-35MG-MCG | 1 | MO |
| KELNOR 1/50 ORAL TABLET 1-50MG-MCG | 1 | MO |
| KURVELO ORAL TABLET 0.15-30MG-MCG | 1 | MO |
| LARIN 1.5/30 ORAL TABLET 1.5-30MG-MCG | 1 | MO |
| LARIN 1/20 ORAL TABLET 1-20MG-MCG | 1 | MO |
| LARIN FE 1.5/30 ORAL TABLET 1.5-30MG-MCG | 1 | MO |
| LARIN FE 1/20 ORAL TABLET 1-20MG-MCG | 1 | MO |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| LEENA ORAL TABLET 0.5/1/0.5-35MG-MCG | 1 | MO |
| LESSINA ORAL TABLET 0.1-20MG-MCG | 1 | MO |
| LEVONEST ORAL TABLET 50-30/75-40/ 125-30MCG | 1 | MO |
| <i>levonorgest-eth estrad 91-day oral tablet 0.15-0.03mg</i> | 1 | MO |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.1-20mg-mcg, 0.15-30mg-mcg</i> | 1 | MO |
| <i>levonorg-eth estrad triphasic oral tablet 50-30/75-40/ 125-30mcg</i> | 1 | MO |
| LEVORA 0.15/30 (28) ORAL TABLET 0.15-30MG-MCG | 1 | MO |
| LORYNA ORAL TABLET 3-0.02MG | 1 | MO |
| LOW-OGESTREL ORAL TABLET 0.3-30MG-MCG | 1 | MO |
| LUTERA ORAL TABLET 0.1-20MG-MCG | 1 | MO |
| <i>marlissa oral tablet 0.15-30mg-mcg</i> | 1 | MO |
| MICROGESTIN 1.5/30 ORAL TABLET 1.5-30MG-MCG | 1 | MO |
| MICROGESTIN 1/20 ORAL TABLET 1-20MG-MCG | 1 | MO |
| MICROGESTIN FE 1.5/30 ORAL TABLET 1.5-30MG-MCG | 1 | MO |
| MICROGESTIN FE 1/20 ORAL TABLET 1-20MG-MCG | 1 | MO |
| MILI ORAL TABLET 0.25-35MG-MCG | 1 | MO |
| NECON 0.5/35 (28) ORAL TABLET 0.5-35MG-MCG | 1 | MO |
| NIKKI ORAL TABLET 3-0.02MG | 1 | MO |
| <i>norethin ace-eth estrad-fe oral tablet 1-20mg-mcg</i> | 1 | MO |
| <i>norethindrone acet-ethinyl est oral tablet 1-20mg-mcg</i> | 1 | MO |
| <i>norethindrone-eth estradiol oral tablet 1-5mg-mcg</i> | 1 | MO |
| <i>norgestimate-eth estradiol oral tablet 0.25-35mg-mcg</i> | 1 | MO |
| <i>norgestim-eth estrad triphasic oral tablet 0.18/0.215/0.25mg-35mcg</i> | 1 | MO |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| NORTREL 0.5/35 (28) ORAL TABLET 0.5-35MG-MCG | 1 | MO |
| NORTREL 1/35 (21) ORAL TABLET 1-35MG-MCG | 1 | MO |
| NORTREL 1/35 (28) ORAL TABLET 1-35MG-MCG | 1 | MO |
| NORTREL 7/7/7 ORAL TABLET 0.5/0.75/1-35MG-MCG | 1 | MO |
| NYLIA 1/35 ORAL TABLET 1-35MG-MCG | 1 | MO |
| NYLIA 7/7/7 ORAL TABLET 0.5/0.75/1-35MG-MCG | 1 | MO |
| NYMYO ORAL TABLET 0.25-35MG-MCG | 1 | MO |
| OCELLA ORAL TABLET 3-0.03MG | 1 | MO |
| OSPHENA ORAL TABLET 60MG | 1 | PA; MO |
| PIMTREA ORAL TABLET 0.15-0.02/0.01MG (21/5) | 1 | MO |
| PIRMELLA 1/35 ORAL TABLET 1-35MG-MCG | 1 | MO |
| PORTIA-28 ORAL TABLET 0.15-30MG-MCG | 1 | MO |
| PREMPHASE ORAL TABLET 0.625-5MG | 1 | MO |
| PREMPRO ORAL TABLET 0.3-1.5MG, 0.45-1.5MG, 0.625-2.5MG, 0.625-5MG | 1 | MO |
| RECLIPSEN ORAL TABLET 0.15-30MG-MCG | 1 | MO |
| SETLAKIN ORAL TABLET 0.15-0.03MG | 1 | MO |
| SPRINTEC 28 ORAL TABLET 0.25-35MG-MCG | 1 | MO |
| SRONYX ORAL TABLET 0.1-20MG-MCG | 1 | MO |
| SYEDA ORAL TABLET 3-0.03MG | 1 | MO |
| TARINA FE 1/20 EQ ORAL TABLET 1-20MG-MCG | 1 | MO |
| TRI-ESTARYLLA ORAL TABLET 0.18/0.215/0.25MG-35MCG | 1 | MO |
| TRI-MILI ORAL TABLET 0.18/0.215/0.25MG-35MCG | 1 | MO |
| TRI-NYMYO ORAL TABLET 0.18/0.215/0.25MG-35MCG | 1 | MO |
| TRI-SPRINTEC ORAL TABLET 0.18/0.215/0.25MG-35MCG | 1 | MO |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| TRIVORA (28) ORAL TABLET 50-30/75-40/ 125-30MCG | 1 | MO |
| TRI-VYLIBRA ORAL TABLET 0.18/0.215/0.25MG-35MCG | 1 | MO |
| VELIVET ORAL TABLET 0.1/0.125/0.15 -0.025MG | 1 | MO |
| VESTURA ORAL TABLET 3-0.02MG | 1 | MO |
| VIENVA ORAL TABLET 0.1-20MG-MCG | 1 | MO |
| VYFEMLA ORAL TABLET 0.4-35MG-MCG | 1 | MO |
| VYLIBRA ORAL TABLET 0.25-35MG-MCG | 1 | MO |
| ZOVIA 1/35 (28) ORAL TABLET 1-35MG-MCG | 1 | MO |
| Progestins | | |
| CAMILA ORAL TABLET 0.35MG | 1 | MO |
| DEBLITANE ORAL TABLET 0.35MG | 1 | MO |
| ERRIN ORAL TABLET 0.35MG | 1 | MO |
| INCASSIA ORAL TABLET 0.35MG | 1 | MO |
| LYLEQ ORAL TABLET 0.35MG | 1 | MO |
| LYZA ORAL TABLET 0.35MG | 1 | MO |
| <i>medroxyprogesterone acetate intramuscular suspension 150mg/ml</i> | 1 | |
| <i>medroxyprogesterone acetate intramuscular suspension prefilled syringe 150mg/ml</i> | 1 | |
| <i>medroxyprogesterone acetate oral tablet 10mg, 2.5mg, 5mg</i> | 1 | MO |
| <i>megestrol acetate oral suspension 40mg/ml</i> | 1 | |
| <i>megestrol acetate oral suspension 625mg/5ml</i> | 1 | MO |
| <i>megestrol acetate oral tablet 20mg, 40mg</i> | 1 | |
| NORA-BE ORAL TABLET 0.35MG | 1 | MO |
| <i>norethindrone acetate oral tablet 5mg</i> | 1 | MO |
| <i>norethindrone oral tablet 0.35mg</i> | 1 | MO |
| <i>progesterone oral capsule 100mg, 200mg</i> | 1 | MO |
| SHAROBEL ORAL TABLET 0.35MG | 1 | MO |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (THYROID) | | |
| <i>Hormonal Agents, Stimulant/ Replacement/ Modifying (Thyroid)</i> | | |
| EUTHYROX ORAL TABLET 100MCG, 112MCG, 125MCG, 137MCG, 150MCG, 175MCG, 200MCG, 25MCG, 50MCG, 75MCG, 88MCG | 1 | MO |
| LEVO-T ORAL TABLET 100MCG, 112MCG, 125MCG, 137MCG, 150MCG, 175MCG, 200MCG, 25MCG, 300MCG, 50MCG, 75MCG, 88MCG | 1 | MO |
| <i>levothyroxine sodium oral tablet 100mcg, 112mcg, 125mcg, 137mcg, 150mcg, 175mcg, 200mcg, 25mcg, 300mcg, 50mcg, 75mcg, 88mcg</i> | 1 | MO |
| LEVOXYL ORAL TABLET 100MCG, 112MCG, 125MCG, 137MCG, 150MCG, 175MCG, 200MCG, 25MCG, 50MCG, 75MCG, 88MCG | 1 | MO |
| <i>liothyronine sodium oral tablet 25mcg, 5mcg, 50mcg</i> | 1 | MO |
| SYNTHROID ORAL TABLET 100MCG, 112MCG, 125MCG, 137MCG, 150MCG, 175MCG, 200MCG, 25MCG, 300MCG, 50MCG, 75MCG, 88MCG | 1 | MO |
| UNITHROID ORAL TABLET 100MCG, 112MCG, 125MCG, 137MCG, 150MCG, 175MCG, 200MCG, 25MCG, 300MCG, 50MCG, 75MCG, 88MCG | 1 | MO |
| HORMONAL AGENTS, SUPPRESSANT (PITUITARY) | | |
| <i>Hormonal Agents, Suppressant (Pituitary)</i> | | |
| <i>cabergoline oral tablet 0.5mg</i> | 1 | |
| ELIGARD SUBCUTANEOUS KIT 22.5MG, 30MG, 45MG, 7.5MG | 1 | PA |
| <i>leuprolide acetate injection kit 1mg/0.2ml</i> | 1 | PA |
| LUPRON DEPOT (1-MONTH) INTRAMUSCULAR KIT 3.75MG, 7.5MG | 1 | PA |
| LUPRON DEPOT (3-MONTH) INTRAMUSCULAR KIT 11.25MG, 22.5MG | 1 | PA |
| LUPRON DEPOT (4-MONTH) INTRAMUSCULAR KIT 30MG | 1 | PA |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------|
| LUPRON DEPOT (6-MONTH) INTRAMUSCULAR KIT 45MG | 1 | PA |
| <i>octreotide acetate injection solution 100mcg/ml, 200mcg/ml, 50mcg/ml</i> | 1 | PA; MO |
| <i>octreotide acetate injection solution 1000mcg/ml, 500mcg/ml</i> | 1 | PA |
| SIGNIFOR SUBCUTANEOUS SOLUTION 0.3MG/ML, 0.6MG/ML, 0.9MG/ML | 1 | PA; QL (60ML per 30 days) |
| SOMAVERT SUBCUTANEOUS SOLUTION RECONSTITUTED 10MG, 15MG, 20MG, 25MG, 30MG | 1 | PA; QL (60 EA per 30 days) |
| SYNAREL NASAL SOLUTION 2MG/ML | 1 | PA |
| TRELSTAR MIXJECT INTRAMUSCULAR SUSPENSION RECONSTITUTED 11.25MG, 22.5MG, 3.75MG | 1 | PA |

HORMONAL AGENTS, SUPPRESSANT (THYROID)

Antithyroid Agents

| | | |
|--|---|----|
| <i>methimazole oral tablet 10mg, 5mg</i> | 1 | MO |
| <i>propylthiouracil oral tablet 50mg</i> | 1 | MO |

IMMUNOLOGICAL AGENTS

Angioedema Agents

| | | |
|--|---|----|
| FIRAZYR SUBCUTANEOUS SOLUTION 30MG/3ML | 1 | PA |
| <i>icatibant acetate subcutaneous solution 30mg/3ml</i> | 1 | PA |
| TAKHZYRO SUBCUTANEOUS SOLUTION 300MG/2ML | 1 | PA |
| TAKHZYRO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 300MG/2ML | 1 | PA |

Immunoglobulins

| | | |
|---|---|-----|
| PANZYGA INTRAVENOUS SOLUTION 1GM/10ML, 10GM/100ML, 2.5GM/25ML, 20GM/200ML, 30GM/300ML, 5GM/50ML | 1 | BvD |
| PRIVIGEN INTRAVENOUS SOLUTION 20GM/200ML | 1 | BvD |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| <i>Immunological Agents, Other</i> | | |
| ARCALYST SUBCUTANEOUS SOLUTION RECONSTITUTED 220MG | 1 | PA |
| COSENTYX (300MG DOSE) SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150MG/ML | 1 | PA |
| COSENTYX SENSOREADY (300MG) SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150MG/ML | 1 | PA |
| COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75MG/0.5ML | 1 | PA |
| DUPIXENT SUBCUTANEOUS SOLUTION PEN-INJECTOR 200MG/1.14ML, 300MG/2ML | 1 | PA |
| DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100MG/0.67ML, 200MG/1.14ML, 300MG/2ML | 1 | PA |
| <i>leflunomide oral tablet 10mg, 20mg</i> | 1 | MO |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24-HOUR 15MG, 30MG, 45MG | 1 | PA |
| SKYRIZI PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150MG/ML | 1 | PA |
| SKYRIZI SUBCUTANEOUS SOLUTION CARTRIDGE 180MG/1.2ML, 360MG/2.4ML | 1 | PA |
| SKYRIZI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150MG/ML | 1 | PA |
| STELARA SUBCUTANEOUS SOLUTION 45MG/0.5ML | 1 | PA |
| STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 45MG/0.5ML, 90MG/ML | 1 | PA |
| TAVNEOS ORAL CAPSULE 10MG | 1 | PA |
| XOLAIR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150MG/ML, 75MG/0.5ML | 1 | PA |
| XOLAIR SUBCUTANEOUS SOLUTION RECONSTITUTED 150MG | 1 | PA |
| <i>Immunostimulants</i> | | |
| ACTIMMUNE SUBCUTANEOUS SOLUTION 2000000UNIT/0.5ML | 1 | PA |
| BESREMI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 500MCG/ML | 1 | PA |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------------|
| PEGASYS SUBCUTANEOUS SOLUTION 180MCG/ML | 1 | PA |
| PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 180MCG/0.5ML | 1 | PA |
| Immunosuppressants | | |
| AZASAN ORAL TABLET 100MG, 75MG | 1 | BvD; MO |
| <i>azathioprine oral tablet 100mg, 50mg, 75mg</i> | 1 | BvD; MO |
| BENLYSTA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200MG/ML | 1 | PA |
| BENLYSTA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200MG/ML | 1 | PA |
| <i>cyclosporine modified oral capsule 100mg, 25mg, 50mg</i> | 1 | BvD; MO |
| <i>cyclosporine modified oral solution 100mg/ml</i> | 1 | BvD; MO |
| <i>cyclosporine oral capsule 100mg, 25mg</i> | 1 | BvD; MO |
| ENBREL MINI SUBCUTANEOUS SOLUTION CARTRIDGE 50MG/ML | 1 | PA |
| ENBREL SUBCUTANEOUS SOLUTION 25MG/0.5ML | 1 | PA |
| ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 25MG/0.5ML, 50MG/ML | 1 | PA |
| ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 50MG/ML | 1 | PA |
| ENSPRYNG SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 120MG/ML | 1 | PA |
| ENVARUSUS XR ORAL TABLET EXTENDED RELEASE 24-HOUR 0.75MG, 1MG, 4MG | 1 | BvD; MO |
| <i>everolimus oral tablet 0.25mg</i> | 1 | BvD; MO; QL (60 EA per 30 days) |
| <i>everolimus oral tablet 0.5mg</i> | 1 | BvD; QL (120 EA per 30 days) |
| <i>everolimus oral tablet 0.75mg, 1mg</i> | 1 | BvD; QL (60 EA per 30 days) |
| GENGRAF ORAL CAPSULE 100MG, 25MG | 1 | BvD; MO |
| GENGRAF ORAL SOLUTION 100MG/ML | 1 | BvD; MO |
| HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS PREFILLED SYRINGE KIT 80MG/0.8ML, 80MG/0.8ML & 40MG/0.4ML | 1 | PA |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------|
| HUMIRA PEN SUBCUTANEOUS PEN-INJECTOR KIT 40MG/0.4ML, 40MG/0.8ML, 80MG/0.8ML | 1 | PA |
| HUMIRA PEN-CD/UC/HS STARTER SUBCUTANEOUS PEN-INJECTOR KIT 40MG/0.8ML, 80MG/0.8ML | 1 | PA |
| HUMIRA PEN-PEDIATRIC UC START SUBCUTANEOUS PEN-INJECTOR KIT 80MG/0.8ML | 1 | PA |
| HUMIRA PEN-PS/UV/ADOL HS START SUBCUTANEOUS PEN-INJECTOR KIT 40MG/0.8ML | 1 | PA |
| HUMIRA PEN-PSOR/UEIT STARTER SUBCUTANEOUS PEN-INJECTOR KIT 80MG/0.8ML & 40MG/0.4ML | 1 | PA |
| HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT 10MG/0.1ML, 20MG/0.2ML, 40MG/0.4ML, 40MG/0.8ML | 1 | PA |
| LUPKYNIS ORAL CAPSULE 7.9MG | 1 | PA; QL (180 EA per 30 days) |
| <i>methotrexate sodium (pf) injection solution 50mg/2ml</i> | 1 | BvD |
| <i>methotrexate sodium injection solution 50mg/2ml</i> | 1 | BvD |
| <i>methotrexate sodium oral tablet 2.5mg</i> | 1 | BvD |
| <i>mycophenolate mofetil oral capsule 250mg</i> | 1 | BvD; MO |
| <i>mycophenolate mofetil oral suspension reconstituted 200mg/ml</i> | 1 | BvD |
| <i>mycophenolate mofetil oral tablet 500mg</i> | 1 | BvD; MO |
| <i>mycophenolate sodium oral tablet delayed release 180mg, 360mg</i> | 1 | BvD; MO |
| PROGRAF ORAL PACKET 0.2MG, 1MG | 1 | BvD; MO |
| REZUROCK ORAL TABLET 200MG | 1 | PA |
| <i>sirolimus oral solution 1mg/ml</i> | 1 | BvD |
| <i>sirolimus oral tablet 0.5mg, 1mg</i> | 1 | BvD; MO |
| <i>sirolimus oral tablet 2mg</i> | 1 | BvD |
| <i>tacrolimus oral capsule 0.5mg, 1mg, 5mg</i> | 1 | BvD; MO |
| TREXALL ORAL TABLET 10MG, 15MG, 5MG, 7.5MG | 1 | BvD |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| Vaccines | | |
| ACTHIB INTRAMUSCULAR SOLUTION RECONSTITUTED | 1 | |
| ADACEL INTRAMUSCULAR SUSPENSION 5-2-15.5 (PREFILLED SYRINGE), 5-2-15.5 LF-MCG/0.5 | 1 | |
| <i>bcg vaccine injection solution reconstituted 50mg</i> | 1 | |
| BEXSERO INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 1 | |
| BOOSTRIX INTRAMUSCULAR SUSPENSION 5-2.5-18.5 LF-MCG/0.5 | 1 | |
| BOOSTRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 5-2.5-18.5 LF-MCG/0.5 | 1 | |
| DAPTACEL INTRAMUSCULAR SUSPENSION 23-15-5 | 1 | |
| <i>diphtheria-tetanus toxoids dt intramuscular suspension 25-5 lfu/0.5ml</i> | 1 | BvD |
| ENGERIX-B INJECTION SUSPENSION 20MCG/ML | 1 | BvD |
| ENGERIX-B INJECTION SUSPENSION PREFILLED SYRINGE 10MCG/0.5ML, 20MCG/ML | 1 | BvD |
| GARDASIL 9 INTRAMUSCULAR SUSPENSION | 1 | |
| GARDASIL 9 INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 1 | |
| HAVRIX INTRAMUSCULAR SUSPENSION 1440 EL U/ML, 720 EL U/0.5ML | 1 | |
| HIBERIX INJECTION SOLUTION RECONSTITUTED 10MCG | 1 | |
| IMOVAX RABIES INTRAMUSCULAR SUSPENSION RECONSTITUTED 2.5UNIT/ML | 1 | BvD |
| INFANRIX INTRAMUSCULAR SUSPENSION 25-58-10 | 1 | |
| IPOL INJECTION INJECTABLE | 1 | |
| IXIARO INTRAMUSCULAR SUSPENSION | 1 | |
| JYNNEOS SUBCUTANEOUS SUSPENSION 0.5ML | 1 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| KINRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5ML | 1 | |
| MENACTRA INTRAMUSCULAR SOLUTION | 1 | |
| MENQUADFI INTRAMUSCULAR SOLUTION | 1 | |
| MENVEO INTRAMUSCULAR SOLUTION RECONSTITUTED | 1 | |
| M-M-R II INJECTION SOLUTION RECONSTITUTED | 1 | |
| PEDIARIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 1 | |
| PEDVAX HIB INTRAMUSCULAR SUSPENSION 7.5MCG/0.5ML | 1 | |
| PENTACEL INTRAMUSCULAR SUSPENSION RECONSTITUTED | 1 | |
| <i>prehevbrio intramuscular suspension 10mcg/ml</i> | 1 | BvD |
| PRIORIX SUBCUTANEOUS SUSPENSION RECONSTITUTED | 1 | |
| PROQUAD SUBCUTANEOUS SUSPENSION RECONSTITUTED | 1 | |
| QUADRACEL INTRAMUSCULAR SUSPENSION, (58 UNT/ML) | 1 | |
| QUADRACEL INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5ML | 1 | |
| RABAVERT INTRAMUSCULAR SUSPENSION RECONSTITUTED | 1 | BvD |
| RECOMBIVAX HB INJECTION SUSPENSION 10MCG/ML, 40MCG/ML, 5MCG/0.5ML | 1 | BvD |
| RECOMBIVAX HB INJECTION SUSPENSION PREFILLED SYRINGE 10MCG/ML, 5MCG/0.5ML | 1 | BvD |
| ROTARIX ORAL SUSPENSION RECONSTITUTED | 1 | |
| ROTATEQ ORAL SOLUTION | 1 | |
| SHINGRIX INTRAMUSCULAR SUSPENSION RECONSTITUTED 50MCG/0.5ML | 1 | |
| TDVAX INTRAMUSCULAR SUSPENSION 2-2 LF/0.5ML | 1 | BvD |
| TENIVAC INTRAMUSCULAR INJECTABLE 5-2 LFU, 5-2 LFU (INJECTION) | 1 | BvD |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| TICOVAC INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 1.2MCG/0.25ML, 2.4MCG/0.5ML | 1 | |
| TRUMENBA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 1 | |
| TWINRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 720-20 ELU-MCG/ML | 1 | |
| TYPHIM VI INTRAMUSCULAR SOLUTION 25MCG/0.5ML | 1 | |
| TYPHIM VI INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 25MCG/0.5ML | 1 | |
| VAQTA INTRAMUSCULAR SUSPENSION 25UNIT/0.5ML, 25UNIT/0.5ML 0.5ML, 50UNIT/ML, 50UNIT/ML 1ML | 1 | |
| VARIVAX SUBCUTANEOUS INJECTABLE 1350 PFU/0.5ML | 1 | |
| YF-VAX SUBCUTANEOUS INJECTABLE, (2.5ML IN 1 VIAL, MULTI-DOSE) | 1 | |

INFLAMMATORY BOWEL DISEASE AGENTS

Aminosalicylates

| | | |
|--|---|----|
| <i>balsalazide disodium oral capsule 750mg</i> | 1 | |
| LIALDA ORAL TABLET DELAYED RELEASE 1.2GM | 1 | MO |
| <i>mesalamine er oral capsule extended release 24-hour 0.375gm</i> | 1 | MO |
| <i>mesalamine oral capsule delayed release 400mg</i> | 1 | MO |
| <i>mesalamine oral tablet delayed release 800mg</i> | 1 | |
| <i>mesalamine rectal enema 4gm</i> | 1 | |
| <i>sulfasalazine oral tablet 500mg</i> | 1 | MO |
| <i>sulfasalazine oral tablet delayed release 500mg</i> | 1 | MO |

Glucocorticoids

| | | |
|---|---|--|
| <i>budesonide er oral tablet extended release 24-hour 9mg</i> | 1 | |
| <i>budesonide oral capsule delayed release particles 3mg</i> | 1 | |
| <i>hydrocortisone rectal enema 100mg/60ml</i> | 1 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------------|
| METABOLIC BONE DISEASE AGENTS | | |
| <i>Metabolic Bone Disease Agents</i> | | |
| <i>alendronate sodium oral tablet 10mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>alendronate sodium oral tablet 35mg, 70mg</i> | 1 | MO; QL (4 EA per 28 days) |
| <i>calcitonin (salmon) nasal solution 200unit/act</i> | 1 | BvD; MO; QL (4ML per 28 days) |
| <i>calcitriol oral capsule 0.25mcg, 0.5mcg</i> | 1 | BvD; MO |
| <i>calcitriol oral solution 1mcg/ml</i> | 1 | BvD; MO |
| <i>cinacalcet hcl oral tablet 30mg</i> | 1 | BvD; MO; QL (60 EA per 30 days) |
| <i>cinacalcet hcl oral tablet 60mg</i> | 1 | BvD; QL (60 EA per 30 days) |
| <i>cinacalcet hcl oral tablet 90mg</i> | 1 | BvD; QL (120 EA per 30 days) |
| <i>ibandronate sodium oral tablet 150mg</i> | 1 | MO; QL (1 EA per 30 days) |
| NATPARA SUBCUTANEOUS CARTRIDGE 100MCG, 25MCG, 50MCG, 75MCG | 1 | PA |
| <i>paricalcitol oral capsule 1mcg, 2mcg, 4mcg</i> | 1 | BvD; MO |
| PROLIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 60MG/ML | 1 | QL (1ML per 180 days) |
| <i>raloxifene hcl oral tablet 60mg</i> | 1 | MO |
| <i>risedronate sodium oral tablet 150mg</i> | 1 | MO; QL (1 EA per 28 days) |
| <i>risedronate sodium oral tablet 30mg</i> | 1 | QL (30 EA per 30 days) |
| <i>risedronate sodium oral tablet 35mg, 35mg (12 pack), 35mg (4 pack)</i> | 1 | MO; QL (4 EA per 28 days) |
| <i>risedronate sodium oral tablet 5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>teriparatide (recombinant) subcutaneous solution pen-injector 620mcg/2.48ml</i> | 1 | PA; QL (2.48ML per 28 days) |
| TYMLOS SUBCUTANEOUS SOLUTION PEN-INJECTOR 3120MCG/1.56ML | 1 | PA; QL (1.56ML per 30 days) |
| XGEVA SUBCUTANEOUS SOLUTION 120MG/1.7ML | 1 | PA; QL (2ML per 28 days) |
| OPHTHALMIC AGENTS | | |
| <i>Ophthalmic Agents, Other</i> | | |
| <i>atropine sulfate ophthalmic solution 1%</i> | 1 | MO |
| <i>bacitra-neomycin-polymyxin-hc ophthalmic ointment 1%</i> | 1 | |
| <i>cyclosporine ophthalmic emulsion 0.05%</i> | 1 | MO; QL (60 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| CYSTADROPS OPHTHALMIC SOLUTION 0.37% | 1 | PA |
| CYSTARAN OPHTHALMIC SOLUTION 0.44% | 1 | PA |
| <i>neomycin-polymyxin-dexameth ophthalmic ointment 3.5-10000-0.1</i> | 1 | |
| <i>neomycin-polymyxin-dexameth ophthalmic suspension 3.5-10000-0.1</i> | 1 | |
| <i>neomycin-polymyxin-gramicidin ophthalmic solution 1.75-10000-.025</i> | 1 | |
| <i>neomycin-polymyxin-hc ophthalmic suspension 3.5-10000-1</i> | 1 | |
| <i>polymyxin b-trimethoprim ophthalmic solution 10000-0.1unit/ml-%</i> | 1 | |
| <i>sulfacetamide-prednisolone ophthalmic solution 10-0.23%</i> | 1 | |
| <i>tobramycin-dexamethasone ophthalmic suspension 0.3-0.1%</i> | 1 | |
| Ophthalmic Anti-Allergy Agents | | |
| <i>azelastine hcl ophthalmic solution 0.05%</i> | 1 | |
| <i>cromolyn sodium ophthalmic solution 4%</i> | 1 | |
| <i>olopatadine hcl ophthalmic solution 0.1%, 0.2%</i> | 1 | |
| Ophthalmic Anti-Infectives | | |
| AZASITE OPHTHALMIC SOLUTION 1% | 1 | |
| <i>bacitracin ophthalmic ointment 500unit/gm</i> | 1 | |
| <i>bacitracin-polymyxin b ophthalmic ointment 500-10000unit/gm</i> | 1 | |
| <i>erythromycin ophthalmic ointment 5mg/gm</i> | 1 | |
| <i>gatifloxacin ophthalmic solution 0.5%</i> | 1 | |
| GENTAK OPHTHALMIC OINTMENT 0.3% | 1 | |
| <i>gentamicin sulfate ophthalmic solution 0.3%</i> | 1 | |
| <i>moxifloxacin hcl ophthalmic solution 0.5%</i> | 1 | |
| NATACYN OPHTHALMIC SUSPENSION 5% | 1 | |
| <i>neomycin-bacitracin zn-polymyx ophthalmic ointment 5-400-10000</i> | 1 | |
| <i>ofloxacin ophthalmic solution 0.3%</i> | 1 | |
| <i>sulfacetamide sodium ophthalmic solution 10%</i> | 1 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| <i>tobramycin ophthalmic solution 0.3%</i> | 1 | |
| Ophthalmic Anti-Inflammatories | | |
| <i>bromfenac sodium (once-daily) ophthalmic solution 0.09%</i> | 1 | |
| BROMSITE OPHTHALMIC SOLUTION 0.075% | 1 | |
| <i>dexamethasone sodium phosphate ophthalmic solution 0.1%</i> | 1 | |
| <i>diclofenac sodium ophthalmic solution 0.1%</i> | 1 | |
| DUREZOL OPHTHALMIC EMULSION 0.05% | 1 | |
| <i>fluorometholone ophthalmic suspension 0.1%</i> | 1 | |
| <i>flurbiprofen sodium ophthalmic solution 0.03%</i> | 1 | |
| ILEVRO OPHTHALMIC SUSPENSION 0.3% | 1 | |
| <i>ketorolac tromethamine ophthalmic solution 0.4%, 0.5%</i> | 1 | |
| <i>loteprednol etabonate ophthalmic suspension 0.5%</i> | 1 | |
| <i>prednisolone acetate ophthalmic suspension 1%</i> | 1 | |
| <i>prednisolone sodium phosphate ophthalmic solution 1%</i> | 1 | |
| Ophthalmic Beta-Adrenergic Blocking Agents | | |
| <i>betaxolol hcl ophthalmic solution 0.5%</i> | 1 | MO |
| <i>carteolol hcl ophthalmic solution 1%</i> | 1 | MO |
| <i>levobunolol hcl ophthalmic solution 0.5%</i> | 1 | MO |
| <i>timolol maleate (once-daily) ophthalmic solution 0.5%</i> | 1 | MO |
| <i>timolol maleate ophthalmic gel forming solution 0.25%, 0.5%</i> | 1 | MO |
| <i>timolol maleate ophthalmic solution 0.25%, 0.5%</i> | 1 | MO |
| Ophthalmic Intraocular Pressure Lowering Agents, Other | | |
| <i>acetazolamide er oral capsule extended release 12-hour 500mg</i> | 1 | MO |
| <i>acetazolamide oral tablet 125mg, 250mg</i> | 1 | MO |
| ALPHAGAN P OPHTHALMIC SOLUTION 0.1% | 1 | MO |
| <i>apraclonidine hcl ophthalmic solution 0.5%</i> | 1 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| AZOPT OPHTHALMIC SUSPENSION 1% | 1 | MO |
| <i>brimonidine tartrate ophthalmic solution 0.15%, 0.2%</i> | 1 | MO |
| <i>brimonidine tartrate-timolol ophthalmic solution 0.2-0.5%</i> | 1 | MO |
| COMBIGAN OPHTHALMIC SOLUTION 0.2-0.5% | 1 | MO |
| <i>dorzolamide hcl ophthalmic solution 2%</i> | 1 | MO |
| <i>dorzolamide hcl-timolol mal ophthalmic solution 22.3-6.8mg/ml</i> | 1 | MO |
| <i>dorzolamide hcl-timolol mal pf ophthalmic solution 2-0.5%</i> | 1 | MO |
| <i>methazolamide oral tablet 25mg, 50mg</i> | 1 | MO |
| <i>pilocarpine hcl ophthalmic solution 1%, 2%, 4%</i> | 1 | MO |
| RHOPRESSA OPHTHALMIC SOLUTION 0.02% | 1 | MO |
| ROCKLATAN OPHTHALMIC SOLUTION 0.02-0.005% | 1 | MO |
| SIMBRINZA OPHTHALMIC SUSPENSION 1-0.2% | 1 | MO |
| Ophthalmic Prostaglandin and Prostaglandin Analogs | | |
| <i>latanoprost ophthalmic solution 0.005%</i> | 1 | MO |
| LUMIGAN OPHTHALMIC SOLUTION 0.01% | 1 | MO |
| <i>travoprost (bak free) ophthalmic solution 0.004%</i> | 1 | MO |
| OTIC AGENTS | | |
| Otic Agents | | |
| <i>acetic acid otic solution 2%</i> | 1 | |
| <i>ciprofloxacin hcl otic solution 0.2%</i> | 1 | |
| <i>ciprofloxacin-dexamethasone otic suspension 0.3-0.1%</i> | 1 | |
| <i>ciprofloxacin-fluocinolone pf otic solution 0.3-0.025%</i> | 1 | |
| <i>fluocinolone acetonide otic oil 0.01%</i> | 1 | |
| <i>neomycin-polymyxin-hc otic solution 1%</i> | 1 | |
| <i>neomycin-polymyxin-hc otic suspension 3.5-10000-1</i> | 1 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------|
| <i>ofloxacin otic solution 0.3%</i> | 1 | |
| RESPIRATORY TRACT/ PULMONARY AGENTS | | |
| <i>Antihistamines</i> | | |
| <i>azelastine hcl nasal solution 0.1%, 0.15%</i> | 1 | QL (30ML per 25 days) |
| <i>cetirizine hcl oral solution 1mg/ml</i> | 1 | |
| <i>cyproheptadine hcl oral syrup 2mg/5ml</i> | 1 | |
| <i>cyproheptadine hcl oral tablet 4mg</i> | 1 | |
| <i>levocetirizine dihydrochloride oral solution 2.5mg/5ml</i> | 1 | |
| <i>levocetirizine dihydrochloride oral tablet 5mg</i> | 1 | |
| <i>Anti-Inflammatories, Inhaled Corticosteroids</i> | | |
| ARNUITY ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100MCG/ACT, 200MCG/ACT, 50MCG/ACT | 1 | MO; QL (30 EA per 30 days) |
| ASMANEX (120 METERED DOSES) INHALATION AEROSOL POWDER BREATH ACTIVATED 220MCG/ACT | 1 | MO; QL (2 EA per 30 days) |
| ASMANEX (30 METERED DOSES) INHALATION AEROSOL POWDER BREATH ACTIVATED 110MCG/ACT, 220MCG/ACT | 1 | MO; QL (2 EA per 30 days) |
| ASMANEX (60 METERED DOSES) INHALATION AEROSOL POWDER BREATH ACTIVATED 220MCG/ACT | 1 | MO; QL (2 EA per 30 days) |
| ASMANEX HFA INHALATION AEROSOL 100MCG/ACT, 200MCG/ACT, 50MCG/ACT | 1 | MO; QL (26GM per 30 days) |
| <i>budesonide inhalation suspension 0.25mg/2ml, 0.5mg/2ml, 1mg/2ml</i> | 1 | BvD; MO |
| FLOVENT DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 100MCG/ACT, 250MCG/ACT, 50MCG/ACT | 1 | MO; QL (60 EA per 30 days) |
| FLOVENT HFA INHALATION AEROSOL 110MCG/ACT, 220MCG/ACT | 1 | MO; QL (24GM per 30 days) |
| FLOVENT HFA INHALATION AEROSOL 44MCG/ACT | 1 | MO; QL (21.2GM per 30 days) |
| <i>flunisolide nasal solution 25mcg/act (0.025%)</i> | 1 | QL (50ML per 30 days) |
| <i>fluticasone propionate nasal suspension 50mcg/act</i> | 1 | QL (16GM per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------|
| <i>mometasone furoate nasal suspension 50mcg/act</i> | 1 | QL (34GM per 30 days) |
| Antileukotrienes | | |
| <i>montelukast sodium oral packet 4mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>montelukast sodium oral tablet 10mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>montelukast sodium oral tablet chewable 4mg, 5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>zafirlukast oral tablet 10mg, 20mg</i> | 1 | MO; QL (60 EA per 30 days) |
| Bronchodilators, Anticholinergic | | |
| ATROVENT HFA INHALATION AEROSOL SOLUTION 17MCG/ACT | 1 | MO; QL (26GM per 30 days) |
| <i>ipratropium bromide inhalation solution 0.02%</i> | 1 | BvD; MO |
| <i>ipratropium bromide nasal solution 0.03%</i> | 1 | MO; QL (60ML per 30 days) |
| <i>ipratropium bromide nasal solution 0.06%</i> | 1 | MO; QL (30ML per 30 days) |
| SPIRIVA HANDIHALER INHALATION CAPSULE 18MCG | 1 | MO; QL (30 EA per 30 days) |
| SPIRIVA RESPIMAT INHALATION AEROSOL SOLUTION 1.25MCG/ACT, 2.5MCG/ACT | 1 | MO; QL (4GM per 30 days) |
| Bronchodilators, Sympathomimetic | | |
| <i>albuterol sulfate hfa inhalation aerosol solution 108 (90 base) mcg/act</i> | 1 | MO; QL (17GM per 30 days) |
| <i>albuterol sulfate hfa inhalation aerosol solution 108 (90 base) mcg/act (nda020503)</i> | 1 | MO; QL (13.4GM per 30 days) |
| <i>albuterol sulfate hfa inhalation aerosol solution 108 (90 base) mcg/act (nda020983)</i> | 1 | MO; QL (36GM per 30 days) |
| <i>albuterol sulfate inhalation nebulization solution (2.5mg/3ml) 0.083%, 0.63mg/3ml, 1.25mg/3ml, 2.5mg/0.5ml</i> | 1 | BvD; MO |
| <i>albuterol sulfate oral syrup 2mg/5ml</i> | 1 | MO |
| <i>albuterol sulfate oral tablet 2mg, 4mg</i> | 1 | MO |
| <i>epinephrine injection solution 0.3mg/0.3ml</i> | 1 | |
| <i>epinephrine injection solution auto-injector 0.15mg/0.15ml, 0.15mg/0.3ml, 0.3mg/0.3ml</i> | 1 | |
| SEREVENT DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 50MCG/ACT | 1 | MO; QL (60 EA per 30 days) |
| <i>terbutaline sulfate oral tablet 2.5mg, 5mg</i> | 1 | MO |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|--------------------------------|
| VENTOLIN HFA INHALATION AEROSOL SOLUTION 108 (90 BASE) MCG/ACT | 1 | MO; QL (36GM per 30 days) |
| Cystic Fibrosis Agents | | |
| CAYSTON INHALATION SOLUTION RECONSTITUTED 75MG | 1 | PA |
| KALYDECO ORAL PACKET 25MG, 50MG, 75MG | 1 | PA |
| KALYDECO ORAL TABLET 150MG | 1 | PA |
| ORKAMBI ORAL PACKET 100-125MG, 150-188MG, 75-94MG | 1 | PA |
| ORKAMBI ORAL TABLET 100-125MG, 200-125MG | 1 | PA |
| PULMOZYME INHALATION SOLUTION 2.5MG/2.5ML | 1 | BvD |
| SYMDEKO ORAL TABLET THERAPY PACK 100-150 & 150MG, 50-75 & 75MG | 1 | PA |
| TOBI PODHALER INHALATION CAPSULE 28MG | 1 | PA |
| <i>tobramycin inhalation nebulization solution 300mg/5ml</i> | 1 | BvD |
| TRIKAFTA ORAL TABLET THERAPY PACK 100-50-75 & 150MG, 50-25-37.5 & 75MG | 1 | PA |
| Phosphodiesterase Inhibitors, Airways Disease | | |
| <i>roflumilast oral tablet 250mcg, 500mcg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>theophylline er oral tablet extended release 12-hour 300mg, 450mg</i> | 1 | MO |
| <i>theophylline er oral tablet extended release 24-hour 400mg, 600mg</i> | 1 | MO |
| Pulmonary Antihypertensives | | |
| ADEMPAS ORAL TABLET 0.5MG, 1MG, 1.5MG, 2MG, 2.5MG | 1 | PA; QL (90 EA per 30 days) |
| <i>ambrisentan oral tablet 10mg, 5mg</i> | 1 | PA; QL (30 EA per 30 days) |
| <i>bosentan oral tablet 125mg, 62.5mg</i> | 1 | PA; QL (60 EA per 30 days) |
| OPSUMIT ORAL TABLET 10MG | 1 | PA; QL (90 EA per 30 days) |
| <i>sildenafil citrate oral tablet 20mg</i> | 1 | PA; MO; QL (90 EA per 30 days) |
| Pulmonary Fibrosis Agents | | |
| ESBRIET ORAL CAPSULE 267MG | 1 | PA |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------|
| OFEV ORAL CAPSULE 100MG, 150MG | 1 | PA |
| <i>pirfenidone oral tablet 267mg, 534mg, 801mg</i> | 1 | PA |
| Respiratory Tract Agents, Other | | |
| <i>acetylcysteine inhalation solution 10%, 20%</i> | 1 | BvD |
| ADVAIR DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 100-50MCG/ACT, 250-50MCG/ACT, 500-50MCG/ACT | 1 | MO; QL (60 EA per 30 days) |
| ADVAIR HFA INHALATION AEROSOL 115-21MCG/ACT, 230-21MCG/ACT, 45-21MCG/ACT | 1 | MO; QL (12GM per 30 days) |
| ANORO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 62.5-25MCG/ACT | 1 | MO; QL (60 EA per 30 days) |
| BREO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-25MCG/ACT, 200-25MCG/ACT | 1 | MO; QL (60 EA per 30 days) |
| BREZTRI AEROSPHERE INHALATION AEROSOL 160-9-4.8MCG/ACT | 1 | MO; QL (10.7GM per 30 days) |
| <i>budesonide-formoterol fumarate inhalation aerosol 160-4.5mcg/act, 80-4.5mcg/act</i> | 1 | MO; QL (10.2GM per 30 days) |
| COMBIVENT RESPIMAT INHALATION AEROSOL SOLUTION 20-100MCG/ACT | 1 | MO; QL (4GM per 20 days) |
| <i>cromolyn sodium inhalation nebulization solution 20mg/2ml</i> | 1 | BvD; MO |
| <i>fluticasone-salmeterol inhalation aerosol powder breath activated 100-50mcg/act, 250-50mcg/act, 500-50mcg/act</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>fluticasone-salmeterol inhalation aerosol powder breath activated 113-14mcg/act, 232-14mcg/act, 55-14mcg/act</i> | 1 | MO; QL (1 EA per 30 days) |
| <i>ipratropium-albuterol inhalation solution 0.5-2.5 (3) mg/3ml</i> | 1 | BvD; MO |
| NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100MG/ML | 1 | PA |
| NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100MG/ML, 40MG/0.4ML | 1 | PA |
| NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED 100MG | 1 | PA |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------|
| TRELEGY ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-62.5-25MCG/ACT, 200-62.5-25MCG/ACT | 1 | MO; QL (60 EA per 30 days) |

SKELETAL MUSCLE RELAXANTS

Skeletal Muscle Relaxants

| | | |
|---|---|--|
| <i>chlorzoxazone oral tablet 250mg, 375mg, 500mg, 750mg</i> | 1 | |
| <i>cyclobenzaprine hcl oral tablet 10mg, 5mg, 7.5mg</i> | 1 | |
| <i>methocarbamol oral tablet 500mg, 750mg</i> | 1 | |
| <i>orphenadrine citrate er oral tablet extended release 12-hour 100mg</i> | 1 | |

SLEEP DISORDER AGENTS

Sleep Promoting Agents

| | | |
|--|---|-------------------------|
| BELSOMRA ORAL TABLET 10MG, 15MG, 20MG, 5MG | 1 | QL (30 EA per 30 days) |
| <i>temazepam oral capsule 15mg, 22.5mg, 30mg</i> | 1 | QL (30 EA per 30 days) |
| <i>temazepam oral capsule 7.5mg</i> | 1 | QL (120 EA per 30 days) |
| <i>zaleplon oral capsule 10mg, 5mg</i> | 1 | QL (30 EA per 30 days) |
| <i>zolpidem tartrate oral tablet 10mg, 5mg</i> | 1 | QL (30 EA per 30 days) |

Wakefulness Promoting Agents

| | | |
|--|---|--------------------------------|
| <i>armodafinil oral tablet 150mg, 200mg, 250mg, 50mg</i> | 1 | PA; MO; QL (30 EA per 30 days) |
| <i>modafinil oral tablet 100mg, 200mg</i> | 1 | PA; MO; QL (60 EA per 30 days) |
| SUNOSI ORAL TABLET 150MG, 75MG | 1 | PA; MO; QL (30 EA per 30 days) |
| XYREM ORAL SOLUTION 500MG/ML | 1 | PA; QL (540ML per 30 days) |
| XYWAV ORAL SOLUTION 500MG/ML | 1 | PA; QL (540ML per 30 days) |

Imperial MAPD 2023 1-Tier (Lista de medicamentos cubiertos)

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|------------------------|
| AGENTES ANTIESPASTICIDAD | | |
| Agentes Antiespasticidad | | |
| <i>baclofen oral tablet 10mg, 20mg, 5mg</i> | 1 | |
| <i>tizanidine hcl oral tablet 2mg, 4mg</i> | 1 | |
| AGENTES ANTIMIASTENICOS | | |
| Parasimpaticomiméticos | | |
| <i>pyridostigmine bromide oral solution 60mg/5ml</i> | 1 | |
| <i>pyridostigmine bromide oral tablet 30mg, 60mg</i> | 1 | |
| AGENTES ANTIMIGRAÑOSOS | | |
| Agonista del Receptor de Serotonina (5-HT) | | |
| <i>naratriptan hcl oral tablet 1mg, 2.5mg</i> | 1 | QL (9 EA per 30 days) |
| <i>rizatriptan benzoate oral tablet 10mg, 5mg</i> | 1 | QL (12 EA per 30 days) |
| <i>rizatriptan benzoate oral tablet dispersible 10mg, 5mg</i> | 1 | QL (12 EA per 30 days) |
| <i>sumatriptan nasal solution 20mg/act</i> | 1 | QL (12 EA per 30 days) |
| <i>sumatriptan nasal solution 5mg/act</i> | 1 | QL (18 EA per 30 days) |
| <i>sumatriptan succinate oral tablet 100mg, 25mg, 50mg</i> | 1 | QL (9 EA per 30 days) |
| <i>sumatriptan succinate refill subcutaneous solution cartridge 4mg/0.5ml, 6mg/0.5ml</i> | 1 | QL (4ML per 30 days) |
| <i>sumatriptan succinate subcutaneous solution 6mg/0.5ml</i> | 1 | QL (4ML per 30 days) |
| <i>sumatriptan succinate subcutaneous solution auto-injector 4mg/0.5ml, 6mg/0.5ml</i> | 1 | QL (4ML per 30 days) |
| <i>zolmitriptan oral tablet 2.5mg, 5mg</i> | 1 | QL (6 EA per 30 days) |
| <i>zolmitriptan oral tablet dispersible 2.5mg, 5mg</i> | 1 | QL (6 EA per 30 days) |
| Alcaloides del Ergot | | |
| <i>dihydroergotamine mesylate nasal solution 4mg/ml</i> | 1 | |
| <i>ergotamine-caffeine oral tablet 1-100mg</i> | 1 | QL (40 EA per 28 days) |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|-----------------------------|
| Profiláctico | | |
| EMGALITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR 120MG/ML | 1 | PA; MO |
| EMGALITY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 120MG/ML | 1 | PA; MO |
| EPRONTIA ORAL SOLUTION 25MG/ML | 1 | MO |
| <i>propranolol hcl er oral capsule extended release 24-hour 80mg</i> | 1 | MO |
| <i>propranolol hcl oral tablet 80mg</i> | 1 | MO |
| <i>topiramate er oral capsule er 24-hour sprinkle 100mg, 150mg, 200mg, 25mg, 50mg</i> | 1 | MO |
| <i>topiramate oral capsule sprinkle 15mg, 25mg</i> | 1 | MO |
| <i>topiramate oral tablet 100mg, 200mg, 25mg, 50mg</i> | 1 | MO |
| UBRELVY ORAL TABLET 100MG, 50MG | 1 | PA; QL (16 EA per 30 days) |
| AGENTES ANTIPARKINSON | | |
| Agentes Antiparkinsonianos, Otros | | |
| <i>amantadine hcl oral capsule 100mg</i> | 1 | MO |
| <i>amantadine hcl oral solution 50mg/5ml</i> | 1 | MO |
| <i>amantadine hcl oral tablet 100mg</i> | 1 | MO |
| <i>carbidopa-levodopa-entacapone oral tablet 12.5-50-200mg, 18.75-75-200mg, 25-100-200mg, 31.25-125-200mg, 37.5-150-200mg, 50-200-200mg</i> | 1 | MO |
| <i>entacapone oral tablet 200mg</i> | 1 | MO |
| Agonistas de la Dopamina | | |
| <i>bromocriptine mesylate oral capsule 5mg</i> | 1 | MO |
| <i>bromocriptine mesylate oral tablet 2.5mg</i> | 1 | MO |
| KYNMOBI SUBLINGUAL FILM 10MG, 15MG, 20MG, 25MG, 30MG | 1 | PA; QL (150 EA per 30 days) |
| NEUPRO TRANSDERMAL PATCH 24-HOUR 1MG/24HR, 2MG/24HR, 3MG/24HR, 4MG/24HR, 6MG/24HR, 8MG/24HR | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|--------------------|
| <i>pramipexole dihydrochloride oral tablet 0.125mg, 0.25mg, 0.5mg, 0.75mg, 1mg, 1.5mg</i> | 1 | MO |
| <i>ropinirole hcl oral tablet 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg, 5mg</i> | 1 | MO |
| Anticolinérgicos | | |
| <i>benztropine mesylate oral tablet 0.5mg, 1mg, 2mg</i> | 1 | MO |
| <i>trihexyphenidyl hcl oral solution 0.4mg/ml</i> | 1 | MO |
| <i>trihexyphenidyl hcl oral tablet 2mg, 5mg</i> | 1 | MO |
| Inhibidores de la Monoaminoxidasa B (MAO-B) | | |
| <i>rasagiline mesylate oral tablet 0.5mg, 1mg</i> | 1 | MO |
| <i>selegiline hcl oral capsule 5mg</i> | 1 | MO |
| <i>selegiline hcl oral tablet 5mg</i> | 1 | MO |
| Precursores de Dopamina y/o Inhibidores de la Descarboxilasa de L-Aminoácidos | | |
| <i>carbidopa oral tablet 25mg</i> | 1 | MO |
| <i>carbidopa-levodopa er oral tablet extended release 25-100mg, 50-200mg</i> | 1 | MO |
| <i>carbidopa-levodopa oral tablet 10-100mg, 25-100mg, 25-250mg</i> | 1 | MO |
| <i>carbidopa-levodopa oral tablet dispersible 10-100mg, 25-100mg, 25-250mg</i> | 1 | MO |
| INBRIJA INHALATION CAPSULE 42MG | 1 | |
| RYTARY ORAL CAPSULE EXTENDED RELEASE 23.75-95MG, 36.25-145MG, 48.75-195MG, 61.25-245MG | 1 | ST; MO |
| AGENTES BIPOLARES | | |
| Estabilizadores del Estado de Ánimo | | |
| <i>divalproex sodium er oral tablet extended release 24-hour 250mg, 500mg</i> | 1 | MO |
| <i>divalproex sodium oral capsule delayed release sprinkle 125mg</i> | 1 | MO |
| <i>divalproex sodium oral tablet delayed release 125mg, 250mg, 500mg</i> | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|--------------------|
| <i>lithium carbonate er oral tablet extended release 300mg, 450mg</i> | 1 | MO |
| <i>lithium carbonate oral capsule 150mg, 300mg, 600mg</i> | 1 | MO |
| <i>lithium carbonate oral tablet 300mg</i> | 1 | MO |

AGENTES CARDIOVASCULARES

Agentes Bloqueadores de los Canales de Calcio, Dihidropiridinas

| | | |
|--|---|----------------------------|
| <i>amlodipine besylate oral tablet 10mg, 2.5mg, 5mg</i> | 1 | MO |
| <i>felodipine er oral tablet extended release 24-hour 10mg, 2.5mg, 5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>isradipine oral capsule 2.5mg, 5mg</i> | 1 | MO |
| KATERZIA ORAL SUSPENSION 1MG/ML | 1 | MO |
| <i>nicardipine hcl oral capsule 20mg, 30mg</i> | 1 | MO |
| <i>nifedipine er oral tablet extended release 24-hour 30mg, 60mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>nifedipine er oral tablet extended release 24-hour 90mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>nifedipine er osmotic release oral tablet extended release 24-hour 30mg, 60mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>nifedipine er osmotic release oral tablet extended release 24-hour 90mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>nifedipine oral capsule 10mg, 20mg</i> | 1 | MO |

Agentes Bloqueadores de los Canales de Calcio, No Dihidropiridinas

| | | |
|--|---|----------------------------|
| CARTIA XT ORAL CAPSULE EXTENDED RELEASE 24-HOUR 120MG, 180MG, 240MG | 1 | MO; QL (60 EA per 30 days) |
| CARTIA XT ORAL CAPSULE EXTENDED RELEASE 24-HOUR 300MG | 1 | MO; QL (30 EA per 30 days) |
| <i>diltiazem hcl er beads oral capsule extended release 24-hour 360mg, 420mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>diltiazem hcl er coated beads oral capsule extended release 24-hour 120mg, 180mg, 240mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>diltiazem hcl er coated beads oral capsule extended release 24-hour 300mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>diltiazem hcl er oral capsule extended release 12-hour 120mg, 60mg, 90mg</i> | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|----------------------------|
| <i>diltiazem hcl oral tablet 120mg, 30mg, 60mg, 90mg</i> | 1 | MO |
| <i>dilt-xr oral capsule extended release 24-hour 120mg, 180mg, 240mg</i> | 1 | MO; QL (60 EA per 30 days) |
| TAZTIA XT ORAL CAPSULE EXTENDED RELEASE 24-HOUR 120MG, 180MG, 240MG | 1 | MO; QL (60 EA per 30 days) |
| TAZTIA XT ORAL CAPSULE EXTENDED RELEASE 24-HOUR 300MG, 360MG | 1 | MO; QL (30 EA per 30 days) |
| TIADYLT ER ORAL CAPSULE EXTENDED RELEASE 24-HOUR 120MG, 180MG, 240MG | 1 | MO; QL (60 EA per 30 days) |
| TIADYLT ER ORAL CAPSULE EXTENDED RELEASE 24-HOUR 300MG, 360MG, 420MG | 1 | MO; QL (30 EA per 30 days) |
| <i>verapamil hcl er oral capsule extended release 24-hour 100mg, 120mg, 180mg, 200mg, 240mg, 300mg, 360mg</i> | 1 | MO |
| <i>verapamil hcl er oral tablet extended release 120mg, 180mg, 240mg</i> | 1 | MO |
| <i>verapamil hcl oral tablet 120mg, 40mg, 80mg</i> | 1 | MO |
| Agentes Bloqueantes Beta-Adrenérgicos | | |
| <i>acebutolol hcl oral capsule 200mg, 400mg</i> | 1 | MO |
| <i>atenolol oral tablet 100mg, 25mg, 50mg</i> | 1 | MO |
| <i>betaxolol hcl oral tablet 10mg, 20mg</i> | 1 | MO |
| <i>bisoprolol fumarate oral tablet 10mg, 5mg</i> | 1 | MO |
| <i>carvedilol oral tablet 12.5mg, 25mg, 3.125mg, 6.25mg</i> | 1 | MO |
| <i>labetalol hcl oral tablet 100mg, 200mg, 300mg</i> | 1 | MO |
| <i>metoprolol succinate er oral tablet extended release 24-hour 100mg, 200mg, 25mg, 50mg</i> | 1 | MO |
| <i>metoprolol tartrate oral tablet 100mg, 25mg, 37.5mg, 50mg, 75mg</i> | 1 | MO |
| <i>nadolol oral tablet 20mg, 40mg, 80mg</i> | 1 | MO |
| <i>nebivolol hcl oral tablet 10mg, 2.5mg, 20mg, 5mg</i> | 1 | MO |
| <i>pindolol oral tablet 10mg, 5mg</i> | 1 | MO |
| <i>propranolol hcl er oral capsule extended release 24-hour 120mg, 160mg, 60mg</i> | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|----------------------------|
| <i>propranolol hcl oral solution 20mg/5ml, 40mg/5ml</i> | 1 | MO |
| <i>propranolol hcl oral tablet 10mg, 20mg, 40mg, 60mg</i> | 1 | MO |
| <i>timolol maleate oral tablet 10mg, 20mg, 5mg</i> | 1 | MO |
| Agentes Cardiovasculares, Otros | | |
| <i>aliskiren fumarate oral tablet 150mg, 300mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>amiloride-hydrochlorothiazide oral tablet 5-50mg</i> | 1 | MO |
| <i>amlodipine besy-benazepril hcl oral capsule 10-20mg, 10-40mg, 2.5-10mg, 5-10mg, 5-20mg, 5-40mg</i> | 1 | MO |
| <i>amlodipine besylate-valsartan oral tablet 10-160mg, 10-320mg, 5-160mg, 5-320mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>amlodipine-atorvastatin oral tablet 10-10mg, 10-20mg, 10-40mg, 10-80mg, 2.5-10mg, 2.5-20mg, 2.5-40mg, 5-10mg, 5-20mg, 5-40mg, 5-80mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>amlodipine-olmesartan oral tablet 10-20mg, 10-40mg, 5-20mg, 5-40mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>atenolol-chlorthalidone oral tablet 100-25mg, 50-25mg</i> | 1 | MO |
| <i>benazepril-hydrochlorothiazide oral tablet 10-12.5mg, 20-12.5mg, 20-25mg, 5-6.25mg</i> | 1 | MO |
| <i>bisoprolol-hydrochlorothiazide oral tablet 10-6.25mg, 2.5-6.25mg, 5-6.25mg</i> | 1 | MO |
| CAMZYOS ORAL CAPSULE 10MG, 15MG, 2.5MG, 5MG | 1 | PA; QL (30 EA per 30 days) |
| <i>candesartan cilexetil-hctz oral tablet 16-12.5mg, 32-12.5mg, 32-25mg</i> | 1 | MO; QL (30 EA per 30 days) |
| CORLANOR ORAL TABLET 5MG, 7.5MG | 1 | PA; MO |
| DIGITEK ORAL TABLET 250MCG | 1 | MO; QL (30 EA per 30 days) |
| <i>digoxin oral solution 0.05mg/ml</i> | 1 | MO; QL (255ML per 30 days) |
| <i>digoxin oral tablet 125mcg, 250mcg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>enalapril-hydrochlorothiazide oral tablet 10-25mg, 5-12.5mg</i> | 1 | MO |
| ENTRESTO ORAL TABLET 24-26MG, 49-51MG, 97-103MG | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|----------------------------|
| <i>fosinopril sodium-hctz oral tablet 10-12.5mg, 20-12.5mg</i> | 1 | MO |
| <i>irbesartan-hydrochlorothiazide oral tablet 150-12.5mg, 300-12.5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>isosorb dinitrate-hydralazine oral tablet 20-37.5mg</i> | 1 | MO |
| <i>lisinopril-hydrochlorothiazide oral tablet 10-12.5mg, 20-12.5mg, 20-25mg</i> | 1 | MO |
| <i>losartan potassium-hctz oral tablet 100-12.5mg, 100-25mg, 50-12.5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>metoprolol-hydrochlorothiazide oral tablet 100-25mg, 100-50mg, 50-25mg</i> | 1 | MO |
| <i>metyrosine oral capsule 250mg</i> | 1 | |
| <i>olmesartan medoxomil-hctz oral tablet 20-12.5mg, 40-12.5mg, 40-25mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>olmesartan-amlodipine-hctz oral tablet 20-5-12.5mg, 40-10-12.5mg, 40-10-25mg, 40-5-12.5mg, 40-5-25mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>pentoxifylline er oral tablet extended release 400mg</i> | 1 | MO |
| <i>quinapril-hydrochlorothiazide oral tablet 10-12.5mg, 20-12.5mg, 20-25mg</i> | 1 | MO |
| <i>ranolazine er oral tablet extended release 12-hour 1000mg, 500mg</i> | 1 | MO |
| <i>spironolactone-hctz oral tablet 25-25mg</i> | 1 | MO |
| <i>telmisartan-hctz oral tablet 40-12.5mg, 80-12.5mg, 80-25mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>triamterene-hctz oral capsule 37.5-25mg</i> | 1 | MO |
| <i>triamterene-hctz oral tablet 37.5-25mg, 75-50mg</i> | 1 | MO |
| <i>valsartan-hydrochlorothiazide oral tablet 160-12.5mg, 160-25mg, 320-12.5mg, 320-25mg, 80-12.5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| VERQUVO ORAL TABLET 10MG, 2.5MG, 5MG | 1 | PA; MO |
| Agentes para Dislipidemias, Derivados del Ácido Fíbrico | | |
| <i>fenofibrate micronized oral capsule 130mg, 134mg, 200mg, 67mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>fenofibrate micronized oral capsule 43mg</i> | 1 | MO; QL (60 EA per 30 days) |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|----------------------------|
| <i>fenofibrate oral capsule 150mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>fenofibrate oral capsule 50mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>fenofibrate oral tablet 145mg, 160mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>fenofibrate oral tablet 48mg, 54mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>fenofibric acid oral capsule delayed release 135mg, 45mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>gemfibrozil oral tablet 600mg</i> | 1 | MO; QL (60 EA per 30 days) |
| Agentes para Dislipidemias, Inhibidores de la HMG COA Reductasa | | |
| <i>atorvastatin calcium oral tablet 10mg, 20mg, 40mg, 80mg</i> | 1 | MO; QL (30 EA per 30 days) |
| LIVALO ORAL TABLET 1MG, 2MG, 4MG | 1 | MO; QL (30 EA per 30 days) |
| <i>lovastatin oral tablet 10mg</i> | 1 | MO; QL (45 EA per 30 days) |
| <i>lovastatin oral tablet 20mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>lovastatin oral tablet 40mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>pravastatin sodium oral tablet 10mg, 20mg, 40mg, 80mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>rosuvastatin calcium oral tablet 10mg, 20mg, 40mg, 5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>simvastatin oral tablet 10mg, 20mg, 40mg, 5mg, 80mg</i> | 1 | MO; QL (30 EA per 30 days) |
| ZYPITAMAG ORAL TABLET 2MG, 4MG | 1 | MO; QL (30 EA per 30 days) |
| Agentes para Dislipidemias, Otros | | |
| <i>cholestyramine light oral packet 4gm</i> | 1 | MO |
| <i>cholestyramine oral packet 4gm</i> | 1 | MO |
| <i>colestipol hcl oral packet 5gm</i> | 1 | MO |
| <i>colestipol hcl oral tablet 1gm</i> | 1 | MO |
| <i>ezetimibe oral tablet 10mg</i> | 1 | MO; QL (30 EA per 30 days) |
| JUXTAPID ORAL CAPSULE 10MG, 20MG, 30MG, 5MG | 1 | PA |
| <i>niacin er (antihyperlipidemic) oral tablet extended release 1000mg, 500mg, 750mg</i> | 1 | MO |
| <i>omega-3-acid ethyl esters oral capsule 1gm</i> | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|-----------------------------|
| REPATHA PUSHTRONEX SYSTEM SUBCUTANEOUS SOLUTION CARTRIDGE 420MG/3.5ML | 1 | PA; MO |
| REPATHA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 140MG/ML | 1 | PA; MO |
| REPATHA SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 140MG/ML | 1 | PA; MO |
| VASCEPA ORAL CAPSULE 0.5GM, 1GM | 1 | MO |
| Agonistas Alfa-Adrenérgicos | | |
| <i>clonidine hcl oral tablet 0.1mg, 0.2mg, 0.3mg</i> | 1 | MO |
| <i>clonidine transdermal patch weekly 0.1mg/24hr, 0.2mg/24hr, 0.3mg/24hr</i> | 1 | MO; QL (4 EA per 28 days) |
| <i>droxidopa oral capsule 100mg, 200mg, 300mg</i> | 1 | PA; QL (180 EA per 30 days) |
| <i>guanfacine hcl oral tablet 1mg, 2mg</i> | 1 | MO |
| <i>midodrine hcl oral tablet 10mg, 2.5mg, 5mg</i> | 1 | |
| Antagonistas del Receptor de Angiotensina II | | |
| <i>candesartan cilexetil oral tablet 16mg, 4mg, 8mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>candesartan cilexetil oral tablet 32mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>irbesartan oral tablet 150mg, 300mg, 75mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>losartan potassium oral tablet 100mg, 25mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>losartan potassium oral tablet 50mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>olmesartan medoxomil oral tablet 20mg, 40mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>olmesartan medoxomil oral tablet 5mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>telmisartan oral tablet 20mg, 40mg, 80mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>valsartan oral tablet 160mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>valsartan oral tablet 320mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>valsartan oral tablet 40mg, 80mg</i> | 1 | MO; QL (90 EA per 30 days) |
| Antiarrítmicos | | |
| <i>amiodarone hcl oral tablet 100mg, 200mg, 400mg</i> | 1 | MO |
| <i>disopyramide phosphate oral capsule 100mg, 150mg</i> | 1 | MO |
| <i>dofetilide oral capsule 125mcg, 250mcg, 500mcg</i> | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|----------------------------|
| <i>flecainide acetate oral tablet 100mg, 150mg, 50mg</i> | 1 | MO |
| <i>mexiletine hcl oral capsule 150mg, 200mg, 250mg</i> | 1 | MO |
| MULTAQ ORAL TABLET 400MG | 1 | MO |
| <i>propafenone hcl oral tablet 150mg, 225mg, 300mg</i> | 1 | MO |
| <i>quinidine sulfate oral tablet 200mg, 300mg</i> | 1 | MO |
| <i>sotalol hcl (af) oral tablet 120mg, 160mg, 80mg</i> | 1 | MO |
| <i>sotalol hcl oral tablet 120mg, 160mg, 240mg, 80mg</i> | 1 | MO |
| Bloqueadores Alfa-Adrenérgicos | | |
| <i>doxazosin mesylate oral tablet 1mg, 2mg, 4mg, 8mg</i> | 1 | MO |
| <i>prazosin hcl oral capsule 1mg, 2mg, 5mg</i> | 1 | MO |
| <i>terazosin hcl oral capsule 1mg, 10mg, 2mg, 5mg</i> | 1 | MO |
| Diuréticos, Ahorradores de Potasio | | |
| <i>amiloride hcl oral tablet 5mg</i> | 1 | MO |
| <i>eplerenone oral tablet 25mg, 50mg</i> | 1 | MO |
| KERENDIA ORAL TABLET 10MG, 20MG | 1 | MO; QL (30 EA per 30 days) |
| <i>spironolactone oral tablet 100mg, 25mg, 50mg</i> | 1 | MO |
| Diuréticos, Bucle | | |
| <i>bumetanide injection solution 0.25mg/ml</i> | 1 | |
| <i>bumetanide oral tablet 0.5mg, 1mg, 2mg</i> | 1 | MO |
| <i>furosemide injection solution 10mg/ml</i> | 1 | BvD |
| <i>furosemide oral solution 10mg/ml, 8mg/ml</i> | 1 | MO |
| <i>furosemide oral tablet 20mg, 40mg, 80mg</i> | 1 | MO |
| <i>torseamide oral tablet 10mg, 100mg, 20mg, 5mg</i> | 1 | MO |
| Diuréticos, Tiazidas | | |
| <i>chlorthalidone oral tablet 25mg, 50mg</i> | 1 | MO |
| <i>hydrochlorothiazide oral capsule 12.5mg</i> | 1 | MO |
| <i>hydrochlorothiazide oral tablet 12.5mg, 25mg, 50mg</i> | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|--------------------|
| <i>indapamide oral tablet 1.25mg, 2.5mg</i> | 1 | MO |
| <i>metolazone oral tablet 10mg, 2.5mg, 5mg</i> | 1 | MO |
| <i>Inhibidores de la Enzima Convertidora de Angiotensina (ECA)</i> | | |
| <i>benazepril hcl oral tablet 10mg, 20mg, 40mg, 5mg</i> | 1 | MO |
| <i>captopril oral tablet 100mg, 12.5mg, 25mg, 50mg</i> | 1 | MO |
| <i>enalapril maleate oral tablet 10mg, 2.5mg, 20mg, 5mg</i> | 1 | MO |
| <i>fosinopril sodium oral tablet 10mg, 20mg, 40mg</i> | 1 | MO |
| <i>lisinopril oral tablet 10mg, 2.5mg, 20mg, 30mg, 40mg, 5mg</i> | 1 | MO |
| <i>moexipril hcl oral tablet 15mg, 7.5mg</i> | 1 | MO |
| <i>perindopril erbumine oral tablet 2mg, 4mg, 8mg</i> | 1 | MO |
| <i>quinapril hcl oral tablet 10mg, 20mg, 40mg, 5mg</i> | 1 | MO |
| <i>ramipril oral capsule 1.25mg, 10mg, 2.5mg, 5mg</i> | 1 | MO |
| <i>trandolapril oral tablet 1mg, 2mg, 4mg</i> | 1 | MO |
| <i>Vasodilatadores Arteriales/Venosos de Acción Directa</i> | | |
| <i>hydralazine hcl oral tablet 10mg, 100mg, 25mg, 50mg</i> | 1 | MO |
| <i>isosorbide dinitrate oral tablet 10mg, 20mg, 30mg, 5mg</i> | 1 | MO |
| <i>isosorbide mononitrate er oral tablet extended release 24-hour 120mg, 30mg, 60mg</i> | 1 | MO |
| <i>isosorbide mononitrate oral tablet 10mg, 20mg</i> | 1 | MO |
| <i>minoxidil oral tablet 10mg, 2.5mg</i> | 1 | MO |
| NITRO-BID TRANSDERMAL OINTMENT 2% | 1 | MO |
| <i>nitroglycerin sublingual tablet sublingual 0.3mg, 0.4mg, 0.6mg</i> | 1 | MO |
| <i>nitroglycerin transdermal patch 24-hour 0.1mg/hr, 0.2mg/hr, 0.4mg/hr, 0.6mg/hr</i> | 1 | MO |
| <i>nitroglycerin translingual solution 0.4mg/spray</i> | 1 | MO |
| RECTIV RECTAL OINTMENT 0.4% | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|-----------------------------|
| AGENTES DE ANTIDEMENCIA | | |
| Agentes Antidemencia, Otros | | |
| <i>memantine hcl er oral capsule extended release 24-hour 14mg, 21mg, 28mg, 7mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>memantine hcl oral solution 2mg/ml</i> | 1 | MO; QL (360ML per 30 days) |
| <i>memantine hcl oral tablet 10mg, 5mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>memantine hcl oral tablet 28 x 5mg & 21 x 10mg</i> | 1 | QL (49 EA per 28 days) |
| NAMZARIC ORAL CAPSULE ER 24-HOUR THERAPY PACK 7 & 14 & 21 & 28 -10MG | 1 | PA |
| NAMZARIC ORAL CAPSULE EXTENDED RELEASE 24-HOUR 14-10MG, 21-10MG, 28-10MG, 7-10MG | 1 | PA; MO |
| Inhibidores de Colinesterasa | | |
| <i>donepezil hcl oral tablet 10mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>donepezil hcl oral tablet 23mg, 5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>donepezil hcl oral tablet dispersible 10mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>donepezil hcl oral tablet dispersible 5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>galantamine hydrobromide er oral capsule extended release 24-hour 16mg, 24mg, 8mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>galantamine hydrobromide oral solution 4mg/ml</i> | 1 | MO; QL (200ML per 30 days) |
| <i>galantamine hydrobromide oral tablet 12mg, 4mg, 8mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>rivastigmine tartrate oral capsule 1.5mg, 3mg, 4.5mg, 6mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>rivastigmine transdermal patch 24-hour 13.3mg/24hr, 4.6mg/24hr, 9.5mg/24hr</i> | 1 | MO; QL (30 EA per 30 days) |
| AGENTES DEL SISTEMA NERVIOSO CENTRAL | | |
| Agentes con Trastorno por Déficit de Atención e Hiperactividad, Sin Anfetaminas | | |
| <i>atomoxetine hcl oral capsule 10mg, 100mg, 18mg, 25mg, 40mg, 60mg, 80mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>dexmethylphenidate hcl oral tablet 10mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>dexmethylphenidate hcl oral tablet 2.5mg</i> | 1 | MO; QL (240 EA per 30 days) |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|--------------------------------|
| <i>dexmethylphenidate hcl oral tablet 5mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>guanfacine hcl er oral tablet extended release 24-hour 1mg, 2mg, 3mg, 4mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>methylphenidate hcl oral tablet 10mg, 20mg, 5mg</i> | 1 | MO; QL (90 EA per 30 days) |
| Agentes de Esclerosis Múltiple | | |
| AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT 30MCG/0.5ML | 1 | PA |
| AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT 30MCG/0.5ML | 1 | PA |
| BETASERON SUBCUTANEOUS KIT 0.3MG | 1 | PA |
| COPAXONE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20MG/ML, 40MG/ML | 1 | PA |
| <i>dalfampridine er oral tablet extended release 12-hour 10mg</i> | 1 | PA; MO; QL (60 EA per 30 days) |
| <i>dimethyl fumarate oral capsule delayed release 120mg, 240mg</i> | 1 | PA |
| <i>dimethyl fumarate starter pack oral 120 & 240mg</i> | 1 | PA |
| <i> fingolimod hcl oral capsule 0.5mg</i> | 1 | PA |
| KESIMPTA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 20MG/0.4ML | 1 | PA |
| MAYZENT ORAL TABLET 0.25MG, 1MG, 2MG | 1 | PA |
| MAYZENT STARTER PACK ORAL TABLET THERAPY PACK 0.25MG, 12 X 0.25MG | 1 | PA |
| Agentes de Fibromialgia | | |
| <i>pregabalin oral capsule 100mg, 150mg, 25mg, 50mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>pregabalin oral capsule 200mg, 225mg, 300mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>pregabalin oral capsule 75mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>pregabalin oral solution 20mg/ml</i> | 1 | MO; QL (900ML per 30 days) |
| SAVELLA ORAL TABLET 100MG, 12.5MG, 25MG, 50MG | 1 | MO; QL (60 EA per 30 days) |
| SAVELLA TITRATION PACK ORAL 12.5 & 25 & 50MG | 1 | QL (55 EA per 28 days) |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|-----------------------------|
| Agentes de Trastorno por Déficit de Atención con Hiperactividad, Anfetaminas | | |
| <i>amphetamine-dextroamphetamine oral tablet 10mg, 12.5mg, 15mg, 20mg, 5mg, 7.5mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>amphetamine-dextroamphetamine oral tablet 30mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>dextroamphetamine sulfate er oral capsule extended release 24-hour 10mg</i> | 1 | MO; QL (180 EA per 30 days) |
| <i>dextroamphetamine sulfate er oral capsule extended release 24-hour 15mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>dextroamphetamine sulfate er oral capsule extended release 24-hour 5mg</i> | 1 | MO; QL (360 EA per 30 days) |
| <i>dextroamphetamine sulfate oral solution 5mg/5ml</i> | 1 | MO; QL (1800ML per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 10mg</i> | 1 | MO; QL (180 EA per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 15mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 20mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 30mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 5mg</i> | 1 | MO; QL (150 EA per 30 days) |
| Sistema Nervioso Central, Otros | | |
| AUSTEDO ORAL TABLET 12MG, 6MG, 9MG | 1 | PA; QL (120 EA per 30 days) |
| EVRYSDI ORAL SOLUTION RECONSTITUTED 0.75MG/ML | 1 | PA |
| NUDEXTA ORAL CAPSULE 20-10MG | 1 | PA; MO |
| <i>riluzole oral tablet 50mg</i> | 1 | PA; MO |
| <i>tetrabenazine oral tablet 12.5mg</i> | 1 | PA; QL (240 EA per 30 days) |
| <i>tetrabenazine oral tablet 25mg</i> | 1 | PA; QL (120 EA per 30 days) |
| AGENTES DENTALES Y ORALES | | |
| Agentes Dentales y Orales | | |
| <i>chlorhexidine gluconate mouth/throat solution 0.12%</i> | 1 | |
| PERIOGARD MOUTH/THROAT SOLUTION 0.12% | 1 | |
| <i>pilocarpine hcl oral tablet 5mg, 7.5mg</i> | 1 | MO |
| <i>triamcinolone acetonide mouth/throat paste 0.1%</i> | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|--------------------|
| AGENTES DERMATOLÓGICOS | | |
| Agentes Dermatológicos, Otros | | |
| <i>calcipotriene external solution 0.005%</i> | 1 | |
| <i>clotrimazole-betamethasone external cream 1-0.05%</i> | 1 | |
| <i>clotrimazole-betamethasone external lotion 1-0.05%</i> | 1 | |
| <i>diclofenac sodium external gel 3%</i> | 1 | PA |
| <i>fluorouracil external cream 5%</i> | 1 | |
| <i>fluorouracil external solution 2%, 5%</i> | 1 | |
| <i>global alcohol prep ease pad 70%</i> | 1 | |
| <i>hydrocortisone ace-pramoxine external cream 1-1%</i> | 1 | |
| HYFTOR EXTERNAL GEL 0.2% | 1 | PA |
| <i>imiquimod external cream 5%</i> | 1 | |
| <i>nystatin-triamcinolone external cream 100000-0.1unit/gm-%</i> | 1 | |
| <i>nystatin-triamcinolone external ointment 100000-0.1unit/gm-%</i> | 1 | |
| PANRETIN EXTERNAL GEL 0.1% | 1 | PA |
| <i>podofilox external solution 0.5%</i> | 1 | |
| REGRANEX EXTERNAL GEL 0.01% | 1 | PA |
| SANTYL EXTERNAL OINTMENT 250UNIT/GM | 1 | |
| <i>silver sulfadiazine external cream 1%</i> | 1 | |
| SSD EXTERNAL CREAM 1% | 1 | |
| Agentes para Acné y Rosácea | | |
| AC CUTANE ORAL CAPSULE 10MG, 20MG, 30MG, 40MG | 1 | |
| <i>acitretin oral capsule 10mg, 17.5mg, 25mg</i> | 1 | PA |
| AMNESTEEM ORAL CAPSULE 10MG, 20MG, 40MG | 1 | |
| <i>benzoyl peroxide-erythromycin external gel 5-3%</i> | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|--------------------|
| CLARAVIS ORAL CAPSULE 10MG, 20MG, 30MG, 40MG | 1 | |
| <i>clindamycin phos-benzoyl perox external gel 1.2-5%</i> | 1 | |
| <i>isotretinoin oral capsule 10mg, 20mg, 30mg, 40mg</i> | 1 | |
| <i>tazarotene external cream 0.1%</i> | 1 | PA |
| <i>tazarotene external gel 0.05%, 0.1%</i> | 1 | PA |
| TAZORAC EXTERNAL CREAM 0.05% | 1 | PA |
| <i>tretinoin external cream 0.025%, 0.05%, 0.1%</i> | 1 | PA |
| <i>tretinoin external gel 0.01%, 0.025%, 0.05%</i> | 1 | PA |
| Agentes para Dermatitis y Pruitus | | |
| <i>alclometasone dipropionate external cream 0.05%</i> | 1 | |
| <i>alclometasone dipropionate external ointment 0.05%</i> | 1 | |
| <i>amcinonide external ointment 0.1%</i> | 1 | |
| <i>ammonium lactate external cream 12%</i> | 1 | |
| <i>ammonium lactate external lotion 12%</i> | 1 | |
| <i>betamethasone dipropionate aug external cream 0.05%</i> | 1 | |
| <i>betamethasone dipropionate aug external lotion 0.05%</i> | 1 | |
| <i>betamethasone dipropionate aug external ointment 0.05%</i> | 1 | |
| <i>betamethasone dipropionate external cream 0.05%</i> | 1 | |
| <i>betamethasone dipropionate external lotion 0.05%</i> | 1 | |
| <i>betamethasone dipropionate external ointment 0.05%</i> | 1 | |
| <i>betamethasone valerate external cream 0.1%</i> | 1 | |
| <i>betamethasone valerate external lotion 0.1%</i> | 1 | |
| <i>betamethasone valerate external ointment 0.1%</i> | 1 | |
| <i>clobetasol propionate e external cream 0.05%</i> | 1 | |
| <i>clobetasol propionate external cream 0.05%</i> | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|-----------------------------|---------------------------|
| <i>clobetasol propionate external gel 0.05%</i> | 1 | |
| <i>clobetasol propionate external ointment 0.05%</i> | 1 | |
| <i>clobetasol propionate external solution 0.05%</i> | 1 | |
| <i>desonide external cream 0.05%</i> | 1 | |
| <i>desonide external lotion 0.05%</i> | 1 | |
| <i>desonide external ointment 0.05%</i> | 1 | |
| <i>desoximetasone external cream 0.05%, 0.25%</i> | 1 | |
| <i>desoximetasone external gel 0.05%</i> | 1 | |
| <i>desoximetasone external ointment 0.25%</i> | 1 | |
| EUCRISA EXTERNAL OINTMENT 2% | 1 | |
| <i>fluocinolone acetonide external cream 0.01%, 0.025%</i> | 1 | |
| <i>fluocinolone acetonide external ointment 0.025%</i> | 1 | |
| <i>fluocinolone acetonide external solution 0.01%</i> | 1 | |
| <i>fluocinonide emulsified base external cream 0.05%</i> | 1 | |
| <i>fluocinonide external gel 0.05%</i> | 1 | |
| <i>fluocinonide external ointment 0.05%</i> | 1 | |
| <i>fluocinonide external solution 0.05%</i> | 1 | |
| <i>fluticasone propionate external cream 0.05%</i> | 1 | |
| <i>fluticasone propionate external ointment 0.005%</i> | 1 | |
| <i>halobetasol propionate external cream 0.05%</i> | 1 | |
| <i>halobetasol propionate external ointment 0.05%</i> | 1 | |
| <i>hydrocortisone (perianal) external cream 2.5%</i> | 1 | |
| <i>hydrocortisone external cream 1%</i> | 1 | |
| <i>hydrocortisone external lotion 2.5%</i> | 1 | |
| <i>hydrocortisone external ointment 1%, 2.5%</i> | 1 | |
| <i>hydrocortisone valerate external cream 0.2%</i> | 1 | |
| <i>hydrocortisone valerate external ointment 0.2%</i> | 1 | |
| <i>mometasone furoate external cream 0.1%</i> | 1 | |
| <i>mometasone furoate external ointment 0.1%</i> | 1 | |
| <i>mometasone furoate external solution 0.1%</i> | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|--------------------|
| <i>pimecrolimus external cream 1%</i> | 1 | |
| <i>prednicarbate external ointment 0.1%</i> | 1 | |
| PROCTO-MED HC EXTERNAL CREAM 2.5% | 1 | |
| PROCTO-PAK EXTERNAL CREAM 1% | 1 | |
| PROCTOSOL HC EXTERNAL CREAM 2.5% | 1 | |
| PROCTOZONE-HC EXTERNAL CREAM 2.5% | 1 | |
| <i>selenium sulfide external lotion 2.5%</i> | 1 | |
| <i>tacrolimus external ointment 0.03%, 0.1%</i> | 1 | |
| <i>triamcinolone acetonide external cream 0.025%, 0.1%, 0.5%</i> | 1 | |
| <i>triamcinolone acetonide external lotion 0.025%, 0.1%</i> | 1 | |
| <i>triamcinolone acetonide external ointment 0.025%, 0.1%, 0.5%</i> | 1 | |

Antiinfecciosos Tópicos

| | | |
|---|---|--|
| <i>ciclopirox external gel 0.77%</i> | 1 | |
| <i>ciclopirox external shampoo 1%</i> | 1 | |
| <i>ciclopirox external solution 8%</i> | 1 | |
| <i>clindamycin phosphate external gel 1%</i> | 1 | |
| <i>clindamycin phosphate external lotion 1%</i> | 1 | |
| <i>clindamycin phosphate external solution 1%</i> | 1 | |
| <i>ery external pad 2%</i> | 1 | |
| <i>erythromycin external gel 2%</i> | 1 | |
| <i>erythromycin external solution 2%</i> | 1 | |
| <i>mupirocin calcium external cream 2%</i> | 1 | |
| <i>mupirocin external ointment 2%</i> | 1 | |

Pediculicidas/Escabicidas

| | | |
|---------------------------------------|---|--|
| <i>malathion external lotion 0.5%</i> | 1 | |
| <i>permethrin external cream 5%</i> | 1 | |

AGENTES GASTROINTESTINALES

Agentes Antidiarreicos

| | | |
|--|---|------------------------|
| <i>alose tron hcl oral tablet 0.5mg, 1mg</i> | 1 | QL (60 EA per 30 days) |
|--|---|------------------------|

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|----------------------------|
| <i>diphenoxylate-atropine oral liquid 2.5-0.025mg/5ml</i> | 1 | |
| <i>diphenoxylate-atropine oral tablet 2.5-0.025mg</i> | 1 | |
| <i>loperamide hcl oral capsule 2mg</i> | 1 | |
| Agentes Contra el Estreñimiento | | |
| <i>constulose oral solution 10gm/15ml</i> | 1 | MO |
| <i>enulose oral solution 10gm/15ml</i> | 1 | MO |
| <i>generlac oral solution 10gm/15ml</i> | 1 | MO |
| <i>lactulose oral solution 10gm/15ml</i> | 1 | MO |
| LINZESS ORAL CAPSULE 145MCG, 290MCG, 72MCG | 1 | MO; QL (30 EA per 30 days) |
| <i>lubiprostone oral capsule 24mcg, 8mcg</i> | 1 | MO; QL (60 EA per 30 days) |
| MOVANTIK ORAL TABLET 12.5MG, 25MG | 1 | QL (30 EA per 30 days) |
| Agentes Gastrointestinales, Otros | | |
| BYLVAY (PELLETS) ORAL CAPSULE SPRINKLE 200MCG | 1 | PA |
| BYLVAY ORAL CAPSULE 1200MCG, 400MCG | 1 | PA |
| CLENPIQ ORAL SOLUTION 10-3.5-12MG-GM -GM/160ML | 1 | |
| GATTEX SUBCUTANEOUS KIT 5MG | 1 | PA |
| GAVILYTE-C ORAL SOLUTION RECONSTITUTED 240GM | 1 | |
| GAVILYTE-G ORAL SOLUTION RECONSTITUTED 236GM | 1 | |
| LIVMARLI ORAL SOLUTION 9.5MG/ML | 1 | PA |
| <i>metoclopramide hcl oral solution 5mg/5ml</i> | 1 | |
| <i>metoclopramide hcl oral tablet 10mg, 5mg</i> | 1 | MO |
| <i>na sulfate-k sulfate-mg sulf oral solution 17.5-3.13-1.6gm/177ml</i> | 1 | |
| <i>peg 3350-kcl-na bicarb-nacl oral solution reconstituted 420gm</i> | 1 | |
| <i>peg-3350/electrolytes oral solution reconstituted 236gm</i> | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|--------------------|
| SUPREP BOWEL PREP KIT ORAL SOLUTION 17.5-3.13-1.6GM/177ML | 1 | |
| SUTAB ORAL TABLET 1479-225-188MG | 1 | |
| <i>ursodiol oral capsule 300mg</i> | 1 | MO |
| <i>ursodiol oral tablet 250mg, 500mg</i> | 1 | MO |
| Antagonistas del Receptor de Histamina2 (H2) | | |
| <i>famotidine oral suspension reconstituted 40mg/5ml</i> | 1 | MO |
| <i>famotidine oral tablet 20mg, 40mg</i> | 1 | MO |
| <i>nizatidine oral capsule 150mg, 300mg</i> | 1 | MO |
| Antiespasmódicos, Gastrointestinales | | |
| <i>dicyclomine hcl oral capsule 10mg</i> | 1 | |
| <i>dicyclomine hcl oral solution 10mg/5ml</i> | 1 | |
| <i>dicyclomine hcl oral tablet 20mg</i> | 1 | |
| <i>glycopyrrolate oral tablet 1mg, 2mg</i> | 1 | |
| Inhibidores de la Bomba de Protones | | |
| <i>dexlansoprazole oral capsule delayed release 30mg, 60mg</i> | 1 | MO |
| <i>esomeprazole magnesium oral capsule delayed release 20mg, 40mg</i> | 1 | MO |
| <i>lansoprazole oral capsule delayed release 15mg, 30mg</i> | 1 | MO |
| <i>omeprazole oral capsule delayed release 10mg, 20mg, 40mg</i> | 1 | MO |
| <i>pantoprazole sodium oral tablet delayed release 20mg, 40mg</i> | 1 | MO |
| Protectores | | |
| <i>misoprostol oral tablet 100mcg, 200mcg</i> | 1 | MO |
| <i>sucralfate oral suspension 1gm/10ml</i> | 1 | MO |
| <i>sucralfate oral tablet 1gm</i> | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|-----------------------------|
| AGENTES GENITOURINARIOS | | |
| Agentes Genitourinarios, Otros | | |
| <i>bethanechol chloride oral tablet 10mg, 25mg, 5mg, 50mg</i> | 1 | |
| ELMIRON ORAL CAPSULE 100MG | 1 | |
| <i>penicillamine oral tablet 250mg</i> | 1 | |
| Agentes para Hipertrofia Prostática Benigna | | |
| <i>alfuzosin hcl er oral tablet extended release 24-hour 10mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>dutasteride oral capsule 0.5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>dutasteride-tamsulosin hcl oral capsule 0.5-0.4mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>finasteride oral tablet 5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>silodosin oral capsule 4mg, 8mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>tamsulosin hcl oral capsule 0.4mg</i> | 1 | MO; QL (60 EA per 30 days) |
| Antiespasmódicos, Urinarios | | |
| <i>darifenacin hydrobromide er oral tablet extended release 24-hour 15mg, 7.5mg</i> | 1 | MO |
| <i>fesoterodine fumarate er oral tablet extended release 24-hour 4mg, 8mg</i> | 1 | MO; QL (30 EA per 30 days) |
| MYRBETRIQ ORAL SUSPENSION RECONSTITUTED ER 8MG/ML | 1 | MO; QL (300ML per 30 days) |
| MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24-HOUR 25MG, 50MG | 1 | MO; QL (30 EA per 30 days) |
| <i>oxybutynin chloride er oral tablet extended release 24-hour 10mg, 15mg, 5mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>oxybutynin chloride oral syrup 5mg/5ml</i> | 1 | MO; QL (600ML per 30 days) |
| <i>oxybutynin chloride oral tablet 5mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>solifenacin succinate oral tablet 10mg, 5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>tolterodine tartrate er oral capsule extended release 24-hour 2mg, 4mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>tolterodine tartrate oral tablet 1mg, 2mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>tropium chloride er oral capsule extended release 24-hour 60mg</i> | 1 | MO; QL (30 EA per 30 days) |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|----------------------------|
| <i>trosipium chloride oral tablet 20mg</i> | 1 | MO; QL (60 EA per 30 days) |
| AGENTES HORMONALES, ESTIMULANTES/ DE REEMPLAZO/ MODIFICADORES (HORMONAS SEXUALES/ MODIFICADORES) | | |
| <i>Agentes Hormonales, Estimulantes/ de Reemplazo/ Modificadores (Hormonas Sexuales/ Modificadores)</i> | | |
| ALTAVERA ORAL TABLET 0.15-30MG-MCG | 1 | MO |
| <i>alyacen 1/35 oral tablet 1-35mg-mcg</i> | 1 | MO |
| APRI ORAL TABLET 0.15-30MG-MCG | 1 | MO |
| ARANELLE ORAL TABLET 0.5/1/0.5-35MG-MCG | 1 | MO |
| AUBRA EQ ORAL TABLET 0.1-20MG-MCG | 1 | MO |
| AVIANE ORAL TABLET 0.1-20MG-MCG | 1 | MO |
| BALZIVA ORAL TABLET 0.4-35MG-MCG | 1 | MO |
| BLISOVI FE 1.5/30 ORAL TABLET 1.5-30MG-MCG | 1 | MO |
| <i>briellyn oral tablet 0.4-35mg-mcg</i> | 1 | MO |
| CRYSSELLE-28 ORAL TABLET 0.3-30MG-MCG | 1 | MO |
| CYRED EQ ORAL TABLET 0.15-30MG-MCG | 1 | MO |
| <i>desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01mg (21/5), 0.15-30mg-mcg</i> | 1 | MO |
| <i>drospirenone-ethinyl estradiol oral tablet 3-0.02mg, 3-0.03mg</i> | 1 | MO |
| ELURYNG VAGINAL RING 0.12-0.015MG/24HR | 1 | MO |
| EMOQUETTE ORAL TABLET 0.15-30MG-MCG | 1 | MO |
| ENPRESSE-28 ORAL TABLET 50-30/75-40/125-30MCG | 1 | MO |
| ENSKYCE ORAL TABLET 0.15-30MG-MCG | 1 | MO |
| ESTARYLLA ORAL TABLET 0.25-35MG-MCG | 1 | MO |
| <i>ethynodiol diac-eth estradiol oral tablet 1-35mg-mcg, 1-50mg-mcg</i> | 1 | MO |
| <i>etonogestrel-ethinyl estradiol vaginal ring 0.12-0.015mg/24hr</i> | 1 | MO |
| FALMINA ORAL TABLET 0.1-20MG-MCG | 1 | MO |
| FEMYNOR ORAL TABLET 0.25-35MG-MCG | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|--------------------|
| ICLEVIA ORAL TABLET 0.15-0.03MG | 1 | MO |
| INTRAROSA VAGINAL INSERT 6.5MG | 1 | PA; MO |
| INTROVALE ORAL TABLET 0.15-0.03MG | 1 | MO |
| ISIBLOOM ORAL TABLET 0.15-30MG-MCG | 1 | MO |
| JASMIEL ORAL TABLET 3-0.02MG | 1 | MO |
| JULEBER ORAL TABLET 0.15-30MG-MCG | 1 | MO |
| JUNEL 1.5/30 ORAL TABLET 1.5-30MG-MCG | 1 | MO |
| JUNEL 1/20 ORAL TABLET 1-20MG-MCG | 1 | MO |
| JUNEL FE 1.5/30 ORAL TABLET 1.5-30MG-MCG | 1 | MO |
| JUNEL FE 1/20 ORAL TABLET 1-20MG-MCG | 1 | MO |
| KARIVA ORAL TABLET 0.15-0.02/0.01MG (21/5) | 1 | MO |
| KELNOR 1/35 ORAL TABLET 1-35MG-MCG | 1 | MO |
| KELNOR 1/50 ORAL TABLET 1-50MG-MCG | 1 | MO |
| KURVELO ORAL TABLET 0.15-30MG-MCG | 1 | MO |
| LARIN 1.5/30 ORAL TABLET 1.5-30MG-MCG | 1 | MO |
| LARIN 1/20 ORAL TABLET 1-20MG-MCG | 1 | MO |
| LARIN FE 1.5/30 ORAL TABLET 1.5-30MG-MCG | 1 | MO |
| LARIN FE 1/20 ORAL TABLET 1-20MG-MCG | 1 | MO |
| LEENA ORAL TABLET 0.5/1/0.5-35MG-MCG | 1 | MO |
| LESSINA ORAL TABLET 0.1-20MG-MCG | 1 | MO |
| LEVONEST ORAL TABLET 50-30/75-40/ 125-30MCG | 1 | MO |
| <i>levonorgest-eth estrad 91-day oral tablet 0.15-0.03mg</i> | 1 | MO |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.1-20mg-mcg, 0.15-30mg-mcg</i> | 1 | MO |
| <i>levonorg-eth estrad triphasic oral tablet 50-30/75-40/ 125-30mcg</i> | 1 | MO |
| LEVORA 0.15/30 (28) ORAL TABLET 0.15-30MG-MCG | 1 | MO |
| LORYNA ORAL TABLET 3-0.02MG | 1 | MO |
| LOW-OGESTREL ORAL TABLET 0.3-30MG-MCG | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|--------------------|
| LUTERA ORAL TABLET 0.1-20MG-MCG | 1 | MO |
| <i>marlissa oral tablet 0.15-30mg-mcg</i> | 1 | MO |
| MICROGESTIN 1.5/30 ORAL TABLET 1.5-30MG-MCG | 1 | MO |
| MICROGESTIN 1/20 ORAL TABLET 1-20MG-MCG | 1 | MO |
| MICROGESTIN FE 1.5/30 ORAL TABLET 1.5-30MG-MCG | 1 | MO |
| MICROGESTIN FE 1/20 ORAL TABLET 1-20MG-MCG | 1 | MO |
| MILI ORAL TABLET 0.25-35MG-MCG | 1 | MO |
| NECON 0.5/35 (28) ORAL TABLET 0.5-35MG-MCG | 1 | MO |
| NIKKI ORAL TABLET 3-0.02MG | 1 | MO |
| <i>norethin ace-eth estrad-fe oral tablet 1-20mg-mcg</i> | 1 | MO |
| <i>norethindrone acet-ethinyl est oral tablet 1-20mg-mcg</i> | 1 | MO |
| <i>norethindrone-eth estradiol oral tablet 1-5mg-mcg</i> | 1 | MO |
| <i>norgestimate-eth estradiol oral tablet 0.25-35mg-mcg</i> | 1 | MO |
| <i>norgestim-eth estrad triphasic oral tablet 0.18/0.215/0.25mg-35mcg</i> | 1 | MO |
| NORTREL 0.5/35 (28) ORAL TABLET 0.5-35MG-MCG | 1 | MO |
| NORTREL 1/35 (21) ORAL TABLET 1-35MG-MCG | 1 | MO |
| NORTREL 1/35 (28) ORAL TABLET 1-35MG-MCG | 1 | MO |
| NORTREL 7/7/7 ORAL TABLET 0.5/0.75/1-35MG-MCG | 1 | MO |
| NYLIA 1/35 ORAL TABLET 1-35MG-MCG | 1 | MO |
| NYLIA 7/7/7 ORAL TABLET 0.5/0.75/1-35MG-MCG | 1 | MO |
| NYMYO ORAL TABLET 0.25-35MG-MCG | 1 | MO |
| OCELLA ORAL TABLET 3-0.03MG | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|-----------------------------|---------------------------|
| OSPHENA ORAL TABLET 60MG | 1 | PA; MO |
| PIMTREA ORAL TABLET 0.15-0.02/0.01MG (21/5) | 1 | MO |
| PIRMELLA 1/35 ORAL TABLET 1-35MG-MCG | 1 | MO |
| PORTIA-28 ORAL TABLET 0.15-30MG-MCG | 1 | MO |
| PREMPHASE ORAL TABLET 0.625-5MG | 1 | MO |
| PREMPRO ORAL TABLET 0.3-1.5MG, 0.45-1.5MG, 0.625-2.5MG, 0.625-5MG | 1 | MO |
| RECLIPSEN ORAL TABLET 0.15-30MG-MCG | 1 | MO |
| SETLAKIN ORAL TABLET 0.15-0.03MG | 1 | MO |
| SPRINTEC 28 ORAL TABLET 0.25-35MG-MCG | 1 | MO |
| SRONYX ORAL TABLET 0.1-20MG-MCG | 1 | MO |
| SYEDA ORAL TABLET 3-0.03MG | 1 | MO |
| TARINA FE 1/20 EQ ORAL TABLET 1-20MG-MCG | 1 | MO |
| TRI-ESTARYLLA ORAL TABLET 0.18/0.215/0.25MG-35MCG | 1 | MO |
| TRI-MILI ORAL TABLET 0.18/0.215/0.25MG-35MCG | 1 | MO |
| TRI-NYMYO ORAL TABLET 0.18/0.215/0.25MG-35MCG | 1 | MO |
| TRI-SPRINTEC ORAL TABLET 0.18/0.215/0.25MG-35MCG | 1 | MO |
| TRIVORA (28) ORAL TABLET 50-30/75-40/125-30MCG | 1 | MO |
| TRI-VYLIBRA ORAL TABLET 0.18/0.215/0.25MG-35MCG | 1 | MO |
| VELIVET ORAL TABLET 0.1/0.125/0.15 -0.025MG | 1 | MO |
| VESTURA ORAL TABLET 3-0.02MG | 1 | MO |
| VIENVA ORAL TABLET 0.1-20MG-MCG | 1 | MO |
| VYFEMLA ORAL TABLET 0.4-35MG-MCG | 1 | MO |
| VYLIBRA ORAL TABLET 0.25-35MG-MCG | 1 | MO |
| ZOVIA 1/35 (28) ORAL TABLET 1-35MG-MCG | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|--------------------|
| Andrógenos | | |
| ANDRODERM TRANSDERMAL PATCH 24-HOUR 2MG/24HR, 4MG/24HR | 1 | MO |
| <i>danazol oral capsule 100mg, 200mg, 50mg</i> | 1 | |
| <i>oxandrolone oral tablet 10mg, 2.5mg</i> | 1 | PA |
| <i>testosterone cypionate intramuscular solution 100mg/ml, 200mg/ml, 200mg/ml (1 ml)</i> | 1 | MO |
| <i>testosterone enanthate intramuscular solution 200mg/ml</i> | 1 | MO |
| <i>testosterone transdermal gel 10mg/act (2%), 12.5mg/act (1%), 20.25mg/1.25gm (1.62%), 20.25mg/act (1.62%), 25mg/2.5gm (1%), 40.5mg/2.5gm (1.62%), 50mg/5gm (1%)</i> | 1 | MO |
| <i>testosterone transdermal solution 30mg/act</i> | 1 | MO |
| Estrógenos | | |
| DUAVEE ORAL TABLET 0.45-20MG | 1 | MO |
| <i>estradiol oral tablet 0.5mg, 1mg, 2mg</i> | 1 | MO |
| <i>estradiol transdermal patch twice weekly 0.025mg/24hr, 0.0375mg/24hr, 0.05mg/24hr, 0.075mg/24hr, 0.1mg/24hr</i> | 1 | MO |
| <i>estradiol transdermal patch weekly 0.025mg/24hr, 0.0375mg/24hr, 0.05mg/24hr, 0.06mg/24hr, 0.075mg/24hr, 0.1mg/24hr</i> | 1 | MO |
| <i>estradiol vaginal cream 0.1mg/gm</i> | 1 | MO |
| <i>estradiol vaginal tablet 10mcg</i> | 1 | MO |
| IMVEXXY MAINTENANCE PACK VAGINAL INSERT 10MCG, 4MCG | 1 | MO |
| IMVEXXY STARTER PACK VAGINAL INSERT 10MCG, 4MCG | 1 | MO |
| MENEST ORAL TABLET 0.3MG, 0.625MG, 1.25MG, 2.5MG | 1 | MO |
| PREMARIN ORAL TABLET 0.3MG, 0.45MG, 0.625MG, 0.9MG, 1.25MG | 1 | MO |
| PREMARIN VAGINAL CREAM 0.625MG/GM | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|--------------------|
| Progestinas | | |
| CAMILA ORAL TABLET 0.35MG | 1 | MO |
| DEBLITANE ORAL TABLET 0.35MG | 1 | MO |
| ERRIN ORAL TABLET 0.35MG | 1 | MO |
| INCASSIA ORAL TABLET 0.35MG | 1 | MO |
| LYLEQ ORAL TABLET 0.35MG | 1 | MO |
| LYZA ORAL TABLET 0.35MG | 1 | MO |
| <i>medroxyprogesterone acetate intramuscular suspension 150mg/ml</i> | 1 | |
| <i>medroxyprogesterone acetate intramuscular suspension prefilled syringe 150mg/ml</i> | 1 | |
| <i>medroxyprogesterone acetate oral tablet 10mg, 2.5mg, 5mg</i> | 1 | MO |
| <i>megestrol acetate oral suspension 40mg/ml</i> | 1 | |
| <i>megestrol acetate oral suspension 625mg/5ml</i> | 1 | MO |
| <i>megestrol acetate oral tablet 20mg, 40mg</i> | 1 | |
| NORA-BE ORAL TABLET 0.35MG | 1 | MO |
| <i>norethindrone acetate oral tablet 5mg</i> | 1 | MO |
| <i>norethindrone oral tablet 0.35mg</i> | 1 | MO |
| <i>progesterone oral capsule 100mg, 200mg</i> | 1 | MO |
| SHAROBEL ORAL TABLET 0.35MG | 1 | MO |
| AGENTES HORMONALES, ESTIMULANTES/ DE REEMPLAZO/ MODIFICADORES (PITUITARIA) | | |
| <i>Agentes Hormonales, Estimulantes/ de Reemplazo/ Modificadores (Pituitaria)</i> | | |
| <i>desmopressin acetate oral tablet 0.1mg, 0.2mg</i> | 1 | MO |
| <i>desmopressin acetate spray nasal solution 0.01%</i> | 1 | MO |
| INCRELEX SUBCUTANEOUS SOLUTION 40MG/4ML | 1 | PA |
| NOCDURNA SUBLINGUAL TABLET SUBLINGUAL 27.7MCG, 55.3MCG | 1 | MO |
| OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE 10MG/1.5ML, 5MG/1.5ML | 1 | PA |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|-----------------------------|
| OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED 5.8MG | 1 | PA |
| AGENTES HORMONALES, ESTIMULANTES/ DE REEMPLAZO/ MODIFICADORES (SUPRARRENALES) | | |
| <i>Agentes Hormonales, Estimulantes/ de Reemplazo/ Modificadores (Suprarrenales)</i> | | |
| <i>dexamethasone oral solution 0.5mg/5ml</i> | 1 | |
| <i>dexamethasone oral tablet 0.5mg, 0.75mg, 1mg, 1.5mg, 2mg, 4mg, 6mg</i> | 1 | |
| <i>fludrocortisone acetate oral tablet 0.1mg</i> | 1 | MO |
| <i>hydrocortisone oral tablet 10mg, 20mg, 5mg</i> | 1 | |
| ISTURISA ORAL TABLET 1MG | 1 | PA; QL (240 EA per 30 days) |
| ISTURISA ORAL TABLET 10MG | 1 | PA; QL (180 EA per 30 days) |
| ISTURISA ORAL TABLET 5MG | 1 | PA; QL (120 EA per 30 days) |
| <i>methylprednisolone oral tablet 16mg, 32mg, 4mg, 8mg</i> | 1 | BvD |
| <i>methylprednisolone oral tablet therapy pack 4mg</i> | 1 | |
| <i>prednisolone oral solution 15mg/5ml</i> | 1 | BvD |
| <i>prednisolone sodium phosphate oral solution 10mg/5ml, 20mg/5ml, 25mg/5ml, 6.7 (5 base) mg/5ml</i> | 1 | BvD |
| <i>prednisolone sodium phosphate oral tablet dispersible 10mg, 15mg, 30mg</i> | 1 | BvD |
| PREDNISONO INTENSOL ORAL CONCENTRATE 5MG/ML | 1 | BvD |
| <i>prednisone oral solution 5mg/5ml</i> | 1 | BvD |
| <i>prednisone oral tablet 1mg, 10mg, 2.5mg, 20mg, 5mg, 50mg</i> | 1 | BvD |
| <i>prednisone oral tablet therapy pack 10mg (21), 10mg (48), 5mg (21), 5mg (48)</i> | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|--------------------|
| AGENTES HORMONALES, ESTIMULANTES/ DE REEMPLAZO/ MODIFICADORES (TIROIDES) | | |
| <i>Agentes Hormonales, Estimulantes/ de Reemplazo/ Modificadores (Tiroides)</i> | | |
| EUTHYROX ORAL TABLET 100MCG, 112MCG, 125MCG, 137MCG, 150MCG, 175MCG, 200MCG, 25MCG, 50MCG, 75MCG, 88MCG | 1 | MO |
| LEVO-T ORAL TABLET 100MCG, 112MCG, 125MCG, 137MCG, 150MCG, 175MCG, 200MCG, 25MCG, 300MCG, 50MCG, 75MCG, 88MCG | 1 | MO |
| <i>levothyroxine sodium oral tablet 100mcg, 112mcg, 125mcg, 137mcg, 150mcg, 175mcg, 200mcg, 25mcg, 300mcg, 50mcg, 75mcg, 88mcg</i> | 1 | MO |
| LEVOXYL ORAL TABLET 100MCG, 112MCG, 125MCG, 137MCG, 150MCG, 175MCG, 200MCG, 25MCG, 50MCG, 75MCG, 88MCG | 1 | MO |
| <i>liothyronine sodium oral tablet 25mcg, 5mcg, 50mcg</i> | 1 | MO |
| SYNTHROID ORAL TABLET 100MCG, 112MCG, 125MCG, 137MCG, 150MCG, 175MCG, 200MCG, 25MCG, 300MCG, 50MCG, 75MCG, 88MCG | 1 | MO |
| UNITHROID ORAL TABLET 100MCG, 112MCG, 125MCG, 137MCG, 150MCG, 175MCG, 200MCG, 25MCG, 300MCG, 50MCG, 75MCG, 88MCG | 1 | MO |
| AGENTES HORMONALES, SUPRESORES (PITUITARIA) | | |
| <i>Agentes Hormonales, Supresores (Pituitaria)</i> | | |
| <i>cabergoline oral tablet 0.5mg</i> | 1 | |
| ELIGARD SUBCUTANEOUS KIT 22.5MG, 30MG, 45MG, 7.5MG | 1 | PA |
| <i>leuprolide acetate injection kit 1mg/0.2ml</i> | 1 | PA |
| LUPRON DEPOT (1-MONTH) INTRAMUSCULAR KIT 3.75MG, 7.5MG | 1 | PA |
| LUPRON DEPOT (3-MONTH) INTRAMUSCULAR KIT 11.25MG, 22.5MG | 1 | PA |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|----------------------------|
| LUPRON DEPOT (4-MONTH) INTRAMUSCULAR KIT 30MG | 1 | PA |
| LUPRON DEPOT (6-MONTH) INTRAMUSCULAR KIT 45MG | 1 | PA |
| <i>octreotide acetate injection solution 100mcg/ml, 200mcg/ml, 500mcg/ml</i> | 1 | PA; MO |
| <i>octreotide acetate injection solution 1000mcg/ml, 500mcg/ml</i> | 1 | PA |
| SIGNIFOR SUBCUTANEOUS SOLUTION 0.3MG/ML, 0.6MG/ML, 0.9MG/ML | 1 | PA; QL (60ML per 30 days) |
| SOMAVERT SUBCUTANEOUS SOLUTION RECONSTITUTED 10MG, 15MG, 20MG, 25MG, 30MG | 1 | PA; QL (60 EA per 30 days) |
| SYNAREL NASAL SOLUTION 2MG/ML | 1 | PA |
| TRELSTAR MIXJECT INTRAMUSCULAR SUSPENSION RECONSTITUTED 11.25MG, 22.5MG, 3.75MG | 1 | PA |

AGENTES HORMONALES, SUPRESORES (TIROIDES)

Agentes Antitiroideos

| | | |
|--|---|----|
| <i>methimazole oral tablet 10mg, 5mg</i> | 1 | MO |
| <i>propylthiouracil oral tablet 50mg</i> | 1 | MO |

AGENTES INMUNOLÓGICOS

Agentes de Angioedema

| | | |
|--|---|----|
| FIRAZYR SUBCUTANEOUS SOLUTION 30MG/3ML | 1 | PA |
| <i>icatibant acetate subcutaneous solution 30mg/3ml</i> | 1 | PA |
| TAKHZYRO SUBCUTANEOUS SOLUTION 300MG/2ML | 1 | PA |
| TAKHZYRO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 300MG/2ML | 1 | PA |

Agentes Inmunológicos, Otros

| | | |
|--|---|----|
| ARCALYST SUBCUTANEOUS SOLUTION RECONSTITUTED 220MG | 1 | PA |
| COSENTYX (300MG DOSE) SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150MG/ML | 1 | PA |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|--------------------|
| COSENTYX SENSOREADY (300MG) SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150MG/ML | 1 | PA |
| COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75MG/0.5ML | 1 | PA |
| DUPIXENT SUBCUTANEOUS SOLUTION PEN-INJECTOR 200MG/1.14ML, 300MG/2ML | 1 | PA |
| DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100MG/0.67ML, 200MG/1.14ML, 300MG/2ML | 1 | PA |
| <i>leflunomide oral tablet 10mg, 20mg</i> | 1 | MO |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24-HOUR 15MG, 30MG, 45MG | 1 | PA |
| SKYRIZI PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150MG/ML | 1 | PA |
| SKYRIZI SUBCUTANEOUS SOLUTION CARTRIDGE 180MG/1.2ML, 360MG/2.4ML | 1 | PA |
| SKYRIZI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150MG/ML | 1 | PA |
| STELARA SUBCUTANEOUS SOLUTION 45MG/0.5ML | 1 | PA |
| STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 45MG/0.5ML, 90MG/ML | 1 | PA |
| TAVNEOS ORAL CAPSULE 10MG | 1 | PA |
| XOLAIR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150MG/ML, 75MG/0.5ML | 1 | PA |
| XOLAIR SUBCUTANEOUS SOLUTION RECONSTITUTED 150MG | 1 | PA |
| <i>Inmunoestimulantes</i> | | |
| ACTIMMUNE SUBCUTANEOUS SOLUTION 2000000UNIT/0.5ML | 1 | PA |
| BESREMI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 500MCG/ML | 1 | PA |
| PEGASYS SUBCUTANEOUS SOLUTION 180MCG/ML | 1 | PA |
| PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 180MCG/0.5ML | 1 | PA |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|---------------------------------|
| Inmunoglobulinas | | |
| PANZYGA INTRAVENOUS SOLUTION 1GM/10ML, 10GM/100ML, 2.5GM/25ML, 20GM/200ML, 30GM/300ML, 5GM/50ML | 1 | BvD |
| PRIVIGEN INTRAVENOUS SOLUTION 20GM/200ML | 1 | BvD |
| Inmunosupresores | | |
| AZASAN ORAL TABLET 100MG, 75MG | 1 | BvD; MO |
| <i>azathioprine oral tablet 100mg, 50mg, 75mg</i> | 1 | BvD; MO |
| BENLYSTA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200MG/ML | 1 | PA |
| BENLYSTA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200MG/ML | 1 | PA |
| <i>cyclosporine modified oral capsule 100mg, 25mg, 50mg</i> | 1 | BvD; MO |
| <i>cyclosporine modified oral solution 100mg/ml</i> | 1 | BvD; MO |
| <i>cyclosporine oral capsule 100mg, 25mg</i> | 1 | BvD; MO |
| ENBREL MINI SUBCUTANEOUS SOLUTION CARTRIDGE 50MG/ML | 1 | PA |
| ENBREL SUBCUTANEOUS SOLUTION 25MG/0.5ML | 1 | PA |
| ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 25MG/0.5ML, 50MG/ML | 1 | PA |
| ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 50MG/ML | 1 | PA |
| ENSPRYNG SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 120MG/ML | 1 | PA |
| ENVARBUS XR ORAL TABLET EXTENDED RELEASE 24-HOUR 0.75MG, 1MG, 4MG | 1 | BvD; MO |
| <i>everolimus oral tablet 0.25mg</i> | 1 | BvD; MO; QL (60 EA per 30 days) |
| <i>everolimus oral tablet 0.5mg</i> | 1 | BvD; QL (120 EA per 30 days) |
| <i>everolimus oral tablet 0.75mg, 1mg</i> | 1 | BvD; QL (60 EA per 30 days) |
| GENGRAF ORAL CAPSULE 100MG, 25MG | 1 | BvD; MO |
| GENGRAF ORAL SOLUTION 100MG/ML | 1 | BvD; MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|-----------------------------|
| HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS PREFILLED SYRINGE KIT 80MG/0.8ML, 80MG/0.8ML & 40MG/0.4ML | 1 | PA |
| HUMIRA PEN SUBCUTANEOUS PEN-INJECTOR KIT 40MG/0.4ML, 40MG/0.8ML, 80MG/0.8ML | 1 | PA |
| HUMIRA PEN-CD/UC/HS STARTER SUBCUTANEOUS PEN-INJECTOR KIT 40MG/0.8ML, 80MG/0.8ML | 1 | PA |
| HUMIRA PEN-PEDIATRIC UC START SUBCUTANEOUS PEN-INJECTOR KIT 80MG/0.8ML | 1 | PA |
| HUMIRA PEN-PS/UV/ADOL HS START SUBCUTANEOUS PEN-INJECTOR KIT 40MG/0.8ML | 1 | PA |
| HUMIRA PEN-PSOR/UEIT STARTER SUBCUTANEOUS PEN-INJECTOR KIT 80MG/0.8ML & 40MG/0.4ML | 1 | PA |
| HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT 10MG/0.1ML, 20MG/0.2ML, 40MG/0.4ML, 40MG/0.8ML | 1 | PA |
| LUPKYNIS ORAL CAPSULE 7.9MG | 1 | PA; QL (180 EA per 30 days) |
| <i>methotrexate sodium (pf) injection solution 50mg/2ml</i> | 1 | BvD |
| <i>methotrexate sodium injection solution 50mg/2ml</i> | 1 | BvD |
| <i>methotrexate sodium oral tablet 2.5mg</i> | 1 | BvD |
| <i>mycophenolate mofetil oral capsule 250mg</i> | 1 | BvD; MO |
| <i>mycophenolate mofetil oral suspension reconstituted 200mg/ml</i> | 1 | BvD |
| <i>mycophenolate mofetil oral tablet 500mg</i> | 1 | BvD; MO |
| <i>mycophenolate sodium oral tablet delayed release 180mg, 360mg</i> | 1 | BvD; MO |
| PROGRAF ORAL PACKET 0.2MG, 1MG | 1 | BvD; MO |
| REZUROCK ORAL TABLET 200MG | 1 | PA |
| <i>sirolimus oral solution 1mg/ml</i> | 1 | BvD |
| <i>sirolimus oral tablet 0.5mg, 1mg</i> | 1 | BvD; MO |
| <i>sirolimus oral tablet 2mg</i> | 1 | BvD |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|--------------------|
| <i>tacrolimus oral capsule 0.5mg, 1mg, 5mg</i> | 1 | BvD; MO |
| TREXALL ORAL TABLET 10MG, 15MG, 5MG, 7.5MG | 1 | BvD |
| Vacunas | | |
| ACTHIB INTRAMUSCULAR SOLUTION RECONSTITUTED | 1 | |
| ADACEL INTRAMUSCULAR SUSPENSION 5-2-15.5 (PREFILLED SYRINGE), 5-2-15.5 LF-MCG/0.5 | 1 | |
| <i>bcg vaccine injection solution reconstituted 50mg</i> | 1 | |
| BEXSERO INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 1 | |
| BOOSTRIX INTRAMUSCULAR SUSPENSION 5-2.5-18.5 LF-MCG/0.5 | 1 | |
| BOOSTRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 5-2.5-18.5 LF-MCG/0.5 | 1 | |
| DAPTACEL INTRAMUSCULAR SUSPENSION 23-15-5 | 1 | |
| <i>diphtheria-tetanus toxoids dt intramuscular suspension 25-5 lfu/0.5ml</i> | 1 | BvD |
| ENGERIX-B INJECTION SUSPENSION 20MCG/ML | 1 | BvD |
| ENGERIX-B INJECTION SUSPENSION PREFILLED SYRINGE 10MCG/0.5ML, 20MCG/ML | 1 | BvD |
| GARDASIL 9 INTRAMUSCULAR SUSPENSION | 1 | |
| GARDASIL 9 INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 1 | |
| HAVRIX INTRAMUSCULAR SUSPENSION 1440 EL U/ML, 720 EL U/0.5ML | 1 | |
| HIBERIX INJECTION SOLUTION RECONSTITUTED 10MCG | 1 | |
| IMOVAX RABIES INTRAMUSCULAR SUSPENSION RECONSTITUTED 2.5UNIT/ML | 1 | BvD |
| INFANRIX INTRAMUSCULAR SUSPENSION 25-58-10 | 1 | |
| IPOL INJECTION INJECTABLE | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|--------------------|
| IXIARO INTRAMUSCULAR SUSPENSION | 1 | |
| JYNNEOS SUBCUTANEOUS SUSPENSION 0.5ML | 1 | |
| KINRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5ML | 1 | |
| MENACTRA INTRAMUSCULAR SOLUTION | 1 | |
| MENQUADFI INTRAMUSCULAR SOLUTION | 1 | |
| MENVEO INTRAMUSCULAR SOLUTION RECONSTITUTED | 1 | |
| M-M-R II INJECTION SOLUTION RECONSTITUTED | 1 | |
| PEDIARIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 1 | |
| PEDVAX HIB INTRAMUSCULAR SUSPENSION 7.5MCG/0.5ML | 1 | |
| PENTACEL INTRAMUSCULAR SUSPENSION RECONSTITUTED | 1 | |
| <i>prehevbrio intramuscular suspension 10mcg/ml</i> | 1 | BvD |
| PRIORIX SUBCUTANEOUS SUSPENSION RECONSTITUTED | 1 | |
| PROQUAD SUBCUTANEOUS SUSPENSION RECONSTITUTED | 1 | |
| QUADRACEL INTRAMUSCULAR SUSPENSION, (58 UNT/ML) | 1 | |
| QUADRACEL INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5ML | 1 | |
| RABAVERT INTRAMUSCULAR SUSPENSION RECONSTITUTED | 1 | BvD |
| RECOMBIVAX HB INJECTION SUSPENSION 10MCG/ML, 40MCG/ML, 5MCG/0.5ML | 1 | BvD |
| RECOMBIVAX HB INJECTION SUSPENSION PREFILLED SYRINGE 10MCG/ML, 5MCG/0.5ML | 1 | BvD |
| ROTARIX ORAL SUSPENSION RECONSTITUTED | 1 | |
| ROTATEQ ORAL SOLUTION | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|--------------------|
| SHINGRIX INTRAMUSCULAR SUSPENSION RECONSTITUTED 50MCG/0.5ML | 1 | |
| TDVAX INTRAMUSCULAR SUSPENSION 2-2 LF/0.5ML | 1 | BvD |
| TENIVAC INTRAMUSCULAR INJECTABLE 5-2 LFU, 5-2 LFU (INJECTION) | 1 | BvD |
| TICOVAC INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 1.2MCG/0.25ML, 2.4MCG/0.5ML | 1 | |
| TRUMENBA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 1 | |
| TWINRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 720-20 ELU-MCG/ML | 1 | |
| TYPHIM VI INTRAMUSCULAR SOLUTION 25MCG/0.5ML | 1 | |
| TYPHIM VI INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 25MCG/0.5ML | 1 | |
| VAQTA INTRAMUSCULAR SUSPENSION 25UNIT/0.5ML, 25UNIT/0.5ML 0.5ML, 50UNIT/ML, 50UNIT/ML 1ML | 1 | |
| VARIVAX SUBCUTANEOUS INJECTABLE 1350 PFU/0.5ML | 1 | |
| YF-VAX SUBCUTANEOUS INJECTABLE, (2.5ML IN 1 VIAL, MULTI-DOSE) | 1 | |

AGENTES METABÓLICOS PARA LA ENFERMEDAD ÓSEA

Agentes Metabólicos para la Enfermedad Ósea

| | | |
|---|---|---------------------------------|
| <i>alendronate sodium oral tablet 10mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>alendronate sodium oral tablet 35mg, 70mg</i> | 1 | MO; QL (4 EA per 28 days) |
| <i>calcitonin (salmon) nasal solution 200unit/act</i> | 1 | BvD; MO; QL (4ML per 28 days) |
| <i>calcitriol oral capsule 0.25mcg, 0.5mcg</i> | 1 | BvD; MO |
| <i>calcitriol oral solution 1mcg/ml</i> | 1 | BvD; MO |
| <i>cinacalcet hcl oral tablet 30mg</i> | 1 | BvD; MO; QL (60 EA per 30 days) |
| <i>cinacalcet hcl oral tablet 60mg</i> | 1 | BvD; QL (60 EA per 30 days) |
| <i>cinacalcet hcl oral tablet 90mg</i> | 1 | BvD; QL (120 EA per 30 days) |
| <i>ibandronate sodium oral tablet 150mg</i> | 1 | MO; QL (1 EA per 30 days) |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|-----------------------------|
| NATPARA SUBCUTANEOUS CARTRIDGE 100MCG, 25MCG, 50MCG, 75MCG | 1 | PA |
| <i>paricalcitol oral capsule 1mcg, 2mcg, 4mcg</i> | 1 | BvD; MO |
| PROLIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 60MG/ML | 1 | QL (1ML per 180 days) |
| <i>raloxifene hcl oral tablet 60mg</i> | 1 | MO |
| <i>risedronate sodium oral tablet 150mg</i> | 1 | MO; QL (1 EA per 28 days) |
| <i>risedronate sodium oral tablet 30mg</i> | 1 | QL (30 EA per 30 days) |
| <i>risedronate sodium oral tablet 35mg, 35mg (12 pack), 35mg (4 pack)</i> | 1 | MO; QL (4 EA per 28 days) |
| <i>risedronate sodium oral tablet 5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>teriparatide (recombinant) subcutaneous solution pen-injector 620mcg/2.48ml</i> | 1 | PA; QL (2.48ML per 28 days) |
| TYMLOS SUBCUTANEOUS SOLUTION PEN-INJECTOR 3120MCG/1.56ML | 1 | PA; QL (1.56ML per 30 days) |
| XGEVA SUBCUTANEOUS SOLUTION 120MG/1.7ML | 1 | PA; QL (2ML per 28 days) |

AGENTES OFTÁLMICOS

Agentes Oftálmicos Antialérgicos

| | | |
|---|---|--|
| <i>azelastine hcl ophthalmic solution 0.05%</i> | 1 | |
| <i>cromolyn sodium ophthalmic solution 4%</i> | 1 | |
| <i>olopatadine hcl ophthalmic solution 0.1%, 0.2%</i> | 1 | |

Agentes Oftálmicos Bloqueadores Beta-Adrenérgicos

| | | |
|--|---|----|
| <i>betaxolol hcl ophthalmic solution 0.5%</i> | 1 | MO |
| <i>carteolol hcl ophthalmic solution 1%</i> | 1 | MO |
| <i>levobunolol hcl ophthalmic solution 0.5%</i> | 1 | MO |
| <i>timolol maleate (once-daily) ophthalmic solution 0.5%</i> | 1 | MO |
| <i>timolol maleate ophthalmic gel forming solution 0.25%, 0.5%</i> | 1 | MO |
| <i>timolol maleate ophthalmic solution 0.25%, 0.5%</i> | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|----------------------------|
| Agentes Oftálmicos para Bajar la Presión Intraocular, Otros | | |
| <i>acetazolamide er oral capsule extended release 12-hour 500mg</i> | 1 | MO |
| <i>acetazolamide oral tablet 125mg, 250mg</i> | 1 | MO |
| ALPHAGAN P OPHTHALMIC SOLUTION 0.1% | 1 | MO |
| <i>apraclonidine hcl ophthalmic solution 0.5%</i> | 1 | |
| AZOPT OPHTHALMIC SUSPENSION 1% | 1 | MO |
| <i>brimonidine tartrate ophthalmic solution 0.15%, 0.2%</i> | 1 | MO |
| <i>brimonidine tartrate-timolol ophthalmic solution 0.2-0.5%</i> | 1 | MO |
| COMBIGAN OPHTHALMIC SOLUTION 0.2-0.5% | 1 | MO |
| <i>dorzolamide hcl ophthalmic solution 2%</i> | 1 | MO |
| <i>dorzolamide hcl-timolol mal ophthalmic solution 2.3-6.8mg/ml</i> | 1 | MO |
| <i>dorzolamide hcl-timolol mal pf ophthalmic solution 2-0.5%</i> | 1 | MO |
| <i>methazolamide oral tablet 25mg, 50mg</i> | 1 | MO |
| <i>pilocarpine hcl ophthalmic solution 1%, 2%, 4%</i> | 1 | MO |
| RHOPRESSA OPHTHALMIC SOLUTION 0.02% | 1 | MO |
| ROCKLATAN OPHTHALMIC SOLUTION 0.02-0.005% | 1 | MO |
| SIMBRINZA OPHTHALMIC SUSPENSION 1-0.2% | 1 | MO |
| Agentes Oftálmicos, Otros | | |
| <i>atropine sulfate ophthalmic solution 1%</i> | 1 | MO |
| <i>bacitra-neomycin-polymyxin-hc ophthalmic ointment 1%</i> | 1 | |
| <i>cyclosporine ophthalmic emulsion 0.05%</i> | 1 | MO; QL (60 EA per 30 days) |
| CYSTADROPS OPHTHALMIC SOLUTION 0.37% | 1 | PA |
| CYSTARAN OPHTHALMIC SOLUTION 0.44% | 1 | PA |
| <i>neomycin-polymyxin-dexameth ophthalmic ointment 3.5-10000-0.1</i> | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|--------------------|
| <i>neomycin-polymyxin-dexameth ophthalmic suspension 3.5-10000-0.1</i> | 1 | |
| <i>neomycin-polymyxin-gramicidin ophthalmic solution 1.75-10000-.025</i> | 1 | |
| <i>neomycin-polymyxin-hc ophthalmic suspension 3.5-10000-1</i> | 1 | |
| <i>polymyxin b-trimethoprim ophthalmic solution 10000-0.1unit/ml-%</i> | 1 | |
| <i>sulfacetamide-prednisolone ophthalmic solution 10-0.23%</i> | 1 | |
| <i>tobramycin-dexamethasone ophthalmic suspension 0.3-0.1%</i> | 1 | |
| Análogos de Prostaglandina y Prostamida Oftálmicos | | |
| <i>latanoprost ophthalmic solution 0.005%</i> | 1 | MO |
| LUMIGAN OPHTHALMIC SOLUTION 0.01% | 1 | MO |
| <i>travoprost (bak free) ophthalmic solution 0.004%</i> | 1 | MO |
| Antiinfecciosos Oftálmicos | | |
| AZASITE OPHTHALMIC SOLUTION 1% | 1 | |
| <i>bacitracin ophthalmic ointment 500unit/gm</i> | 1 | |
| <i>bacitracin-polymyxin b ophthalmic ointment 500-10000unit/gm</i> | 1 | |
| <i>erythromycin ophthalmic ointment 5mg/gm</i> | 1 | |
| <i>gatifloxacin ophthalmic solution 0.5%</i> | 1 | |
| GENTAK OPHTHALMIC OINTMENT 0.3% | 1 | |
| <i>gentamicin sulfate ophthalmic solution 0.3%</i> | 1 | |
| <i>moxifloxacin hcl ophthalmic solution 0.5%</i> | 1 | |
| NATACYN OPHTHALMIC SUSPENSION 5% | 1 | |
| <i>neomycin-bacitracin zn-polymyx ophthalmic ointment 5-400-10000</i> | 1 | |
| <i>ofloxacin ophthalmic solution 0.3%</i> | 1 | |
| <i>sulfacetamide sodium ophthalmic solution 10%</i> | 1 | |
| <i>tobramycin ophthalmic solution 0.3%</i> | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|--------------------|
| Antiinflamatorios Oftálmicos | | |
| <i>bromfenac sodium (once-daily) ophthalmic solution 0.09%</i> | 1 | |
| BROMSITE OPHTHALMIC SOLUTION 0.075% | 1 | |
| <i>dexamethasone sodium phosphate ophthalmic solution 0.1%</i> | 1 | |
| <i>diclofenac sodium ophthalmic solution 0.1%</i> | 1 | |
| DUREZOL OPHTHALMIC EMULSION 0.05% | 1 | |
| <i>fluorometholone ophthalmic suspension 0.1%</i> | 1 | |
| <i>flurbiprofen sodium ophthalmic solution 0.03%</i> | 1 | |
| ILEVRO OPHTHALMIC SUSPENSION 0.3% | 1 | |
| <i>ketorolac tromethamine ophthalmic solution 0.4%, 0.5%</i> | 1 | |
| <i>loteprednol etabonate ophthalmic suspension 0.5%</i> | 1 | |
| <i>prednisolone acetate ophthalmic suspension 1%</i> | 1 | |
| <i>prednisolone sodium phosphate ophthalmic solution 1%</i> | 1 | |
| AGENTES ÓTICOS | | |
| Agentes Óticos | | |
| <i>acetic acid otic solution 2%</i> | 1 | |
| <i>ciprofloxacin hcl otic solution 0.2%</i> | 1 | |
| <i>ciprofloxacin-dexamethasone otic suspension 0.3-0.1%</i> | 1 | |
| <i>ciprofloxacin-fluocinolone pf otic solution 0.3-0.025%</i> | 1 | |
| <i>fluocinolone acetonide otic oil 0.01%</i> | 1 | |
| <i>neomycin-polymyxin-hc otic solution 1%</i> | 1 | |
| <i>neomycin-polymyxin-hc otic suspension 3.5-10000-1</i> | 1 | |
| <i>ofloxacin otic solution 0.3%</i> | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|--------------------------------|
| AGENTES PARA ENFERMEDAD INTESTINAL INFLAMATORIA | | |
| Aminosalicilatos | | |
| <i>balsalazide disodium oral capsule 750mg</i> | 1 | |
| LIALDA ORAL TABLET DELAYED RELEASE 1.2GM | 1 | MO |
| <i>mesalamine er oral capsule extended release 24-hour 0.375gm</i> | 1 | MO |
| <i>mesalamine oral capsule delayed release 400mg</i> | 1 | MO |
| <i>mesalamine oral tablet delayed release 800mg</i> | 1 | |
| <i>mesalamine rectal enema 4gm</i> | 1 | |
| <i>sulfasalazine oral tablet 500mg</i> | 1 | MO |
| <i>sulfasalazine oral tablet delayed release 500mg</i> | 1 | MO |
| Glucocorticoides | | |
| <i>budesonide er oral tablet extended release 24-hour 9mg</i> | 1 | |
| <i>budesonide oral capsule delayed release particles 3mg</i> | 1 | |
| <i>hydrocortisone rectal enema 100mg/60ml</i> | 1 | |
| AGENTES PARA TRASTORNO DEL SUEÑO | | |
| Agentes Promotores de la Vigilia | | |
| <i>armodafinil oral tablet 150mg, 200mg, 250mg, 50mg</i> | 1 | PA; MO; QL (30 EA per 30 days) |
| <i>modafinil oral tablet 100mg, 200mg</i> | 1 | PA; MO; QL (60 EA per 30 days) |
| SUNOSI ORAL TABLET 150MG, 75MG | 1 | PA; MO; QL (30 EA per 30 days) |
| XYREM ORAL SOLUTION 500MG/ML | 1 | PA; QL (540ML per 30 days) |
| XYWAV ORAL SOLUTION 500MG/ML | 1 | PA; QL (540ML per 30 days) |
| Agentes Promotores del Sueño | | |
| BELSOMRA ORAL TABLET 10MG, 15MG, 20MG, 5MG | 1 | QL (30 EA per 30 days) |
| <i>temazepam oral capsule 15mg, 22.5mg, 30mg</i> | 1 | QL (30 EA per 30 days) |
| <i>temazepam oral capsule 7.5mg</i> | 1 | QL (120 EA per 30 days) |
| <i>zaleplon oral capsule 10mg, 5mg</i> | 1 | QL (30 EA per 30 days) |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|----------------------------|
| <i>zolpidem tartrate oral tablet 10mg, 5mg</i> | 1 | QL (30 EA per 30 days) |
| AGENTES PARA TRASTORNO GENÉTICO, DE ENZIMAS o PROTEÍNAS: REEMPLAZO, MODIFICADORES, TRATAMIENTO | | |
| <i>Agentes para Trastorno Genético, de Enzimas o Proteínas: Reemplazo, Modificadores, Tratamiento</i> | | |
| <i>betaine oral powder</i> | 1 | |
| CREON ORAL CAPSULE DELAYED RELEASE PARTICLES 12000-38000UNIT, 24000-76000UNIT, 3000-9500UNIT, 36000-114000UNIT, 6000-19000UNIT | 1 | MO |
| <i>cromolyn sodium oral concentrate 100mg/5ml</i> | 1 | MO |
| CYSTAGON ORAL CAPSULE 150MG, 50MG | 1 | PA; MO |
| ENDARI ORAL PACKET 5GM | 1 | PA |
| GALAFOLD ORAL CAPSULE 123MG | 1 | PA |
| <i>miglustat oral capsule 100mg</i> | 1 | PA |
| <i>nitisinone oral capsule 10mg, 2mg, 5mg</i> | 1 | PA |
| ORFADIN ORAL CAPSULE 20MG | 1 | PA |
| PROLASTIN-C INTRAVENOUS SOLUTION RECONSTITUTED 1000MG | 1 | PA |
| RAVICTI ORAL LIQUID 1.1GM/ML | 1 | PA |
| <i>sapropterin dihydrochloride oral packet 100mg, 500mg</i> | 1 | PA |
| <i>sapropterin dihydrochloride oral tablet 100mg</i> | 1 | PA |
| TEGSEDI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 284MG/1.5ML | 1 | PA |
| VYNDAMAX ORAL CAPSULE 61MG | 1 | PA; QL (30 EA per 30 days) |
| XURIDEN ORAL PACKET 2GM | 1 | PA |
| ZENPEP ORAL CAPSULE DELAYED RELEASE PARTICLES 10000-32000UNIT, 15000-47000UNIT, 20000-63000UNIT, 25000-79000UNIT, 3000-10000UNIT, 40000-126000UNIT, 5000-24000UNIT | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|--------------------|
| AGENTES PARA TRATAMIENTO DE ABUSO DE SUSTANCIAS/ANTI-ADICCIÓN | | |
| Agentes para Dejar de Fumar | | |
| <i>bupropion hcl er (smoking det) oral tablet extended release 12-hour 150mg</i> | 1 | |
| NICOTROL INHALATION INHALER 10MG | 1 | |
| <i>varenicline tartrate oral tablet 0.5mg, 1mg</i> | 1 | |
| <i>varenicline tartrate oral tablet therapy pack 0.5mg x 11 & 1mg x 42</i> | 1 | |
| Agentes para la Reversión de Opioides | | |
| KLOXXADO NASAL LIQUID 8MG/0.1ML | 1 | |
| <i>naloxone hcl injection solution 0.4mg/ml</i> | 1 | |
| <i>naloxone hcl injection solution cartridge 0.4mg/ml</i> | 1 | |
| <i>naloxone hcl injection solution prefilled syringe 2mg/2ml</i> | 1 | |
| <i>naloxone hcl nasal liquid 4mg/0.1ml</i> | 1 | |
| NARCAN NASAL LIQUID 4MG/0.1ML | 1 | |
| ZIMHI INJECTION SOLUTION PREFILLED SYRINGE 5MG/0.5ML | 1 | |
| Dependencia de Opioides | | |
| <i>buprenorphine hcl sublingual tablet sublingual 2mg, 8mg</i> | 1 | |
| <i>buprenorphine hcl-naloxone hcl sublingual tablet sublingual 2-0.5mg, 8-2mg</i> | 1 | |
| SUBOXONE SUBLINGUAL FILM 12-3MG, 2-0.5MG, 4-1MG, 8-2MG | 1 | |
| Disuasivos de Alcohol/Anti-Deseo | | |
| <i>acamprosate calcium oral tablet delayed release 333mg</i> | 1 | MO |
| <i>disulfiram oral tablet 250mg</i> | 1 | MO |
| <i>naltrexone hcl oral tablet 50mg</i> | 1 | |
| VIVITROL INTRAMUSCULAR SUSPENSION RECONSTITUTED 380MG | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|-----------------------------|
| AGENTES PARA TRATAMIENTO DE LA GOTA | | |
| <i>Agentes para Tratamiento de la Gota</i> | | |
| <i>allopurinol oral tablet 100mg, 300mg</i> | 1 | MO |
| <i>colchicine oral capsule 0.6mg</i> | 1 | |
| <i>colchicine oral tablet 0.6mg</i> | 1 | |
| <i>colchicine-probenecid oral tablet 0.5-500mg</i> | 1 | MO |
| <i>febuxostat oral tablet 40mg, 80mg</i> | 1 | PA; MO |
| <i>probenecid oral tablet 500mg</i> | 1 | MO |
| AGENTES PULMONARES/ TRACTO RESPIRATORIO | | |
| <i>Agentes de Fibrosis Pulmonar</i> | | |
| ESBRIET ORAL CAPSULE 267MG | 1 | PA |
| OFEV ORAL CAPSULE 100MG, 150MG | 1 | PA |
| <i>pirfenidone oral tablet 267mg, 534mg, 801mg</i> | 1 | PA |
| <i>Agentes del Tracto Respiratorio, Otros</i> | | |
| <i>acetylcysteine inhalation solution 10%, 20%</i> | 1 | BvD |
| ADVAIR DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 100-50MCG/ACT, 250-50MCG/ACT, 500-50MCG/ACT | 1 | MO; QL (60 EA per 30 days) |
| ADVAIR HFA INHALATION AEROSOL 115-21MCG/ACT, 230-21MCG/ACT, 45-21MCG/ACT | 1 | MO; QL (12GM per 30 days) |
| ANORO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 62.5-25MCG/ACT | 1 | MO; QL (60 EA per 30 days) |
| BREO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-25MCG/ACT, 200-25MCG/ACT | 1 | MO; QL (60 EA per 30 days) |
| BREZTRI AEROSPHERE INHALATION AEROSOL 160-9-4.8MCG/ACT | 1 | MO; QL (10.7GM per 30 days) |
| <i>budesonide-formoterol fumarate inhalation aerosol 160-4.5mcg/act, 80-4.5mcg/act</i> | 1 | MO; QL (10.2GM per 30 days) |
| COMBIVENT RESPIMAT INHALATION AEROSOL SOLUTION 20-100MCG/ACT | 1 | MO; QL (4GM per 20 days) |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|----------------------------|
| <i>cromolyn sodium inhalation nebulization solution 20mg/2ml</i> | 1 | BvD; MO |
| <i>fluticasone-salmeterol inhalation aerosol powder breath activated 100-50mcg/act, 250-50mcg/act, 500-50mcg/act</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>fluticasone-salmeterol inhalation aerosol powder breath activated 113-14mcg/act, 232-14mcg/act, 55-14mcg/act</i> | 1 | MO; QL (1 EA per 30 days) |
| <i>ipratropium-albuterol inhalation solution 0.5-2.5 (3) mg/3ml</i> | 1 | BvD; MO |
| NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100MG/ML | 1 | PA |
| NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100MG/ML, 40MG/0.4ML | 1 | PA |
| NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED 100MG | 1 | PA |
| TRELEGY ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-62.5-25MCG/ACT, 200-62.5-25MCG/ACT | 1 | MO; QL (60 EA per 30 days) |
| Agentes para Fibrosis Quística | | |
| CAYSTON INHALATION SOLUTION RECONSTITUTED 75MG | 1 | PA |
| KALYDECO ORAL PACKET 25MG, 50MG, 75MG | 1 | PA |
| KALYDECO ORAL TABLET 150MG | 1 | PA |
| ORKAMBI ORAL PACKET 100-125MG, 150-188MG, 75-94MG | 1 | PA |
| ORKAMBI ORAL TABLET 100-125MG, 200-125MG | 1 | PA |
| PULMOZYME INHALATION SOLUTION 2.5MG/2.5ML | 1 | BvD |
| SYMDEKO ORAL TABLET THERAPY PACK 100-150 & 150MG, 50-75 & 75MG | 1 | PA |
| TOBI PODHALER INHALATION CAPSULE 28MG | 1 | PA |
| <i>tobramycin inhalation nebulization solution 300mg/5ml</i> | 1 | BvD |
| TRIKAFTA ORAL TABLET THERAPY PACK 100-50-75 & 150MG, 50-25-37.5 & 75MG | 1 | PA |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|--------------------------------|
| Antihipertensivos Pulmonares | | |
| ADEMPAS ORAL TABLET 0.5MG, 1MG, 1.5MG, 2MG, 2.5MG | 1 | PA; QL (90 EA per 30 days) |
| <i>ambrisentan oral tablet 10mg, 5mg</i> | 1 | PA; QL (30 EA per 30 days) |
| <i>bosentan oral tablet 125mg, 62.5mg</i> | 1 | PA; QL (60 EA per 30 days) |
| OPSUMIT ORAL TABLET 10MG | 1 | PA; QL (90 EA per 30 days) |
| <i>sildenafil citrate oral tablet 20mg</i> | 1 | PA; MO; QL (90 EA per 30 days) |
| Antihistamínicos | | |
| <i>azelastine hcl nasal solution 0.1%, 0.15%</i> | 1 | QL (30ML per 25 days) |
| <i>cetirizine hcl oral solution 1mg/ml</i> | 1 | |
| <i>cyproheptadine hcl oral syrup 2mg/5ml</i> | 1 | |
| <i>cyproheptadine hcl oral tablet 4mg</i> | 1 | |
| <i>levocetirizine dihydrochloride oral solution 2.5mg/5ml</i> | 1 | |
| <i>levocetirizine dihydrochloride oral tablet 5mg</i> | 1 | |
| Antiinflamatorios, Corticosteroides Inhalados | | |
| ARNUITY ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100MCG/ACT, 200MCG/ACT, 50MCG/ACT | 1 | MO; QL (30 EA per 30 days) |
| ASMANEX (120 METERED DOSES) INHALATION AEROSOL POWDER BREATH ACTIVATED 220MCG/ACT | 1 | MO; QL (2 EA per 30 days) |
| ASMANEX (30 METERED DOSES) INHALATION AEROSOL POWDER BREATH ACTIVATED 110MCG/ACT, 220MCG/ACT | 1 | MO; QL (2 EA per 30 days) |
| ASMANEX (60 METERED DOSES) INHALATION AEROSOL POWDER BREATH ACTIVATED 220MCG/ACT | 1 | MO; QL (2 EA per 30 days) |
| ASMANEX HFA INHALATION AEROSOL 100MCG/ACT, 200MCG/ACT, 50MCG/ACT | 1 | MO; QL (26GM per 30 days) |
| <i>budesonide inhalation suspension 0.25mg/2ml, 0.5mg/2ml, 1mg/2ml</i> | 1 | BvD; MO |
| FLOVENT DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 100MCG/ACT, 250MCG/ACT, 50MCG/ACT | 1 | MO; QL (60 EA per 30 days) |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|-----------------------------|-----------------------------|
| FLOVENT HFA INHALATION AEROSOL 110MCG/ACT, 220MCG/ACT | 1 | MO; QL (24GM per 30 days) |
| FLOVENT HFA INHALATION AEROSOL 44MCG/ACT | 1 | MO; QL (21.2GM per 30 days) |
| <i>flunisolide nasal solution 25mcg/act (0.025%)</i> | 1 | QL (50ML per 30 days) |
| <i>fluticasone propionate nasal suspension 50mcg/act</i> | 1 | QL (16GM per 30 days) |
| <i>mometasone furoate nasal suspension 50mcg/act</i> | 1 | QL (34GM per 30 days) |
| Antileucotrienos | | |
| <i>montelukast sodium oral packet 4mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>montelukast sodium oral tablet 10mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>montelukast sodium oral tablet chewable 4mg, 5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>zafirlukast oral tablet 10mg, 20mg</i> | 1 | MO; QL (60 EA per 30 days) |
| Broncodilatadores, Anticolinérgicos | | |
| ATROVENT HFA INHALATION AEROSOL SOLUTION 17MCG/ACT | 1 | MO; QL (26GM per 30 days) |
| <i>ipratropium bromide inhalation solution 0.02%</i> | 1 | BvD; MO |
| <i>ipratropium bromide nasal solution 0.03%</i> | 1 | MO; QL (60ML per 30 days) |
| <i>ipratropium bromide nasal solution 0.06%</i> | 1 | MO; QL (30ML per 30 days) |
| SPIRIVA HANDIHALER INHALATION CAPSULE 18MCG | 1 | MO; QL (30 EA per 30 days) |
| SPIRIVA RESPIMAT INHALATION AEROSOL SOLUTION 1.25MCG/ACT, 2.5MCG/ACT | 1 | MO; QL (4GM per 30 days) |
| Broncodilatadores, Simpaticomiméticos | | |
| <i>albuterol sulfate hfa inhalation aerosol solution 108 (90 base) mcg/act</i> | 1 | MO; QL (17GM per 30 days) |
| <i>albuterol sulfate hfa inhalation aerosol solution 108 (90 base) mcg/act (nda020503)</i> | 1 | MO; QL (13.4GM per 30 days) |
| <i>albuterol sulfate hfa inhalation aerosol solution 108 (90 base) mcg/act (nda020983)</i> | 1 | MO; QL (36GM per 30 days) |
| <i>albuterol sulfate inhalation nebulization solution (2.5mg/3ml) 0.083%, 0.63mg/3ml, 1.25mg/3ml, 2.5mg/0.5ml</i> | 1 | BvD; MO |
| <i>albuterol sulfate oral syrup 2mg/5ml</i> | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|----------------------------|
| <i>albuterol sulfate oral tablet 2mg, 4mg</i> | 1 | MO |
| <i>epinephrine injection solution 0.3mg/0.3ml</i> | 1 | |
| <i>epinephrine injection solution auto-injector 0.15mg/0.15ml, 0.15mg/0.3ml, 0.3mg/0.3ml</i> | 1 | |
| SEREVENT DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 50MCG/ACT | 1 | MO; QL (60 EA per 30 days) |
| <i>terbutaline sulfate oral tablet 2.5mg, 5mg</i> | 1 | MO |
| VENTOLIN HFA INHALATION AEROSOL SOLUTION 108 (90 BASE) MCG/ACT | 1 | MO; QL (36GM per 30 days) |

Inhibidores de la Fosfodiesterasa, Enfermedad de las Vías Respiratorias

| | | |
|--|---|----------------------------|
| <i>roflumilast oral tablet 250mcg, 500mcg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>theophylline er oral tablet extended release 12-hour 300mg, 450mg</i> | 1 | MO |
| <i>theophylline er oral tablet extended release 24-hour 400mg, 600mg</i> | 1 | MO |

ANALGÉSICOS

Analgésicos Opioides, de Acción Corta

| | | |
|---|---|-----------------------------|
| <i>acetaminophen-codeine #3 oral tablet 300-30mg</i> | 1 | QL (360 EA per 30 days) |
| <i>acetaminophen-codeine oral solution 120-12mg/5ml</i> | 1 | QL (5000ML per 30 days) |
| <i>acetaminophen-codeine oral tablet 300-15mg, 300-60mg</i> | 1 | QL (360 EA per 30 days) |
| <i>codeine sulfate oral tablet 15mg, 30mg, 60mg</i> | 1 | QL (180 EA per 30 days) |
| <i>fentanyl citrate buccal lozenge on a handle 1200mcg, 1600mcg, 200mcg, 400mcg, 600mcg, 800mcg</i> | 1 | PA; QL (120 EA per 30 days) |
| <i>hydrocodone-acetaminophen oral solution 7.5-325mg/15ml</i> | 1 | QL (5500ML per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 10-325mg, 5-325mg, 7.5-325mg</i> | 1 | QL (360 EA per 30 days) |
| <i>hydrocodone-ibuprofen oral tablet 10-200mg, 5-200mg, 7.5-200mg</i> | 1 | QL (150 EA per 30 days) |
| <i>hydromorphone hcl oral liquid 1mg/ml</i> | 1 | QL (1920ML per 30 days) |
| <i>hydromorphone hcl oral tablet 2mg, 4mg</i> | 1 | QL (360 EA per 30 days) |
| <i>hydromorphone hcl oral tablet 8mg</i> | 1 | QL (240 EA per 30 days) |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|-----------------------------|----------------------------|
| <i>morphine sulfate (concentrate) oral solution 20mg/ml</i> | 1 | QL (600ML per 30 days) |
| <i>morphine sulfate oral solution 10mg/5ml</i> | 1 | QL (1800ML per 30 days) |
| <i>morphine sulfate oral solution 20mg/5ml</i> | 1 | QL (1500ML per 30 days) |
| <i>morphine sulfate oral tablet 15mg, 30mg</i> | 1 | QL (180 EA per 30 days) |
| <i>oxycodone hcl oral concentrate 100mg/5ml</i> | 1 | QL (180ML per 30 days) |
| <i>oxycodone hcl oral solution 5mg/5ml</i> | 1 | QL (1080ML per 30 days) |
| <i>oxycodone hcl oral tablet 10mg, 15mg, 20mg, 30mg, 5mg</i> | 1 | QL (180 EA per 30 days) |
| <i>oxycodone-acetaminophen oral solution 5-325mg/5ml</i> | 1 | QL (1080ML per 30 days) |
| <i>oxycodone-acetaminophen oral tablet 10-325mg, 2.5-325mg, 5-325mg, 7.5-325mg</i> | 1 | QL (360 EA per 30 days) |
| <i>tramadol hcl oral tablet 100mg</i> | 1 | QL (120 EA per 30 days) |
| <i>tramadol hcl oral tablet 50mg</i> | 1 | QL (240 EA per 30 days) |
| <i>tramadol-acetaminophen oral tablet 37.5-325mg</i> | 1 | QL (240 EA per 30 days) |
| Analgésicos Opioides, de Acción Prolongada | | |
| <i>fentanyl transdermal patch 72-hour 100mcg/hr, 12mcg/hr, 25mcg/hr, 37.5mcg/hr, 50mcg/hr, 62.5mcg/hr, 75mcg/hr, 87.5mcg/hr</i> | 1 | PA; QL (10 EA per 30 days) |
| <i>methadone hcl oral tablet 10mg, 5mg</i> | 1 | QL (240 EA per 30 days) |
| <i>morphine sulfate er oral tablet extended release 100mg, 15mg, 200mg, 30mg, 60mg</i> | 1 | QL (90 EA per 30 days) |
| <i>oxycodone hcl er oral tablet er 12-hour abuse-deterrent 10mg, 20mg, 40mg, 80mg</i> | 1 | |
| Analgésicos | | |
| <i>butalbital-apap-caffeine oral tablet 50-325-40mg</i> | 1 | QL (180 EA per 30 days) |
| <i>butalbital-asa-caff-codeine oral capsule 50-325-40-30mg</i> | 1 | QL (180 EA per 30 days) |
| <i>butalbital-aspirin-caffeine oral capsule 50-325-40mg</i> | 1 | QL (180 EA per 30 days) |
| Fármacos Anti-Inflamatorios No Esteroideos | | |
| <i>celecoxib oral capsule 100mg, 200mg, 400mg, 50mg</i> | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|--------------------|
| <i>diclofenac potassium oral tablet 50mg</i> | 1 | MO |
| <i>diclofenac sodium er oral tablet extended release 24-hour 100mg</i> | 1 | MO |
| <i>diclofenac sodium external gel 1%</i> | 1 | |
| <i>diclofenac sodium oral tablet delayed release 25mg, 50mg, 75mg</i> | 1 | MO |
| <i>diflunisal oral tablet 500mg</i> | 1 | MO |
| <i>etodolac oral capsule 200mg, 300mg</i> | 1 | MO |
| <i>etodolac oral tablet 400mg, 500mg</i> | 1 | MO |
| <i>flurbiprofen oral tablet 100mg</i> | 1 | MO |
| IBU ORAL TABLET 600MG, 800MG | 1 | MO |
| <i>ibuprofen oral suspension 100mg/5ml</i> | 1 | |
| <i>ibuprofen oral tablet 400mg, 600mg, 800mg</i> | 1 | MO |
| <i>indomethacin er oral capsule extended release 75mg</i> | 1 | MO |
| <i>indomethacin oral capsule 25mg, 50mg</i> | 1 | MO |
| <i>ketorolac tromethamine oral tablet 10mg</i> | 1 | |
| <i>meloxicam oral tablet 15mg, 7.5mg</i> | 1 | MO |
| <i>nabumetone oral tablet 500mg, 750mg</i> | 1 | MO |
| <i>naproxen oral suspension 125mg/5ml</i> | 1 | MO |
| <i>naproxen oral tablet 250mg, 375mg, 500mg</i> | 1 | MO |
| <i>naproxen oral tablet delayed release 375mg, 500mg</i> | 1 | MO |
| <i>naproxen sodium oral tablet 275mg, 550mg</i> | 1 | MO |
| <i>oxaprozin oral tablet 600mg</i> | 1 | MO |
| <i>piroxicam oral capsule 10mg, 20mg</i> | 1 | MO |
| <i>sulindac oral tablet 150mg, 200mg</i> | 1 | MO |

ANESTÉSICOS

Anestésicos Locales

| | | |
|---|---|----------------------------|
| <i>lidocaine external patch 5%</i> | 1 | PA; QL (90 EA per 30 days) |
| <i>lidocaine hcl external solution 4%</i> | 1 | QL (50ML per 30 days) |
| <i>lidocaine viscous hcl mouth/throat solution 2%</i> | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|-------------------------|
| <i>lidocaine-prilocaine external cream 2.5-2.5%</i> | 1 | QL (30GM per 30 days) |
| ANSIOLÍTICOS | | |
| Ansiolíticos, Otros | | |
| <i>bupirone hcl oral tablet 10mg, 15mg, 30mg, 5mg, 7.5mg</i> | 1 | |
| <i>hydroxyzine hcl oral syrup 10mg/5ml</i> | 1 | |
| <i>hydroxyzine hcl oral tablet 10mg, 25mg, 50mg</i> | 1 | |
| <i>hydroxyzine pamoate oral capsule 100mg, 25mg, 50mg</i> | 1 | |
| <i>oxazepam oral capsule 10mg, 15mg, 30mg</i> | 1 | QL (120 EA per 30 days) |
| Benzodiazepinas | | |
| ALPRAZOLAM INTENSOL ORAL CONCENTRATE 1MG/ML | 1 | QL (300ML per 30 days) |
| <i>alprazolam oral tablet 0.25mg, 0.5mg</i> | 1 | QL (120 EA per 30 days) |
| <i>alprazolam oral tablet 1mg</i> | 1 | QL (240 EA per 30 days) |
| <i>alprazolam oral tablet 2mg</i> | 1 | QL (150 EA per 30 days) |
| <i>chlordiazepoxide hcl oral capsule 10mg, 25mg, 5mg</i> | 1 | QL (120 EA per 30 days) |
| <i>clonazepam oral tablet 0.5mg, 1mg</i> | 1 | QL (90 EA per 30 days) |
| <i>clonazepam oral tablet 2mg</i> | 1 | QL (300 EA per 30 days) |
| <i>clonazepam oral tablet dispersible 0.125mg, 0.25mg, 0.5mg, 1mg</i> | 1 | QL (90 EA per 30 days) |
| <i>clonazepam oral tablet dispersible 2mg</i> | 1 | QL (300 EA per 30 days) |
| <i>clorazepate dipotassium oral tablet 15mg, 3.75mg, 7.5mg</i> | 1 | QL (180 EA per 30 days) |
| DIAZEPAM INTENSOL ORAL CONCENTRATE 5MG/ML | 1 | QL (240ML per 30 days) |
| <i>diazepam oral solution 5mg/5ml</i> | 1 | QL (1200ML per 30 days) |
| <i>diazepam oral tablet 10mg, 2mg</i> | 1 | QL (120 EA per 30 days) |
| <i>diazepam oral tablet 5mg</i> | 1 | QL (240 EA per 30 days) |
| LORAZEPAM INTENSOL ORAL CONCENTRATE 2MG/ML | 1 | QL (240ML per 30 days) |
| <i>lorazepam oral tablet 0.5mg, 1mg, 2mg</i> | 1 | QL (150 EA per 30 days) |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|--------------------|
| ANTIBACTERIANOS | | |
| Aminoglucósidos | | |
| <i>amikacin sulfate injection solution 500mg/2ml</i> | 1 | BvD |
| ARIKAYCE INHALATION SUSPENSION 590MG/8.4ML | 1 | PA |
| <i>gentamicin in saline intravenous solution 0.8-0.9mg/ml-%, 1-0.9mg/ml-%, 1.2-0.9mg/ml-%, 1.6-0.9mg/ml-%</i> | 1 | |
| <i>gentamicin sulfate external cream 0.1%</i> | 1 | |
| <i>gentamicin sulfate external ointment 0.1%</i> | 1 | |
| <i>gentamicin sulfate injection solution 40mg/ml</i> | 1 | |
| <i>neomycin sulfate oral tablet 500mg</i> | 1 | |
| <i>paromomycin sulfate oral capsule 250mg</i> | 1 | |
| <i>tobramycin sulfate injection solution 10mg/ml, 80mg/2ml</i> | 1 | BvD |
| ZEMDRI INTRAVENOUS SOLUTION 500MG/10ML | 1 | |
| Antibacterianos, Otros | | |
| <i>aztreonam injection solution reconstituted 1gm</i> | 1 | |
| <i>aztreonam injection solution reconstituted 2gm</i> | 1 | BvD |
| <i>clindamycin hcl oral capsule 150mg, 300mg, 75mg</i> | 1 | |
| <i>clindamycin palmitate hcl oral solution reconstituted 75mg/5ml</i> | 1 | |
| <i>clindamycin phosphate in d5w intravenous solution 300mg/50ml, 600mg/50ml, 900mg/50ml</i> | 1 | |
| <i>clindamycin phosphate injection solution 300mg/2ml, 600mg/4ml, 900mg/6ml</i> | 1 | BvD |
| <i>clindamycin phosphate vaginal cream 2%</i> | 1 | |
| <i>colistimethate sodium (cba) injection solution reconstituted 150mg</i> | 1 | BvD |
| <i>daptomycin intravenous solution reconstituted 350mg, 500mg</i> | 1 | |
| FIRVANQ ORAL SOLUTION RECONSTITUTED 25MG/ML, 50MG/ML | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|--------------------|
| <i>linezolid intravenous solution 600mg/300ml</i> | 1 | PA |
| <i>linezolid oral tablet 600mg</i> | 1 | PA |
| <i>methenamine hippurate oral tablet 1gm</i> | 1 | |
| <i>metronidazole external cream 0.75%</i> | 1 | |
| <i>metronidazole external gel 0.75%, 1%</i> | 1 | |
| <i>metronidazole external lotion 0.75%</i> | 1 | |
| <i>metronidazole intravenous solution 500mg/100ml</i> | 1 | BvD |
| <i>metronidazole oral tablet 250mg, 500mg</i> | 1 | |
| <i>metronidazole vaginal gel 0.75%</i> | 1 | |
| <i>nitrofurantoin macrocrystal oral capsule 100mg, 25mg, 50mg</i> | 1 | |
| <i>nitrofurantoin monohyd macro oral capsule 100mg</i> | 1 | |
| <i>tigecycline intravenous solution reconstituted 50mg</i> | 1 | BvD |
| <i>tinidazole oral tablet 250mg, 500mg</i> | 1 | |
| <i>trimethoprim oral tablet 100mg</i> | 1 | |
| <i>vancomycin hcl intravenous solution reconstituted 1gm, 10gm, 500mg, 750mg</i> | 1 | |
| <i>vancomycin hcl oral capsule 125mg, 250mg</i> | 1 | |
| <i>vancomycin hcl oral solution reconstituted 250mg/5ml</i> | 1 | |
| XIFAXAN ORAL TABLET 200MG | 1 | |
| XIFAXAN ORAL TABLET 550MG | 1 | MO |
| Betalactámicos, Cefalosporinas | | |
| <i>cefaclor er oral tablet extended release 12-hour 500mg</i> | 1 | |
| <i>cefaclor oral capsule 250mg, 500mg</i> | 1 | |
| <i>cefaclor oral suspension reconstituted 125mg/5ml, 250mg/5ml, 375mg/5ml</i> | 1 | |
| <i>cefadroxil oral capsule 500mg</i> | 1 | |
| <i>cefadroxil oral suspension reconstituted 250mg/5ml, 500mg/5ml</i> | 1 | |
| <i>cefadroxil oral tablet 1gm</i> | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|-----------------------------|---------------------------|
| <i>cefazolin sodium injection solution reconstituted 1gm, 10gm, 500mg</i> | 1 | |
| <i>cefdinir oral capsule 300mg</i> | 1 | |
| <i>cefdinir oral suspension reconstituted 125mg/5ml, 250mg/5ml</i> | 1 | |
| <i>cefepime hcl injection solution reconstituted 1gm, 2gm</i> | 1 | |
| <i>cefixime oral capsule 400mg</i> | 1 | |
| <i>cefixime oral suspension reconstituted 100mg/5ml, 200mg/5ml</i> | 1 | |
| <i>cefotetan disodium injection solution reconstituted 1gm, 2gm</i> | 1 | BvD |
| <i>cefoxitin sodium intravenous solution reconstituted 1gm, 10gm, 2gm</i> | 1 | BvD |
| <i>cefpodoxime proxetil oral suspension reconstituted 100mg/5ml, 50mg/5ml</i> | 1 | |
| <i>cefpodoxime proxetil oral tablet 100mg, 200mg</i> | 1 | |
| <i>cefprozil oral suspension reconstituted 125mg/5ml, 250mg/5ml</i> | 1 | |
| <i>cefprozil oral tablet 250mg, 500mg</i> | 1 | |
| <i>ceftazidime injection solution reconstituted 1gm, 6gm</i> | 1 | |
| <i>ceftazidime intravenous solution reconstituted 2gm</i> | 1 | |
| <i>ceftriaxone sodium injection solution reconstituted 1gm, 2gm, 250mg, 500mg</i> | 1 | |
| <i>ceftriaxone sodium intravenous solution reconstituted 10gm</i> | 1 | |
| <i>cefuroxime axetil oral tablet 250mg, 500mg</i> | 1 | |
| <i>cefuroxime sodium injection solution reconstituted 750mg</i> | 1 | BvD |
| <i>cefuroxime sodium intravenous solution reconstituted 1.5gm</i> | 1 | BvD |
| <i>cephalexin oral capsule 250mg, 500mg</i> | 1 | |
| <i>cephalexin oral suspension reconstituted 125mg/5ml, 250mg/5ml</i> | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|--------------------|
| <i>cephalexin oral tablet 250mg, 500mg</i> | 1 | |
| TEFLARO INTRAVENOUS SOLUTION RECONSTITUTED 400MG, 600MG | 1 | BvD |
| Betalactámicos, Penicilinas | | |
| <i>amoxicillin oral capsule 250mg, 500mg</i> | 1 | |
| <i>amoxicillin oral suspension reconstituted 125mg/5ml, 200mg/5ml, 250mg/5ml, 400mg/5ml</i> | 1 | |
| <i>amoxicillin oral tablet 500mg, 875mg</i> | 1 | |
| <i>amoxicillin oral tablet chewable 125mg, 250mg</i> | 1 | |
| <i>amoxicillin-pot clavulanate er oral tablet extended release 12-hour 1000-62.5mg</i> | 1 | |
| <i>amoxicillin-pot clavulanate oral suspension reconstituted 200-28.5mg/5ml, 250-62.5mg/5ml, 400-57mg/5ml, 600-42.9mg/5ml</i> | 1 | |
| <i>amoxicillin-pot clavulanate oral tablet 250- 125mg, 500- 125mg, 875- 125mg</i> | 1 | |
| <i>amoxicillin-pot clavulanate oral tablet chewable 200-28.5mg, 400-57mg</i> | 1 | |
| <i>ampicillin oral capsule 500mg</i> | 1 | |
| <i>ampicillin sodium injection solution reconstituted 1gm, 125mg</i> | 1 | BvD |
| <i>ampicillin sodium intravenous solution reconstituted 10gm</i> | 1 | BvD |
| <i>ampicillin-sulbactam sodium injection solution reconstituted 1.5 (1-0.5) gm, 3 (2-1) gm</i> | 1 | |
| <i>ampicillin-sulbactam sodium intravenous solution reconstituted 15 (10-5) gm</i> | 1 | |
| BICILLIN L-A INTRAMUSCULAR SUSPENSION 2400000UNIT/4ML | 1 | |
| BICILLIN L-A INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 1200000UNIT/2ML, 600000UNIT/ML | 1 | |
| <i>dicloxacillin sodium oral capsule 250mg, 500mg</i> | 1 | |
| <i>nafcillin sodium injection solution reconstituted 1gm, 2gm</i> | 1 | BvD |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|-----------------------------|---------------------------|
| <i>nafcillin sodium intravenous solution reconstituted 10gm</i> | 1 | BvD |
| <i>oxacillin sodium in dextrose intravenous solution 1gm/50ml, 2gm/50ml</i> | 1 | BvD |
| <i>oxacillin sodium injection solution reconstituted 1gm, 2gm</i> | 1 | BvD |
| <i>oxacillin sodium intravenous solution reconstituted 10gm</i> | 1 | BvD |
| <i>penicillin g pot in dextrose intravenous solution 40000unit/ml, 60000unit/ml</i> | 1 | |
| <i>penicillin g potassium injection solution reconstituted 2000000unit</i> | 1 | BvD |
| <i>penicillin g procaine intramuscular suspension 600000unit/ml</i> | 1 | |
| <i>penicillin g sodium injection solution reconstituted 5000000unit</i> | 1 | BvD |
| <i>penicillin v potassium oral solution reconstituted 125mg/5ml, 250mg/5ml</i> | 1 | |
| <i>penicillin v potassium oral tablet 250mg, 500mg</i> | 1 | |
| <i>piperacillin sod-tazobactam so intravenous solution reconstituted 2.25 (2-0.25) gm, 3.375 (3-0.375) gm, 4.5 (4-0.5) gm</i> | 1 | |
| Carbapenémicos | | |
| <i>ertapenem sodium injection solution reconstituted 1gm</i> | 1 | |
| <i>imipenem-cilastatin intravenous solution reconstituted 250mg, 500mg</i> | 1 | |
| <i>meropenem intravenous solution reconstituted 1gm, 500mg</i> | 1 | |
| Macrólidos | | |
| <i>azithromycin intravenous solution reconstituted 500mg</i> | 1 | BvD |
| <i>azithromycin oral packet 1gm</i> | 1 | |
| <i>azithromycin oral suspension reconstituted 100mg/5ml, 200mg/5ml</i> | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|----------------------------|
| <i>azithromycin oral tablet 250mg, 250mg (6 pack), 500mg, 500mg (3 pack), 600mg</i> | 1 | |
| <i>clarithromycin er oral tablet extended release 24-hour 500mg</i> | 1 | |
| <i>clarithromycin oral suspension reconstituted 125mg/5ml, 250mg/5ml</i> | 1 | |
| <i>clarithromycin oral tablet 250mg, 500mg</i> | 1 | |
| DIFICID ORAL SUSPENSION RECONSTITUTED 40MG/ML | 1 | PA; QL (136ML per 10 days) |
| DIFICID ORAL TABLET 200MG | 1 | PA; QL (20 EA per 10 days) |
| ERYTHROCIN LACTOBIONATE INTRAVENOUS SOLUTION RECONSTITUTED 500MG | 1 | BvD |
| <i>erythromycin base oral capsule delayed release particles 250mg</i> | 1 | |
| <i>erythromycin base oral tablet 250mg, 500mg</i> | 1 | |
| <i>erythromycin ethylsuccinate oral suspension reconstituted 200mg/5ml, 400mg/5ml</i> | 1 | |
| <i>erythromycin ethylsuccinate oral tablet 400mg</i> | 1 | |
| <i>erythromycin oral tablet delayed release 250mg, 333mg, 500mg</i> | 1 | |
| Quinolonas | | |
| <i>ciprofloxacin hcl ophthalmic solution 0.3%</i> | 1 | |
| <i>ciprofloxacin hcl oral tablet 100mg, 250mg, 500mg, 750mg</i> | 1 | |
| <i>ciprofloxacin in d5w intravenous solution 200mg/100ml</i> | 1 | BvD |
| <i>levofloxacin in d5w intravenous solution 500mg/100ml, 750mg/150ml</i> | 1 | |
| <i>levofloxacin intravenous solution 25mg/ml</i> | 1 | |
| <i>levofloxacin oral solution 25mg/ml</i> | 1 | |
| <i>levofloxacin oral tablet 250mg, 500mg, 750mg</i> | 1 | |
| <i>moxifloxacin hcl in nacl intravenous solution 400mg/250ml</i> | 1 | BvD |
| <i>moxifloxacin hcl oral tablet 400mg</i> | 1 | |
| <i>ofloxacin oral tablet 300mg, 400mg</i> | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|--------------------------------|
| Sulfonamidas | | |
| <i>sulfacetamide sodium (acne) external lotion 10%</i> | 1 | |
| <i>sulfadiazine oral tablet 500mg</i> | 1 | |
| <i>sulfamethoxazole-trimethoprim oral suspension 200-40mg/5ml</i> | 1 | |
| <i>sulfamethoxazole-trimethoprim oral tablet 400-80mg, 800-160mg</i> | 1 | |
| Tetraciclinas | | |
| DOXY 100 INTRAVENOUS SOLUTION RECONSTITUTED 100MG | 1 | BvD |
| <i>doxycycline hyclate oral capsule 100mg, 50mg</i> | 1 | |
| <i>doxycycline hyclate oral tablet 100mg, 20mg</i> | 1 | |
| <i>doxycycline monohydrate oral capsule 100mg, 50mg</i> | 1 | |
| <i>doxycycline monohydrate oral tablet 100mg, 50mg, 75mg</i> | 1 | |
| <i>minocycline hcl oral capsule 100mg, 50mg, 75mg</i> | 1 | |
| <i>minocycline hcl oral tablet 100mg, 50mg, 75mg</i> | 1 | |
| <i>tetracycline hcl oral capsule 250mg, 500mg</i> | 1 | |
| ANTICONVULSIVOS | | |
| Agentes de Aumento del Ácido Gamma-Aminobutírico (GABA) | | |
| <i>clobazam oral suspension 2.5mg/ml</i> | 1 | MO; QL (480ML per 30 days) |
| <i>clobazam oral tablet 10mg, 20mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>diazepam rectal gel 10mg, 2.5mg, 20mg</i> | 1 | |
| <i>gabapentin oral capsule 100mg, 300mg, 400mg</i> | 1 | MO; QL (270 EA per 30 days) |
| <i>gabapentin oral solution 250mg/5ml</i> | 1 | MO |
| <i>gabapentin oral tablet 600mg, 800mg</i> | 1 | MO; QL (180 EA per 30 days) |
| NAYZILAM NASAL SOLUTION 5MG/0.1ML | 1 | |
| SYMPAZAN ORAL FILM 10MG, 20MG | 1 | ST; QL (60 EA per 30 days) |
| SYMPAZAN ORAL FILM 5MG | 1 | ST; MO; QL (60 EA per 30 days) |
| <i>tiagabine hcl oral tablet 12mg, 16mg, 2mg, 4mg</i> | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|-----------------------------|
| VALTOCO 10MG DOSE NASAL LIQUID 10MG/0.1ML | 1 | ST |
| VALTOCO 15MG DOSE NASAL LIQUID THERAPY PACK 7.5MG/0.1ML | 1 | ST |
| VALTOCO 20MG DOSE NASAL LIQUID THERAPY PACK 10MG/0.1ML | 1 | ST |
| VALTOCO 5MG DOSE NASAL LIQUID 5MG/0.1ML | 1 | ST |
| <i>vigabatrin oral packet 500mg</i> | 1 | PA; QL (180 EA per 30 days) |
| <i>vigabatrin oral tablet 500mg</i> | 1 | PA; QL (180 EA per 30 days) |
| Agentes del Canal de Sodio | | |
| APTIOM ORAL TABLET 200MG, 400MG, 800MG | 1 | ST; QL (30 EA per 30 days) |
| APTIOM ORAL TABLET 600MG | 1 | ST; QL (60 EA per 30 days) |
| <i>carbamazepine er oral capsule extended release 12-hour 100mg, 200mg, 300mg</i> | 1 | MO |
| <i>carbamazepine er oral tablet extended release 12-hour 100mg, 200mg, 400mg</i> | 1 | MO |
| <i>carbamazepine oral suspension 100mg/5ml</i> | 1 | MO |
| <i>carbamazepine oral tablet 200mg</i> | 1 | MO |
| <i>carbamazepine oral tablet chewable 100mg</i> | 1 | MO |
| DILANTIN ORAL CAPSULE 30MG | 1 | ST; MO |
| EPITOL ORAL TABLET 200MG | 1 | MO |
| <i>lacosamide oral solution 10mg/ml</i> | 1 | MO; QL (1395ML per 30 days) |
| <i>lacosamide oral tablet 100mg, 150mg, 200mg, 50mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>oxcarbazepine oral suspension 300mg/5ml</i> | 1 | MO |
| <i>oxcarbazepine oral tablet 150mg, 300mg, 600mg</i> | 1 | MO |
| <i>phenytoin oral suspension 125mg/5ml</i> | 1 | MO |
| <i>phenytoin oral tablet chewable 50mg</i> | 1 | MO |
| <i>phenytoin sodium extended oral capsule 100mg, 200mg, 300mg</i> | 1 | MO |
| <i>rufinamide oral suspension 40mg/ml</i> | 1 | QL (2760ML per 30 days) |
| <i>rufinamide oral tablet 200mg</i> | 1 | MO; QL (480 EA per 30 days) |
| <i>rufinamide oral tablet 400mg</i> | 1 | QL (240 EA per 30 days) |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|--------------------------------|
| Agentes Modificadores de los Canales de Calcio | | |
| CELONTIN ORAL CAPSULE 300MG | 1 | ST; MO |
| <i>ethosuximide oral capsule 250mg</i> | 1 | MO |
| <i>ethosuximide oral solution 250mg/5ml</i> | 1 | MO |
| ZONISADE ORAL SUSPENSION 100MG/5ML | 1 | MO; QL (900ML per 30 days) |
| <i>zonisamide oral capsule 100mg, 25mg, 50mg</i> | 1 | MO |
| Anticonvulsivos, Otros | | |
| BRIVIACT ORAL SOLUTION 10MG/ML | 1 | MO; QL (600ML per 30 days) |
| BRIVIACT ORAL TABLET 10MG, 100MG, 25MG, 50MG, 75MG | 1 | MO; QL (60 EA per 30 days) |
| DIACOMIT ORAL CAPSULE 250MG, 500MG | 1 | PA; MO |
| DIACOMIT ORAL PACKET 250MG, 500MG | 1 | PA; MO |
| EPIDIOLEX ORAL SOLUTION 100MG/ML | 1 | PA; MO |
| <i>felbamate oral suspension 600mg/5ml</i> | 1 | |
| <i>felbamate oral tablet 400mg, 600mg</i> | 1 | MO |
| FINTEPLA ORAL SOLUTION 2.2MG/ML | 1 | PA; MO |
| FYCOMPA ORAL SUSPENSION 0.5MG/ML | 1 | ST; MO; QL (720ML per 30 days) |
| FYCOMPA ORAL TABLET 10MG, 12MG, 4MG, 6MG | 1 | ST; QL (30 EA per 30 days) |
| FYCOMPA ORAL TABLET 2MG, 8MG | 1 | ST; MO; QL (30 EA per 30 days) |
| <i>lamotrigine er oral tablet extended release 24-hour 100mg, 200mg, 25mg, 250mg, 300mg, 50mg</i> | 1 | MO |
| <i>lamotrigine oral kit 25 & 50 & 100mg</i> | 1 | |
| <i>lamotrigine oral tablet 100mg, 150mg, 200mg, 25mg</i> | 1 | MO |
| <i>lamotrigine oral tablet chewable 25mg, 5mg</i> | 1 | MO |
| <i>lamotrigine oral tablet dispersible 100mg, 200mg, 25mg, 50mg</i> | 1 | MO |
| <i>lamotrigine starter kit-blue oral kit 35 x 25mg</i> | 1 | |
| <i>lamotrigine starter kit-green oral kit 84 x 25mg & 14x100mg</i> | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|---------------------------------|
| <i>lamotrigine starter kit-orange oral kit 42 x 25mg & 7 x 100mg</i> | 1 | |
| <i>levetiracetam er oral tablet extended release 24-hour 500mg, 750mg</i> | 1 | MO |
| <i>levetiracetam oral solution 100mg/ml</i> | 1 | MO |
| <i>levetiracetam oral tablet 1000mg, 250mg, 500mg, 750mg</i> | 1 | MO |
| <i>phenobarbital oral elixir 20mg/5ml</i> | 1 | MO; QL (1500ML per 30 days) |
| <i>phenobarbital oral tablet 100mg, 16.2mg, 32.4mg, 64.8mg, 97.2mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>phenobarbital oral tablet 15mg, 60mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>phenobarbital oral tablet 30mg</i> | 1 | MO; QL (300 EA per 30 days) |
| <i>primidone oral tablet 250mg, 50mg</i> | 1 | MO |
| SPRITAM ORAL TABLET DISINTEGRATING SOLUBLE 1000MG | 1 | ST; MO; QL (90 EA per 30 days) |
| SPRITAM ORAL TABLET DISINTEGRATING SOLUBLE 250MG, 500MG, 750MG | 1 | ST; MO; QL (120 EA per 30 days) |
| <i>valproic acid oral capsule 250mg</i> | 1 | MO |
| <i>valproic acid oral solution 250mg/5ml</i> | 1 | MO |
| XCOPRI (250MG DAILY DOSE) ORAL TABLET THERAPY PACK 100 & 150MG | 1 | MO; QL (56 EA per 28 days) |
| XCOPRI (350MG DAILY DOSE) ORAL TABLET THERAPY PACK 150 & 200MG | 1 | MO; QL (56 EA per 28 days) |
| XCOPRI ORAL TABLET 100MG, 150MG, 200MG, 50MG | 1 | MO; QL (60 EA per 30 days) |
| XCOPRI ORAL TABLET THERAPY PACK 14 X 12.5MG & 14 X 25MG, 14 X 150MG & 14 X 200MG, 14 X 50MG & 14 X 100MG | 1 | QL (28 EA per 28 days) |

ANTIDEPRESIVOS

Antidepressivos, Otros

| | | |
|---|---|--------------------------------|
| AUVELITY ORAL TABLET EXTENDED RELEASE 45-105MG | 1 | ST; MO; QL (60 EA per 30 days) |
| <i>bupropion hcl er (sr) oral tablet extended release 12-hour 100mg</i> | 1 | MO; QL (120 EA per 30 days) |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|-----------------------------|---------------------------------|
| <i>bupropion hcl er (sr) oral tablet extended release 12-hour 150mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>bupropion hcl er (sr) oral tablet extended release 12-hour 200mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>bupropion hcl er (xl) oral tablet extended release 24-hour 150mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>bupropion hcl er (xl) oral tablet extended release 24-hour 300mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>bupropion hcl er (xl) oral tablet extended release 24-hour 450mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>bupropion hcl oral tablet 100mg</i> | 1 | MO; QL (180 EA per 30 days) |
| <i>bupropion hcl oral tablet 75mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>mirtazapine oral tablet 15mg, 30mg, 45mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>mirtazapine oral tablet 7.5mg</i> | 1 | MO; QL (45 EA per 30 days) |
| <i>mirtazapine oral tablet dispersible 15mg, 30mg, 45mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>olanzapine-fluoxetine hcl oral capsule 12-25mg, 12-50mg, 6-50mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>olanzapine-fluoxetine hcl oral capsule 3-25mg, 6-25mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>Inhibidores de la Monoaminoxidasa</i> | | |
| <i>EMSAM TRANSDERMAL PATCH 24-HOUR 12MG/24HR, 6MG/24HR, 9MG/24HR</i> | 1 | ST; QL (30 EA per 30 days) |
| <i>MARPLAN ORAL TABLET 10MG</i> | 1 | ST; MO; QL (180 EA per 30 days) |
| <i>phenelzine sulfate oral tablet 15mg</i> | 1 | MO |
| <i>tranylcypromine sulfate oral tablet 10mg</i> | 1 | MO |
| <i>ISRS/IRSN (Inhibidor Selectivo de la Recaptación de Serotonina/Inhibidor de la Recaptación de Serotonina y Norepinefrina)</i> | | |
| <i>citalopram hydrobromide oral capsule 30mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>citalopram hydrobromide oral solution 10mg/5ml</i> | 1 | MO; QL (600ML per 30 days) |
| <i>citalopram hydrobromide oral tablet 10mg, 40mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>citalopram hydrobromide oral tablet 20mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>desvenlafaxine er oral tablet extended release 24-hour 100mg, 50mg</i> | 1 | MO; QL (30 EA per 30 days) |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|-----------------------------|--------------------------------|
| <i>desvenlafaxine succinate er oral tablet extended release 24-hour 100mg, 25mg, 50mg</i> | 1 | MO; QL (30 EA per 30 days) |
| DRIZALMA SPRINKLE ORAL CAPSULE DELAYED RELEASE SPRINKLE 20MG, 30MG, 40MG, 60MG | 1 | MO; QL (60 EA per 30 days) |
| <i>duloxetine hcl oral capsule delayed release particles 20mg, 30mg, 40mg, 60mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>escitalopram oxalate oral solution 5mg/5ml</i> | 1 | MO; QL (600ML per 30 days) |
| <i>escitalopram oxalate oral tablet 10mg</i> | 1 | MO; QL (45 EA per 30 days) |
| <i>escitalopram oxalate oral tablet 20mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>escitalopram oxalate oral tablet 5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| FETZIMA ORAL CAPSULE EXTENDED RELEASE 24-HOUR 120MG, 20MG, 40MG, 80MG | 1 | MO; QL (30 EA per 30 days) |
| FETZIMA TITRATION ORAL CAPSULE ER 24-HOUR THERAPY PACK 20 & 40MG | 1 | QL (28 EA per 28 days) |
| <i>fluoxetine hcl oral capsule 10mg, 20mg, 40mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>fluoxetine hcl oral solution 20mg/5ml</i> | 1 | MO; QL (600ML per 30 days) |
| <i>fluoxetine hcl oral tablet 10mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>fluoxetine hcl oral tablet 20mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>fluvoxamine maleate oral tablet 100mg, 25mg, 50mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>nefazodone hcl oral tablet 100mg, 150mg, 200mg, 250mg, 50mg</i> | 1 | MO |
| <i>paroxetine hcl oral suspension 10mg/5ml</i> | 1 | MO; QL (900ML per 30 days) |
| <i>paroxetine hcl oral tablet 10mg, 20mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>paroxetine hcl oral tablet 30mg, 40mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>sertraline hcl oral capsule 150mg, 200mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>sertraline hcl oral concentrate 20mg/ml</i> | 1 | MO; QL (300ML per 30 days) |
| <i>sertraline hcl oral tablet 100mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>sertraline hcl oral tablet 25mg, 50mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>trazodone hcl oral tablet 100mg, 150mg, 300mg, 50mg</i> | 1 | MO |
| TRINTELLIX ORAL TABLET 10MG, 20MG, 5MG | 1 | ST; MO; QL (30 EA per 30 days) |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|----------------------------|
| <i>venlafaxine besylate er oral tablet extended release 24-hour 112.5mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>venlafaxine hcl er oral capsule extended release 24-hour 150mg, 37.5mg, 75mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>venlafaxine hcl er oral tablet extended release 24-hour 150mg, 225mg, 37.5mg, 75mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>venlafaxine hcl oral tablet 100mg, 25mg, 37.5mg, 50mg, 75mg</i> | 1 | MO; QL (90 EA per 30 days) |
| VIIBRYD STARTER PACK ORAL KIT 10 & 20MG | 1 | QL (30 EA per 30 days) |
| <i>vilazodone hcl oral tablet 10mg, 20mg, 40mg</i> | 1 | MO; QL (30 EA per 30 days) |
| Tricíclicos | | |
| <i>amitriptyline hcl oral tablet 10mg, 100mg, 150mg, 25mg, 50mg, 75mg</i> | 1 | MO |
| <i>amoxapine oral tablet 100mg, 150mg, 25mg, 50mg</i> | 1 | MO |
| <i>clomipramine hcl oral capsule 25mg, 50mg, 75mg</i> | 1 | MO |
| <i>desipramine hcl oral tablet 10mg, 100mg, 150mg, 25mg, 50mg, 75mg</i> | 1 | MO |
| <i>doxepin hcl oral capsule 10mg, 100mg, 150mg, 25mg, 50mg, 75mg</i> | 1 | MO |
| <i>doxepin hcl oral concentrate 10mg/ml</i> | 1 | MO |
| <i>imipramine hcl oral tablet 10mg, 25mg, 50mg</i> | 1 | MO |
| <i>nortriptyline hcl oral capsule 10mg, 25mg, 50mg, 75mg</i> | 1 | MO |
| <i>nortriptyline hcl oral solution 10mg/5ml</i> | 1 | MO |
| <i>protriptyline hcl oral tablet 10mg, 5mg</i> | 1 | MO |
| <i>trimipramine maleate oral capsule 100mg, 25mg, 50mg</i> | 1 | MO |
| ANTIEMÉTICOS | | |
| Antieméticos, Otros | | |
| <i>meclizine hcl oral tablet 12.5mg, 25mg</i> | 1 | |
| <i>prochlorperazine maleate oral tablet 10mg, 5mg</i> | 1 | BvD; MO |
| <i>prochlorperazine rectal suppository 25mg</i> | 1 | |
| <i>promethazine hcl oral syrup 6.25mg/5ml</i> | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|-----------------------------|
| <i>promethazine hcl oral tablet 12.5mg, 25mg, 50mg</i> | 1 | |
| <i>promethazine hcl rectal suppository 12.5mg, 25mg</i> | 1 | |
| <i>scopolamine transdermal patch 72-hour 1mg/3days</i> | 1 | |
| Complementos de Terapia Emetogénica | | |
| <i>aprepitant oral capsule 125mg, 40mg, 80mg</i> | 1 | BvD; QL (30 EA per 30 days) |
| <i>aprepitant oral capsule 80 & 125mg</i> | 1 | BvD; QL (12 EA per 30 days) |
| <i>dronabinol oral capsule 10mg, 2.5mg, 5mg</i> | 1 | PA; QL (60 EA per 30 days) |
| <i>granisetron hcl oral tablet 1mg</i> | 1 | BvD; QL (60 EA per 30 days) |
| <i>ondansetron hcl oral solution 4mg/5ml</i> | 1 | BvD |
| <i>ondansetron hcl oral tablet 4mg, 8mg</i> | 1 | BvD |
| <i>ondansetron oral tablet dispersible 4mg, 8mg</i> | 1 | BvD |
| VARUBI (180MG DOSE) ORAL TABLET THERAPY PACK 2 X 90MG | 1 | BvD |
| ANTIMICOBACTERIANOS | | |
| Antimicobacterianos, Otros | | |
| <i>dapsone oral tablet 100mg, 25mg</i> | 1 | MO |
| PRIFTIN ORAL TABLET 150MG | 1 | |
| <i>rifabutin oral capsule 150mg</i> | 1 | |
| Antituberculosos | | |
| <i>ethambutol hcl oral tablet 100mg, 400mg</i> | 1 | |
| <i>isoniazid oral syrup 50mg/5ml</i> | 1 | MO |
| <i>isoniazid oral tablet 100mg, 300mg</i> | 1 | MO |
| <i>pyrazinamide oral tablet 500mg</i> | 1 | |
| <i>rifampin intravenous solution reconstituted 600mg</i> | 1 | |
| <i>rifampin oral capsule 150mg, 300mg</i> | 1 | |
| SIRTURO ORAL TABLET 100MG, 20MG | 1 | PA |
| TRECTOR ORAL TABLET 250MG | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|--------------------|
| ANTIMICÓTICOS | | |
| <i>Antimicóticos</i> | | |
| ABELCET INTRAVENOUS SUSPENSION 5MG/ML | 1 | BvD |
| AMBISOME INTRAVENOUS SUSPENSION RECONSTITUTED 50MG | 1 | BvD |
| <i>amphotericin b intravenous solution reconstituted 50mg</i> | 1 | BvD |
| <i>casposfungin acetate intravenous solution reconstituted 50mg, 70mg</i> | 1 | |
| <i>ciclopirox olamine external cream 0.77%</i> | 1 | |
| <i>ciclopirox olamine external suspension 0.77%</i> | 1 | |
| <i>clotrimazole external cream 1%</i> | 1 | |
| <i>clotrimazole external solution 1%</i> | 1 | |
| <i>clotrimazole mouth/throat troche 10mg</i> | 1 | |
| <i>econazole nitrate external cream 1%</i> | 1 | |
| ERAXIS INTRAVENOUS SOLUTION RECONSTITUTED 100MG, 50MG | 1 | BvD |
| <i>fluconazole in sodium chloride intravenous solution 200-0.9mg/100ml-%, 400-0.9mg/200ml-%</i> | 1 | BvD |
| <i>fluconazole oral suspension reconstituted 10mg/ml, 40mg/ml</i> | 1 | |
| <i>fluconazole oral tablet 100mg, 150mg, 200mg, 50mg</i> | 1 | |
| <i>flucytosine oral capsule 250mg, 500mg</i> | 1 | |
| <i>griseofulvin microsize oral suspension 125mg/5ml</i> | 1 | |
| <i>griseofulvin microsize oral tablet 500mg</i> | 1 | |
| <i>griseofulvin ultramicrosize oral tablet 125mg, 250mg</i> | 1 | |
| <i>itraconazole oral capsule 100mg</i> | 1 | PA |
| <i>itraconazole oral solution 10mg/ml</i> | 1 | PA |
| JUBLIA EXTERNAL SOLUTION 10% | 1 | |
| <i>ketoconazole external cream 2%</i> | 1 | |
| <i>ketoconazole external shampoo 2%</i> | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|----------------------------|
| <i>ketoconazole oral tablet 200mg</i> | 1 | |
| NOXAFIL ORAL PACKET 300MG | 1 | PA |
| NOXAFIL ORAL SUSPENSION 40MG/ML | 1 | PA |
| NYAMYC EXTERNAL POWDER 100000UNIT/GM | 1 | |
| <i>nystatin external cream 100000unit/gm</i> | 1 | |
| <i>nystatin external ointment 100000unit/gm</i> | 1 | |
| <i>nystatin external powder 100000unit/gm</i> | 1 | |
| <i>nystatin mouth/throat suspension 100000unit/ml</i> | 1 | |
| <i>nystatin oral tablet 500000unit</i> | 1 | |
| NYSTOP EXTERNAL POWDER 100000UNIT/GM | 1 | |
| <i>posaconazole oral tablet delayed release 100mg</i> | 1 | PA; MO |
| <i>terbinafine hcl oral tablet 250mg</i> | 1 | |
| <i>terconazole vaginal cream 0.4%, 0.8%</i> | 1 | |
| <i>terconazole vaginal suppository 80mg</i> | 1 | |
| <i>voriconazole intravenous solution reconstituted 200mg</i> | 1 | PA |
| <i>voriconazole oral suspension reconstituted 40mg/ml</i> | 1 | PA |
| <i>voriconazole oral tablet 200mg, 50mg</i> | 1 | PA |
| ANTINEOPLÁSICOS | | |
| Agentes Alquilantes | | |
| <i>cyclophosphamide oral capsule 25mg, 50mg</i> | 1 | BvD |
| <i>cyclophosphamide oral tablet 25mg, 50mg</i> | 1 | BvD |
| GLEOSTINE ORAL CAPSULE 10MG, 100MG, 40MG | 1 | PA |
| LEUKERAN ORAL TABLET 2MG | 1 | |
| MATULANE ORAL CAPSULE 50MG | 1 | PA |
| VALCHLOR EXTERNAL GEL 0.016% | 1 | PA; QL (60GM per 14 days) |
| Agentes Antiangiogénicos | | |
| <i>lenalidomide oral capsule 10mg, 15mg, 2.5mg, 20mg, 25mg, 5mg</i> | 1 | PA; QL (28 EA per 28 days) |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|-----------------------------|
| POMALYST ORAL CAPSULE 1MG, 2MG, 3MG, 4MG | 1 | PA; QL (21 EA per 28 days) |
| THALOMID ORAL CAPSULE 100MG, 200MG, 50MG | 1 | PA; QL (30 EA per 30 days) |
| THALOMID ORAL CAPSULE 150MG | 1 | PA; QL (60 EA per 30 days) |
| Antiandrógenos | | |
| <i>abiraterone acetate oral tablet 250mg, 500mg</i> | 1 | PA; QL (120 EA per 30 days) |
| <i>bicalutamide oral tablet 50mg</i> | 1 | |
| ERLEADA ORAL TABLET 60MG | 1 | PA; QL (120 EA per 30 days) |
| LYSODREN ORAL TABLET 500MG | 1 | |
| <i>nilutamide oral tablet 150mg</i> | 1 | QL (60 EA per 30 days) |
| NUBEQA ORAL TABLET 300MG | 1 | PA; QL (120 EA per 30 days) |
| XTANDI ORAL CAPSULE 40MG | 1 | PA; QL (120 EA per 30 days) |
| XTANDI ORAL TABLET 40MG | 1 | PA; QL (120 EA per 30 days) |
| XTANDI ORAL TABLET 80MG | 1 | PA; QL (90 EA per 30 days) |
| YONSA ORAL TABLET 125MG | 1 | PA; QL (120 EA per 30 days) |
| Antiestrógenos/Modificadores | | |
| EMCYT ORAL CAPSULE 140MG | 1 | |
| SOLTAMOX ORAL SOLUTION 10MG/5ML | 1 | PA; MO |
| <i>tamoxifen citrate oral tablet 10mg, 20mg</i> | 1 | MO |
| <i>toremifene citrate oral tablet 60mg</i> | 1 | PA |
| Antimetabolitos | | |
| DROXIA ORAL CAPSULE 200MG, 300MG, 400MG | 1 | MO |
| <i>hydroxyurea oral capsule 500mg</i> | 1 | |
| INQOVI ORAL TABLET 35-100MG | 1 | PA |
| <i>mercaptopurine oral tablet 50mg</i> | 1 | |
| ONUREG ORAL TABLET 200MG, 300MG | 1 | PA |
| PURIXAN ORAL SUSPENSION 2000MG/100ML | 1 | |
| TABLOID ORAL TABLET 40MG | 1 | PA |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|-----------------------------|
| Antineoplásticos, Otros | | |
| IDHIFA ORAL TABLET 100MG | 1 | PA; QL (30 EA per 30 days) |
| IDHIFA ORAL TABLET 50MG | 1 | PA; QL (60 EA per 30 days) |
| KISQALI FEMARA (400MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5MG | 1 | PA |
| KISQALI FEMARA (600MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5MG | 1 | PA |
| KISQALI FEMARA(200MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5MG | 1 | PA |
| <i>leucovorin calcium oral tablet 10mg, 15mg, 25mg, 5mg</i> | 1 | |
| LONSURF ORAL TABLET 15-6.14MG, 20-8.19MG | 1 | PA |
| LUMAKRAS ORAL TABLET 120MG | 1 | PA; QL (240 EA per 30 days) |
| LYNPARZA ORAL TABLET 100MG | 1 | PA; QL (180 EA per 30 days) |
| LYNPARZA ORAL TABLET 150MG | 1 | PA; QL (120 EA per 30 days) |
| MESNEX ORAL TABLET 400MG | 1 | |
| NINLARO ORAL CAPSULE 2.3MG, 3MG, 4MG | 1 | PA |
| ORGOVYX ORAL TABLET 120MG | 1 | PA; QL (60 EA per 30 days) |
| SYNRIBO SUBCUTANEOUS SOLUTION RECONSTITUTED 3.5MG | 1 | PA |
| VIJOICE ORAL TABLET THERAPY PACK 125MG, 200 & 50MG, 50MG | 1 | PA |
| WELIREG ORAL TABLET 40MG | 1 | PA; QL (90 EA per 30 days) |
| XATMEP ORAL SOLUTION 2.5MG/ML | 1 | BvD |
| XPOVIO (100MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50MG | 1 | PA |
| XPOVIO (40MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40MG | 1 | PA |
| XPOVIO (40MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40MG | 1 | PA |
| XPOVIO (60MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60MG | 1 | PA |
| XPOVIO (60MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20MG | 1 | PA |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|-----------------------------|
| XPOVIO (80MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40MG | 1 | PA |
| XPOVIO (80MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20MG | 1 | PA |
| ZOLINZA ORAL CAPSULE 100MG | 1 | PA; QL (120 EA per 30 days) |
| <i>Inhibidores de Aromatasa, 3ra Generación</i> | | |
| <i>anastrozole oral tablet 1mg</i> | 1 | MO |
| <i>exemestane oral tablet 25mg</i> | 1 | MO |
| <i>letrozole oral tablet 2.5mg</i> | 1 | MO |
| <i>Inhibidores de Blanco Molecular</i> | | |
| ALECENSA ORAL CAPSULE 150MG | 1 | PA |
| ALUNBRIG ORAL TABLET 180MG | 1 | PA; QL (30 EA per 30 days) |
| ALUNBRIG ORAL TABLET 30MG | 1 | PA; QL (180 EA per 30 days) |
| ALUNBRIG ORAL TABLET 90MG | 1 | PA; QL (60 EA per 30 days) |
| ALUNBRIG ORAL TABLET THERAPY PACK 90 & 180MG | 1 | PA; QL (30 EA per 30 days) |
| AYVAKIT ORAL TABLET 100MG, 200MG, 25MG, 300MG, 50MG | 1 | PA; QL (30 EA per 30 days) |
| BALVERSA ORAL TABLET 3MG | 1 | PA; QL (90 EA per 30 days) |
| BALVERSA ORAL TABLET 4MG | 1 | PA; QL (60 EA per 30 days) |
| BALVERSA ORAL TABLET 5MG | 1 | PA; QL (30 EA per 30 days) |
| BOSULIF ORAL TABLET 100MG | 1 | PA; QL (120 EA per 30 days) |
| BOSULIF ORAL TABLET 400MG, 500MG | 1 | PA; QL (30 EA per 30 days) |
| BRAFTOVI ORAL CAPSULE 75MG | 1 | PA; QL (180 EA per 30 days) |
| BRUKINSA ORAL CAPSULE 80MG | 1 | PA; QL (120 EA per 30 days) |
| CABOMETYX ORAL TABLET 20MG, 40MG, 60MG | 1 | PA |
| CALQUENCE ORAL CAPSULE 100MG | 1 | PA; QL (60 EA per 30 days) |
| CALQUENCE ORAL TABLET 100MG | 1 | PA; QL (60 EA per 30 days) |
| CAPRELSA ORAL TABLET 100MG | 1 | PA; QL (60 EA per 30 days) |
| CAPRELSA ORAL TABLET 300MG | 1 | PA; QL (30 EA per 30 days) |
| COMETRIQ (100MG DAILY DOSE) ORAL KIT 80 & 20MG | 1 | PA; QL (56 EA per 28 days) |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|-----------------------------|
| COMETRIQ (140MG DAILY DOSE) ORAL KIT 3 X 20MG & 80MG | 1 | PA; QL (112 EA per 28 days) |
| COMETRIQ (60MG DAILY DOSE) ORAL KIT 20MG | 1 | PA; QL (84 EA per 28 days) |
| COPIKTRA ORAL CAPSULE 15MG, 25MG | 1 | PA; QL (60 EA per 30 days) |
| COTELLIC ORAL TABLET 20MG | 1 | PA; QL (63 EA per 28 days) |
| DAURISMO ORAL TABLET 100MG, 25MG | 1 | PA |
| ERIVEDGE ORAL CAPSULE 150MG | 1 | PA |
| <i>erlotinib hcl oral tablet 100mg, 150mg</i> | 1 | PA; QL (30 EA per 30 days) |
| <i>erlotinib hcl oral tablet 25mg</i> | 1 | PA; QL (90 EA per 30 days) |
| <i>everolimus oral tablet 10mg, 2.5mg, 5mg, 7.5mg</i> | 1 | PA; QL (30 EA per 30 days) |
| <i>everolimus oral tablet soluble 2mg, 3mg</i> | 1 | PA; QL (30 EA per 30 days) |
| <i>everolimus oral tablet soluble 5mg</i> | 1 | PA; QL (60 EA per 30 days) |
| EXKIVITY ORAL CAPSULE 40MG | 1 | PA |
| FOTIVDA ORAL CAPSULE 0.89MG, 1.34MG | 1 | PA; QL (21 EA per 28 days) |
| GAVRETO ORAL CAPSULE 100MG | 1 | PA; QL (120 EA per 30 days) |
| GILOTRIF ORAL TABLET 20MG, 30MG, 40MG | 1 | PA; QL (30 EA per 30 days) |
| IBRANCE ORAL CAPSULE 100MG, 125MG, 75MG | 1 | PA |
| IBRANCE ORAL TABLET 100MG, 125MG, 75MG | 1 | PA |
| ICLUSIG ORAL TABLET 10MG, 30MG, 45MG | 1 | PA; QL (30 EA per 30 days) |
| ICLUSIG ORAL TABLET 15MG | 1 | PA; QL (60 EA per 30 days) |
| <i>imatinib mesylate oral tablet 100mg</i> | 1 | PA; QL (90 EA per 30 days) |
| <i>imatinib mesylate oral tablet 400mg</i> | 1 | PA; QL (60 EA per 30 days) |
| IMBRUVICA ORAL CAPSULE 140MG | 1 | PA; QL (120 EA per 30 days) |
| IMBRUVICA ORAL CAPSULE 70MG | 1 | PA; QL (28 EA per 28 days) |
| IMBRUVICA ORAL SUSPENSION 70MG/ML | 1 | PA; QL (240ML per 30 days) |
| IMBRUVICA ORAL TABLET 140MG, 280MG, 420MG, 560MG | 1 | PA; QL (28 EA per 28 days) |
| INLYTA ORAL TABLET 1MG | 1 | PA; QL (180 EA per 30 days) |
| INLYTA ORAL TABLET 5MG | 1 | PA; QL (60 EA per 30 days) |
| INREBIC ORAL CAPSULE 100MG | 1 | PA; QL (120 EA per 30 days) |
| IRESSA ORAL TABLET 250MG | 1 | PA |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|-----------------------------|-----------------------------|
| JAKAFI ORAL TABLET 10MG, 15MG, 20MG, 25MG, 5MG | 1 | PA; QL (60 EA per 30 days) |
| KISQALI (200MG DOSE) ORAL TABLET THERAPY PACK 200MG | 1 | PA |
| KISQALI (400MG DOSE) ORAL TABLET THERAPY PACK 200MG | 1 | PA |
| KISQALI (600MG DOSE) ORAL TABLET THERAPY PACK 200MG | 1 | PA |
| KOSELUGO ORAL CAPSULE 10MG | 1 | PA; QL (240 EA per 30 days) |
| KOSELUGO ORAL CAPSULE 25MG | 1 | PA; QL (120 EA per 30 days) |
| <i>lapatinib ditosylate oral tablet 250mg</i> | 1 | PA; QL (180 EA per 30 days) |
| LENVIMA (10MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10MG | 1 | PA |
| LENVIMA (12MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 3 X 4MG | 1 | PA |
| LENVIMA (14MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 & 4MG | 1 | PA |
| LENVIMA (18MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10MG & 2 X 4MG | 1 | PA |
| LENVIMA (20MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 10MG | 1 | PA |
| LENVIMA (24MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 10MG & 4MG | 1 | PA |
| LENVIMA (4MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 4MG | 1 | PA |
| LENVIMA (8MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 4MG | 1 | PA |
| LORBRENA ORAL TABLET 100MG | 1 | PA; QL (30 EA per 30 days) |
| LORBRENA ORAL TABLET 25MG | 1 | PA; QL (120 EA per 30 days) |
| MEKINIST ORAL TABLET 0.5MG | 1 | PA; QL (120 EA per 30 days) |
| MEKINIST ORAL TABLET 2MG | 1 | PA; QL (30 EA per 30 days) |
| MEKTOVI ORAL TABLET 15MG | 1 | PA; QL (180 EA per 30 days) |
| NERLYNX ORAL TABLET 40MG | 1 | PA; QL (180 EA per 30 days) |
| ODOMZO ORAL CAPSULE 200MG | 1 | PA |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|-----------------------------|
| PEMAZYRE ORAL TABLET 13.5MG, 4.5MG, 9MG | 1 | PA; QL (14 EA per 21 days) |
| PIQRAY (200MG DAILY DOSE) ORAL TABLET THERAPY PACK 200MG | 1 | PA |
| PIQRAY (250MG DAILY DOSE) ORAL TABLET THERAPY PACK 200 & 50MG | 1 | PA |
| PIQRAY (300MG DAILY DOSE) ORAL TABLET THERAPY PACK 2 X 150MG | 1 | PA |
| QINLOCK ORAL TABLET 50MG | 1 | PA; QL (90 EA per 30 days) |
| RETEVMO ORAL CAPSULE 40MG | 1 | PA; QL (120 EA per 30 days) |
| RETEVMO ORAL CAPSULE 80MG | 1 | PA; QL (180 EA per 30 days) |
| ROZLYTREK ORAL CAPSULE 100MG | 1 | PA; QL (150 EA per 30 days) |
| ROZLYTREK ORAL CAPSULE 200MG | 1 | PA; QL (90 EA per 30 days) |
| RUBRACA ORAL TABLET 200MG, 250MG, 300MG | 1 | PA |
| RYDAPT ORAL CAPSULE 25MG | 1 | PA; QL (240 EA per 30 days) |
| SCEMBLIX ORAL TABLET 20MG, 40MG | 1 | PA |
| <i>sorafenib tosylate oral tablet 200mg</i> | 1 | PA; QL (120 EA per 30 days) |
| SPRYCEL ORAL TABLET 100MG, 50MG, 70MG, 80MG | 1 | PA; QL (60 EA per 30 days) |
| SPRYCEL ORAL TABLET 140MG | 1 | PA; QL (30 EA per 30 days) |
| SPRYCEL ORAL TABLET 20MG | 1 | PA; QL (90 EA per 30 days) |
| STIVARGA ORAL TABLET 40MG | 1 | PA; QL (84 EA per 28 days) |
| <i>sunitinib malate oral capsule 12.5mg, 25mg, 37.5mg, 50mg</i> | 1 | PA; QL (28 EA per 28 days) |
| TABRECTA ORAL TABLET 150MG, 200MG | 1 | PA; QL (120 EA per 30 days) |
| TAFINLAR ORAL CAPSULE 50MG | 1 | PA; QL (180 EA per 30 days) |
| TAFINLAR ORAL CAPSULE 75MG | 1 | PA; QL (120 EA per 30 days) |
| TAGRISSE ORAL TABLET 40MG, 80MG | 1 | PA |
| TALZENNA ORAL CAPSULE 0.25MG | 1 | PA; QL (120 EA per 30 days) |
| TALZENNA ORAL CAPSULE 0.5MG | 1 | PA; QL (60 EA per 30 days) |
| TALZENNA ORAL CAPSULE 0.75MG, 1MG | 1 | PA; QL (30 EA per 30 days) |
| TASIGNA ORAL CAPSULE 150MG, 200MG, 50MG | 1 | PA; QL (120 EA per 30 days) |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|-----------------------------|
| TAZVERIK ORAL TABLET 200MG | 1 | PA; QL (240 EA per 30 days) |
| TEPMETKO ORAL TABLET 225MG | 1 | PA; QL (60 EA per 30 days) |
| TIBSOVO ORAL TABLET 250MG | 1 | PA; QL (60 EA per 30 days) |
| TRUSELTIQ (100MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 100MG | 1 | PA; QL (21 EA per 28 days) |
| TRUSELTIQ (125MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 100 & 25MG | 1 | PA; QL (42 EA per 28 days) |
| TRUSELTIQ (50MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 25MG | 1 | PA; QL (42 EA per 28 days) |
| TRUSELTIQ (75MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 25MG | 1 | PA; QL (63 EA per 28 days) |
| TUKYSA ORAL TABLET 150MG, 50MG | 1 | PA; QL (120 EA per 30 days) |
| TURALIO ORAL CAPSULE 200MG | 1 | PA; QL (120 EA per 30 days) |
| VENCLEXTA ORAL TABLET 10MG, 100MG, 50MG | 1 | PA |
| VENCLEXTA STARTING PACK ORAL TABLET THERAPY PACK 10 & 50 & 100MG | 1 | PA |
| VERZENIO ORAL TABLET 100MG, 150MG, 200MG, 50MG | 1 | PA |
| VITRAKVI ORAL CAPSULE 100MG | 1 | PA; QL (60 EA per 30 days) |
| VITRAKVI ORAL CAPSULE 25MG | 1 | PA; QL (180 EA per 30 days) |
| VITRAKVI ORAL SOLUTION 20MG/ML | 1 | PA; QL (310ML per 30 days) |
| VIZIMPRO ORAL TABLET 15MG, 30MG, 45MG | 1 | PA; QL (30 EA per 30 days) |
| VONJO ORAL CAPSULE 100MG | 1 | PA |
| VOTRIENT ORAL TABLET 200MG | 1 | PA; QL (120 EA per 30 days) |
| XALKORI ORAL CAPSULE 200MG, 250MG | 1 | PA; QL (120 EA per 30 days) |
| XOSPATA ORAL TABLET 40MG | 1 | PA; QL (90 EA per 30 days) |
| ZEJULA ORAL CAPSULE 100MG | 1 | PA; QL (90 EA per 30 days) |
| ZELBORAF ORAL TABLET 240MG | 1 | PA; QL (240 EA per 30 days) |
| ZYDELIG ORAL TABLET 100MG, 150MG | 1 | PA; QL (60 EA per 30 days) |
| ZYKADIA ORAL TABLET 150MG | 1 | PA; QL (150 EA per 30 days) |
| Retinoides | | |
| <i>bexarotene external gel 1%</i> | 1 | PA |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|-----------------------------|
| <i>bexarotene oral capsule 75mg</i> | 1 | PA; QL (300 EA per 30 days) |
| <i>tretinoin oral capsule 10mg</i> | 1 | |
| ANTIPARASITARIOS | | |
| <i>Antihelmínticos</i> | | |
| <i>albendazole oral tablet 200mg</i> | 1 | |
| EMVERM ORAL TABLET CHEWABLE 100MG | 1 | |
| <i>ivermectin oral tablet 3mg</i> | 1 | PA |
| <i>Antiprotozoarios</i> | | |
| <i>atovaquone oral suspension 750mg/5ml</i> | 1 | |
| <i>atovaquone-proguanil hcl oral tablet 250-100mg, 62.5-25mg</i> | 1 | |
| <i>benznidazole oral tablet 100mg, 12.5mg</i> | 1 | |
| <i>chloroquine phosphate oral tablet 250mg, 500mg</i> | 1 | MO |
| COARTEM ORAL TABLET 20-120MG | 1 | |
| <i>hydroxychloroquine sulfate oral tablet 100mg, 200mg, 300mg, 400mg</i> | 1 | MO |
| LAMPIT ORAL TABLET 120MG, 30MG | 1 | |
| <i>mefloquine hcl oral tablet 250mg</i> | 1 | MO |
| <i>nitazoxanide oral tablet 500mg</i> | 1 | QL (40 EA per 30 days) |
| <i>pentamidine isethionate inhalation solution reconstituted 300mg</i> | 1 | BvD |
| <i>pentamidine isethionate injection solution reconstituted 300mg</i> | 1 | BvD |
| <i>primaquine phosphate oral tablet 26.3 (15 base) mg</i> | 1 | |
| <i>quinine sulfate oral capsule 324mg</i> | 1 | PA |
| ANTIPSIÓTICOS | | |
| <i>Atípico/2da Generación</i> | | |
| ABILIFY MAINTENA INTRAMUSCULAR PREFILLED SYRINGE 300MG, 400MG | 1 | |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 300MG, 400MG | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|----------------------------|
| <i>aripiprazole oral solution 1mg/ml</i> | 1 | MO; QL (750ML per 30 days) |
| <i>aripiprazole oral tablet 10mg, 15mg, 2mg, 20mg, 30mg, 5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>aripiprazole oral tablet dispersible 10mg</i> | 1 | QL (90 EA per 30 days) |
| <i>aripiprazole oral tablet dispersible 15mg</i> | 1 | QL (60 EA per 30 days) |
| <i>asenapine maleate sublingual tablet sublingual 10mg, 2.5mg, 5mg</i> | 1 | MO; QL (60 EA per 30 days) |
| CAPLYTA ORAL CAPSULE 10.5MG, 21MG, 42MG | 1 | |
| FANAPT ORAL TABLET 1MG, 10MG, 12MG, 2MG, 4MG, 6MG, 8MG | 1 | ST; QL (60 EA per 30 days) |
| FANAPT TITRATION PACK ORAL TABLET 1 & 2 & 4 & 6MG | 1 | ST; QL (60 EA per 30 days) |
| INVEGA HAFYERA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 1092MG/3.5ML, 1560MG/5ML | 1 | |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 117MG/0.75ML, 156MG/ML, 234MG/1.5ML, 39MG/0.25ML, 78MG/0.5ML | 1 | |
| INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 273MG/0.88ML, 410MG/1.32ML, 546MG/1.75ML, 819MG/2.63ML | 1 | |
| LATUDA ORAL TABLET 120MG, 20MG, 40MG, 60MG, 80MG | 1 | ST |
| LYBALVI ORAL TABLET 10-10MG, 15-10MG, 20-10MG, 5-10MG | 1 | ST; QL (30 EA per 30 days) |
| NUPLAZID ORAL CAPSULE 34MG | 1 | PA |
| NUPLAZID ORAL TABLET 10MG | 1 | PA |
| <i>olanzapine intramuscular solution reconstituted 10mg</i> | 1 | QL (60 EA per 30 days) |
| <i>olanzapine oral tablet 10mg, 15mg, 2.5mg, 5mg, 7.5mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>olanzapine oral tablet 20mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>olanzapine oral tablet dispersible 10mg, 5mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>olanzapine oral tablet dispersible 15mg, 20mg</i> | 1 | MO; QL (30 EA per 30 days) |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|-----------------------------|
| <i>paliperidone er oral tablet extended release 24-hour 1.5mg, 3mg, 9mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>paliperidone er oral tablet extended release 24-hour 6mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>quetiapine fumarate er oral tablet extended release 24-hour 150mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>quetiapine fumarate er oral tablet extended release 24-hour 200mg, 300mg, 400mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>quetiapine fumarate er oral tablet extended release 24-hour 50mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>quetiapine fumarate oral tablet 100mg, 25mg, 300mg, 400mg, 50mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>quetiapine fumarate oral tablet 200mg</i> | 1 | MO; QL (30 EA per 30 days) |
| REXULTI ORAL TABLET 0.25MG, 0.5MG, 1MG, 2MG, 3MG, 4MG | 1 | |
| RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 12.5MG, 25MG, 37.5MG, 50MG | 1 | |
| <i>risperidone oral solution 1mg/ml</i> | 1 | MO; QL (480ML per 30 days) |
| <i>risperidone oral tablet 0.25mg, 1mg, 2mg, 3mg, 4mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>risperidone oral tablet 0.5mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>risperidone oral tablet dispersible 0.25mg, 1mg, 2mg, 3mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>risperidone oral tablet dispersible 0.5mg, 4mg</i> | 1 | MO; QL (120 EA per 30 days) |
| SECUADO TRANSDERMAL PATCH 24-HOUR 3.8MG/24HR, 5.7MG/24HR, 7.6MG/24HR | 1 | ST; QL (30 EA per 30 days) |
| VRAYLAR ORAL CAPSULE 1.5MG | 1 | ST; QL (60 EA per 30 days) |
| VRAYLAR ORAL CAPSULE 3MG, 4.5MG, 6MG | 1 | ST; QL (30 EA per 30 days) |
| VRAYLAR ORAL CAPSULE THERAPY PACK 1.5 & 3MG | 1 | ST; QL (7 EA per 28 days) |
| <i>ziprasidone hcl oral capsule 20mg, 40mg, 60mg, 80mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>ziprasidone mesylate intramuscular solution reconstituted 20mg</i> | 1 | QL (6 EA per 3 days) |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|----------------------------|
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION RECONSTITUTED 210MG | 1 | ST |
| Resistente al Tratamiento | | |
| <i>clozapine oral tablet 100mg, 200mg, 25mg, 50mg</i> | 1 | QL (120 EA per 30 days) |
| <i>clozapine oral tablet dispersible 100mg, 12.5mg, 150mg, 200mg, 25mg</i> | 1 | QL (120 EA per 30 days) |
| VERSACLOZ ORAL SUSPENSION 50MG/ML | 1 | ST; QL (540ML per 30 days) |
| Típico/1ra Generación | | |
| <i>chlorpromazine hcl oral concentrate 100mg/ml, 30mg/ml</i> | 1 | MO |
| <i>chlorpromazine hcl oral tablet 10mg, 25mg</i> | 1 | BvD; MO |
| <i>chlorpromazine hcl oral tablet 100mg, 200mg, 50mg</i> | 1 | MO |
| <i>fluphenazine decanoate injection solution 25mg/ml</i> | 1 | |
| <i>fluphenazine hcl injection solution 2.5mg/ml</i> | 1 | |
| <i>fluphenazine hcl oral concentrate 5mg/ml</i> | 1 | MO |
| <i>fluphenazine hcl oral elixir 2.5mg/5ml</i> | 1 | MO |
| <i>fluphenazine hcl oral tablet 1mg, 10mg, 2.5mg, 5mg</i> | 1 | MO |
| <i>haloperidol decanoate intramuscular solution 100mg/ml, 100mg/ml 1 ml, 50mg/ml, 50mg/ml(1ml)</i> | 1 | |
| <i>haloperidol lactate injection solution 5mg/ml</i> | 1 | |
| <i>haloperidol lactate oral concentrate 2mg/ml</i> | 1 | MO |
| <i>haloperidol oral tablet 0.5mg, 1mg, 10mg, 2mg, 20mg, 5mg</i> | 1 | MO |
| <i>loxapine succinate oral capsule 10mg, 25mg, 5mg, 50mg</i> | 1 | MO |
| <i>molindone hcl oral tablet 10mg, 25mg, 5mg</i> | 1 | MO |
| <i>perphenazine oral tablet 16mg, 2mg</i> | 1 | MO |
| <i>perphenazine oral tablet 4mg, 8mg</i> | 1 | BvD; MO |
| <i>pimozide oral tablet 1mg, 2mg</i> | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|----------------------------|
| <i>thioridazine hcl oral tablet 10mg, 100mg, 25mg, 50mg</i> | 1 | MO |
| <i>thiothixene oral capsule 1mg, 10mg, 2mg, 5mg</i> | 1 | MO |
| <i>trifluoperazine hcl oral tablet 1mg, 10mg, 2mg, 5mg</i> | 1 | MO |
| ANTIVIRALES | | |
| Agentes Anti-Citomegalovirus (CMV) | | |
| LIVTENCITY ORAL TABLET 200MG | 1 | PA |
| PREVYMIS ORAL TABLET 240MG, 480MG | 1 | PA; QL (28 EA per 28 days) |
| <i>valganciclovir hcl oral solution reconstituted 50mg/ml</i> | 1 | MO |
| <i>valganciclovir hcl oral tablet 450mg</i> | 1 | MO |
| ZIRGAN OPHTHALMIC GEL 0.15% | 1 | |
| Agentes Antigripales | | |
| <i>oseltamivir phosphate oral capsule 30mg, 45mg, 75mg</i> | 1 | |
| <i>oseltamivir phosphate oral suspension reconstituted 6mg/ml</i> | 1 | |
| RELENZA DISKHALER INHALATION AEROSOL POWDER BREATH ACTIVATED 5MG/ACT | 1 | |
| <i>rimantadine hcl oral tablet 100mg</i> | 1 | |
| XOFLUZA (40MG DOSE) ORAL TABLET THERAPY PACK 1 X 40MG | 1 | |
| XOFLUZA (80MG DOSE) ORAL TABLET THERAPY PACK 1 X 80MG | 1 | |
| Agentes Antiherpéticos | | |
| <i>acyclovir oral capsule 200mg</i> | 1 | |
| <i>acyclovir oral suspension 200mg/5ml</i> | 1 | |
| <i>acyclovir oral tablet 400mg, 800mg</i> | 1 | |
| <i>acyclovir sodium intravenous solution 50mg/ml</i> | 1 | BvD |
| <i>famciclovir oral tablet 125mg, 250mg, 500mg</i> | 1 | |
| <i>trifluridine ophthalmic solution 1%</i> | 1 | |
| <i>valacyclovir hcl oral tablet 1gm, 500mg</i> | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|-----------------------------|
| Agentes Anti-VIH, Inhibidores de la Transcriptasa Inversa de Nucleósidos y Nucleótidos (NRTI) | | |
| <i>abacavir sulfate oral solution 20mg/ml</i> | 1 | MO; QL (960ML per 30 days) |
| <i>abacavir sulfate oral tablet 300mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>abacavir sulfate-lamivudine oral tablet 600-300mg</i> | 1 | MO; QL (30 EA per 30 days) |
| CIMDUO ORAL TABLET 300-300MG | 1 | QL (30 EA per 30 days) |
| DELSTRIGO ORAL TABLET 100-300-300MG | 1 | QL (30 EA per 30 days) |
| DESCOVY ORAL TABLET 120-15MG, 200-25MG | 1 | QL (30 EA per 30 days) |
| <i>efavirenz-emtricitab-tenofo df oral tablet 600-200-300mg</i> | 1 | QL (30 EA per 30 days) |
| <i>efavirenz-lamivudine-tenofovir oral tablet 400-300-300mg, 600-300-300mg</i> | 1 | QL (30 EA per 30 days) |
| <i>emtricitabine oral capsule 200mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>emtricitabine-tenofovir df oral tablet 100-150mg, 133-200mg, 167-250mg, 200-300mg</i> | 1 | QL (30 EA per 30 days) |
| EMTRIVA ORAL SOLUTION 10MG/ML | 1 | MO; QL (680ML per 28 days) |
| JULUCA ORAL TABLET 50-25MG | 1 | QL (30 EA per 30 days) |
| <i>lamivudine oral solution 10mg/ml</i> | 1 | MO; QL (900ML per 30 days) |
| <i>lamivudine oral tablet 150mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>lamivudine oral tablet 300mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>lamivudine-zidovudine oral tablet 150-300mg</i> | 1 | MO; QL (60 EA per 30 days) |
| ODEFSEY ORAL TABLET 200-25-25MG | 1 | QL (30 EA per 30 days) |
| <i>tenofovir disoproxil fumarate oral tablet 300mg</i> | 1 | MO; QL (30 EA per 30 days) |
| TRIZIVIR ORAL TABLET 300-150-300MG | 1 | QL (60 EA per 30 days) |
| VIREAD ORAL POWDER 40MG/GM | 1 | QL (240GM per 30 days) |
| VIREAD ORAL TABLET 150MG, 200MG, 250MG | 1 | QL (30 EA per 30 days) |
| <i>zidovudine oral capsule 100mg</i> | 1 | MO; QL (180 EA per 30 days) |
| <i>zidovudine oral syrup 50mg/5ml</i> | 1 | MO; QL (1680ML per 28 days) |
| <i>zidovudine oral tablet 300mg</i> | 1 | MO; QL (60 EA per 30 days) |
| Agentes Anti-VIH, Inhibidores de la Integrasa (INSTI) | | |
| BIKTARVY ORAL TABLET 30-120-15MG, 50-200-25MG | 1 | QL (30 EA per 30 days) |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|-----------------------------|
| DOVATO ORAL TABLET 50-300MG | 1 | QL (30 EA per 30 days) |
| GENVOYA ORAL TABLET 150-150-200-10MG | 1 | QL (30 EA per 30 days) |
| ISENTRESS HD ORAL TABLET 600MG | 1 | QL (60 EA per 30 days) |
| ISENTRESS ORAL PACKET 100MG | 1 | MO; QL (60 EA per 30 days) |
| ISENTRESS ORAL TABLET 400MG | 1 | QL (60 EA per 30 days) |
| ISENTRESS ORAL TABLET CHEWABLE 100MG, 25MG | 1 | MO; QL (180 EA per 30 days) |
| STRIBILD ORAL TABLET 150-150-200-300MG | 1 | QL (30 EA per 30 days) |
| SYMTUZA ORAL TABLET 800-150-200-10MG | 1 | QL (30 EA per 30 days) |
| TIVICAY ORAL TABLET 10MG | 1 | MO; QL (60 EA per 30 days) |
| TIVICAY ORAL TABLET 25MG, 50MG | 1 | QL (60 EA per 30 days) |
| TIVICAY PD ORAL TABLET SOLUBLE 5MG | 1 | MO; QL (360 EA per 30 days) |
| Agentes Anti-VIH, Inhibidores de la Proteasa (PI) | | |
| APTIVUS ORAL CAPSULE 250MG | 1 | QL (120 EA per 30 days) |
| <i>atazanavir sulfate oral capsule 150mg, 200mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>atazanavir sulfate oral capsule 300mg</i> | 1 | MO; QL (30 EA per 30 days) |
| EVOTAZ ORAL TABLET 300-150MG | 1 | QL (30 EA per 30 days) |
| <i>fosamprenavir calcium oral tablet 700mg</i> | 1 | QL (120 EA per 30 days) |
| LEXIVA ORAL SUSPENSION 50MG/ML | 1 | MO; QL (1575ML per 28 days) |
| <i>lopinavir-ritonavir oral solution 400-100mg/5ml</i> | 1 | MO; QL (400ML per 30 days) |
| <i>lopinavir-ritonavir oral tablet 100-25mg</i> | 1 | MO; QL (300 EA per 30 days) |
| <i>lopinavir-ritonavir oral tablet 200-50mg</i> | 1 | MO; QL (150 EA per 30 days) |
| NORVIR ORAL PACKET 100MG | 1 | MO; QL (360 EA per 30 days) |
| NORVIR ORAL SOLUTION 80MG/ML | 1 | MO; QL (480ML per 30 days) |
| PREZCOBIX ORAL TABLET 800-150MG | 1 | QL (30 EA per 30 days) |
| PREZISTA ORAL SUSPENSION 100MG/ML | 1 | QL (360ML per 30 days) |
| PREZISTA ORAL TABLET 150MG | 1 | MO; QL (240 EA per 30 days) |
| PREZISTA ORAL TABLET 600MG | 1 | QL (60 EA per 30 days) |
| PREZISTA ORAL TABLET 75MG | 1 | MO; QL (480 EA per 30 days) |
| PREZISTA ORAL TABLET 800MG | 1 | QL (30 EA per 30 days) |
| REYATAZ ORAL PACKET 50MG | 1 | MO; QL (180 EA per 30 days) |
| <i>ritonavir oral tablet 100mg</i> | 1 | MO; QL (360 EA per 30 days) |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|-----------------------------|
| VIRACEPT ORAL TABLET 250MG | 1 | QL (300 EA per 30 days) |
| VIRACEPT ORAL TABLET 625MG | 1 | QL (120 EA per 30 days) |
| Agentes Anti-VIH, Inhibidores de la Transcriptasa Inversa No Nucleósidos (NNRTI) | | |
| COMPLERA ORAL TABLET 200-25-300MG | 1 | QL (30 EA per 30 days) |
| EDURANT ORAL TABLET 25MG | 1 | QL (30 EA per 30 days) |
| <i>efavirenz oral capsule 200mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>efavirenz oral capsule 50mg</i> | 1 | MO; QL (360 EA per 30 days) |
| <i>efavirenz oral tablet 600mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>etravirine oral tablet 100mg</i> | 1 | QL (120 EA per 30 days) |
| <i>etravirine oral tablet 200mg</i> | 1 | QL (60 EA per 30 days) |
| INTELENCE ORAL TABLET 25MG | 1 | MO; QL (120 EA per 30 days) |
| <i>nevirapine er oral tablet extended release 24-hour 100mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>nevirapine er oral tablet extended release 24-hour 400mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>nevirapine oral suspension 50mg/5ml</i> | 1 | MO; QL (1200ML per 30 days) |
| <i>nevirapine oral tablet 200mg</i> | 1 | MO; QL (60 EA per 30 days) |
| PIFELTRO ORAL TABLET 100MG | 1 | QL (30 EA per 30 days) |
| Agentes Anti-VIH, Otros | | |
| FUZEON SUBCUTANEOUS SOLUTION RECONSTITUTED 90MG | 1 | QL (60 EA per 30 days) |
| <i>maraviroc oral tablet 150mg, 300mg</i> | 1 | QL (120 EA per 30 days) |
| RUKOBIA ORAL TABLET EXTENDED RELEASE 12-HOUR 600MG | 1 | QL (60 EA per 30 days) |
| SELZENTRY ORAL SOLUTION 20MG/ML | 1 | QL (1800ML per 30 days) |
| SELZENTRY ORAL TABLET 25MG | 1 | MO; QL (120 EA per 30 days) |
| SELZENTRY ORAL TABLET 75MG | 1 | QL (60 EA per 30 days) |
| TRIUMEQ ORAL TABLET 600-50-300MG | 1 | QL (30 EA per 30 days) |
| TRIUMEQ PD ORAL TABLET SOLUBLE 60-5-30MG | 1 | QL (180 EA per 30 days) |
| TYBOST ORAL TABLET 150MG | 1 | MO; QL (30 EA per 30 days) |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|----------------------------|
| Agentes Contra la Hepatitis B (VHB) | | |
| <i>adefovir dipivoxil oral tablet 10mg</i> | 1 | QL (30 EA per 30 days) |
| BARACLUDE ORAL SOLUTION 0.05MG/ML | 1 | QL (600ML per 30 days) |
| <i>entecavir oral tablet 0.5mg, 1mg</i> | 1 | MO; QL (30 EA per 30 days) |
| EPIVIR HBV ORAL SOLUTION 5MG/ML | 1 | MO |
| <i>lamivudine oral tablet 100mg</i> | 1 | MO; QL (90 EA per 30 days) |
| VEMLIDY ORAL TABLET 25MG | 1 | QL (30 EA per 30 days) |
| Agentes Contra la Hepatitis C (VHC) | | |
| MAVYRET ORAL PACKET 50-20MG | 1 | PA |
| MAVYRET ORAL TABLET 100-40MG | 1 | PA |
| <i>ribavirin oral capsule 200mg</i> | 1 | |
| <i>ribavirin oral tablet 200mg</i> | 1 | |
| <i>sofosbuvir-velpatasvir oral tablet 400-100mg</i> | 1 | PA |
| VOSEVI ORAL TABLET 400-100-100MG | 1 | PA |
| ELECTROLITOS/MINERALES/METALES/VITAMINAS | | |
| <i>Electrolitos/Minerales/Metales/Vitaminas</i> | | |
| CLINIMIX E/DEXTROSE (2.75/5) INTRAVENOUS SOLUTION 2.75% | 1 | BvD |
| CLINIMIX E/DEXTROSE (4.25/10) INTRAVENOUS SOLUTION 4.25% | 1 | BvD |
| CLINIMIX E/DEXTROSE (4.25/5) INTRAVENOUS SOLUTION 4.25% | 1 | BvD |
| CLINIMIX E/DEXTROSE (5/15) INTRAVENOUS SOLUTION 5% | 1 | BvD |
| CLINIMIX E/DEXTROSE (5/20) INTRAVENOUS SOLUTION 5% | 1 | BvD |
| CLINIMIX/DEXTROSE (4.25/10) INTRAVENOUS SOLUTION 4.25% | 1 | BvD |
| CLINIMIX/DEXTROSE (4.25/5) INTRAVENOUS SOLUTION 4.25% | 1 | BvD |
| CLINIMIX/DEXTROSE (5/15) INTRAVENOUS SOLUTION 5% | 1 | BvD |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|-----------------------------|
| CLINIMIX/DEXTROSE (5/20) INTRAVENOUS SOLUTION 5% | 1 | BvD |
| <i>dextrose intravenous solution 10%, 5%</i> | 1 | BvD |
| <i>dextrose-nacl intravenous solution 10-0.2%, 10-0.45%, 2.5-0.45%</i> | 1 | BvD |
| <i>dextrose-nacl intravenous solution 5-0.2%, 5-0.45%, 5-0.9%</i> | 1 | |
| DOJOLVI ORAL LIQUID 100% | 1 | PA |
| INTRALIPID INTRAVENOUS EMULSION 20%, 30% | 1 | BvD |
| ISOLYTE-P IN D5W INTRAVENOUS SOLUTION | 1 | BvD |
| <i>levocarnitine oral solution 1gm/10ml</i> | 1 | MO |
| <i>levocarnitine oral tablet 330mg</i> | 1 | MO |
| NUTRILIPID INTRAVENOUS EMULSION 20% | 1 | BvD |
| PREMASOL INTRAVENOUS SOLUTION 10% | 1 | BvD |
| <i>prenatal oral tablet 27-1mg</i> | 1 | |
| PROSOL INTRAVENOUS SOLUTION 20% | 1 | BvD |
| TPN ELECTROLYTES INTRAVENOUS CONCENTRATE | 1 | BvD |
| TRAVASOL INTRAVENOUS SOLUTION 10% | 1 | BvD |
| TROPHAMINE INTRAVENOUS SOLUTION 10% | 1 | BvD |
| Ligantes de Fosfato | | |
| AURYXIA ORAL TABLET 1GM 210MG(Fe) | 1 | PA; MO |
| <i>calcium acetate (phos binder) oral capsule 667mg</i> | 1 | MO |
| <i>calcium acetate oral tablet 667mg</i> | 1 | MO |
| <i>sevelamer carbonate oral packet 0.8gm</i> | 1 | QL (540 EA per 30 days) |
| <i>sevelamer carbonate oral packet 2.4gm</i> | 1 | QL (180 EA per 30 days) |
| <i>sevelamer carbonate oral tablet 800mg</i> | 1 | MO; QL (540 EA per 30 days) |
| VELPHORO ORAL TABLET CHEWABLE 500MG | 1 | MO |
| Modificadores de Electrolitos/Minerales/Metales | | |
| <i>deferasirox granules oral packet 180mg, 360mg, 90mg</i> | 1 | PA |
| <i>deferasirox oral tablet 180mg, 360mg</i> | 1 | PA |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|-----------------------------|
| <i>deferasirox oral tablet 90mg</i> | 1 | PA; MO |
| <i>deferasirox oral tablet soluble 125mg, 250mg, 500mg</i> | 1 | PA |
| <i>deferiprone oral tablet 1000mg, 500mg</i> | 1 | PA |
| FERRIPROX ORAL SOLUTION 100MG/ML | 1 | PA |
| FERRIPROX TWICE-A-DAY ORAL TABLET 1000MG | 1 | PA |
| LOKELMA ORAL PACKET 10GM, 5GM | 1 | MO |
| <i>sodium polystyrene sulfonate oral powder</i> | 1 | |
| SPS ORAL SUSPENSION 15GM/60ML | 1 | |
| <i>tolvaptan oral tablet 15mg</i> | 1 | PA; QL (120 EA per 30 days) |
| <i>tolvaptan oral tablet 30mg</i> | 1 | PA; QL (60 EA per 30 days) |
| <i>trientine hcl oral capsule 250mg</i> | 1 | PA |
| Reemplazo de Electrolitos/Minerales | | |
| <i>carglumic acid oral tablet soluble 200mg</i> | 1 | PA |
| ISOLYTE-S PH 7.4 INTRAVENOUS SOLUTION | 1 | BvD |
| <i>kcl in dextrose-nacl intravenous solution 10-5-0.45 meq/l-%-%, 20-5-0.2 meq/l-%-%, 20-5-0.45 meq/l-%-%, 20-5-0.9 meq/l-%-%, 30-5-0.45 meq/l-%-%, 40-5-0.45 meq/l-%-%, 40-5-0.9 meq/l-%-%</i> | 1 | BvD |
| <i>kcl-lactated ringers-d5w intravenous solution 20 meq/l</i> | 1 | BvD |
| KLOR-CON 10 ORAL TABLET EXTENDED RELEASE 10 MEQ | 1 | MO |
| KLOR-CON M10 ORAL TABLET EXTENDED RELEASE 10 MEQ | 1 | MO |
| KLOR-CON M15 ORAL TABLET EXTENDED RELEASE 15 MEQ | 1 | MO |
| KLOR-CON M20 ORAL TABLET EXTENDED RELEASE 20 MEQ | 1 | MO |
| KLOR-CON ORAL PACKET 20 MEQ | 1 | MO |
| KLOR-CON ORAL TABLET EXTENDED RELEASE 8 MEQ | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|--------------------|
| <i>magnesium sulfate injection solution 50%, 50% (10ml syringe)</i> | 1 | |
| PLASMA-LYTE 148 INTRAVENOUS SOLUTION | 1 | BvD |
| PLASMA-LYTE A INTRAVENOUS SOLUTION | 1 | BvD |
| <i>potassium chloride crys er oral tablet extended release 10 meq, 15 meq, 20 meq</i> | 1 | MO |
| <i>potassium chloride er oral capsule extended release 10 meq, 8 meq</i> | 1 | MO |
| <i>potassium chloride er oral tablet extended release 10 meq, 20 meq, 8 meq</i> | 1 | MO |
| <i>potassium chloride in nacl intravenous solution 20-0.45 meq/l-%, 20-0.9 meq/l-%, 40-0.9 meq/l-%</i> | 1 | BvD |
| <i>potassium chloride intravenous solution 2 meq/ml, 2 meq/ml (20 ml), 20 meq/100ml</i> | 1 | BvD |
| <i>potassium chloride oral packet 20 meq</i> | 1 | MO |
| <i>potassium chloride oral solution 20 meq/15ml (10%), 40 meq/15ml (20%)</i> | 1 | MO |
| <i>potassium citrate er oral tablet extended release 10 meq (1080mg), 15 meq (1620mg), 5 meq (540mg)</i> | 1 | |
| <i>potassium cl in dextrose 5% intravenous solution 20 meq/l</i> | 1 | BvD |
| <i>sodium chloride intravenous solution 0.45%, 0.9%, 3%, 5%</i> | 1 | |
| <i>sodium chloride irrigation solution 0.9%</i> | 1 | |
| <i>sodium fluoride oral tablet 2.2 (1 f) mg</i> | 1 | |

PRODUCTOS Y MODIFICADORES DE SANGRE

Agentes Modificadores de Plaquetas

| | | |
|---|---|----|
| <i>aspirin-dipyridamole er oral capsule extended release 12-hour 25-200mg</i> | 1 | MO |
| BRILINTA ORAL TABLET 60MG, 90MG | 1 | MO |
| CABLIVI INJECTION KIT 11MG | 1 | PA |
| <i>cilostazol oral tablet 100mg, 50mg</i> | 1 | MO |
| <i>clopidogrel bisulfate oral tablet 75mg</i> | 1 | MO |
| <i>prasugrel hcl oral tablet 10mg, 5mg</i> | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|-----------------------|
| Anticoagulantes | | |
| ELIQUIS DVT/PE STARTER PACK ORAL TABLET THERAPY PACK 5MG | 1 | |
| ELIQUIS ORAL TABLET 2.5MG, 5MG | 1 | MO |
| <i>enoxaparin sodium injection solution prefilled syringe 100mg/ml, 150mg/ml</i> | 1 | QL (60ML per 30 days) |
| <i>enoxaparin sodium injection solution prefilled syringe 120mg/0.8ml, 80mg/0.8ml</i> | 1 | QL (48ML per 30 days) |
| <i>enoxaparin sodium injection solution prefilled syringe 30mg/0.3ml</i> | 1 | QL (18ML per 30 days) |
| <i>enoxaparin sodium injection solution prefilled syringe 40mg/0.4ml</i> | 1 | QL (24ML per 30 days) |
| <i>enoxaparin sodium injection solution prefilled syringe 60mg/0.6ml</i> | 1 | QL (36ML per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 10mg/0.8ml</i> | 1 | QL (24ML per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 2.5mg/0.5ml</i> | 1 | QL (15ML per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 5mg/0.4ml</i> | 1 | QL (12ML per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 7.5mg/0.6ml</i> | 1 | QL (18ML per 30 days) |
| <i>heparin sodium (porcine) injection solution 1000unit/ml, 10000unit/ml, 20000unit/ml, 5000unit/ml</i> | 1 | BvD |
| JANTOVEN ORAL TABLET 1MG, 10MG, 2MG, 2.5MG, 3MG, 4MG, 5MG, 6MG, 7.5MG | 1 | MO |
| <i>warfarin sodium oral tablet 1mg, 10mg, 2mg, 2.5mg, 3mg, 4mg, 5mg, 6mg, 7.5mg</i> | 1 | MO |
| XARELTO ORAL SUSPENSION RECONSTITUTED 1MG/ML | 1 | MO |
| XARELTO ORAL TABLET 10MG, 15MG, 2.5MG, 20MG | 1 | MO |
| XARELTO STARTER PACK ORAL TABLET THERAPY PACK 15 & 20MG | 1 | |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|-----------------------------|
| Productos y Modificadores de Sangre, Otros | | |
| <i>anagrelide hcl oral capsule 0.5mg, 1mg</i> | 1 | MO |
| LEUKINE INJECTION SOLUTION RECONSTITUTED 250MCG | 1 | PA |
| PROMACTA ORAL PACKET 12.5MG | 1 | PA; QL (360 EA per 30 days) |
| PROMACTA ORAL PACKET 25MG | 1 | PA; QL (180 EA per 30 days) |
| PROMACTA ORAL TABLET 12.5MG, 25MG, 50MG, 75MG | 1 | PA; QL (60 EA per 30 days) |
| RETACRIT INJECTION SOLUTION 10000UNIT/ML, 10000UNIT/ML(1ML), 20000UNIT/ML, 4000UNIT/ML, 40000UNIT/ML | 1 | PA; QL (12ML per 28 days) |
| RETACRIT INJECTION SOLUTION 2000UNIT/ML | 1 | PA; QL (23ML per 30 days) |
| RETACRIT INJECTION SOLUTION 3000UNIT/ML | 1 | PA; QL (16ML per 30 days) |
| <i>tranexamic acid oral tablet 650mg</i> | 1 | |
| ZARXIO INJECTION SOLUTION PREFILLED SYRINGE 300MCG/0.5ML, 480MCG/0.8ML | 1 | PA |
| ZIEXTENZO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 6MG/0.6ML | 1 | PA |
| REGULADORES DE GLUCOSA EN SANGRE | | |
| Agentes Antidiabéticos | | |
| <i>acarbose oral tablet 100mg, 25mg, 50mg</i> | 1 | MO |
| <i>glimepiride oral tablet 1mg, 2mg, 4mg</i> | 1 | MO |
| <i>glipizide er oral tablet extended release 24-hour 10mg, 2.5mg, 5mg</i> | 1 | MO |
| <i>glipizide oral tablet 10mg, 5mg</i> | 1 | MO |
| <i>glipizide-metformin hcl oral tablet 2.5-250mg, 2.5-500mg, 5-500mg</i> | 1 | MO |
| <i>glyburide-metformin oral tablet 1.25-250mg, 2.5-500mg, 5-500mg</i> | 1 | MO |
| INVOKAMET ORAL TABLET 150-1000MG, 150-500MG, 50-1000MG, 50-500MG | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|--------------------|
| INVOKAMET XR ORAL TABLET EXTENDED RELEASE 24-HOUR 150-1000MG, 150-500MG, 50-1000MG, 50-500MG | 1 | MO |
| INVOKANA ORAL TABLET 100MG, 300MG | 1 | MO |
| JANUMET ORAL TABLET 50-1000MG, 50-500MG | 1 | MO |
| JANUMET XR ORAL TABLET EXTENDED RELEASE 24-HOUR 100-1000MG, 50-1000MG, 50-500MG | 1 | MO |
| JANUVIA ORAL TABLET 100MG, 25MG, 50MG | 1 | MO |
| JARDIANCE ORAL TABLET 10MG, 25MG | 1 | MO |
| <i>metformin hcl er oral tablet extended release 24-hour 500mg, 750mg</i> | 1 | MO |
| <i>metformin hcl oral tablet 1000mg, 500mg, 850mg</i> | 1 | MO |
| <i>migliitol oral tablet 100mg, 25mg, 50mg</i> | 1 | MO |
| <i>nateglinide oral tablet 120mg, 60mg</i> | 1 | MO |
| OZEMPIC (0.25 OR 0.5MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2MG/1.5ML | 1 | MO |
| OZEMPIC (1MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 4MG/3ML | 1 | MO |
| OZEMPIC (2MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 8MG/3ML | 1 | MO |
| <i>pioglitazone hcl oral tablet 15mg, 30mg, 45mg</i> | 1 | MO |
| <i>pioglitazone hcl-glimepiride oral tablet 30-2mg, 30-4mg</i> | 1 | MO |
| <i>pioglitazone hcl-metformin hcl oral tablet 15-500mg, 15-850mg</i> | 1 | MO |
| <i>repaglinide oral tablet 0.5mg, 1mg, 2mg</i> | 1 | MO |
| RYBELSUS ORAL TABLET 14MG, 3MG, 7MG | 1 | MO |
| SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR 2700MCG/2.7ML | 1 | PA; MO |
| SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR 1500MCG/1.5ML | 1 | PA; MO |
| SYNJARDY ORAL TABLET 12.5-1000MG, 12.5-500MG, 5-1000MG, 5-500MG | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|--|----------------------|--------------------|
| SYNJARDY XR ORAL TABLET EXTENDED RELEASE 24-HOUR 10-1000MG, 12.5-1000MG, 25-1000MG, 5-1000MG | 1 | MO |
| TRULICITY SUBCUTANEOUS SOLUTION PEN-INJECTOR 0.75MG/0.5ML, 1.5MG/0.5ML, 3MG/0.5ML, 4.5MG/0.5ML | 1 | MO |
| VICTOZA SUBCUTANEOUS SOLUTION PEN-INJECTOR 18MG/3ML | 1 | MO |
| XULTOPHY SUBCUTANEOUS SOLUTION PEN-INJECTOR 100-3.6UNIT-MG/ML | 1 | MO |
| Agentes Glucémicos | | |
| BAQSIMI ONE PACK NASAL POWDER 3MG/DOSE | 1 | |
| <i>diazoxide oral suspension 50mg/ml</i> | 1 | |
| GLUCAGEN HYPOKIT INJECTION SOLUTION RECONSTITUTED 1MG | 1 | |
| <i>glucagon emergency injection kit 1mg</i> | 1 | |
| KORLYM ORAL TABLET 300MG | 1 | PA |
| Insulinas | | |
| ASSURE ID INSULIN SAFETY SYR 29G X 1/2" 1ML | 1 | |
| COMFORT ASSIST INSULIN SYRINGE 29G X 1/2" 1ML | 1 | |
| <i>cvs gauze sterile pad 2"x2"</i> | 1 | |
| EXEL COMFORT POINT PEN NEEDLE 29G X 12MM | 1 | |
| FIASP FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100UNIT/ML | 1 | MO |
| FIASP INJECTION SOLUTION 100UNIT/ML | 1 | MO |
| FIASP PENFILL SUBCUTANEOUS SOLUTION CARTRIDGE 100UNIT/ML | 1 | MO |
| LANTUS SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 100UNIT/ML | 1 | MO |
| LANTUS SUBCUTANEOUS SOLUTION 100UNIT/ML | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|--------------------|
| LEVEMIR FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100UNIT/ML | 1 | MO |
| LEVEMIR SUBCUTANEOUS SOLUTION 100UNIT/ML | 1 | MO |
| NOVOLIN 70/30 FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100UNIT/ML | 1 | MO |
| NOVOLIN 70/30 SUBCUTANEOUS SUSPENSION (70-30) 100UNIT/ML | 1 | MO |
| NOVOLIN N FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR 100UNIT/ML | 1 | MO |
| NOVOLIN N SUBCUTANEOUS SUSPENSION 100UNIT/ML | 1 | MO |
| NOVOLIN R FLEXPEN INJECTION SOLUTION PEN-INJECTOR 100UNIT/ML | 1 | MO |
| NOVOLIN R INJECTION SOLUTION 100UNIT/ML | 1 | MO |
| NOVOLOG FLEXPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100UNIT/ML | 1 | MO |
| NOVOLOG INJECTION SOLUTION 100UNIT/ML | 1 | MO |
| NOVOLOG MIX 70/30 FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100UNIT/ML | 1 | MO |
| NOVOLOG MIX 70/30 SUBCUTANEOUS SUSPENSION (70-30) 100UNIT/ML | 1 | MO |
| NOVOLOG PENFILL SUBCUTANEOUS SOLUTION CARTRIDGE 100UNIT/ML | 1 | MO |
| <i>preferred plus insulin syringe 28g x 1/2" 0.5 ml</i> | 1 | |
| RELI-ON INSULIN SYRINGE 29G 0.3ML | 1 | |
| SOLIQUA SUBCUTANEOUS SOLUTION PEN-INJECTOR 100-33 UNT-MCG/ML | 1 | MO |
| TOUJEO MAX SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 300UNIT/ML | 1 | MO |
| TOUJEO SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 300UNIT/ML | 1 | MO |

| Nombre del medicamento | Nivel de medicamento | Requisitos/Limites |
|---|----------------------|--------------------|
| TRESIBA FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100UNIT/ML, 200UNIT/ML | 1 | MO |
| TRESIBA SUBCUTANEOUS SOLUTION 100UNIT/ML | 1 | MO |

RELAJANTES DEL MÚSCULO ESQUELÉTICO

Relajantes del Músculo Esquelético

| | | |
|---|---|--|
| <i>chlorzoxazone oral tablet 250mg, 375mg, 500mg, 750mg</i> | 1 | |
| <i>cyclobenzaprine hcl oral tablet 10mg, 5mg, 7.5mg</i> | 1 | |
| <i>methocarbamol oral tablet 500mg, 750mg</i> | 1 | |
| <i>orphenadrine citrate er oral tablet extended release 12-hour 100mg</i> | 1 | |

Index of Drugs / Índice de drogas

A

| | | | | | |
|-----------------------------------|---------------|-------------------------------------|----------|--------------------------------|-------------------|
| abacavir sulfate | 54, 186 | alyacen 1/35..... | 85, 128 | ARNUITY ELLIPTA | 102, 152 |
| abacavir sulfate-lamivudine | | amantadine hcl..... | 47, 108 | asenapine maleate | 50, 182 |
| | 54, 186 | AMBISOME..... | 36, 172 | ASMANEX (120 METERED | |
| ABELCET..... | 36, 172 | ambrisentan | 104, 152 | DOSES) | 102, 152 |
| ABILIFY MAINTENA | 49, 181 | amcinonide..... | 73, 122 | ASMANEX (30 METERED | |
| abiraterone acetate | 39, 174 | amikacin sulfate | 22, 158 | DOSES) | 102, 152 |
| acamprosate calcium | 21, 149 | amiloride hcl..... | 68, 116 | ASMANEX (60 METERED | |
| acarbose | 57, 194 | amiloride-hydrochlorothiazide..... | | DOSES) | 102, 152 |
| ACCUTANE | 72, 121 | | 66, 112 | ASMANEX HFA | 102, 152 |
| acebutolol hcl | 64, 111 | amiodarone hcl..... | 64, 115 | aspirin-dipyridamole er | 62, 192 |
| acetaminophen-codeine | 20, 154 | amitriptyline hcl | 35, 170 | ASSURE ID INSULIN SAFETY | |
| acetaminophen-codeine #3 | | amlodipine besy-benazepril hcl | | SYR | 59, 196 |
| | 20, 154 | | 66, 112 | atazanavir sulfate | 55, 187 |
| acetazolamide | 100, 144 | amlodipine besylate..... | 65, 110 | atenolol | 64, 111 |
| acetazolamide er..... | 100, 144 | amlodipine besylate-valsartan | | atenolol-chlorthalidone | 66, 112 |
| acetic acid..... | 101, 146 | | 66, 112 | atomoxetine hcl..... | 71, 118 |
| acetylcysteine..... | 105, 150 | amlodipine-atorvastatin ... | 66, 112 | atorvastatin calcium..... | 69, 114 |
| acitretin | 72, 121 | amlodipine-olmesartan | 66, 112 | atovaquone | 47, 181 |
| ACTHIB..... | 95, 140 | ammonium lactate | 73, 122 | atovaquone-proguanil hcl | |
| ACTIMMUNE | 92, 137 | AMNESTEEM | 72, 121 | | 47, 181 |
| acyclovir | 52, 185 | amoxapine | 35, 170 | atropine sulfate..... | 98, 144 |
| acyclovir sodium..... | 52, 185 | amoxicillin | 25, 161 | ATROVENT HFA..... | 103, 153 |
| ADACEL..... | 95, 140 | amoxicillin-pot clavulanate..... | | AUBRA EQ | 85, 128 |
| adefovir dipivoxil..... | 52, 189 | | 25, 161 | AURYXIA | 79, 190 |
| ADEMPAS | 104, 152 | amoxicillin-pot clavulanate er..... | | AUSTEDO..... | 71, 120 |
| ADVAIR DISKUS..... | 105, 150 | | 25, 161 | AUVELITY..... | 32, 167 |
| ADVAIR HFA..... | 105, 150 | amphetamine- | | AVIANE..... | 85, 128 |
| albendazole..... | 46, 181 | dextroamphetamine..... | 70, 120 | AVONEX PEN..... | 71, 119 |
| albuterol sulfate..... | 103, 153, 154 | amphoteric b..... | 36, 172 | AVONEX PREFILLED | 71, 119 |
| albuterol sulfate hfa | 103, 153 | ampicillin | 25, 161 | AYVAKIT | 42, 176 |
| alclometasone dipropionate..... | | ampicillin sodium | 25, 161 | AZASAN..... | 93, 138 |
| | 73, 122 | ampicillin-sulbactam sodium..... | | AZASITE | 99, 145 |
| ALECENSA | 42, 176 | | 26, 161 | azathioprine | 93, 138 |
| alendronate sodium | 98, 142 | anagrelide hcl..... | 62, 194 | azelastrine hcl | 99, 102, 143, 152 |
| alfuzosin hcl er | 83, 127 | anastrozole | 42, 176 | azithromycin..... | 27, 162, 163 |
| aliskiren fumarate | 66, 112 | ANDRODERM..... | 84, 132 | AZOPT | 101, 144 |
| allopurinol..... | 37, 150 | ANORO ELLIPTA..... | 105, 150 | aztreonam | 22, 23, 158 |
| alosetron hcl..... | 79, 124 | apraclonidine hcl | 100, 144 | | |
| ALPHAGAN P | 100, 144 | aprepitant | 35, 171 | | |
| alprazolam | 56, 157 | APRI | 85, 128 | | |
| ALPRAZOLAM INTENSOL..... | | APTIOM | 31, 165 | | |
| | 56, 157 | APTIVUS..... | 55, 187 | | |
| ALTAVERA | 85, 128 | ARANELLE | 85, 128 | | |
| ALUNBRIG..... | 42, 176 | ARCALYST | 92, 136 | | |
| | | ARIKAYCE | 22, 158 | | |
| | | aripiprazole | 49, 182 | | |
| | | armodafinil | 106, 147 | | |

B

| | |
|-------------------------------|---------|
| bacitracin..... | 99, 145 |
| bacitracin-polymyxin b | 99, 145 |
| bacitra-neomycin-polymyxin-hc | |
| | 98, 144 |
| baclofen | 52, 107 |
| balsalazide disodium | 97, 147 |
| BALVERSA | 42, 176 |

BALZIVA85, 128
 BAQSIMI ONE PACK.....59, 196
 BARACLUDE52, 189
 bcg vaccine95, 140
 BELSOMRA 106, 147
 benazepril hcl63, 117
 benazepril-hydrochlorothiazide
66, 112
 BENLYSTA93, 138
 benznidazole47, 181
 benzoyl peroxide-erythromycin
72, 121
 bethtropine mesylate47, 109
 BESREMI.....92, 137
 betaine81, 148
 betamethasone dipropionate
73, 122
 betamethasone dipropionate aug
73, 122
 betamethasone valerate ..73, 122
 BETASERON.....71, 119
 betaxolol hcl 64, 100, 111, 143
 bethanechol chloride83, 127
 bexarotene 46, 180, 181
 BEXSERO.....95, 140
 bicalutamide.....40, 174
 BICILLIN L-A26, 161
 BIKTARVY53, 186
 bisoprolol fumarate64, 111
 bisoprolol-hydrochlorothiazide
66, 112
 BLISOVI FE 1.5/30.....85, 128
 BOOSTRIX95, 140
 bosentan 104, 152
 BOSULIF.....42, 176
 BRAFTOVI42, 176
 BREO ELLIPTA..... 105, 150
 BREZTRI AEROSPHERE 1
05, 150
 briellyn85, 128
 BRILINTA.....62, 192
 brimonidine tartrate 101, 144
 brimonidine tartrate-timolol
101, 144
 BRIVIACT28, 166
 bromfenac sodium (once-daily)
100, 146
 bromocriptine mesylate ...48, 108
 BROMSITE 100, 146
 BRUKINSA.....42, 176
 budesonide 97, 102, 147, 152
 budesonide er97, 147

budesonide-formoterol fumarate
 105, 150
 bumetanide68, 116
 buprenorphine hcl.....21, 149
 buprenorphine hcl-naloxone hcl
21, 149
 bupropion hcl.....33, 168
 bupropion hcl er (smoking det)
22, 149
 bupropion hcl er (sr)
32, 167, 168
 bupropion hcl er (xl)...32, 33, 168
 buspirone hcl.....56, 157
 butalbital-apap-caffeine ...19, 155
 butalbital-asa-caff-codeine
19, 155
 butalbital-aspirin-caffeine.....
19, 155
 BYLVAY80, 125
 BYLVAY (PELLETS)80, 125

C

cabergoline90, 135
 CABLIVI62, 192
 CABOMETYX.....42, 176
 calcipotriene75, 121
 calcitonin (salmon)98, 142
 calcitriol98, 142
 calcium acetate79, 190
 calcium acetate (phos binder).....
79, 190
 CALQUENCE42, 176
 CAMILA.....89, 133
 CAMZYOS66, 112
 candesartan cilexetil63, 115
 candesartan cilexetil-hctz
66, 112
 CAPLYTA.....50, 182
 CAPRELSA42, 176
 captopril63, 117
 carbamazepine.....31, 165
 carbamazepine er.....31, 165
 carbidopa48, 109
 carbidopa-levodopa48, 109
 carbidopa-levodopa er.....48, 109
 carbidopa-levodopa-entacapone
47, 108
 carglumic acid76, 191
 carteolol hcl100, 143
 CARTIA XT65, 110
 carvedilol64, 111
 caspofungin acetate36, 172

CAYSTON..... 104, 151
 cefaclor24, 159
 cefaclor er24, 159
 cefadroxil.....24, 159
 cefazolin sodium24, 160
 cefdinir24, 160
 cefepime hcl24, 160
 cefixime24, 160
 cefotetan disodium24, 160
 cefoxitin sodium24, 160
 cefpodoxime proxetil24, 160
 cefprozil.....24, 160
 ceftazidime24, 25, 160
 ceftriaxone sodium25, 160
 cefuroxime axetil25, 160
 cefuroxime sodium25, 160
 celecoxib19, 155
 CELONTIN.....30, 166
 cephalixin25, 160, 161
 cetirizine hcl102, 152
 chlordiazepoxide hcl.....56, 157
 chlorhexidine gluconate ...72, 120
 chloroquine phosphate47, 181
 chlorpromazine hcl48, 184
 chlorthalidone.....68, 116
 chlorzoxazone 106, 198
 cholestyramine69, 114
 cholestyramine light.....69, 114
 ciclopirox76, 124
 ciclopirox olamine.....36, 172
 cilostazol62, 192
 CIMDUO54, 186
 cinacalcet hcl.....98, 142
 ciprofloxacin hcl.....
27, 101, 146, 163
 ciprofloxacin in d5w27, 163
 ciprofloxacin-dexamethasone
101, 146
 ciprofloxacin-fluocinolone pf
101, 146
 citalopram hydrobromide
33, 168
 CLARAVIS72, 122
 clarithromycin27, 163
 clarithromycin er27, 163
 CLENPIQ80, 125
 clindamycin hcl.....23, 158
 clindamycin palmitate hcl.....
23, 158
 clindamycin phos-benzoyl perox
72, 122
 clindamycin phosphate
23, 76, 124, 158

| | | |
|-----------------------------------|---------------------------------|------------------------------------|
| clindamycin phosphate in d5w | COMPLERA..... | dexamethasone..... |
|23, 158 | 53, 188 | 83, 134 |
| CLINIMIX E/DEXTROSE (2.75/5) | constulose..... | dexamethasone sodium |
|78, 189 | 79, 125 | phosphate..... |
| CLINIMIX E/DEXTROSE | COPAXONE..... | 100, 146 |
| (4.25/10)..... | 72, 119 | dexlansoprazole..... |
| 78, 189 | COPIKTRA..... | 81, 126 |
| CLINIMIX E/DEXTROSE | CORLANOR..... | dexmethylphenidate hcl..... |
| (4.25/5)..... | 66, 112 | |
| 78, 189 | COSENTYX..... | 71, 118, 119 |
| CLINIMIX E/DEXTROSE (4.25/5) | COSENTYX (300 MG DOSE)..... | dextroamphetamine sulfate..... |
|78, 189 |92, 137 |70, 120 |
| CLINIMIX E/DEXTROSE (5/15) | COSENTYX SENSOREADY | dextroamphetamine sulfate er.... |
|78, 189 | (300 MG)..... |70, 120 |
| CLINIMIX E/DEXTROSE (5/20) | COTELLIC..... | dextrose..... |
|78, 189 | 43, 177 | 78, 190 |
| CLINIMIX/DEXTROSE (4.25/10) | CREON..... | dextrose-nacl..... |
|78, 189 | 81, 148 | 78, 190 |
| CLINIMIX/DEXTROSE (4.25/5) | cromolyn sodium..... | DIACOMIT..... |
|78, 189 |81, 99, 105, 143, 148, 151 | 28, 29, 166 |
| CLINIMIX/DEXTROSE (5/15)..... | CRYSELLE-28..... | diazepam..... |
|78, 189 | 85, 128 | 30, 57, 157, 164 |
| CLINIMIX/DEXTROSE (5/20)..... | cvs gauze sterile..... | DIAZEPAM INTENSOL...57, 157 |
|78, 190 | 59, 196 | diazoxide..... |
| clobazam..... | cyclobenzaprine hcl..... | 59, 196 |
| 30, 164 | 106, 198 | diclofenac potassium..... |
| clobetasol propionate..... | cyclophosphamide..... | 19, 156 |
|73, 122, 123 | 39, 173 | diclofenac sodium..... |
| clobetasol propionate e...73, 122 | cyclosporine..... |19, 75, 100, 121, 146, 156 |
| clomipramine hcl..... | 93, 98, 138, 144 | diclofenac sodium er..... |
| 35, 170 | cyclosporine modified..... | 19, 156 |
| clonazepam..... | 93, 138 | dicloxacillin sodium..... |
| 56, 157 | cyproheptadine hcl..... | 26, 161 |
| clonidine..... | 102, 152 | dicyclomine hcl..... |
| 62, 115 | CYRED EQ..... | 80, 126 |
| clonidine hcl..... | CYSTADROPS..... | DIFICID..... |
| 62, 115 | 99, 144 | 27, 163 |
| clopidogrel bisulfate..... | CYSTAGON..... | diflunisal..... |
| 62, 192 | 81, 148 | 19, 156 |
| clorazepate dipotassium..... | CYSTARAN..... | DIGITEK..... |
|57, 157 | 99, 144 | 66, 112 |
| clotrimazole..... | | digoxin..... |
| 36, 172 | | 67, 112 |
| clotrimazole-betamethasone..... | | dihydroergotamine mesylate..... |
|75, 121 | |38, 107 |
| clozapine..... | | DILANTIN..... |
| 51, 184 | | 31, 165 |
| COARTEM..... | | diltiazem hcl..... |
| 47, 181 | | 65, 111 |
| codeine sulfate..... | | diltiazem hcl er..... |
| 20, 154 | | 65, 110 |
| colchicine..... | | diltiazem hcl er beads..... |
| 37, 150 | | 65, 110 |
| colchicine-probenecid..... | | diltiazem hcl er coated beads..... |
| 37, 150 | |65, 110 |
| colestipol hcl..... | | dilt-xr..... |
| 69, 114 | | 65, 111 |
| colistimethate sodium (cba)..... | | dimethyl fumarate..... |
|23, 158 | | 72, 119 |
| COMBIGAN..... | | dimethyl fumarate starter pack... |
| 101, 144 | |72, 119 |
| COMBIVENT RESPIMAT..... | | diphenoxylate-atropine..... |
|105, 150 | |79, 80, 125 |
| COMETRIQ (100 MG DAILY | | diphtheria-tetanus toxoids dt..... |
| DOSE)..... | |95, 140 |
| 42, 176 | | disopyramide phosphate..... |
| COMETRIQ (140 MG DAILY | |64, 115 |
| DOSE)..... | | disulfiram..... |
| 42, 177 | | 21, 149 |
| COMETRIQ (60 MG DAILY | | divalproex sodium..... |
| DOSE)..... | | 57, 109 |
| 42, 177 | | divalproex sodium er..... |
| COMFORT ASSIST INSULIN | | 57, 109 |
| SYRINGE..... | | dofetilide..... |
| 59, 196 | | 64, 115 |
| | | DOJOLVI..... |
| | | 78, 190 |
| | | donepezil hcl..... |
| | | 32, 118 |
| | | dorzolamide hcl..... |
| | | 101, 144 |
| | | dorzolamide hcl-timolol mal..... |
| | |101, 144 |

D

| | |
|------------------------------------|--------------|
| dalfampridine er..... | 72, 119 |
| danazol..... | 84, 132 |
| dapsone..... | 39, 171 |
| DAPTACEL..... | 95, 140 |
| daptomycin..... | 23, 158 |
| darifenacin hydrobromide er..... | 82, 127 |
| DAURISMO..... | 43, 177 |
| DEBLITANE..... | 89, 133 |
| deferasirox..... | 77, 190, 191 |
| deferasirox granules..... | 77, 190 |
| deferiprone..... | 77, 191 |
| DELSTRIGO..... | 54, 186 |
| DESCOVY..... | 54, 186 |
| desipramine hcl..... | 35, 170 |
| desmopressin acetate..... | 84, 133 |
| desmopressin acetate spray..... | 84, 133 |
| desogestrel-ethinyl estradiol..... | 86, 128 |
| desonide..... | 73, 123 |
| desoximetasone..... | 74, 123 |
| desvenlafaxine er..... | 33, 168 |
| desvenlafaxine succinate er..... | 33, 169 |

dorzolamide hcl-timolol mal pf
 101, 144
 DOVATO.....53, 187
 doxazosin mesylate63, 116
 doxepin hcl.....35, 170
 DOXY 100.....28, 164
 doxycycline hyclate28, 164
 doxycycline monohydrate 28, 164
 DRIZALMA SPRINKLE.....33, 169
 dronabinol35, 171
 drospirenone-ethinyl estradiol.....
86, 128
 DROXIA40, 174
 droxidopa62, 115
 DUAVEE85, 132
 duloxetine hcl33, 169
 DUPIXENT92, 137
 DUREZOL..... 100, 146
 dutasteride83, 127
 dutasteride-tamsulosin hcl.....
83, 127

E

econazole nitrate36, 172
 EDURANT.....53, 188
 efavirenz53, 188
 efavirenz-emtricitab-tenofo df
54, 186
 efavirenz-lamivudine-tenofovir....
54, 186
 ELIGARD90, 135
 ELIQUIS.....61, 193
 ELIQUIS DVT/PE STARTER
 PACK.....61, 193
 ELMIRON.....83, 127
 ELURYNG.....86, 128
 EMCYT40, 174
 EMGALITY.....38, 108
 EMOQUETTE86, 128
 EMSAM.....33, 168
 emtricitabine.....54, 186
 emtricitabine-tenofovir df .54, 186
 EMTRIVA.....54, 186
 EMVERM46, 181
 enalapril maleate63, 117
 enalapril-hydrochlorothiazide.....
67, 112
 ENBREL.....93, 138
 ENBREL MINI93, 138
 ENBREL SURECLICK.....93, 138
 ENDARI81, 148
 ENGERIX-B95, 140

enoxaparin sodium61, 193
 ENPRESSE-2886, 128
 ENSKYCE86, 128
 ENSPRYNG.....93, 138
 entacapone47, 108
 entecavir52, 189
 ENTRESTO67, 112
 enulose79, 125
 ENVARSUS XR93, 138
 EPIDIOLEX29, 166
 epinephrine103, 154
 EPITOL.....31, 165
 EPIVIR HBV.....52, 189
 eplerenone68, 116
 EPRONTIA.....38, 108
 ERAXIS.....36, 172
 ERIVEDGE43, 177
 ERLEADA40, 174
 erlotinib hcl.....43, 177
 ERRIN.....89, 133
 ertapenem sodium.....26, 162
 ery.....76, 124
 ERYTHROCIN LACTOBIONATE
27, 163
 erythromycin.....
 27, 76, 99, 124, 145, 163
 erythromycin base27, 163
 erythromycin ethylsuccinate
27, 163
 ESBRIET.....104, 150
 escitalopram oxalate
33, 34, 169
 esomeprazole magnesium
81, 126
 ESTARYLLA86, 128
 estradiol85, 132
 ethambutol hcl.....39, 171
 ethosuximide30, 166
 ethynodiol diac-eth estradiol.....
86, 128
 etodolac19, 156
 etonogestrel-ethinyl estradiol.....
86, 128
 etravirine53, 188
 EUCRISA74, 123
 EUTHYROX90, 135
 everolimus..... 43, 93, 138, 177
 EVOTAZ55, 187
 EVRYSDI71, 120
 EXEL COMFORT POINT PEN
 NEEDLE59, 196
 exemestane42, 176

EXKIVITY.....43, 177
 ezetimibe.....69, 114

F

FALMINA86, 128
 famciclovir53, 185
 famotidine81, 126
 FANAPT.....50, 182
 FANAPT TITRATION PACK.....
50, 182
 febuxostat37, 150
 felbamate29, 166
 felodipine er65, 110
 FEMYNOR.....86, 128
 fenofibrate68, 114
 fenofibrate micronized68, 113
 fenofibric acid.....68, 114
 fentanyl20, 155
 fentanyl citrate.....20, 154
 FERRIPROX77, 191
 FERRIPROX TWICE-A-DAY.....
78, 191
 fesoterodine fumarate er
82, 127
 FETZIMA.....34, 169
 FETZIMA TITRATION34, 169
 FIASP59, 196
 FIASP FLEXTOUCH59, 196
 FIASP PENFILL59, 196
 finasteride83, 127
 fingolimod hcl72, 119
 FINTEPLA.....29, 166
 FIRAZYR.....91, 136
 FIRVANQ23, 158
 flecainide acetate64, 116
 FLOVENT DISKUS102, 152
 FLOVENT HFA102, 153
 fluconazole36, 172
 fluconazole in sodium chloride....
36, 172
 flucytosine36, 172
 fludrocortisone acetate83, 134
 flunisolide102, 153
 fluocinolone acetonide.....
74, 101, 123, 146
 fluocinonide74, 123
 fluocinonide emulsified base.....
74, 123
 fluorometholone100, 146
 fluorouracil75, 121
 fluoxetine hcl34, 169
 fluphenazine decanoate ..49, 184

fluphenazine hcl49, 184
 flurbiprofen19, 156
 flurbiprofen sodium100, 146
 fluticasone propionate
74, 102, 123, 153
 fluticasone-salmeterol ...105, 151
 fluvoxamine maleate34, 169
 fondaparinux sodium61, 193
 fosamprenavir calcium.....55, 187
 fosinopril sodium63, 117
 fosinopril sodium-hctz.....67, 113
 FOTIVDA43, 177
 furosemide68, 116
 FUZEON54, 188
 FYCOMPA29, 166

G

gabapentin30, 164
 GALAFOLD.....81, 148
 galantamine hydrobromide
32, 118
 galantamine hydrobromide er
32, 118
 GARDASIL 995, 140
 gatifloxacin99, 145
 GATTEX.....80, 125
 GAVILYTE-C.....80, 125
 GAVILYTE-G.....80, 125
 GAVRETO43, 177
 gemfibrozil.....68, 114
 generlac79, 125
 GENGRAF93, 138
 GENTAK99, 145
 gentamicin in saline22, 158
 gentamicin sulfate
22, 99, 145, 158
 GENVOYA53, 187
 GILOTRIF43, 177
 GLEOSTINE.....39, 173
 glimepiride.....57, 194
 glipizide57, 194
 glipizide er57, 194
 glipizide-metformin hcl.....57, 194
 global alcohol prep ease.....
75, 121
 GLUCAGEN HYPOKIT....59, 196
 glucagon emergency59, 196
 glyburide-metformin.....57, 194
 glycopyrrolate80, 126
 granisetron hcl.....35, 171
 griseofulvin microsize36, 172

griseofulvin ultramicrosize
36, 172
 guanfacine hcl62, 115
 guanfacine hcl er71, 119

H

halobetasol propionate74, 123
 haloperidol49, 184
 haloperidol decanoate49, 184
 haloperidol lactate49, 184
 HAVRIX.....95, 140
 heparin sodium (porcine)
61, 193
 HIBERIX.....95, 140
 HUMIRA.....94, 139
 HUMIRA PEDIATRIC CROHNS
 START93, 139
 HUMIRA PEN.....94, 139
 HUMIRA PEN-CD/UC/HS
 STARTER94, 139
 HUMIRA PEN-PEDIATRIC UC
 START94, 139
 HUMIRA PEN-PS/UV/ADOL HS
 START94, 139
 HUMIRA PEN-PSOR/UEVIT
 STARTER94, 139
 hydralazine hcl70, 117
 hydrochlorothiazide68, 116
 hydrocodone-acetaminophen
20, 154
 hydrocodone-ibuprofen....20, 154
 hydrocortisone.....
74, 83, 97, 123, 134, 147
 hydrocortisone (perianal).....
74, 123
 hydrocortisone ace-pramoxine ...
75, 121
 hydrocortisone valerate ...74, 123
 hydromorphone hcl.....20, 154
 hydroxychloroquine sulfate
47, 181
 hydroxyurea40, 174
 hydroxyzine hcl56, 157
 hydroxyzine pamoate56, 157
 HYFTOR75, 121

I

ibandronate sodium98, 142
 IBRANCE43, 177
 IBU19, 156
 ibuprofen19, 156
 icatibant acetate91, 136

ICLEVIA86, 129
 ICLUSIG.....43, 177
 IDHIFA40, 41, 175
 ILEVRO.....100, 146
 imatinib mesylate.....43, 177
 IMBRUVICA43, 177
 imipenem-cilastatin.....27, 162
 imipramine hcl35, 170
 imiquimod.....75, 121
 IMOVAX RABIES95, 140
 IMVEXXY MAINTENANCE
 PACK.....85, 132
 IMVEXXY STARTER PACK.....
85, 132
 INBRIJA48, 109
 INCASSIA89, 133
 INCRELEX84, 133
 indapamide68, 117
 indomethacin.....19, 156
 indomethacin er.....19, 156
 INFANRIX95, 140
 INLYTA43, 177
 INQOVI40, 174
 INREBIC43, 177
 INTELENCE53, 188
 INTRALIPID78, 190
 INTRAROSA86, 129
 INTROVALE.....86, 129
 INVEGA HAFYERA.....50, 182
 INVEGA SUSTENNA50, 182
 INVEGA TRINZA.....50, 182
 INVOKAMET58, 194
 INVOKAMET XR58, 195
 INVOKANA58, 195
 IPOL.....95, 140
 ipratropium bromide103, 153
 ipratropium-albuterol105, 151
 irbesartan63, 115
 irbesartan-hydrochlorothiazide ...
67, 113
 IRESSA.....43, 177
 ISENTRESS.....53, 187
 ISENTRESS HD.....53, 187
 ISIBLOOM.....86, 129
 ISOLYTE-P IN D5W78, 190
 ISOLYTE-S PH 7.4.....76, 191
 isoniazid39, 171
 isosorb dinitrate-hydralazine.....
67, 113
 isosorbide dinitrate70, 117
 isosorbide mononitrate70, 117
 isosorbide mononitrate er
70, 117

isotretinoin.....72, 122
 isradipine.....65, 110
 ISTURISA83, 134
 itraconazole.....36, 37, 172
 ivermectin.....46, 181
 IXIARO.....95, 141

J

JAKAFI.....43, 178
 JANTOVEN.....61, 193
 JANUMET58, 195
 JANUMET XR58, 195
 JANUVIA.....58, 195
 JARDIANCE.....58, 195
 JASMIEL86, 129
 JUBLIA.....37, 172
 JULEBER.....86, 129
 JULUCA.....54, 186
 JUNEL 1.5/30.....86, 129
 JUNEL 1/20.....86, 129
 JUNEL FE 1.5/3086, 129
 JUNEL FE 1/2086, 129
 JUXTAPID.....69, 114
 JYNNEOS95, 141

K

KALYDECO104, 151
 KARIVA.....86, 129
 KATERZIA65, 110
 kcl in dextrose-nacl.....76, 191
 kcl-lactated ringers-d5w...76, 191
 KELNOR 1/3586, 129
 KELNOR 1/5086, 129
 KERENDIA.....68, 116
 KESIMPTA.....72, 119
 ketoconazole.....37, 172, 173
 ketorolac tromethamine
19, 100, 146, 156
 KINRIX.....96, 141
 KISQALI (200 MG DOSE)
43, 178
 KISQALI (400 MG DOSE)
43, 178
 KISQALI (600 MG DOSE)
44, 178
 KISQALI FEMARA (400 MG
 DOSE)41, 175
 KISQALI FEMARA (600 MG
 DOSE)41, 175
 KISQALI FEMARA(200 MG
 DOSE)41, 175
 KLOR-CON76, 191

KLOR-CON 1076, 191
 KLOR-CON M1076, 191
 KLOR-CON M1576, 191
 KLOR-CON M2076, 191
 KLOXXADO21, 149
 KORLYM.....59, 196
 KOSELUGO.....44, 178
 KURVELO.....86, 129
 KYNMOBI48, 108

L

labetalol hcl64, 111
 lacosamide.....31, 165
 lactulose.....79, 125
 lamivudine.....52, 54, 186, 189
 lamivudine-zidovudine54, 186
 lamotrigine29, 166
 lamotrigine er29, 166
 lamotrigine starter kit-blue
29, 166
 lamotrigine starter kit-green
29, 166
 lamotrigine starter kit-orange
29, 167
 LAMPIT.....47, 181
 lansoprazole.....81, 126
 LANTUS.....59, 196
 LANTUS SOLOSTAR.....59, 196
 lapatinib ditosylate.....44, 178
 LARIN 1.5/30.....86, 129
 LARIN 1/2086, 129
 LARIN FE 1.5/3086, 129
 LARIN FE 1/2086, 129
 latanoprost101, 145
 LATUDA.....50, 182
 LEENA87, 129
 leflunomide.....92, 137
 lenalidomide.....40, 173
 LENVIMA (10 MG DAILY DOSE)
44, 178
 LENVIMA (12 MG DAILY DOSE)
44, 178
 LENVIMA (14 MG DAILY DOSE)
44, 178
 LENVIMA (18 MG DAILY DOSE)
44, 178
 LENVIMA (20 MG DAILY DOSE)
44, 178
 LENVIMA (24 MG DAILY DOSE)
44, 178
 LENVIMA (4 MG DAILY DOSE)
44, 178

LENVIMA (8 MG DAILY DOSE)
44, 178
 LESSINA.....87, 129
 letrozole42, 176
 leucovorin calcium.....41, 175
 LEUKERAN.....39, 173
 LEUKINE.....62, 194
 leuprolide acetate.....90, 135
 LEVEMIR60, 197
 LEVEMIR FLEXTOUCH..60, 197
 levetiracetam.....29, 167
 levetiracetam er.....29, 167
 levobunolol hcl100, 143
 levocarnitine.....79, 190
 levocetirizine dihydrochloride.....
102, 152
 levofloxacin28, 163
 levofloxacin in d5w28, 163
 LEVONEST87, 129
 levonorgest-eth estrad 91-day
87, 129
 levonorgestrel-ethinyl estrad.....
87, 129
 levonorg-eth estrad triphasic
87, 129
 LEVORA 0.15/30 (28)87, 129
 LEVO-T.....90, 135
 levothyroxine sodium.....90, 135
 LEVOXYL.....90, 135
 LEXIVA55, 187
 LIALDA97, 147
 lidocaine.....21, 156
 lidocaine hcl21, 156
 lidocaine viscous hcl.....21, 156
 lidocaine-prilocaine.....21, 157
 linezolid.....23, 159
 LINZESS79, 125
 liothyronine sodium90, 135
 lisinopril63, 117
 lisinopril-hydrochlorothiazide
67, 113
 lithium carbonate.....57, 110
 lithium carbonate er.....57, 110
 LIVALO69, 114
 LIVMARLI.....80, 125
 LITENCITY52, 185
 LOKELMA78, 191
 LONSURF.....41, 175
 loperamide hcl.....80, 125
 lopinavir-ritonavir55, 187
 lorazepam57, 157
 LORAZEPAM INTENSOL
57, 157

LORBRENA44, 178
 LORYNA87, 129
 losartan potassium63, 115
 losartan potassium-hctz...67, 113
 loteprednol etabonate.... 100, 146
 lovastatin69, 114
 LOW-OGESTREL87, 129
 loxapine succinate.....49, 184
 lubiprostone79, 125
 LUMAKRAS41, 175
 LUMIGAN..... 101, 145
 LUPKYNIS94, 139
 LUPRON DEPOT (1-MONTH)....
90, 135
 LUPRON DEPOT (3-MONTH)....
90, 135
 LUPRON DEPOT (4-MONTH)....
90, 136
 LUPRON DEPOT (6-MONTH)....
91, 136
 LUTERA.....87, 130
 LYBALVI50, 182
 LYLEQ89, 133
 LYNPARZA41, 175
 LYSODREN40, 174
 LYZA.....89, 133

M

magnesium sulfate77, 192
 malathion75, 124
 maraviroc55, 188
 marlissa.....87, 130
 MARPLAN.....33, 168
 MATULANE39, 173
 MAVYRET.....52, 189
 MAYZENT.....72, 119
 MAYZENT STARTER PACK.....
72, 119
 meclizine hcl.....35, 170
 medroxyprogesterone acetate....
89, 133
 mefloquine hcl47, 181
 meggestrol acetate.....89, 133
 MEKINIST44, 178
 MEKTOVI.....44, 178
 meloxicam19, 156
 memantine hcl.....32, 118
 memantine hcl er.....31, 118
 MENACTRA96, 141
 MENEST85, 132
 MENQUADFI.....96, 141
 MENVEO96, 141

mercaptopurine40, 174
 meropenem27, 162
 mesalamine97, 147
 mesalamine er.....97, 147
 MESNEX.....41, 175
 metformin hcl.....58, 195
 metformin hcl er58, 195
 methadone hcl.....20, 155
 methazolamide101, 144
 methenamine hippurate...23, 159
 methimazole.....91, 136
 methocarbamol106, 198
 methotrexate sodium94, 139
 methotrexate sodium (pf).....
94, 139
 methylphenidate hcl71, 119
 methylprednisolone83, 134
 metoclopramide hcl80, 125
 metolazone68, 117
 metoprolol succinate er ...64, 111
 metoprolol tartrate64, 111
 metoprolol-hydrochlorothiazide
67, 113
 metronidazole.....23, 159
 metyrosine67, 113
 mexiletine hcl64, 116
 MICROGESTIN 1.5/3087, 130
 MICROGESTIN 1/2087, 130
 MICROGESTIN FE 1.5/30.....
87, 130
 MICROGESTIN FE 1/20.....
87, 130
 midodrine hcl.....63, 115
 miglitol.....58, 195
 miglustat.....81, 148
 MILI.....87, 130
 minocycline hcl.....28, 164
 minoxidil70, 117
 mirtazapine33, 168
 misoprostol.....81, 126
 M-M-R II.....96, 141
 modafinil.....106, 147
 moexipril hcl63, 117
 molindone hcl.....49, 184
 mometasone furoate
74, 103, 123, 153
 montelukast sodium103, 153
 morphine sulfate.....20, 155
 morphine sulfate (concentrate)
20, 155
 morphine sulfate er.....20, 155
 MOVANTI-K79, 125

moxifloxacin hcl.....
28, 99, 145, 163
 moxifloxacin hcl in nacl....28, 163
 MULTAQ64, 116
 mupirocin76, 124
 mupirocin calcium.....76, 124
 mycophenolate mofetil....94, 139
 mycophenolate sodium....94, 139
 MYRBETRIQ.....82, 127

N

na sulfate-k sulfate-mg sulf.....
80, 125
 nabumetone19, 156
 nadolol64, 111
 nafcillin sodium.....26, 161, 162
 naloxone hcl.....22, 149
 naltrexone hcl.....21, 149
 NAMZARIC32, 118
 naproxen19, 156
 naproxen sodium.....19, 156
 naratriptan hcl38, 107
 NARCAN.....22, 149
 NATACYN.....99, 145
 nateglinide.....58, 195
 NATPARA98, 143
 NAYZILAM30, 164
 nebivolol hcl64, 111
 NECON 0.5/35 (28)87, 130
 nefazodone hcl.....34, 169
 neomycin sulfate22, 158
 neomycin-bacitracin zn-polymyx
99, 145
 neomycin-polymyxin-dexameth
99, 144, 145
 neomycin-polymyxin-gramicidin
99, 145
 neomycin-polymyxin-hc.....
99, 101, 145, 146
 NERLYNX44, 178
 NEUPRO.....48, 108
 nevirapine53, 188
 nevirapine er53, 188
 niacin er (antihyperlipidemic).....
69, 114
 nifedipine hcl65, 110
 NICOTROL22, 149
 nifedipine.....65, 110
 nifedipine er65, 110
 nifedipine er osmotic release.....
65, 110
 NIKKI87, 130

nilutamide.....40, 174
 NINLARO.....41, 175
 nitazoxanide.....47, 181
 nitisinone.....81, 148
 NITRO-BID.....70, 117
 nitrofurantoin macrocrystal
23, 159
 nitrofurantoin monohyd macro
23, 159
 nitroglycerin.....70, 117
 nizatidine.....81, 126
 NOCDURNA84, 133
 NORA-BE.....89, 133
 norethin ace-eth estrad-fe
87, 130
 norethindrone.....89, 133
 norethindrone acetate89, 133
 norethindrone acet-ethinyl est
87, 130
 norethindrone-eth estradiol.....
87, 130
 norgestimate-eth estradiol.....
87, 130
 norgestim-eth estrad triphasic
87, 130
 NORTREL 0.5/35 (28)88, 130
 NORTREL 1/35 (21)88, 130
 NORTREL 1/35 (28)88, 130
 NORTREL 7/7/788, 130
 nortriptyline hcl35, 170
 NORVIR.....55, 187
 NOVOLIN 70/3060, 197
 NOVOLIN 70/30 FLEXPEN
60, 197
 NOVOLIN N60, 197
 NOVOLIN N FLEXPEN ...60, 197
 NOVOLIN R60, 197
 NOVOLIN R FLEXPEN ...60, 197
 NOVOLOG.....60, 197
 NOVOLOG FLEXPEN.....60, 197
 NOVOLOG MIX 70/3060, 197
 NOVOLOG MIX 70/30 FLEXPEN
60, 197
 NOVOLOG PENFILL.....60, 197
 NOXAFIL.....37, 173
 NUBEQA.....40, 174
 NUCALA105, 151
 NUEDEXTA71, 120
 NUPLAZID50, 182
 NUTRILIPID79, 190
 NYAMYC.....37, 173
 NYLIA 1/35.....88, 130
 NYLIA 7/7/788, 130

NYMYO.....88, 130
 nystatin37, 173
 nystatin-triamcinolone75, 121
 NYSTOP37, 173

O

OCELLA.....88, 130
 octreotide acetate.....91, 136
 ODEFSEY54, 186
 ODOMZO.....44, 178
 OFEV105, 150
 ofloxacin.....
28, 99, 102, 145, 146, 163
 olanzapine.....50, 182
 olanzapine-fluoxetine hcl
33, 168
 olmesartan medoxomil63, 115
 olmesartan medoxomil-hctz.....
67, 113
 olmesartan-amlodipine-hctz.....
67, 113
 olopatadine hcl99, 143
 omega-3-acid ethyl esters
69, 114
 omeprazole81, 126
 OMNITROPE84, 133, 134
 ondansetron36, 171
 ondansetron hcl.....36, 171
 ONUREG40, 174
 OPSUMIT.....104, 152
 ORFADIN.....82, 148
 ORGOVYX.....41, 175
 ORKAMBI104, 151
 orphenadrine citrate er ..106, 198
 oseltamivir phosphate56, 185
 OSPHENA88, 131
 oxacillin sodium26, 162
 oxacillin sodium in dextrose.....
26, 162
 oxandrolone84, 132
 oxaprozin20, 156
 oxazepam56, 157
 oxcarbazepine.....31, 165
 oxybutynin chloride.....82, 127
 oxybutynin chloride er82, 127
 oxycodone hcl21, 155
 oxycodone hcl er20, 155
 oxycodone-acetaminophen.....
21, 155
 OZEMPIC (0.25 OR 0.5
 MG/DOSE).....58, 195

OZEMPIC (1 MG/DOSE).....
58, 195
 OZEMPIC (2 MG/DOSE).....
58, 195

P

paliperidone er50, 183
 PANRETIN.....75, 121
 pantoprazole sodium81, 126
 PANZYGA.....91, 138
 paricalcitol98, 143
 paromomycin sulfate22, 158
 paroxetine hcl.....34, 169
 PEDIARIX96, 141
 PEDVAX HIB.....96, 141
 peg 3350-kcl-na bicarb-nacl
80, 125
 peg-3350/electrolytes80, 125
 PEGASYS.....93, 137
 PEMAZYRE44, 179
 penicillamine83, 127
 penicillin g pot in dextrose
26, 162
 penicillin g potassium26, 162
 penicillin g procaine26, 162
 penicillin g sodium26, 162
 penicillin v potassium26, 162
 PENTACEL96, 141
 pentamidine isethionate...47, 181
 pentoxifylline er67, 113
 perindopril erbumine.....63, 117
 PERIOGARD.....72, 120
 permethrin75, 124
 perphenazine49, 184
 phenelzine sulfate33, 168
 phenobarbital29, 167
 phenytoin31, 165
 phenytoin sodium extended.....
31, 165
 PIFELTRO54, 188
 pilocarpine hcl
72, 101, 120, 144
 pimecrolimus74, 124
 pimozide.....49, 184
 PIMTREA.....88, 131
 pindolol64, 111
 pioglitazone hcl58, 195
 pioglitazone hcl-glimepiride
58, 195
 pioglitazone hcl-metformin hcl
58, 195

piperacillin sod-tazobactam so ...
26, 162
 PIQRAY (200 MG DAILY DOSE)
44, 179
 PIQRAY (250 MG DAILY DOSE)
44, 179
 PIQRAY (300 MG DAILY DOSE)
44, 179
 pirfenidone 105, 150
 PIRMELLA 1/3588, 131
 piroxicam.....20, 156
 PLASMA-LYTE 148.....77, 192
 PLASMA-LYTE A77, 192
 podofilox.....75, 121
 polymyxin b-trimethoprim
99, 145
 POMALYST40, 174
 PORTIA-2888, 131
 posaconazole37, 173
 potassium chloride77, 192
 potassium chloride crys er.....
77, 192
 potassium chloride er77, 192
 potassium chloride in nacl
77, 192
 potassium citrate er77, 192
 potassium cl in dextrose 5%.....
77, 192
 pramipexole dihydrochloride.....
48, 109
 prasugrel hcl.....62, 192
 pravastatin sodium69, 114
 prazosin hcl.....63, 116
 prednicarbate74, 124
 prednisolone83, 134
 prednisolone acetate 100, 146
 prednisolone sodium phosphate
 83, 100, 134, 146
 prednisone84, 134
 PREDNISONO INTENSOL.....
84, 134
 preferred plus insulin syringe.....
60, 197
 pregabalin71, 119
 prehevbrio96, 141
 PREMARIN85, 132
 PREMASOL79, 190
 PREMPHASE88, 131
 PREMPRO88, 131
 prenatal79, 190
 PREVYMIS52, 185
 PREZCOBIX55, 187
 PREZISTA55, 187

PRIFTIN39, 171
 primaquine phosphate47, 181
 primidone29, 167
 PRIORIX96, 141
 PRIVIGEN.....91, 138
 probenecid37, 150
 prochlorperazine35, 170
 prochlorperazine maleate
35, 170
 PROCTO-MED HC.....74, 124
 PROCTO-PAK74, 124
 PROCTOSOL HC.....74, 124
 PROCTOZONE-HC.....74, 124
 progesterone89, 133
 PROGRAF94, 139
 PROLASTIN-C82, 148
 PROLIA.....98, 143
 PROMACTA.....62, 194
 promethazine hcl.....35, 170, 171
 propafenone hcl64, 116
 propranolol hcl...38, 64, 108, 112
 propranolol hcl er
38, 64, 108, 111
 propylthiouracil91, 136
 PROQUAD96, 141
 PROSOL79, 190
 protriptyline hcl35, 170
 PULMOZYME104, 151
 PURIXAN40, 174
 pyrazinamide.....39, 171
 pyridostigmine bromide ...39, 107

Q

QINLOCK.....45, 179
 QUADRACEL.....96, 141
 quetiapine fumarate.....51, 183
 quetiapine fumarate er.....
50, 51, 183
 quinapril hcl63, 117
 quinapril-hydrochlorothiazide
67, 113
 quinidine sulfate64, 116
 quinine sulfate47, 181

R

RABAVERT96, 141
 raloxifene hcl98, 143
 ramipril63, 117
 ranolazine er67, 113
 rasagiline mesylate.....48, 109
 RAVICTI.....82, 148
 RECLIPSEN.....88, 131

RECOMBIVAX HB96, 141
 RECTIV.....70, 117
 REGRANEX.....75, 121
 RELENZA DISKHALER...56, 185
 RELI-ON INSULIN SYRINGE.....
60, 197
 repaglinide58, 195
 REPATHA69, 115
 REPATHA PUSHTRONEX
 SYSTEM.....69, 115
 REPATHA SURECLICK..69, 115
 RETACRIT62, 194
 RETEVMO45, 179
 REXULTI.....51, 183
 REYATAZ55, 187
 REZUROCK.....94, 139
 RHOPRESSA.....101, 144
 ribavirin52, 189
 rifabutin39, 171
 rifampin39, 171
 riluzole71, 120
 rimantadine hcl.....56, 185
 RINVOQ.....92, 137
 risedronate sodium.....98, 143
 RISPERDAL CONSTA ...51, 183
 risperidone51, 183
 ritonavir55, 187
 rivastigmine32, 118
 rivastigmine tartrate.....32, 118
 rizatriptan benzoate.....38, 107
 ROCKLATAN101, 144
 roflumilast.....104, 154
 ropinirole hcl.....48, 109
 rosuvastatin calcium69, 114
 ROTARIX.....96, 141
 ROTATEQ.....96, 141
 ROZLYTREK.....45, 179
 RUBRACA45, 179
 rufinamide31, 165
 RUKOBIA.....55, 188
 RYBELSUS58, 195
 RYDAPT45, 179
 RYTARY48, 109

S

SANTYL.....75, 121
 sapropterin dihydrochloride
82, 148
 SAVELLA71, 119
 SAVELLA TITRATION PACK.....
71, 119
 SCEMBLIX.....45, 179

scopolamine.....35, 171
 SECUADO51, 183
 selegiline hcl.....48, 109
 selenium sulfide74, 124
 SELZENTRY55, 188
 SEREVENT DISKUS..... 103, 154
 sertraline hcl.....34, 169
 SETLAKIN.....88, 131
 sevelamer carbonate79, 190
 SHAROBEL89, 133
 SHINGRIX.....96, 142
 SIGNIFOR.....91, 136
 sildenafil citrate 104, 152
 silodosin83, 127
 silver sulfadiazine75, 121
 SIMBRINZA 101, 144
 simvastatin69, 114
 sirolimus.....94, 139
 SIRTURO.....39, 171
 SKYRIZI.....92, 137
 SKYRIZI PEN.....92, 137
 sodium chloride77, 192
 sodium fluoride.....77, 192
 sodium polystyrene sulfonate
78, 191
 sofosbuvir-velpatasvir.....52, 189
 solifenacin succinate82, 127
 SOLIQUA.....60, 197
 SOLTAMOX40, 174
 SOMAVERT91, 136
 sorafenib tosylate45, 179
 sotalol hcl64, 116
 sotalol hcl (af).....64, 116
 SPIRIVA HANDIHALER
103, 153
 SPIRIVA RESPIMAT 103, 153
 spironolactone68, 116
 spironolactone-hctz67, 113
 SPRINTEC 2888, 131
 SPRITAM.....29, 30, 167
 SPRYCEL45, 179
 SPS.....78, 191
 SRONYX.....88, 131
 SSD75, 121
 STELARA.....92, 137
 STIVARGA.....45, 179
 STRIBILD.....53, 187
 SUBOXONE.....21, 149
 sucralfate81, 126
 sulfacetamide sodium.....99, 145
 sulfacetamide sodium (acne).....
28, 164

sulfacetamide-prednisolone.....
99, 145
 sulfadiazine28, 164
 sulfamethoxazole-trimethoprim
28, 164
 sulfasalazine97, 147
 sulindac.....20, 156
 sumatriptan38, 107
 sumatriptan succinate38, 107
 sumatriptan succinate refill
38, 107
 sunitinib malate45, 179
 SUNOSI 106, 147
 SUPREP BOWEL PREP KIT.....
80, 126
 SUTAB.....80, 126
 SYEDA.....88, 131
 SYMDEKO 104, 151
 SYMLINPEN 120.....58, 195
 SYMLINPEN 6058, 195
 SYMPAZAN30, 164
 SYMTUZA.....53, 187
 SYNAREL91, 136
 SYNJARDY59, 195
 SYNJARDY XR59, 196
 SYNRIBO.....41, 175
 SYNTHROID.....90, 135

T

TABLOID.....40, 174
 TABRECTA45, 179
 tacrolimus..... 75, 94, 124, 140
 TAFINLAR.....45, 179
 TAGRISSO45, 179
 TAKHZYRO91, 136
 TALZENNA45, 179
 tamoxifen citrate40, 174
 tamsulosin hcl83, 127
 TARINA FE 1/20 EQ88, 131
 TASIGNA45, 179
 TAVNEOS.....92, 137
 tazarotene73, 122
 TAZORAC.....73, 122
 TAZTIA XT 65, 66, 111
 TAZVERIK45, 180
 TDVAX.....96, 142
 TEFLARO25, 161
 TEGSEDI82, 148
 telmisartan63, 115
 telmisartan-hctz.....67, 113
 temazepam 106, 147
 TENIVAC96, 142

tenofovir disoproxil fumarate.....
54, 186
 TEPMETKO45, 180
 terazosin hcl.....63, 116
 terbinafine hcl.....37, 173
 terbutaline sulfate 103, 154
 terconazole37, 173
 teriparatide (recombinant)
98, 143
 testosterone84, 132
 testosterone cypionate84, 132
 testosterone enanthate.....84, 132
 tetrabenazine71, 120
 tetracycline hcl28, 164
 THALOMID40, 174
 theophylline er 104, 154
 thioridazine hcl49, 185
 thiothixene.....49, 185
 TIADYLT ER66, 111
 tiagabine hcl.....30, 164
 TIBSOVO.....45, 180
 TICOVAC.....97, 142
 tigecycline23, 159
 timolol maleate
 65, 100, 112, 143
 timolol maleate (once-daily).....
 100, 143
 tinidazole23, 159
 TIVICAY53, 187
 TIVICAY PD53, 187
 tizanidine hcl52, 107
 TOBI PODHALER 104, 151
 tobramycin 100, 104, 145, 151
 tobramycin sulfate22, 158
 tobramycin-dexamethasone
99, 145
 tolterodine tartrate82, 127
 tolterodine tartrate er82, 127
 tolvaptan78, 191
 topiramate38, 108
 topiramate er38, 108
 toremifene citrate.....40, 174
 torsemide68, 116
 TOUJEO MAX SOLOSTAR.....
60, 197
 TOUJEO SOLOSTAR60, 197
 TPN ELECTROLYTES.....79, 190
 tramadol hcl21, 155
 tramadol-acetaminophen.....
21, 155
 trandolapril63, 117
 tranexamic acid62, 194
 tranlycypromine sulfate.....33, 168

TRAVASOL.....79, 190
 travoprost (bak free) 101, 145
 trazodone hcl.....34, 169
 TRECATOR39, 171
 TRELEGY ELLIPTA 106, 151
 TRELSTAR MIXJECT91, 136
 TRESIBA.....61, 198
 TRESIBA FLEXTOUCH ..60, 198
 tretinoin 46, 73, 122, 181
 TREXALL.....94, 140
 triamcinolone acetonide.....
 72, 75, 120, 124
 triamterene-hctz67, 113
 trientine hcl.....78, 191
 TRI-ESTARYLLA.....88, 131
 trifluoperazine hcl49, 185
 trifluridine53, 185
 trihexyphenidyl hcl.....47, 109
 TRIKAFTA..... 104, 151
 trimethoprim23, 159
 TRI-MILI.....88, 131
 trimipramine maleate35, 170
 TRINTELLIX.....34, 169
 TRI-NYMYO.....88, 131
 TRI-SPRINTEC88, 131
 TRIUMEQ55, 188
 TRIUMEQ PD.....55, 188
 TRIVORA (28).....89, 131
 TRI-VYLIBRA89, 131
 TRIZIVIR.....54, 186
 TROPHAMINE79, 190
 trospium chloride83, 128
 trospium chloride er82, 127
 TRULICITY59, 196
 TRUMENBA97, 142
 TRUSELTIQ (100MG DAILY
 DOSE)45, 180
 TRUSELTIQ (125MG DAILY
 DOSE)45, 180
 TRUSELTIQ (50MG DAILY
 DOSE)46, 180
 TRUSELTIQ (75MG DAILY
 DOSE)46, 180
 TUKYSA.....46, 180
 TURALIO46, 180
 TWINRIX.....97, 142
 TYBOST.....55, 188
 TYMLOS98, 143
 TYPHIM VI.....97, 142

U

UBRELVY38, 108
 UNITHROID90, 135
 ursodiol80, 126

V

valacyclovir hcl53, 185
 VALCHLOR.....39, 173
 valganciclovir hcl52, 185
 valproic acid30, 167
 valsartan63, 115
 valsartan-hydrochlorothiazide.....
67, 113
 VALTOCO 10 MG DOSE
30, 165
 VALTOCO 15 MG DOSE
30, 165
 VALTOCO 20 MG DOSE
31, 165
 VALTOCO 5 MG DOSE
31, 165
 vancomycin hcl.....23, 24, 159
 VAQTA.....97, 142
 varenicline tartrate.....22, 149
 VARIVAX97, 142
 VARUBI (180 MG DOSE).....
36, 171
 VASCEPA69, 115
 VELIVET89, 131
 VELPHORO79, 190
 VEMLIDY52, 189
 VENCLEXTA.....46, 180
 VENCLEXTA STARTING PACK
46, 180
 venlafaxine besylate er....34, 170
 venlafaxine hcl34, 170
 venlafaxine hcl er34, 170
 VENTOLIN HFA104, 154
 verapamil hcl66, 111
 verapamil hcl er66, 111
 VERQUVO68, 113
 VERSACLOZ51, 184
 VERZENIO.....46, 180
 VESTURA89, 131
 VICTOZA59, 196
 VIENVA.....89, 131
 vigabatrin31, 165
 VIIBRYD STARTER PACK.....
34, 170
 VIJOICE41, 175
 vilazodone hcl34, 170

VIRACEPT55, 188
 VIREAD.....54, 186
 VITRAKVI.....46, 180
 VIVITROL.....21, 149
 VIZIMPRO.....46, 180
 VONJO46, 180
 voriconazole37, 173
 VOSEVI.....52, 189
 VOTRIENT.....46, 180
 VRAYLAR51, 183
 VYFEMLA89, 131
 VYLIBRA.....89, 131
 VYNDAMAX.....82, 148

W

warfarin sodium61, 193
 WELIREG41, 175

X

XALKORI46, 180
 XARELTO61, 193
 XARELTO STARTER PACK
61, 193
 XATMEP41, 175
 XCOPRI30, 167
 XCOPRI (250 MG DAILY DOSE)
30, 167
 XCOPRI (350 MG DAILY DOSE)
30, 167
 XGEVA98, 143
 XIFAXAN.....24, 159
 XOFLUZA (40 MG DOSE).....
56, 185
 XOFLUZA (80 MG DOSE).....
56, 185
 XOLAIR.....92, 137
 XOSPATA.....46, 180
 XPOVIO (100 MG ONCE
 WEEKLY).....41, 175
 XPOVIO (40 MG ONCE
 WEEKLY).....41, 175
 XPOVIO (40 MG TWICE
 WEEKLY).....41, 175
 XPOVIO (60 MG ONCE
 WEEKLY).....41, 175
 XPOVIO (60 MG TWICE
 WEEKLY).....41, 175
 XPOVIO (80 MG ONCE
 WEEKLY).....41, 176
 XPOVIO (80 MG TWICE
 WEEKLY).....41, 176
 XTANDI.....40, 174

| | |
|---------------|----------|
| XULTOPHY..... | 59, 196 |
| XURIDEN..... | 82, 148 |
| XYREM..... | 106, 147 |
| XYWAV..... | 106, 147 |

Y

| | |
|-------------|---------|
| YF-VAX..... | 97, 142 |
| YONSA..... | 40, 174 |

Z

| | |
|------------------|----------|
| zafirlukast..... | 103, 153 |
| zaleplon..... | 106, 147 |
| ZARXIO..... | 62, 194 |
| ZEJULA..... | 46, 180 |
| ZELBORAF..... | 46, 180 |
| ZEMDRI..... | 22, 158 |
| ZENPEP..... | 82, 148 |
| zidovudine..... | 54, 186 |
| ZIEXTENZO..... | 62, 194 |
| ZIMHI..... | 22, 149 |

| | |
|---------------------------|----------|
| ziprasidone hcl..... | 51, 183 |
| ziprasidone mesylate..... | 51, 183 |
| ZIRGAN..... | 52, 185 |
| ZOLINZA..... | 42, 176 |
| zolmitriptan..... | 39, 107 |
| zolpidem tartrate..... | 106, 148 |
| ZONISADE..... | 30, 166 |
| zonisamide..... | 30, 166 |
| ZOVIA 1/35 (28)..... | 89, 131 |
| ZYDELIG..... | 46, 180 |
| ZYKADIA..... | 46, 180 |
| ZYPITAMAG..... | 69, 114 |
| ZYPREXA RELPREVV..... | 51, 184 |

To learn what the abbreviations on this table mean, see the beginning of the drug list table.

(Para saber qué significan las abreviaturas en esta tabla, consulte el comienzo de la tabla de la lista de medicamentos.)

This formulary was updated on 02/21/2023. For more recent information or other questions, please contact Imperial Insurance Companies at 1-800-838-8271 October 1 – March 31: Monday – Sunday, from 8:00 a.m. – 8:00 p.m. PST or April 1 – September 30: Monday – Friday, from 8:00 a.m. – 8:00 p.m. PST, or visit www.imperialhealthplan.com.

Imperial Insurance Companies (HMO) (HMO SNP) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex.

ATTENTION: If you speak English, language assistance services, free of charge, are available to you. Call 1-800-838-8271 (TTY: 711).

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-800-838-8271 (TTY: 711).

Este formulario se actualizó el 21/02/2023. Para obtener información más reciente o si tiene otras preguntas, comuníquese con el Departamento de Membresía de Imperial Insurance Companies llamando al 1-800-838-8271, del 1 de octubre al 31 de marzo: lunes a domingo, de 8:00 a.m. a 8:00 p.m. PST o del 1 de abril al 30 de septiembre: lunes a viernes, de 8:00 a.m. a 8:00 p.m. PST, o visite www.imperialhealthplan.com.

Imperial Insurance Companies (HMO) (HMO SNP) cumple con leyes federales de derechos civiles aplicables y no discrimina basándose en raza, color, origen nacional, edad, discapacidad, o sexo.

ATENCIÓN: Si habla inglés, tiene a su disposición servicios de asistencia lingüística gratuitos. Llame al 1-800-838-8271 (TTY: 711).

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-800-838-8271 (TTY: 711).